{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f2b1d406-70b1-40be-9490-be2ed3e5d55d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from langchain.document_loaders import PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain_community.vectorstores import LanceDB\n",
    "from langchain_community.embeddings import HuggingFaceEmbeddings\n",
    "import lancedb\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain_openai import ChatOpenAI\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "48f3786f-d47e-4b7a-a6d3-3cf55fef71cd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded 286 pages\n"
     ]
    }
   ],
   "source": [
    "PDF_PATH = \"Kenya-ARV-Guidelines-2022-Final-1.pdf\"\n",
    "\n",
    "loader = PyPDFLoader(PDF_PATH)\n",
    "documents = loader.load()\n",
    "\n",
    "print(f\"Loaded {len(documents)} pages\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "98dd4b72-0a7f-45fe-8299-98b9e39295e5",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "fbbd212a-64df-4fcb-9b94-a0970806df10",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Created 1013 chunks\n"
     ]
    }
   ],
   "source": [
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=800,\n",
    "    chunk_overlap=150,\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \" \"]\n",
    ")\n",
    "\n",
    "chunks = text_splitter.split_documents(documents)\n",
    "print(f\"Created {len(chunks)} chunks\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "0dfead11-828f-468e-86b0-397281847f5c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=' \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 0}),\n",
       " Document(page_content='', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 1}),\n",
       " Document(page_content='  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content=' \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content=' \\n \\ni Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health . \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content=' \\n \\nii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content=' \\n \\niii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix \\nList of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2 \\n2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2 \\n2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4 \\n3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15 \\n4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31 \\n4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34 \\n4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content=' \\n \\nv 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40 \\n4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5 \\n5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7 \\n5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31 \\n5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1 \\n6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7 \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10 \\n8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13 \\n9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1 \\n9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6 \\n9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1 \\n10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content=' \\n \\nvii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2 \\n11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5 \\n11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12 \\n11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1 \\n12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content=' \\n \\nix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15 \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39 \\nFigure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3 \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7 \\nTable 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2 \\nTable 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9 \\nTable 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29 \\nTable 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content=' \\n \\nxi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13 \\nTable 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23 \\nTable 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32 \\nTable 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5 \\nTable 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1 \\nTable 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10 \\nTable 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1 \\nTable 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4 \\nTable 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content=' \\n \\nxiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up. ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9. \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently  \\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?    \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content=' Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ ) ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.  \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.  \\n      \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further . \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia  \\n   \\n \\n \\n \\n \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in  \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic\\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE\\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence  \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event  \\n         \\n         \\n         \\n         \\n         \\n         \\n \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='  \\nAnnexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years \\nweighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3 \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.  \\n   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction  \\n \\n \\n \\n \\n \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)  \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts  \\n \\n   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability  \\n• Potentially lead to \\ndeath  \\nExamples:  \\n• Decline in \\npulmonary \\ncapacity from TB \\nor MAC infection  \\n• Neurologic \\ncomplications \\nfrom cryptococcal \\ninfection  \\n• Loss of vision from \\nCMV retinitis \\ninfection  • Treat the OI and manage the associated \\nsymptoms  \\n• Manage t he IRIS -associated inflammation:  \\no If NOT KS: give 1 to 2 mg/kg prednisone for \\n1 to 2 weeks. Follow with a period of \\nindividualized tapering of the dose  \\no Do not use corticosteroids for the \\nmanagement of KS -related IRIS  \\n• Closely monitor patients on corticosteroid \\ntherapy for:  \\no Hyperglycemia  \\no Hypertension  \\no Mental status changes  \\no Avascular necrosis  \\no Worsening of an existing infection  \\no Predisposition to a new infection (e.g., TB \\nand CMV)  \\n    \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 59 Annex 17: HTS Adult Screening Tool Enhancement  \\n  \\nCounty: …………………………………………. Sub -County Name: ………………………………….  \\n \\nFacility Name:……………………………… Facility MFL Code: ……………………………………  \\n1 Today’s Date                                              Gender                                             AGE  \\n \\n………………………….                            \\n2 Have you ever tested for HIV Before?  \\nIf yes, what was the HIV result?         Positive                      Negative  \\nIf positive, Date of ART initiation. ……………………. (Not eligible for testing)  \\nIf Negative, when is the most recent HIV test?   Months              Years  \\n \\n3 If negative or status unknown, determine  behavioural risk of HIV acquisition  by \\nasking the following questions:  \\n• Unprotected sex within the last 3 months  \\n• Unknown status of the sexual partners  \\n• New sexual partner within the last 3 months  \\n• Multiple sexual partners  \\n• intergenerational relationships  \\n• Symptoms of sexually transmitted infection (refer to MoH syndromic \\nchart) or history of STI  \\n• Pregnancy for females  \\n• Assessing h istory of recurrent illnesses without resolution of symptoms, \\nacute or chronic febrile illness (symptoms ≥ 14 days) and any other \\nconditions suggestive of HIV  \\n4 Possible Risk exposures:  \\n• Defilement  \\n• Traditional /non -medical procedures e.g., scarification, plastic tooth \\nextraction , Circumcision, uvulectomy etc.  \\n5 If Risk noted or clinical assessment suggest HIV, eligible for testing  \\n6. If No risk noted and assessment does not suggest, not eligible  \\nName  Institutions  \\n \\n  \\n M\\nM\\nM  F \\n  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 280}),\n",
       " Document(page_content=\" Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 60 Annex 1 8: List of Contributors and Affiliation  \\n  Name  Affiliation    Name  Affiliation  \\n1 Abraham Katana  CDC  61 Jonah Magare  MOH NASCOP  \\n2 Adrian Gardner  Moi University  62 Jonah Maswai   DoD  \\n3 Agnes Langat  CDC  63 Jonah Onentiah  MOH NASCOP  \\n4 Alice Njoroge  Kajiado County  64 Jonathan Mwangi  CDC  \\n5 Ambrose Juma  MOH NASCOP  65 Joseph Mbuthia  Mater Hospital  \\n6 Anne Marie \\nMacharia  KNH  66 Joseph Nkuranga  UON  \\n7 Anthony Wachira  MOH NASCOP  67 Judith Lusike  CHAI  \\n8 Appolonia Aoko  CDC  68 Julius Kisio  Murang'a County  \\n9 Barbara Mambo  MOH NASCOP  69 Julius Oliech  CDC  \\n10 Brandwell Mwangi  CHAI  70 Justine Odionyi  EGPAF  \\n11 Brenda Opanga  MOH NASCOP  71 Justus Ogada  CHAI  \\n12 Celestine \\nImuuraget  DOD  72 Kenneth Masamaro  CDC  \\n13 Christine Kisia  WHO  73 Lazarus Momanyi  MOH NASCOP  \\n14 Claver Kimathi  Isiolo County  74 Lennah Nyabiage  CDC  \\n15 Collins Etemesi  MOH NASCOP  75 Leonard Kingwara  MOH NHRL  \\n16 Dalton Wamalwa  UON  76 Leonard Soo  USAID  \\n17 Daniel Kimani  CDC  77 Loice Achieng Ombajo  UON  \\n18 Daniel Were  JHPIEGO  78 Margaret Ndubi  UNAIDS  \\n19 Davis Karambi  CHAI  79 Mary Mugambi  MOH NASCOP  \\n20 Deborah Carpenter  CDC  80 Mary Nyangasi  MOH NCCP  \\n21 Deborah Goldstein  USAID  81 Marybeth Maritim  UON  \\n22 Deborah Ikonge  MOH NASCOP  82 Maureen Inimah  MOH NASCOP  \\n23 Dennis Osiemo  USAID  83 Maureen Syowai  ICAP at Columbia \\nUniversity  \\n24 Diana Marangu  UoN  84 Mike Ekisa  Kakamega County  \\n25 Dinah Mamai   CHS  85 Muthoni Karanja  DOD  \\n26 Dorcus Abuya  UNICEF  86 Nancy Bowen  MOH NHRL  \\n27 Doreen Muriithi  JHPIEGO  87 Nandita Sugandhi  ICAP at Columbia \\nUniversity  \\n28 Dorothy Mwagae  MOH NASCOP  88 Natella Rakhmanina  EGPAF  \\n29 Douglas Gaitho  AKUH  89 Nelson Otwoma  NEPHAK  \\n30 Dunstan Achwoka  USAID  90 Newton Omale  MOH NASCOP  \\n31 Edith Apondi  AMPATH Plus  91 Odylia Muhenje  CDC  \\n32 Elaine Abrams   ICAP at Columbia \\nUniversity  92 Pacific Akinyi  MOH NASCOP  \\n33 Elizabeth Irungu  JHPIEGO  93 Patricia Oluoch  USAID  \\n34 Elizabeth Katiku  CDC  94 Patricia Ongwen  JHPIEGO  \", metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 281}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 61 35 Elizabeth Mueni  NMS  95 Philip Kimani  CHAI  \\n36 Elizabeth Onyango  MOH NCD  96 Rogers Simiyu  EGPAF  \\n37 Elizabeth Washika  MOH NASCOP  97 Rose Ayugi  MOH NASCOP  \\n38 Emma Momanyi  CIHEB  98 Rose Wafula  MOH NASCOP  \\n39 Eric Mutua  MOH NASCOP  99 Ruby Fayorsey                  ICAP at Columbia \\nUniversity  \\n40 Evelyn Ngugi  CDC  100  Ruth Kamau  MOH NASCOP  \\n41 Everline Ashiono  USAID Dumisha Afya  101  Ruth Korir  Mathari Hospital  \\n42 Felicistas Makokha  NyaWest RTWG  102  Ruth Musyoki  MOH NASCOP  \\n43 Francis Ndwiga  MOH NASCOP  103  Ruth Nduati  UoN  \\n44 Frank Basiye  CDC  104  Salome Okutoyi  USAID  \\n45 George Siberry  USAID  105  Sarafuina Sikwata  MOH NASCOP  \\n46 Grace Rabut  MOH NASCOP  106  Sarah Masyuko  MOH NASCOP  \\n47 Helen Chun  CDC  107  Shobha Vakil                     ICAP at Columbia \\nUniversity  \\n48 Herb Herwell  CHAI  108  Sospeter Gitonga  MOH NASCOP  \\n49 Herman Wayenga  CDC  109  Steve Oyule  DoD  \\n50 Immaculate \\nMutisya  CDC  110  Susan Njogo  ARC Kenya  \\n51 Irene Mukui  DnDI  111  Teresa Simiyu  USAID  \\n52 Isabella Yonga  USAID  112  Terezah Alwar  UNICEF  \\n53 Ivy Kasirye  WHO  113  Vakil, Shobha  ICAP  \\n54 Jafred Mwangi  MOH NASCOP  114  Valeria Makory  MOH NASCOP  \\n55 James Wagude  NyaWest RTWG  115  Valerie Obare  MOH NASCOP  \\n56 Janet Muema  MOH NASCOP  116  Veronica Irungu  CHS  \\n57 Japheth Gituku  MOH NASCOP  117  Virginia Karanja  CHS  \\n58 Jeremy Penner  UBC  118  Wangui Kamau  KNH  \\n59 Joan -Paula Bor  MOH NCCP  119  Wanjiku Ndegwa  MOH NASCOP  \\n60 John Mungai  CHAI  120  Winifred Nyanya  MOH NASCOP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 282}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 62 Annex 19: List of Participating Organizations and Agencies  \\nContributing Organizations  \\nCenter for Health Solutions  \\nAga Khan University Hospital  \\nAMPATH Plus  \\nARC Kenya  \\nCenter for Disease Control  \\nCIHEB Kenya  \\nClinton Health Access Initiative  \\nCouncil of Governors  \\nDepartment of Defence  \\nDnDI  \\nEGPAF  \\nICAP at Columbia University  \\nJHPIEGO  \\nKenyatta Nati onal Hospital  \\nMater Hospital  Mathari National TRH  \\nMOH Department of NCD  \\nMOH Division of NCCP  \\nMOH NASCOP  \\nMOH NHRL  \\nMOH NLTP  \\nMoi University  \\nNairobi Metropolis Services  \\nNEPHAK  \\nUCSF  \\nUNICEF  \\nUniversity of British Columbia  \\nUniversity of Nairobi  \\nUSAID  \\nWorld Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 283}),\n",
       " Document(page_content=' \\n63 - 264   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 284}),\n",
       " Document(page_content=' \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 285})]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "d7ee6b4d-196c-46af-961c-998bf7ce1250",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content='© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content='by NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content='i Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='Disease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='and treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='health sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health .', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='ii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='person, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='Financial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='iii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='List of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='v 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P),', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='vii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='ix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='xi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='xiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='FTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='AIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Support  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='DAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='EDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='FLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='self-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='Consists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='transmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='be screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='important during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='have been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='confirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='after assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='monitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='integrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='and repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='continued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='rifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='immediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='pregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='other populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='screening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='In Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='tools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='delivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='blood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='whereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='and injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='infected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='HIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='and be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='Adolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='disclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='unknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='multiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='post -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='correct use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='confidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='During the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='algorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Explain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='members, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Post -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='If the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Child HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Child confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='Results  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='initiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='gestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='Confirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='results and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='consent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='on individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='distinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='HIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='test kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='REPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='after 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='Disclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='in the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='the receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='Integrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='The purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='suppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='which national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='the provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='Those suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='on ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='Reference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='before confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='management of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='be focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='o Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='psychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='years of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='dermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='concurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='laboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='Creatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='signs or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='treatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='pneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='includes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='presumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='Focus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='may also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='clinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='important during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='Patients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='adolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='Adherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='until complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='negative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='preparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='every contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='service delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='on ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='ART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='standard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='o Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='group. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='management of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='and follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='training centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='Family planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='considered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='after birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='continue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='topical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='Dose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='patients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='awaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='special test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='pregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='adolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='infusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='fluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='months apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='Fluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='Patien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='on history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='good as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='Category 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='discordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='appropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='for cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='adherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='cardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='o Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='diuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g.,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='o If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='symptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='consider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='treatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='specialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='nephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='to be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='o Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='depression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='doing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='bothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='program)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='health team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='o Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='an anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='depres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='Patients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='guidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='fit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='with no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='Maintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='key areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='living with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='The following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='immune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='respondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='good, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='and challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='Support structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='All PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='o Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='o Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='Messages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='o Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='malnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='Weight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='care:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='feeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='and risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='Guidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='Age  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='born to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='specific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='doses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='Guidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='intermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='an adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='level of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='after which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='patients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='counselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='significantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='emphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='taken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='has not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='Note: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='established that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='for HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='HIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='HIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='Antiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='PLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='counselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='treatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='the patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='o Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='message  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='ready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='be conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='support of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='C. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='strategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='and Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='of a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='initiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='sessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='volunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='same day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='with the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='confirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='records  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='women: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='confirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='Every provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='MMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='Table 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='medications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='Counselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='patient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='he/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='the next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='status?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='etc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='identified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='another care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='place  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='Treatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='can be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='potential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='is important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='conducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='o Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='enhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='Monthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='days  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='support ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='TWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='line ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='attend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='contact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='systems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='scheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='HIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='PCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='weeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='All other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='Infants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='a child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='daily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='Clinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='anti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='available as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='RAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='o There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='these supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='load, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='efavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='first VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='providing enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='and providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='VL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='monitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='Gynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='DRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='medical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='symptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='specifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='hours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='liver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='HBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='consider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='Action  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='that may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='The goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='Treatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='VL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='(0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='the primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='ABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='results; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='should be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='out inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='of excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='the TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='Table 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='including PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='more intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='receive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='unknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='HIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='prevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='Table 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='cessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='months after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='HIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='Manage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='and 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='prophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='be treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='their own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='women without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='with Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='cessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='AZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='If older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='Table 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='under 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='appropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='Continued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='to eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='can pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='transmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='patients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='LPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='bronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='guidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='reviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='SL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='GeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='o Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='the eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='TB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='the PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='regimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='neuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='ACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='Table 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection);', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='management (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='Table 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='duration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='to EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='algorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='and for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='outcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='discuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Comorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='completion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='consider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='there is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='prevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='HCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='settings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='o Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='smoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR),', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='disease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='ARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='children. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='Patients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further .', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='ARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='Duration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='assault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='syndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='Breastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='To avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='o With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='The risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='you use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='to determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='STI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='o Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='o Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='in advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='Continuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='months and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='appropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='An “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='Daily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='STI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='initiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='initiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='at high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='suspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='Visit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='for discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='the previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='adherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='new HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='optimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='Every effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='received specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='testing by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='and sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='infection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='o Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='HIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='additional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='services.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='TB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='Treatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='o NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='episodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='lymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='using clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='about HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='immediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='adolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='main points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='your ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='affected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='the ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='and the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='have a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='someone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='them ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='of ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='been a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='understand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='service for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='breakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='Section 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='then you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='strategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='adherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='Cognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='remembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='to the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='possible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='confirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='and how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='come up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='Session 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='since the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='is failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='the table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Describe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Has Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='o Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='o Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='adherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='ABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='RAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='Notes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='tab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='Annexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='EFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='weighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='mg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='liquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='dissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='RTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='approach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='LPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content='Efavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='first 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='been reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='acidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='Decrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='with 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='raised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content='during the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='ddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='disease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content='Insomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='increased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='increase the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='toxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='Delamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='effect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content='increased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content='exceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='monitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='Increases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content='administered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='interactions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='PIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='starting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content='ATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='If must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='rifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='Delamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content='(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='counselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='Is the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='o High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " ...]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "ba71b26d-823c-4e02-8908-cbfecb914560",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Chunking wit LLM"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "e900a4d5-9823-4696-a6cc-ba083918f363",
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "load_dotenv()  # OPENAI_API_KEY from .env\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "fb9afb69-57b6-4955-8e1c-6d294c26b305",
   "metadata": {},
   "outputs": [],
   "source": [
    "from openai import OpenAI\n",
    "\n",
    "openai_client = OpenAI()\n",
    "\n",
    "\n",
    "def llm(prompt, model='gpt-4o-mini'):\n",
    "    messages = [\n",
    "        {\"role\": \"user\", \"content\": prompt}\n",
    "    ]\n",
    "\n",
    "    response = openai_client.responses.create(\n",
    "        model='gpt-4o-mini',\n",
    "        input=messages\n",
    "    )\n",
    "\n",
    "    return response.output_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "7d06a282-8f5b-458a-9448-f0eadea0a9c9",
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_template = \"\"\"\n",
    "Split the provided document into logical sections\n",
    "that make sense for a Q&A system.\n",
    "\n",
    "Each section should be self-contained and cover\n",
    "a specific topic or concept.\n",
    "\n",
    "<DOCUMENT>\n",
    "{document}\n",
    "</DOCUMENT>\n",
    "\n",
    "Use this format:\n",
    "\n",
    "## Section Name\n",
    "\n",
    "Section content with all relevant details\n",
    "\n",
    "---\n",
    "\n",
    "## Another Section Name\n",
    "\n",
    "Another section content\n",
    "\n",
    "---\n",
    "\"\"\".strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f1162596-6344-4fbb-a8ae-b221823a1c6b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def intelligent_chunking(text):\n",
    "    prompt = prompt_template.format(document=text)\n",
    "    response = llm(prompt)\n",
    "    sections = response.split('---')\n",
    "    sections = [s.strip() for s in sections if s.strip()]\n",
    "    return sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "f9575d54-ada2-44ba-88c0-c94e14540082",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=' \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 0}),\n",
       " Document(page_content='', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 1}),\n",
       " Document(page_content='  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content=' \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content=' \\n \\ni Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health . \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content=' \\n \\nii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content=' \\n \\niii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix \\nList of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2 \\n2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2 \\n2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4 \\n3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15 \\n4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31 \\n4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34 \\n4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content=' \\n \\nv 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40 \\n4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5 \\n5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7 \\n5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31 \\n5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1 \\n6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7 \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10 \\n8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13 \\n9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1 \\n9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6 \\n9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1 \\n10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content=' \\n \\nvii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2 \\n11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5 \\n11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12 \\n11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1 \\n12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content=' \\n \\nix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15 \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39 \\nFigure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3 \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7 \\nTable 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2 \\nTable 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9 \\nTable 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29 \\nTable 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content=' \\n \\nxi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13 \\nTable 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23 \\nTable 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32 \\nTable 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5 \\nTable 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1 \\nTable 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10 \\nTable 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1 \\nTable 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4 \\nTable 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content=' \\n \\nxiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up. ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9. \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently  \\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?    \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content=' Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ ) ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.  \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.  \\n      \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further . \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia  \\n   \\n \\n \\n \\n \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in  \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic\\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE\\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence  \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event  \\n         \\n         \\n         \\n         \\n         \\n         \\n \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='  \\nAnnexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years \\nweighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3 \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.  \\n   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction  \\n \\n \\n \\n \\n \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)  \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts  \\n \\n   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability  \\n• Potentially lead to \\ndeath  \\nExamples:  \\n• Decline in \\npulmonary \\ncapacity from TB \\nor MAC infection  \\n• Neurologic \\ncomplications \\nfrom cryptococcal \\ninfection  \\n• Loss of vision from \\nCMV retinitis \\ninfection  • Treat the OI and manage the associated \\nsymptoms  \\n• Manage t he IRIS -associated inflammation:  \\no If NOT KS: give 1 to 2 mg/kg prednisone for \\n1 to 2 weeks. Follow with a period of \\nindividualized tapering of the dose  \\no Do not use corticosteroids for the \\nmanagement of KS -related IRIS  \\n• Closely monitor patients on corticosteroid \\ntherapy for:  \\no Hyperglycemia  \\no Hypertension  \\no Mental status changes  \\no Avascular necrosis  \\no Worsening of an existing infection  \\no Predisposition to a new infection (e.g., TB \\nand CMV)  \\n    \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 59 Annex 17: HTS Adult Screening Tool Enhancement  \\n  \\nCounty: …………………………………………. Sub -County Name: ………………………………….  \\n \\nFacility Name:……………………………… Facility MFL Code: ……………………………………  \\n1 Today’s Date                                              Gender                                             AGE  \\n \\n………………………….                            \\n2 Have you ever tested for HIV Before?  \\nIf yes, what was the HIV result?         Positive                      Negative  \\nIf positive, Date of ART initiation. ……………………. (Not eligible for testing)  \\nIf Negative, when is the most recent HIV test?   Months              Years  \\n \\n3 If negative or status unknown, determine  behavioural risk of HIV acquisition  by \\nasking the following questions:  \\n• Unprotected sex within the last 3 months  \\n• Unknown status of the sexual partners  \\n• New sexual partner within the last 3 months  \\n• Multiple sexual partners  \\n• intergenerational relationships  \\n• Symptoms of sexually transmitted infection (refer to MoH syndromic \\nchart) or history of STI  \\n• Pregnancy for females  \\n• Assessing h istory of recurrent illnesses without resolution of symptoms, \\nacute or chronic febrile illness (symptoms ≥ 14 days) and any other \\nconditions suggestive of HIV  \\n4 Possible Risk exposures:  \\n• Defilement  \\n• Traditional /non -medical procedures e.g., scarification, plastic tooth \\nextraction , Circumcision, uvulectomy etc.  \\n5 If Risk noted or clinical assessment suggest HIV, eligible for testing  \\n6. If No risk noted and assessment does not suggest, not eligible  \\nName  Institutions  \\n \\n  \\n M\\nM\\nM  F \\n  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 280}),\n",
       " Document(page_content=\" Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 60 Annex 1 8: List of Contributors and Affiliation  \\n  Name  Affiliation    Name  Affiliation  \\n1 Abraham Katana  CDC  61 Jonah Magare  MOH NASCOP  \\n2 Adrian Gardner  Moi University  62 Jonah Maswai   DoD  \\n3 Agnes Langat  CDC  63 Jonah Onentiah  MOH NASCOP  \\n4 Alice Njoroge  Kajiado County  64 Jonathan Mwangi  CDC  \\n5 Ambrose Juma  MOH NASCOP  65 Joseph Mbuthia  Mater Hospital  \\n6 Anne Marie \\nMacharia  KNH  66 Joseph Nkuranga  UON  \\n7 Anthony Wachira  MOH NASCOP  67 Judith Lusike  CHAI  \\n8 Appolonia Aoko  CDC  68 Julius Kisio  Murang'a County  \\n9 Barbara Mambo  MOH NASCOP  69 Julius Oliech  CDC  \\n10 Brandwell Mwangi  CHAI  70 Justine Odionyi  EGPAF  \\n11 Brenda Opanga  MOH NASCOP  71 Justus Ogada  CHAI  \\n12 Celestine \\nImuuraget  DOD  72 Kenneth Masamaro  CDC  \\n13 Christine Kisia  WHO  73 Lazarus Momanyi  MOH NASCOP  \\n14 Claver Kimathi  Isiolo County  74 Lennah Nyabiage  CDC  \\n15 Collins Etemesi  MOH NASCOP  75 Leonard Kingwara  MOH NHRL  \\n16 Dalton Wamalwa  UON  76 Leonard Soo  USAID  \\n17 Daniel Kimani  CDC  77 Loice Achieng Ombajo  UON  \\n18 Daniel Were  JHPIEGO  78 Margaret Ndubi  UNAIDS  \\n19 Davis Karambi  CHAI  79 Mary Mugambi  MOH NASCOP  \\n20 Deborah Carpenter  CDC  80 Mary Nyangasi  MOH NCCP  \\n21 Deborah Goldstein  USAID  81 Marybeth Maritim  UON  \\n22 Deborah Ikonge  MOH NASCOP  82 Maureen Inimah  MOH NASCOP  \\n23 Dennis Osiemo  USAID  83 Maureen Syowai  ICAP at Columbia \\nUniversity  \\n24 Diana Marangu  UoN  84 Mike Ekisa  Kakamega County  \\n25 Dinah Mamai   CHS  85 Muthoni Karanja  DOD  \\n26 Dorcus Abuya  UNICEF  86 Nancy Bowen  MOH NHRL  \\n27 Doreen Muriithi  JHPIEGO  87 Nandita Sugandhi  ICAP at Columbia \\nUniversity  \\n28 Dorothy Mwagae  MOH NASCOP  88 Natella Rakhmanina  EGPAF  \\n29 Douglas Gaitho  AKUH  89 Nelson Otwoma  NEPHAK  \\n30 Dunstan Achwoka  USAID  90 Newton Omale  MOH NASCOP  \\n31 Edith Apondi  AMPATH Plus  91 Odylia Muhenje  CDC  \\n32 Elaine Abrams   ICAP at Columbia \\nUniversity  92 Pacific Akinyi  MOH NASCOP  \\n33 Elizabeth Irungu  JHPIEGO  93 Patricia Oluoch  USAID  \\n34 Elizabeth Katiku  CDC  94 Patricia Ongwen  JHPIEGO  \", metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 281}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 61 35 Elizabeth Mueni  NMS  95 Philip Kimani  CHAI  \\n36 Elizabeth Onyango  MOH NCD  96 Rogers Simiyu  EGPAF  \\n37 Elizabeth Washika  MOH NASCOP  97 Rose Ayugi  MOH NASCOP  \\n38 Emma Momanyi  CIHEB  98 Rose Wafula  MOH NASCOP  \\n39 Eric Mutua  MOH NASCOP  99 Ruby Fayorsey                  ICAP at Columbia \\nUniversity  \\n40 Evelyn Ngugi  CDC  100  Ruth Kamau  MOH NASCOP  \\n41 Everline Ashiono  USAID Dumisha Afya  101  Ruth Korir  Mathari Hospital  \\n42 Felicistas Makokha  NyaWest RTWG  102  Ruth Musyoki  MOH NASCOP  \\n43 Francis Ndwiga  MOH NASCOP  103  Ruth Nduati  UoN  \\n44 Frank Basiye  CDC  104  Salome Okutoyi  USAID  \\n45 George Siberry  USAID  105  Sarafuina Sikwata  MOH NASCOP  \\n46 Grace Rabut  MOH NASCOP  106  Sarah Masyuko  MOH NASCOP  \\n47 Helen Chun  CDC  107  Shobha Vakil                     ICAP at Columbia \\nUniversity  \\n48 Herb Herwell  CHAI  108  Sospeter Gitonga  MOH NASCOP  \\n49 Herman Wayenga  CDC  109  Steve Oyule  DoD  \\n50 Immaculate \\nMutisya  CDC  110  Susan Njogo  ARC Kenya  \\n51 Irene Mukui  DnDI  111  Teresa Simiyu  USAID  \\n52 Isabella Yonga  USAID  112  Terezah Alwar  UNICEF  \\n53 Ivy Kasirye  WHO  113  Vakil, Shobha  ICAP  \\n54 Jafred Mwangi  MOH NASCOP  114  Valeria Makory  MOH NASCOP  \\n55 James Wagude  NyaWest RTWG  115  Valerie Obare  MOH NASCOP  \\n56 Janet Muema  MOH NASCOP  116  Veronica Irungu  CHS  \\n57 Japheth Gituku  MOH NASCOP  117  Virginia Karanja  CHS  \\n58 Jeremy Penner  UBC  118  Wangui Kamau  KNH  \\n59 Joan -Paula Bor  MOH NCCP  119  Wanjiku Ndegwa  MOH NASCOP  \\n60 John Mungai  CHAI  120  Winifred Nyanya  MOH NASCOP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 282}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 62 Annex 19: List of Participating Organizations and Agencies  \\nContributing Organizations  \\nCenter for Health Solutions  \\nAga Khan University Hospital  \\nAMPATH Plus  \\nARC Kenya  \\nCenter for Disease Control  \\nCIHEB Kenya  \\nClinton Health Access Initiative  \\nCouncil of Governors  \\nDepartment of Defence  \\nDnDI  \\nEGPAF  \\nICAP at Columbia University  \\nJHPIEGO  \\nKenyatta Nati onal Hospital  \\nMater Hospital  Mathari National TRH  \\nMOH Department of NCD  \\nMOH Division of NCCP  \\nMOH NASCOP  \\nMOH NHRL  \\nMOH NLTP  \\nMoi University  \\nNairobi Metropolis Services  \\nNEPHAK  \\nUCSF  \\nUNICEF  \\nUniversity of British Columbia  \\nUniversity of Nairobi  \\nUSAID  \\nWorld Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 283}),\n",
       " Document(page_content=' \\n63 - 264   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 284}),\n",
       " Document(page_content=' \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 285})]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "90b40334-11fa-46e2-b9db-600992282296",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cc39d928c11b420288a32bcecffcb07d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Processing docs:   0%|          | 0/286 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total chunks created: 1277\n"
     ]
    }
   ],
   "source": [
    "from tqdm.auto import tqdm\n",
    "from concurrent.futures import ThreadPoolExecutor, as_completed\n",
    "\n",
    "guides_chunks = []\n",
    "\n",
    "def process_doc(doc):\n",
    "    \"\"\"\n",
    "    Splits a single document into sections and returns a list of section dicts.\n",
    "    \"\"\"\n",
    "    doc_content = doc.page_content\n",
    "    doc_metadata = doc.metadata\n",
    "    sections = intelligent_chunking(doc_content)\n",
    "    return [{**doc_metadata, 'section': section} for section in sections]\n",
    "\n",
    "# Use ThreadPoolExecutor to process multiple docs in parallel\n",
    "with ThreadPoolExecutor() as executor:\n",
    "    futures = [executor.submit(process_doc, doc) for doc in documents]\n",
    "    \n",
    "    # Create a tqdm progress bar with total=len(futures)\n",
    "    for future in tqdm(as_completed(futures), total=len(futures), desc=\"Processing docs\"):\n",
    "        # future.result() blocks until the future is done\n",
    "        guides_chunks.extend(future.result())\n",
    "\n",
    "print(f\"Total chunks created: {len(guides_chunks)}\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "f98dafab-73db-4417-ae3a-e1cecd70b761",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Embedding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "4c4bdf41-4487-4163-ad7a-cd4ca3b17431",
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=\"sentence-transformers/all-MiniLM-L6-v2\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "87537556-e949-4a71-a383-95c9a838020a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 0,\n",
       "  'section': 'Sure! Please provide the document you would like me to split into logical sections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 1,\n",
       "  'section': 'Sure, please provide the document you would like me to split into logical sections for your Q&A system.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Copyright Information\\n\\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health Kenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying or recording, without the prior written permission of the National AIDS and STI Control Program (NASCOP), Ministry of Health Kenya, except for non-commercial uses permitted by copyright law.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Purpose of Guidelines\\n\\nThe Kenya HIV Prevention and Treatment Guidelines, 2022 edition, contain relevant information required by healthcare providers in the use of Antiretrovirals (ARVs) as of the date of issue. All reasonable precautions have been taken by NASCOP to verify the information contained in this guideline document.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Contact Information\\n\\nFor clarifications, contact the National AIDS and STI Control Program (NASCOP) at:\\n- P.O. Box 19361 - 00202, Nairobi, Kenya\\n- Tel: +254 (020) 2630867\\n- Email: info@nascop.or.ke\\n- Website: www.nascop.or.ke'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Recommended Citation\\n\\nThe recommended citation for this document is:\\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, 2022 Edition. Nairobi, Kenya: NASCOP, Aug 2022. Print.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Design and Layout\\n\\nDesign and layout by Collins Etemesi - NASCOP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## ISBN Information\\n\\nISBN: 13-978-9966-038-31-9'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Acknowledgements\\n\\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya has been a long-awaited document, heavily impacted by the COVID-19 pandemic. The update was a collaborative effort involving multiple stakeholders, both individuals and institutions, with extensive consultations led by the NASCOP HIV Care and Treatment Program. \\n\\nI acknowledge all the institutions, both local and international, government ministries, and departments whose staff dedicated long hours, both virtually and in person, to the review, writing, and finalization of this document.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Recognition of Efforts\\n\\nI appreciate the efforts of the Ministry of Health officers at NASCOP and other institutions who provided coordination and leadership during the review process. Special thanks to the guidelines review secretariat and the special task force who worked tirelessly to produce a high-quality document. \\n\\nParticular appreciation goes to the NASCOP team and the numerous technical advisors who were instrumental in compiling the evidence review and developing the guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Acknowledgment of Contributors\\n\\nSpecial thanks to the consultants: Jeremy Penner, Irene Mukui, and Herb Harwell for their dedication to this process.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Financial Support\\n\\nFinancial support for the review process, printing, and launch of this document was provided by several organizations, including the Global Fund, UNITAID through CHAI, the US government via the Centers for Disease Control and Prevention, ICAP at Columbia University through the USAID-funded RISE-Kenya Project, WHO, and UNICEF-Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Author Information\\n\\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Overview of Kenya HIV Prevention and Treatment Guidelines\\n\\nThe Kenya HIV Prevention and Treatment Guidelines, 2022 edition, offers comprehensive protocols and recommendations to address the HIV epidemic in Kenya. These guidelines are designed to ensure effective prevention, treatment, and care for individuals affected by HIV, aiming to reduce transmission rates and improve quality of life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Prevention Strategies\\n\\nThis section outlines various preventive measures, including safe sex practices, pre-exposure prophylaxis (PrEP), and condom distribution. Emphasis is placed on community education and access to preventive services to reduce the incidence of new infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Testing and Diagnosis\\n\\nGuidelines for HIV testing and diagnosis are detailed here, including strategies for routine testing, informed consent, and confidentiality considerations. The section also discusses rapid testing methods and the importance of early diagnosis in improving health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Treatment Protocols\\n\\nThis section provides comprehensive treatment guidelines for individuals diagnosed with HIV. It covers antiretroviral therapy (ART), treatment adherence, and monitoring strategies to manage the health of individuals living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Care and Support Services\\n\\nThe guidelines highlight necessary care and support services available for individuals living with HIV. This includes nutritional support, mental health services, and social support networks aimed at improving overall wellbeing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Special Populations\\n\\nThis section discusses tailored interventions for key populations at higher risk for HIV, such as men who have sex with men, sex workers, and people who inject drugs. It emphasizes the need for targeted strategies to improve access to health services for these groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': \"## Implementation and Monitoring\\n\\nDetails on the implementation frameworks and monitoring processes are provided here. This section outlines the roles of healthcare providers, community organizations, and the government's role in ensuring the effective roll-out of the guidelines.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Conclusion\\n\\nThe conclusion summarizes the key points of the Kenya HIV Prevention and Treatment Guidelines, emphasizing the importance of a collective effort in combating the HIV epidemic in Kenya through community engagement, education, and comprehensive health services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Foreword\\n\\nKenya is committed to achieving the UNAIDS 95–95–95 testing and treatment targets among people living with HIV within all sub-populations and age groups. The 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya’ is an update of the comprehensive HIV prevention, care, and treatment guidelines released in 2018. These guidelines align with the Ministry of Health’s mission of providing the highest standard of health for all Kenyans and support one of the Government of Kenya’s Big Four Agenda on Universal Health Coverage.\\n\\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV Disease to reduce HIV/AIDS-related morbidity and mortality. While Kenya has made tremendous progress in HIV prevention, care, and treatment through the introduction of better medicines, diagnostics, and patient-centered approaches in service delivery, Advanced HIV Disease continues to be a challenge. These guidelines intend to widen access to key diagnostics and medicines to manage the most common causes of illness and death. Further, emphasis on integrated delivery of patient-centered HIV, TB, NCDs, mental health, and sexual and reproductive health services has been included.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Key Recommendations\\n\\nThese guidelines provide key recommendations on:\\n\\n- HIV testing services and linkage to prevention and treatment\\n- Initial evaluation and follow-up of people living with HIV (PLHIV)\\n- Standard package of care for PLHIV\\n- Adherence preparation, monitoring, and support\\n- Antiretroviral therapy in infants, children, adolescents, and adults\\n- Prevention of mother-to-child transmission of HIV, syphilis, and viral hepatitis\\n- TB/HIV coinfection management\\n- Hepatitis B & C/HIV co-infection management\\n- Use of ARVs for post and pre-exposure prophylaxis for HIV-uninfected populations\\n- HIV services for people who inject drugs'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Purpose of the Guidelines\\n\\nThe guidelines are an important tool meant to be utilized by service providers at all levels of the health sector in Kenya. They are presented in a simplified manner using a public health approach to HIV prevention and treatment. It is hoped that this guidance document provides the much-needed framework and impetus to move towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key national health strategic objective.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Closing Remarks\\n\\nDr. Patrick Amoth, EBS  \\nAg. Director General for Health,  \\nMinistry of Health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Management of Patients Switching to ART\\n\\nAnnex 9 E: Management Protocol for Patients Switching to 3rd Line ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Pediatric Dosing Guidelines\\n\\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice-Daily Dosing in Infants and Children 4 Weeks of Age and Older.  \\nAnnex 10 B: Simplified Dosing of Child-Friendly Solid and Oral Liquid Formulations for Once-Daily Dosing in Infants and Children 4 Weeks of Age and Older.  \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice-Daily Dosing in Infants Less than 4 Weeks of Age.  \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of Age.  \\nAnnex 10 E: TB Preventive Therapy dosing.  \\nAnnex 10 F: Ritonavir Dosing for Super-Boosting LPV/r in Children Taking Rifampicin.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Overlapping Toxicities\\n\\nAnnex 11: Overlapping toxicities between ARVs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Use of Antiretroviral Medications in Adults\\n\\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults.  \\nAnnex 12 B: Use of Non-Nucleoside Reverse Transcriptase Inhibitors for Adults.  \\nAnnex 12 C: Use of Protease Inhibitors in Adults.  \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Drug-Drug Interactions\\n\\nAnnex 13 A: Drug-Drug Interactions - NNRTIs.  \\nAnnex 13 B: Drug-Drug Interactions – PIs.  \\nAnnex 13 C: Drug-Drug Interactions – INSTIs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Community ART Distribution\\n\\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Clinical Considerations\\n\\nAnnex 15: Creatinine Clearance.  \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome.  \\nAnnex 17: HTS Adult Screening Tool Enhancement.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Contributors and Participating Organizations\\n\\nAnnex 18: List of Contributors and Affiliation.  \\nAnnex 19: List of Participating Organizations and Agencies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## List of Figures\\n\\nThis section provides an overview of the figures contained in the document, detailing various algorithms and management strategies related to healthcare practices.\\n\\n1. **Figure 2.1:** Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age (Page 9)\\n2. **Figure 2.2:** Birth Testing Algorithm (Page 11)\\n3. **Figure 2.3:** HIV Testing Services Algorithm (Page 13)\\n4. **Figure 2.4:** Dual HIV/syphilis Testing Algorithm (Page 15)\\n5. **Figure 2.5:** Managing Patients on ART Who Present with a New Negative HIV Antibody Test (Page 20)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## HIV Testing and Diagnosis\\n\\nThis section covers the algorithms relevant to HIV testing and diagnosis, highlighting the process for infants, children, and dual testing.\\n\\n- **Algorithms for Early Diagnosis:** (Figure 2.1)\\n- **Birth Testing Protocol:** (Figure 2.2)\\n- **General HIV Testing Services:** (Figure 2.3)\\n- **Dual Testing for HIV/Syphilis:** (Figure 2.4)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Care Management for HIV Patients\\n\\nThis section describes the management approaches for patients receiving Antiretroviral Therapy (ART).\\n\\n- **Handling New Negative HIV Antibody Tests:** Management of patients on ART who receive a new negative test (Figure 2.5).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Screening and Assessment\\n\\nThis section focuses on various health screenings and assessments pertinent to HIV-infected patients, including mental health and nutrition.\\n\\n1. **Cryptococcal Meningitis Screening:** Routine screening for HIV-infected adults and adolescents (Figure 4.1).\\n2. **Generalized Anxiety Disorder Assessment:** Tools used to assess anxiety (Figure 4.2).\\n3. **Management of Malnutrition:** Strategies for severe acute malnutrition in children (Figure 4.3) and adults with HIV (Figure 4.4).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Adherence to ART\\n\\nDetailed exploration of patient adherence strategies, monitoring, and support systems for those on ART.\\n\\n1. **Preparation and Support for Adherence:** (Figure 5.1).\\n2. **Counselling for Second or Third Line ART Initiation:** (Figure 5.2).\\n3. **Support for Patients who Default from Care:** (Figure 5.3).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Optimizing ART Regimens\\n\\nA focused review on optimizing ART regimens based on weight and age categories in children and adolescents.\\n\\n1. **For Children and Adolescents < 15 Years Weighing < 30 kg:** (Figure 6.1).\\n2. **For Children and Adolescents ≥ 30 kg or ≥ 15 Years:** (Figure 6.2).\\n3. **Managing Adverse Drug Reactions:** (Figure 6.3).\\n4. **Single Drug Substitutions:** (Figure 6.4).\\n5. **TDF-Associated Kidney Toxicity Management:** (Figure 6.5).\\n6. **Viral Load Monitoring Protocol:** (Figure 6.6).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Tuberculosis Diagnosis\\n\\nThis section features algorithms related to the diagnosis of tuberculosis, especially among people living with HIV.\\n\\n1. **GeneXpert Ultra Algorithm:** (Figure 8.1).\\n2. **Use of TB-LAM for TB Diagnosis in PLHIV:** (Figure 8.2).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nGuidelines and schema for implementing and following up on PrEP for individuals at risk of HIV infection.\\n\\n1. **Package of Services for PrEP:** (Figure 11.1).\\n2. **Follow-Up for Daily Oral PrEP:** (Figure 11.2).\\n3. **Event-Driven PrEP Schema:** (Figure 11.3).\\n4. **Initiation and Follow-Up for Event-Driven PrEP:** (Figure 11.4).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '## Nutritional Services\\n\\nThis section covers various nutritional services aimed at improving health through dietary assessment and support, including specific interventions for patients.\\n\\n### Nutritional Assessment, Counselling and Support (NACS)\\n\\nDetails the process and importance of nutritional assessments and the counselling needed to support individuals in managing their dietary needs effectively.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '## Prevention of Other Infections\\n\\nFocuses on preventative measures against infections, emphasizing the importance of immunization, malaria prevention, and safe water practices.\\n\\n### Immunizations\\n\\nDiscusses the role and importance of immunizations in preventing infectious diseases.\\n\\n### Malaria\\n\\nCovers strategies and interventions for malaria prevention and management.\\n\\n### Safe Water, Sanitation and Hygiene\\n\\nDetails the significance of access to safe water, sanitation practices, and hygiene in preventing infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nExplains the significance of adherence to antiretroviral therapy (ART) and the various strategies employed to prepare and support patients throughout their treatment journey.\\n\\n### Undetectable = Untransmittable (U=U)\\n\\nIntroduces the U=U concept, emphasizing the implications for viral transmission.\\n\\n#### Benefits of U=U\\n\\nHighlights the advantages of understanding and implementing U=U for patients and healthcare providers.\\n\\n#### Considerations for Implementation of U=U within Clinical Settings\\n\\nDiscusses the necessary factors to consider when incorporating U=U into clinical practices.\\n\\n#### Messaging to Patients on U=U\\n\\nOutlines effective communication strategies for conveying the U=U message to patients.\\n\\n#### How Patients Can Discuss U=U with Others\\n\\nGuides patients on how to share the U=U information with their peers.\\n\\n#### Counselling Patients About Other Prevention Combination Interventions\\n\\nAddresses the importance of discussing additional preventive measures alongside U=U.\\n\\n#### Application of U=U in Other Settings\\n\\nExplores potential applications of U=U beyond the clinical environment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### ART Adherence Preparation and Support\\n\\nCovers the preparation and support mechanisms for patients starting antiretroviral therapy.\\n\\n#### Treatment Preparation as Part of HIV Testing Services\\n\\nDetails how treatment preparation integrates with HIV testing.\\n\\n#### ART Treatment Preparation\\n\\nOutlines the steps involved in preparing patients for ART.\\n\\n#### Age-Specific Treatment Preparation and Support\\n\\nFocuses on tailored approaches for different age groups to ensure optimal support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### Adherence Monitoring, Counselling and Support During the First 3 Months of ART\\n\\nEmphasizes the critical initial months of ART where adherence support is crucial.\\n\\n#### Adherence Monitoring\\n\\nDescribes methods for monitoring patient adherence during the early stages of treatment.\\n\\n#### Adherence Counselling and Support During the First 3 Months of ART\\n\\nDiscusses counseling techniques specific to supporting patients in the first three months of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load < 200 copies/ml\\n\\nFocuses on strategies for patients who are managing to suppress their viral load effectively.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral Load ≥ 200 copies/ml\\n\\nAddresses the challenges and support mechanisms for patients who are struggling to suppress their viral load.\\n\\n#### Enhanced Adherence Assessments\\n\\nDetails enhanced assessment techniques for understanding adherence in these patients.\\n\\n#### Enhanced Adherence Counselling\\n\\nOffers counseling strategies tailored to patients with unsuppressed viral load.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### Treatment Preparation for 2nd Line or 3rd Line ART\\n\\nCovers the necessary preparations for patients transitioning to second or third line ART regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### Identifying, Tracing, and Supporting Patients Who Default from Care\\n\\nDiscusses strategies for identifying and supporting patients who disengage from their care plans.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '## Antiretroviral Therapy in Infants, Children, Adolescents, and Adults\\n\\nExplains antiretroviral therapy protocols and considerations across different age groups.\\n\\n### Eligibility for ART\\n\\nDefines the criteria for ART eligibility.\\n\\n### Timing of ART Initiation\\n\\nDiscusses the appropriate timing for starting ART in patients.\\n\\n### First-Line ART for Infants, Children, Adolescents, and Adults (Including Pregnant and Breastfeeding Women)\\n\\nDetails the first-line ART regimens tailored for various demographics, including special considerations for pregnant and breastfeeding women.\\n\\n### Dosing and Administration of Dolutegravir (DTG)\\n\\nOutlines the dosing and administration guidelines for Dolutegravir, a common ART medication.\\n\\n### Monitoring and Changing ART\\n\\nCovers the monitoring processes and criteria for adjusting ART regimens.\\n\\n#### Optimizing Therapy for Patients Who Have Suppressed Viral Load on First Line ART\\n\\nExplores strategies for optimizing therapy for patients who are successfully suppressing their viral load on first-line treatments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## Antiretroviral Therapy (ART) Changes\\n\\n### 6.5.2 Changing ARVs Due to Adverse Drug Reactions\\nDetails on the protocols for changing antiretroviral medications in response to adverse drug reactions.\\n\\n### 6.5.3 Changing ARVs Due to Drug-Drug Interactions\\nGuidelines on modifying ART when drug-drug interactions are identified that could impact treatment efficacy or safety.\\n\\n### 6.5.4 Changing ARVs Due to Treatment Failure\\nInstructions on how to handle situations where patients experience treatment failure requiring changes in their ARV regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\n### 7.1 Antiretroviral Therapy for HIV-positive Pregnant and Breastfeeding Women and Infant Prophylaxis\\nOverview of ART recommendations for HIV-positive pregnant and breastfeeding women, including infant prophylaxis protocols.\\n\\n### 7.2 Syphilis Elimination for Pregnant and Breastfeeding Women and Infant Treatment\\nStrategies and guidelines for eliminating syphilis in pregnant and breastfeeding women, along with treatment for infants.\\n\\n### 7.3 Hepatitis B Elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis\\nProtocols for the elimination of Hepatitis B in mothers and the prophylaxis of infants.\\n\\n### 7.4 Infant and Young Child Nutrition in the Context of HIV\\nGuidelines focusing on nutrition for infants and young children affected by HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## TB/HIV Co-infection, Prevention and Management\\n\\n### 8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)\\nProcedures for screening people living with HIV (PLHIV) for tuberculosis, emphasizing intensified case finding.\\n\\n### 8.2 TB Preventive Therapy (TPT)\\nDetails on TB preventive therapy including:\\n\\n- **8.2.1 Indications for TPT**: When TPT should be initiated.\\n- **8.2.2 Contraindications to TPT**: Situations where TPT should not be given.\\n- **8.2.3 Dose and Duration of TPT**: Recommendations on dosages and treatment timeframes.\\n- **8.2.4 Follow-up of Patients on TPT**: Guidelines for monitoring patients receiving TPT.\\n\\n### 8.3 Identifying and Managing Drug Toxicities from TPT\\nInformation on recognizing and managing adverse effects related to TPT, including:\\n\\n- **8.3.1 Peripheral Neuropathy**: Management of suspected INH-induced peripheral neuropathy.\\n- **8.3.2 Drug-Induced Liver Injury (DILI)**: Identification and management related to specific antituberculosis drugs.\\n- **8.3.3 Management of TPT-associated Rash**: Handling rashes associated with TPT.\\n\\n### 8.4 ART for TB/HIV Co-infection\\nProtocols for administering ART to patients co-infected with TB and HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## HBV/HIV and HCV/HIV Co-infection Prevention and Management\\n\\n### 9.1 Hepatitis B/HIV Co-infection\\nOverview of co-infection management, covering:\\n\\n- **9.1.1 Screening**: Recommended screening processes.\\n- **9.1.2 Prevention**: Preventive measures for HBV in HIV-positive patients.\\n- **9.1.3 Treatment**: Treatment options for HIV and HBV co-infected patients.\\n\\n### 9.2 Hepatitis C/HIV Co-infection\\nOverview of management practices for HCV co-infection, including:\\n\\n- **9.2.1 Screening**: Recommended methods for HCV screening.\\n- **9.2.2 Prevention**: Preventative strategies against HCV for those living with HIV.\\n- **9.2.3 Treatment of HIV/HCV Co-infection**: Treatment protocols applicable to co-infected individuals.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## ARVs for Post-exposure Prophylaxis (PEP)\\n\\n### 10.1 What is PEP?\\nDefinitions and explanations regarding post-exposure prophylaxis for HIV.\\n\\n### 10.2 Recommended ARVs for PEP\\nList and detailing of antiretroviral medications recommended for use in post-exposure prophylaxis.\\n\\n### 10.3 Eligibility For PEP\\nCriteria that must be met for individuals to qualify for PEP.\\n\\n### 10.4 Management and Follow Up\\nGuidelines for the management of patients receiving PEP, including follow-up recommendations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Foreword\\n\\nThis section provides introductory remarks and context for the document.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Acknowledgements\\n\\nThis section expresses gratitude to individuals and organizations that contributed to the development of the document.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Table of Contents\\n\\nThis section lists the contents of the document for easy navigation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## List of Figures\\n\\nThis section details the figures presented within the document, enhancing visual understanding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## List of Tables\\n\\nThis section outlines the tables included in the document for reference and clarity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Acronyms and Abbreviations\\n\\nThis section defines acronyms and abbreviations used throughout the document for improved comprehension.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Summary of Key Recommendations\\n\\nThis section summarizes the crucial recommendations outlined in the document regarding HIV services.\\n\\n### 1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention\\n\\nOverview of essential HTS and the importance of linking individuals to treatment and prevention.\\n\\n### 1.2 Initial Evaluation and Follow-up for PLHIV\\n\\nInsights on the evaluation and follow-up procedures for People Living with HIV (PLHIV).\\n\\n### 1.3 Standard Package of Care for PLHIV\\n\\nDetails on the comprehensive care approach for PLHIV.\\n\\n### 1.4 Adherence Preparation, Monitoring and Support\\n\\nGuidance on the preparation and support needed for adherence to treatment.\\n\\n### 1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults\\n\\nInformation regarding antiretroviral therapy tailored to different age groups.\\n\\n### 1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV\\n\\nStrategies focused on preventing transmission of infections from mother to child.\\n\\n### 1.7 TB/HIV Co-infection Prevention and Management\\n\\nApproaches for preventing and managing co-infection of TB and HIV.\\n\\n### 1.8 HBV/HIV and HCV/HIV Co-infection Prevention and Management\\n\\nDetails on managing and preventing co-infections of HBV/HIV and HCV/HIV.\\n\\n### 1.9 ARVs for Post-exposure Prophylaxis (PEP)\\n\\nInformation about the use of antiretrovirals for PEP after potential exposure to HIV.\\n\\n### 1.10 Pre-Exposure Prophylaxis (PrEP)\\n\\nOverview of PrEP as a preventive measure for at-risk populations.\\n\\n### 1.11 People Who Inject Drugs (PWID) and HIV\\n\\nInsights into the challenges and strategies around HIV in PWID populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## HIV Testing Services and Linkage to Treatment and Prevention\\n\\nThis section details the various facets of HIV testing services and their linkage to treatment.\\n\\n### 2.1 Settings for HIV Testing\\n\\n#### 2.1.1 Facility-based Testing\\n\\nDetails on conducting HIV tests within healthcare facilities.\\n\\n#### 2.1.2 Community-based Testing\\n\\nOverview of HIV testing approaches utilized in community settings.\\n\\n### 2.2 HTS Strategies\\n\\n#### 2.2.1 HIV Self-Testing (HIVST)\\n\\nInformation on the self-testing methodology for HIV.\\n\\n#### 2.2.2 Index Testing\\n\\nExplanation of index testing strategy and its applications.\\n\\n#### 2.2.3 Voluntary Counselling and Testing (VCT)\\n\\nOverview of VCT as a method for HIV testing and counseling.\\n\\n#### 2.2.4 Social Network Strategy (SNS)\\n\\nInsights into the SNS approach for HIV testing outreach.\\n\\n### 2.3 Package of HIV Testing Services\\n\\nComprehensive details on the services included in the HIV testing package.\\n\\n### 2.4 Age-Specific HIV Testing Algorithms\\n\\n#### 2.4.1 Early Infant Diagnosis\\n\\nGuidelines on diagnosing HIV in infants.\\n\\n#### 2.4.2 Diagnosis of HIV Infection in the Older Child, Adolescents, and Adults\\n\\nTesting algorithms for older children, adolescents, and adults.\\n\\n#### 2.4.3 HIV Testing for Pregnant Women\\n\\nSpecific recommendations for HIV testing during pregnancy.\\n\\n### 2.5 Retesting Recommendations for HIV Negative Persons\\n\\nGuidelines on when and how to retest individuals with a negative HIV status.\\n\\n### 2.6 Inconclusive HIV Status\\n\\nProcedures and recommendations for handling inconclusive test results.\\n\\n### 2.7 Approach to Patients on ART with a Discrepant HIV Test Result\\n\\nStrategies for managing patients on antiretroviral therapy who receive conflicting HIV test results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 7,\n",
       "  'section': '## Initial Evaluation and Follow Up\\n\\n### 3.1 Introduction\\nOverview of the importance of initial evaluations and follow-up for People Living with HIV (PLHIV).\\n\\n### 3.2 Initial Clinical Evaluation of PLHIV\\nDetails on how to conduct the initial clinical evaluation for PLHIV to assess their health status.\\n\\n### 3.3 Initial Laboratory Evaluation of PLHIV\\nInformation about the laboratory tests necessary for the initial evaluation of PLHIV.\\n\\n### 3.4 Management of Patients Who Present with Advanced HIV Disease\\nGuidelines for managing patients diagnosed with advanced stages of HIV.\\n\\n### 3.5 Follow-Up of PLHIV after ART Initiation\\nOverview of follow-up care for PLHIV who have started Antiretroviral Therapy (ART).\\n\\n#### 3.5.1 First 6 Months after ART Initiation\\nSpecific guidance on monitoring and care in the initial six months post-ART initiation.\\n\\n#### 3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 Months of ART\\nApproach for care delivery for patients who are more than six months post-ART initiation.\\n\\n### 3.6 Summary of Clinical and Laboratory Monitoring of PLHIV on ART\\nRecap of essential clinical and laboratory monitoring processes for PLHIV undergoing ART.\\n\\n### 3.7 Differentiated Care for Children, Adolescents, and Pregnant/Breastfeeding Women\\nStrategies for providing tailored care for these specific populations of PLHIV.\\n\\n### 3.8 ART Prescription, Dispensing, and Distribution for Clients Established on ART\\nGuidelines for the prescription and distribution of ART to those established on the treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 7,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\n### 4.1 Antiretroviral Therapy\\nOverview of the antiretroviral therapy options available for PLHIV.\\n\\n### 4.2 PHDP, GBV/IPV & HIV Education/Counselling\\nDiscussion on the importance of education and counseling related to HIV, including strategies for integrating GBV/IPV awareness.\\n\\n#### 4.2.1 Screening for Gender-Based Violence (GBV)/Intimate-Partner Violence (IPV)\\nGuidelines for screening and identifying GBV/IPV in PLHIV.\\n\\n#### 4.2.2 HIV Education/Counselling\\nMethods for educating and counseling PLHIV regarding their condition and care.\\n\\n### 4.3 Specific Opportunistic Infection Screening and Prevention\\nStrategies for screening and preventing opportunistic infections in PLHIV.\\n\\n#### 4.3.1 Cotrimoxazole Preventive Therapy (CPT)\\nInformation on the use of CPT for the prevention of specific infections.\\n\\n#### 4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV\\nGuidelines on the prevention and management of TB in PLHIV.\\n\\n#### 4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment\\nApproach to screening and treating CM in PLHIV.\\n\\n### 4.4 Reproductive Health Services\\nOverview of reproductive health services available for PLHIV.\\n\\n#### 4.4.1 Sexually Transmitted Infections\\nGuidelines for managing STIs among PLHIV.\\n\\n#### 4.4.2 Family Planning and Pre-Conception Counselling\\nInformation on family planning options and pre-conception counseling for PLHIV.\\n\\n#### 4.4.3 Maternal Healthcare\\nGuidelines for ensuring maternal healthcare for pregnant and breastfeeding women living with HIV.\\n\\n### 4.5 Non-communicable Diseases Screening and Management\\nOverview of screening and management of non-communicable diseases among PLHIV.\\n\\n#### 4.5.1 Metabolic Disorders\\nInformation on the management of metabolic disorders in PLHIV.\\n\\n#### 4.5.2 Cancer Prevention, Early Detection and Management among PLHIV\\nStrategies for cancer prevention and management in the context of HIV.\\n\\n### 4.6 Mental Health Screening and Management\\nApproaches for screening and managing mental health issues among PLHIV.\\n\\n#### 4.6.1 Depression\\nGuidelines for identifying and managing depression in PLHIV.\\n\\n#### 4.6.2 Alcohol and Drug Use/Addiction\\nStrategies for addressing substance abuse issues in PLHIV.\\n\\n#### 4.6.3 Anxiety\\nManagement strategies for anxiety disorders in PLHIV.\\n\\n#### 4.6.4 Stress and Stress Management\\nInformation on stress management techniques for PLHIV.\\n\\n#### 4.6.5 Experiences of Trauma\\nGuidelines for addressing trauma experiences among PLHIV.\\n\\n#### 4.6.6 Psychosis\\nApproaches to manage psychosis in the context of HIV.\\n\\n#### 4.6.7 Self-Care\\nInformation on self-care practices for improving wellbeing among PLHIV.\\n\\n#### 4.6.8 Wellbeing\\nStrategies for promoting overall wellbeing in PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': '## Summary of Key Recommendations\\n\\nAn overview of the critical suggestions and guidelines for the management of HIV testing and care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': '## HIV Testing Services (HTS) and Linkage to Treatment and Prevention\\n\\n- **Voluntary Testing**: HIV testing should be voluntary, ethical, and conducted in environments that ensure Consent, Confidentiality, Counseling, Correct results, Connection (linkage), and Creating an enabling environment.\\n- **Testing Settings**: HIV testing can be conducted in:\\n  - Facility-based settings\\n  - Community-based settings\\n- **Targeted Testing**: Implement targeted HIV testing through:\\n  - Index client listing of contacts\\n  - HIV self-testing\\n  - HTS screening tools to identify individuals at risk of HIV infection as eligible for testing.\\n- **Serial Testing**: Utilize approved rapid HIV antibody testing kits to diagnose HIV infection in:\\n  - Children older than 18 months\\n  - Adolescents\\n  - Adults\\n  - An HIV-positive diagnosis will be made using three consecutive reactive assays.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': '## Initial Evaluation and Follow-up for PLHIV\\n\\n- **Initial Clinical Evaluation**: Key components of initial clinical evaluation for People Living with HIV (PLHIV) include:\\n  - CD4 monitoring is essential for:\\n    - Baseline investigation for all PLHIV\\n    - Patients with suspected treatment failure\\n    - Those returning to care after interrupting treatment for more than three months\\n    - Patients on fluconazole maintenance therapy or dapsone for prophylaxis.\\n- **Advanced HIV Disease (AHD)**: Defined as:\\n  - Adults, adolescents, and children aged five years and older with a CD4 cell count of less than 200 cells/mm³, or\\n  - WHO clinical stage 3 or 4 disease, or\\n  - All children younger than five years old.\\n- **Care Package for AHD**: All PLHIV presenting with AHD should receive a comprehensive package of care, including:\\n  - Timely initiation of ART\\n  - Screening\\n  - Diagnosis and management of opportunistic infections\\n  - Prophylaxis as needed.\\n- **Viral Load (VL) Monitoring**: Frequency of routine VL monitoring is as follows:\\n  - For PCR positive HIV-exposed infants (HEIs): at baseline during ART initiation.\\n  - For ages 0-24 years: 3 months after ART initiation, then every 6 months.\\n  - For ages ≥ 25 years: 3 months after ART initiation, then at month 12, and then annually.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Risk Reduction Counseling\\n\\nThis section covers the strategies and methods implemented in risk reduction counseling to help individuals minimize their risk of HIV exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Preventing HIV Exposure\\n\\nDetails preventive measures and practices aimed at reducing the likelihood of HIV transmission.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nAn overview of Pre-Exposure Prophylaxis, including its purpose and how it is used to prevent HIV.\\n\\n### Indications for PrEP and Criteria for Eligibility\\n\\nThis sub-section outlines the specific medical indications for PrEP and the criteria that determine whether an individual is eligible to receive it.\\n\\n#### Indications for PrEP\\n\\nExplains the various situations in which PrEP is recommended for individuals at risk of HIV.\\n\\n#### HIV Risk Assessment\\n\\nDescribes the process of assessing an individual’s risk for HIV infection to determine the need for PrEP.\\n\\n#### Criteria for PrEP Eligibility\\n\\nDetails the specific medical and risk factors that must be evaluated to qualify someone for PrEP.\\n\\n### Package of PrEP Service\\n\\nCovers the comprehensive package of services associated with PrEP.\\n\\n#### Pre-Initiation Checklist\\n\\nA checklist for healthcare providers to ensure all necessary steps are taken before initiating PrEP.\\n\\n#### Pre-Initiation Client Education\\n\\nDetails educational components provided to clients prior to starting PrEP.\\n\\n### Recommended ARVs for PrEP\\n\\nInformation on the antiretroviral medications recommended for use in PrEP.\\n\\n### Schema for Follow-up for Daily Oral PrEP\\n\\nProvides a structured follow-up schedule for patients on daily oral PrEP.\\n\\n### Event-Driven PrEP (On Demand PrEP or 2+1+1 PrEP)\\n\\nDescribes the alternative dosing strategy for PrEP known as event-driven or on-demand PrEP.\\n\\n### Managing Clinical and Laboratory Results on Initial and Follow-Up Assessment\\n\\nGuidelines on how to manage the clinical and laboratory results obtained during initial and follow-up assessments for PrEP users.\\n\\n### Contra-indications to Oral PrEP (Daily or ED PrEP)\\n\\nLists the medical conditions and factors that would contraindicate the use of oral PrEP.\\n\\n### Criteria for Discontinuing Oral PrEP\\n\\nDescribes when and why PrEP should be discontinued based on patient health and circumstances.\\n\\n### Restarting PrEP\\n\\nGuidelines for restarting PrEP after discontinuation.\\n\\n### Improving Adherence to PrEP\\n\\nStrategies and techniques to help ensure that patients adhere to their PrEP regimen effectively.\\n\\n### Monitoring Sero-conversion among PrEP Users\\n\\nExplains the process and importance of monitoring for HIV sero-conversion in individuals who are using PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## People Who Inject Drugs (PWID) and HIV\\n\\nAn overview of the intersection between injection drug use and HIV infection, including specific challenges and considerations for this population.\\n\\n### ART in HIV Positive PWID\\n\\nDiscusses antiretroviral therapy (ART) specifically tailored for people who inject drugs and are HIV positive.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Annexes\\n\\nA collection of annexes that provide additional resources and information related to HIV care.\\n\\n### Annex 1: WHO Clinical Staging of HIV Infection in Infants and Children\\n\\nDetails the clinical staging criteria for HIV infection specifically in infants and children.\\n\\n### Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults\\n\\nInformation on how HIV infection is staged in adolescents and adults.\\n\\n### Annex 3: Normal Developmental Milestones in Children\\n\\nOutlines the developmental milestones that are considered normal for children.\\n\\n### Annex 4: Tanner Staging of Sexual Maturity in Adolescents\\n\\nDetails the Tanner stages that assess sexual maturity in adolescents.\\n\\n#### Annex 4 A: Tanner Staging of Sexual Maturity in Girls\\n\\nSpecific criteria for assessing sexual maturity in girls.\\n\\n#### Annex 4 B: Tanner Staging of Sexual Maturity in Boys\\n\\nSpecific criteria for assessing sexual maturity in boys.\\n\\n### Annex 5: Age-Appropriate Disclosure for Children and Adolescents\\n\\nGuidelines on how to appropriately disclose HIV status to children and adolescents.\\n\\n### Annex 6: Transitioning from Adolescent to Adult HIV Services\\n\\nDiscusses the importance and methods for transitioning young patients from adolescent-specific HIV services to adult services.\\n\\n### Annex 7: 2018 HIV Testing Services Algorithm\\n\\nPresents a flowchart or algorithm to guide HIV testing services.\\n\\n### Annex 8: HIV Education and Adherence Counseling Content Guide\\n\\nProvides a framework for educating patients and offering counseling to promote adherence to HIV treatment.\\n\\n### Annex 9 A: Enhanced Adherence Counseling Content Guide\\n\\nA more in-depth guide on counseling practices aimed at enhancing medication adherence.\\n\\n### Annex 9 B: Case Summary Form\\n\\nA form used for summarizing specific cases in the context of HIV care.\\n\\n### Annex 9 C: Enhanced Adherence Counseling Form\\n\\nA structured form for documenting adherence counseling sessions.\\n\\n### Annex 9 D: Home Visit Checklist\\n\\nA checklist for healthcare providers to follow during home visits for patients receiving HIV care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## HIV Testing Services\\n\\nThis section covers the recommendations for HIV testing services (HTS) tailored to different populations and settings, as well as an overview of the HIV Testing Services Package.\\n\\n- **Table 2.1**: HTS Recommendations for Different Populations and Settings (Page 3)\\n- **Table 2.2**: Summary of HIV Testing Services Package (Page 6)\\n- **Table 2.3**: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results (Page 10)\\n- **Table 2.4**: Approaches to Improve Linkage to Treatment and Prevention Services (Page 16)\\n- **Table 2.5**: Recommendations for Retesting HIV Negative Clients (Page 18)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Clinical Evaluation for People Living with HIV (PLHIV)\\n\\nThis section describes the initial clinical evaluations and necessary laboratory investigations for individuals diagnosed with HIV.\\n\\n- **Table 3.1**: Initial Clinical Evaluation for PLHIV (History and Physical Examination) (Page 2)\\n- **Table 3.2**: Baseline Laboratory Investigations for PLHIV (Page 4)\\n- **Table 3.3**: Differentiated Care Based on Initial Patient Presentation (Page 7)\\n- **Table 3.4**: Management of Patients Who Are Presenting Well (WHO Stage 1 or 2, and CD4 count > 200 cell/mm³) (Page 8)\\n- **Table 3.5**: Differentiated Follow-up of Patients Beyond the First 6 Months of ART (Page 9)\\n- **Table 3.6**: Summary of Clinical and Laboratory Monitoring for PLHIV (Page 11)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Comprehensive Care for PLHIV\\n\\nThis section outlines the components of care provided to people living with HIV, including preventive measures and management strategies.\\n\\n- **Table 4.1**: Components of the Standard Package of Care for PLHIV (Page 2)\\n- **Table 4.2**: Domains and Components for PHDP Services (Page 5)\\n- **Table 4.2a**: Components of Screening for GBV/IPV (LIVES) (Page 7)\\n- **Table 4.3**: Co-trimoxazole Preventive Therapy (Page 8)\\n- **Table 4.4**: Daily Dose of Cotrimoxazole Preventive Therapy (Page 9)\\n- **Table 4.5**: Management of Drug-Associated Skin Rash (Page 9)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Management of Specific Health Conditions\\n\\nThis section provides guidelines for managing co-morbid conditions and specific health issues faced by PLHIV.\\n\\n- **Table 4.6a**: Standard Cotrimoxazole Desensitization Regimen (8 days) (Page 10)\\n- **Table 4.6b**: Rapid Cotrimoxazole Desensitization Regimen (6 hours) (Page 10)\\n- **Table 4.7**: Treatment of Cryptococcal Meningitis (Page 12)\\n- **Table 4.8**: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria (Page 16)\\n- **Table 4.9**: Pre-Conception Counselling Messages and Services for PLHIV (Page 17)\\n- **Table 4.10**: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV (Page 19)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Screening and Management of Non-Communicable Diseases\\n\\nThis section deals with screening and initial management strategies for non-communicable diseases relevant to PLHIV.\\n\\n- **Table 4.11**: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV (Page 20)\\n- **Table 4.12**: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV (Page 21)\\n- **Table 4.12**: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV (Page 22)\\n- **Table 4.13**: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV (Page 23)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Mental Health and Substance Use Screening\\n\\nThis section focuses on mental health assessments and substance use screenings for PLHIV.\\n\\n- **Table 4.15**: Patient Health Questionnaire -9 (PHQ-9) for Depression Screening (Page 26)\\n- **Table 4.16**: CRAFFT Screening Interview for Adolescents (Page 28)\\n- **Table 4.17**: CAGE-AID Screening Questions for Adults (Page 29)\\n- **Table 4.18**: Addiction Support Based on Stages of Change (Page 30)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Nutritional Assessments and Interpretations\\n\\nThis section outlines the methodologies for nutritional assessments specific to various demographics, including children and pregnant or lactating women.\\n\\n- **Table 4.19**: Interpretation of MUAC Results for Children and Pregnant/Lactating Women (Page 37)\\n- **Table 4.20**: Interpretation of Z-scores for Children (Page 37)\\n- **Table 4.21**: Interpretation of BMI Results for Adults (Page 40)\\n- **Table 4.22**: Kenya Expanded Program on Immunizations 2016 Schedule (Page 40)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines Overview\\n\\nThis section provides a general overview of the Kenya HIV Prevention and Treatment Guidelines for 2022, outlining key requirements for the evaluation and management of people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '## Monitoring and Follow-Up for Pregnant or Breastfeeding Women\\n\\n- Pregnant or breastfeeding individuals should undergo evaluation at the confirmation of pregnancy if already on Antiretroviral Therapy (ART) or three months after initiating ART.\\n- Subsequent evaluations should happen every six months until the complete cessation of breastfeeding.\\n- Drug substitution should only occur if there is no viral load (VL) result available from the prior six months or three months after any regimen modification.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '## Differentiated Care for PLHIV\\n\\nPLHIV should receive differentiated care based on:\\n- Initial evaluation (advanced vs. well) \\n- Follow-up status (established vs. not established on ART)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis package consists of eight components aimed at providing comprehensive care and support to PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '### 1. Antiretroviral Therapy (ART)\\n\\n- All PLHIV are eligible for ART, irrespective of CD4 cell count, WHO clinical stage, age, pregnancy status, or comorbidities.\\n- ART should be initiated as soon as the patient is ready, preferably within two weeks of HIV diagnosis (with exceptions for specific conditions like cryptococcal meningitis or TB meningitis).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '### 2. Positive Health, Dignity, and Prevention\\n\\n- Patients should receive counseling and support for:\\n  - Disclosure of HIV status\\n  - Partner/family testing and engagement\\n  - Condom use\\n  - Family planning\\n  - Screening for sexually transmitted infections\\n  - Treatment adherence\\n  - Pre-exposure prophylaxis for HIV-negative sexual partners\\n- Females aged 15-49 years and emancipated minors should be screened for Intimate Partner Violence (IPV) as part of this care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '### 3. Education and Counseling\\n\\n- All PLHIV should be provided with comprehensive HIV education and counseling as part of the standard package of care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '### 4. Screening for and Prevention of Specific Opportunistic Infections\\n\\n- Cotrimoxazole Preventive Therapy (CPT) is no longer recommended as lifelong prophylaxis and is advised for specific subpopulations, unless they have an allergy to sulfur drugs or develop toxicity from it:\\n    - HIV Exposed Infants\\n    - HIV-infected children under 15 years of age\\n    - All PLHIV over 15 years of age living in malaria-endemic zones, presenting with WHO stage 3 or 4 events, suspected treatment failure, or who are pregnant/breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## HIV Prevention and Treatment Guidelines Overview\\n\\nThis section provides a general overview of the guidelines for HIV prevention and treatment in Kenya, including background information and objectives.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Complementary Foods for Children 6 -24 Months Old\\n\\n### Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nA comprehensive list of recommended complementary foods suitable for children aged 6 to 24 months old to support nutritional needs while managing HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Tuberculosis (TB) Diagnosis in Children\\n\\n### Table 8.1: TB Diagnosis in Children <10 Years Old  \\nDetailing the diagnostic criteria and methods applicable for diagnosing TB in children under 10 years old.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## TB Treatment Regimens\\n\\n### Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents, and Adults  \\nOutlining the standard treatment regimen for individuals of varying ages diagnosed with drug-susceptible TB.\\n\\n### Table 8.3: Recommended TPT Regimens for PLHIV  \\nSummarizing the recommended Tuberculosis Preventive Therapy (TPT) regimens specifically for People Living with HIV (PLHIV).\\n\\n### Table 8.4: Grading and Management of DILI  \\nGuidelines on grading and managing Drug-Induced Liver Injury (DILI) associated with TB treatment.\\n\\n### Table 8.5: Management of TPT-Associated Skin Rash  \\nRecommendations for managing skin rashes in patients on TPT.\\n\\n### Table 8.6: Preferred ART Regimens for TB/HIV Co-infection for Patients Newly Initiating 1st Line ART  \\nThe preferred antiretroviral therapy (ART) regimens for patients who are newly starting ART while being co-infected with TB.\\n\\n### Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART  \\nInformation on ART regimens for patients who develop TB while already on suppressive ART.\\n\\n### Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART  \\nAddressing ART options for patients failing first-line treatment and subsequently diagnosed with TB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Hepatitis B and Co-infection Management\\n\\n### Table 9.1: Hepatitis B Vaccination Schedule for HIV-positive Adolescents and Adults  \\nVaccination schedule for administering Hepatitis B vaccines to HIV-positive individuals.\\n\\n### Table 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co-infection  \\nInitial assessment guidelines for patients co-infected with HIV and Hepatitis B virus (HBV).\\n\\n### Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function  \\nGuidance on how to adjust medication dosages for patients with renal impairment.\\n\\n### Table 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co-infection  \\nAssessment protocols for patients co-infected with HIV and Hepatitis C virus (HCV).\\n\\n### Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nRecommended Direct-Acting Antivirals (DAA) for treating HCV in PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Post-Exposure Prophylaxis (PEP)\\n\\n### Table 10.1: Recommended ARVs for PEP  \\nA list of antiretrovirals recommended for post-exposure prophylaxis.\\n\\n### Table 10.2: Recommendations for PEP Management and Follow-up  \\nSteps and considerations for managing PEP in patients.\\n\\n### Table 10.3: Considerations for Special Circumstances  \\nGuidelines for handling PEP in unique or special scenarios.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## HIV Screening and Initial Assessment\\n\\n### Table 11.1: HIV Screening Questions  \\nKey screening questions to assess HIV risk and status.\\n\\n### Table 11.2: Pre-Initiation Assessment Checklist  \\nA checklist for assessing patients before initiating ART.\\n\\n### Table 11.3: Client Education Checklist  \\nChecklist for educating clients about HIV, treatment options, and self-care.\\n\\n### Table 11.4: Antiretrovirals for Use in PrEP  \\nList of antiretrovirals available for Pre-Exposure Prophylaxis (PrEP).\\n\\n### Table 11.5: Initial & Follow-up Laboratory Tests  \\nInitial and follow-up laboratory tests required for patients considering or on ART.\\n\\n### Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow-up Assessment  \\nHow to manage and interpret clinical and laboratory results during assessments.\\n\\n### Table 11.7: Summary of PrEP Initial and Follow-up Assessment  \\nOverview of initial and follow-up assessment criteria for individuals on PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Harm Reduction for People Who Inject Drugs (PWID)\\n\\n### Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nAn overview of interventions and strategies designed to reduce harm among individuals who inject drugs.\\n\\n### Table 12.2: Summary of ART Recommendations for PWID  \\nRecommended ART protocols for people who engage in injecting drug use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 21,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\n- The adherence preparation, monitoring, and support required by a patient should be tailored to their level of adherence and the stage of ART initiation and follow-up.\\n- All patients with durable viral suppression (2 consecutive viral load results with < 50 copies) should be offered messaging on Undetectable=Untransmittable (U=U).\\n- Follow-up should preferably be provided by the same care provider or team at every visit, especially during the first 3 months of care.\\n- The level of disclosure for all children/adolescents should be assessed during the first visit, with ongoing care including a plan for age-appropriate disclosure.\\n- All patients are at risk of new or worsening barriers to adherence; thus, monitoring, counselling, and support should continue even post-viral suppression.\\n- Service delivery points providing ARVs must have a system to identify missed appointments and take action within 24 hours.\\n- In cases of ART failure, regimens should not be changed until the reasons for treatment failure are identified and addressed urgently.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 21,\n",
       "  'section': '## Antiretroviral Therapy for Infants, Children, Adolescents, and Adults\\n\\n- The goal of ART is to suppress viral replication to reduce the patient’s viral load (VL) to undetectable levels (<50 copies/LDL).\\n- All individuals with confirmed HIV infection are eligible for ART, regardless of CD4 count, WHO clinical stage, age, pregnancy or breastfeeding status, co-infections, risk group, or other criteria, as long as they are willing and ready to start ART.\\n- ART should be initiated as soon as possible, ideally on the same day as confirming the HIV diagnosis and preferably within 2 weeks.\\n- Preferred first-line ART regimens are:\\n  - Birth to 4 weeks: AZT + 3TC + NVP\\n  - > 4 weeks to < 15 years:\\n    - < 30 kg: ABC + 3TC + DTG\\n    - ≥ 30 kg: TDF + 3TC + DTG\\n  - ≥ 15 years: TDF + 3TC + DTG\\n- Children and adolescents who are virally suppressed but not on the preferred first-line ART regimen should be assessed for and transitioned to the preferred regimen.\\n- Treatment failure is suspected when a patient has a VL ≥ 1000 copies/ml after at least 3 months on ART. Confirmation of treatment failure occurs with a VL ≥ 1000 copies/ml after assessing for adherence issues and repeating the VL after at least 3 months of excellent adherence to allow for viral re-suppression.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Acronyms and Definitions\\n\\nThis section provides a list of acronyms commonly used in the Kenya HIV Prevention and Treatment Guidelines along with their definitions. Understanding these terms is crucial for healthcare providers and individuals involved in HIV prevention and treatment.\\n\\n- CHV: Community Health Volunteer\\n- CITC: Client-Initiated HIV Testing and Counselling\\n- CM: Cryptococcal Meningitis\\n- CMV: Cytomegalovirus\\n- CNS: Central Nervous System\\n- CPT: Cotrimoxazole Preventive Therapy\\n- CrCl: Creatinine Clearance\\n- PEP: Post-Exposure Prophylaxis\\n- CTX: Cotrimoxazole\\n- PrEP: Pre-Exposure Prophylaxis\\n- CYP450: Cytochrome P450\\n- DAAs: Direct Acting Antiviral Therapies\\n- DBS: Dried Blood Spot\\n- DICEs: Drop-In-Centres\\n- DMS: Director of Medical Services\\n- DNA: Deoxyribonucleic Acid\\n- DOT: Directly Observed Therapy\\n- DRT: Drug Resistance Testing\\n- EID: Early Infant Diagnosis\\n- eMTCT: Elimination of Mother to Child Transmission\\n- FBC: Full Blood Count\\n- FTC: Emtricitabine\\n- GIT: Gastrointestinal Tract\\n- GOK: Government of Kenya\\n- GBV: Gender-Based Violence\\n- Hb: Hemoglobin\\n- HCV: Hepatitis C Virus\\n- HCW: Health Care Worker\\n- HEI: HIV Exposed Infant\\n- HIV: Human Immunodeficiency Virus\\n- HIVST: HIV Self-testing\\n- WHO: World Health Organization'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': \"## Key Concepts in HIV Treatment\\n\\nThis section focuses on important concepts relevant to the treatment and prevention of HIV. Healthcare providers should be well-versed in these topics to ensure effective patient management.\\n\\n- **PrEP (Pre-Exposure Prophylaxis)**: Medication taken by HIV-negative individuals to reduce the risk of contracting HIV.\\n- **PEP (Post-Exposure Prophylaxis)**: Emergency medication taken after possible exposure to HIV to prevent infection.\\n- **CPT (Cotrimoxazole Preventive Therapy)**: A therapy used to prevent opportunistic infections in people living with HIV.\\n- **Viral Load (VL)**: A measure of the amount of HIV in a person's blood, important for monitoring the effectiveness of treatment.\\n- **Drug Resistance Testing (DRT)**: Testing to determine if the virus has developed resistance to certain antiretroviral drugs.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Testing and Diagnosis\\n\\nHere, we cover the different types of testing and diagnostic measures implemented to identify HIV and related infections, essential for timely intervention.\\n\\n- **HIV Testing**:\\n  - **CITC**: Client-initiated testing where individuals seek HIV testing on their own.\\n  - **PITC**: Provider-initiated testing where health care providers offer testing to clients.\\n  - **HIVST**: Self-testing kits that allow individuals to test themselves for HIV.\\n\\n- **Early Infant Diagnosis (EID)**: Testing infants exposed to HIV shortly after birth to determine their HIV status.\\n\\n- **Additional Tests**:\\n  - **FBC (Full Blood Count)**: Assesses blood health including immune status.\\n  - **sCrAg (Serum Cryptococcal Antigen)**: Testing for cryptococcal meningitis risk in PLHIV.\\n  - **RNA (Ribonucleic Acid)**: Used in viral load testing to assess the level of HIV in the blood.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Health and Support Services\\n\\nThis section outlines the services and support systems available to individuals affected by HIV, including treatment and counseling options.\\n\\n- **Community Health Volunteer (CHV)**: Trained individuals providing education, counseling, and referral services to communities.\\n- **Drop-In-Centres (DICEs)**: Centers providing services to key populations, including testing, treatment, and psychosocial support.\\n- **Opioid Substitution Therapy (OST)**: A treatment for individuals with substance use disorders, particularly those who inject drugs (PWID).\\n\\n- **Positive Health, Dignity, and Prevention (PHDP)**: An approach that encourages PLHIV to lead healthy lives while preventing the transmission of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Preventive Measures\\n\\nThis section focuses on measures to prevent the transmission of HIV and other sexually transmitted infections (STIs).\\n\\n- **Voluntary Medical Male Circumcision (VMMC)**: A preventive surgical procedure that reduces the risk of HIV transmission in men.\\n- **Family Planning (FP)**: Services that provide education and resources for reproductive health, crucial for preventing unintended pregnancies among those living with HIV.\\n- **Emergency Contraceptive Pill (ECP)**: A method to prevent pregnancy after unprotected sex, relevant for sexually active individuals.\\n\\n- **Prevention of Mother-to-Child Transmission (PMTCT)**: Strategies aimed at preventing the transmission of HIV from an infected mother to her child during pregnancy, childbirth, or breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Vaccinations in Adolescents and Adults Living with HIV\\n\\nTable 4.23: Vaccinations in Adolescents and Adults Living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Treatment Preparation and Adherence Counselling Guide\\n\\nTable 5.1: Treatment Preparation and Adherence Counselling Guide.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Components of HIV Education\\n\\nTable 5.2: Components of HIV Education (see Annex 8 for detailed content guide).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Adherence Support and Retention Interventions\\n\\nTable 5.3: Adherence Support and Retention Interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## ART Readiness Assessment\\n\\nTable 5.4: ART Readiness Assessment Form.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Involvement of Child/Adolescent in HIV Education\\n\\nTable 5.5: Age-appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Unique Considerations for Caregivers, Children, and Adolescents\\n\\nTable 5.6: Unique Considerations for Caregivers, Children, and Adolescents.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Treatment Preparation and Support for Children\\n\\nTable 5.7: Treatment Preparation and Support for Children (≤ 9 years) and Caregivers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Treatment Preparation and Support for Adolescents\\n\\nTable 5.8: Treatment Preparation and Support for Adolescents (10-19 years).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Treatment Preparation and Support for Adults\\n\\nTable 5.9: Treatment Preparation and Support for Adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Adherence Monitoring Strategies\\n\\nTable 5.10: Adherence Monitoring Strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Morisky Medication Adherence Scale\\n\\nTable 5.11: Morisky Medication Adherence Scale (MMAS-4).\\n\\nTable 5.12: Morisky Medication Adherence Scale (MMAS-8).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Adherence Rates Based on Pill Counts\\n\\nTable 5.13: Adherence Rate Based on Pill Counts.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Adherence Counselling in the First 3 Months of ART\\n\\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Assessment for Barriers to Adherence\\n\\nTable 5.15: Assessment for Barriers to Adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Adherence Support for Patients with Low Viral Load\\n\\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Viral Load Monitoring\\n\\nTable 5.17: Viral Load Monitoring Cut-Offs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Enhanced Adherence Counselling Sessions\\n\\nTable 5.18: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed content guide).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Timing of ART Initiation\\n\\nTable 6.1: Special Considerations for Timing of ART Initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Preferred First-Line ART Regimens\\n\\nTable 6.2: Preferred First-Line ART Regimens and Dosing for Children, Adolescents, and Adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Use of Alternative ARVs\\n\\nTable 6.3: Use of Alternative ARVs in First-Line Regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Dosing and Administration of Dolutegravir\\n\\nTable 6.4: Dosing and Administration of Dolutegravir.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Common Significant Adverse Drug Reactions\\n\\nTable 6.5: Common Significant Adverse Drug Reactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## ARV Adjustments in Impairment\\n\\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Management of AZT-Associated Bone Marrow Suppression\\n\\nTable 6.7: Management of AZT-Associated Bone Marrow Suppression.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Management of Drug-Related Hepatotoxicity\\n\\nTable 6.8: Management of Drug-Related Hepatotoxicity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Abacavir Hypersensitivity Reaction\\n\\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Recommended Second-Line ART Regimens\\n\\nTable 6.10: Recommended Second-Line ART Regimens in Infants, Children, Adolescents, and Adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Possible Third-Line ART Options\\n\\nTable 6.11: Possible Third-Line ART in Children, Adolescents, and Adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Antenatal Care for HIV Positive Women\\n\\nTable 7.1: Essential Package of Antenatal Care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Use of ART in Pregnant and Breastfeeding Women\\n\\nTable 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## ARV Prophylaxis for HIV-Exposed Infants\\n\\nTable 7.3: ARV Prophylaxis for HIV-Exposed Infants.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Dosing of ARVs for Infant Prophylaxis\\n\\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age.\\n\\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age.\\n\\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 23,\n",
       "  'section': '## HIV Testing and Prophylaxis for Infants\\n\\n- All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact thereafter. If the result is negative, another DNA PCR should be conducted at 6 months, and if that is also negative, a repeat DNA PCR at 12 months is required.\\n- All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP. After this period, NVP should be continued until 6 weeks after complete cessation of breastfeeding.\\n- All infants, regardless of HIV status, should be exclusively breastfed for the first 6 months of life. Appropriate complementary foods should be introduced at 6 months, and breastfeeding should continue up to 24 months or beyond.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 23,\n",
       "  'section': '## TB/HIV Co-infection Prevention and Management\\n\\n- All healthcare settings must implement TB infection control recommendations to mitigate the risk of TB transmission among patients, visitors, and staff.\\n- Symptom-based TB screening using the ICF tool is mandatory for all PLHIV at every clinic visit:\\n  - Patients who screen negative should be assessed for and provided with TB preventive therapy (TPT).\\n  - Patients who screen positive (presumptive TB) must undergo definitive diagnostic pathways.\\n- The GeneXpert Ultra MTB/Rif test is the recommended method for diagnosing TB and rifampicin resistance in all presumptive TB cases.\\n- TB-LAM can serve as an adjunct rapid point-of-care diagnostic test for PLHIV with advanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm³, or CD4% ≤ 25% for children ≤ 5 years) with presumptive TB, any signs of severe illness, or those currently admitted to the hospital.\\n- Patients diagnosed with TB/HIV co-infection should start anti-TB treatment immediately and initiate ART as soon as anti-TB medications are well-tolerated, preferably within 2 weeks. However, if they have TB meningitis, ART should be deferred for 4 to 8 weeks.\\n- Patients already on ART who develop TB should begin anti-TB treatment immediately while continuing ART, adjusting the regimen as necessary based on drug-drug interactions and monitoring for toxicity.\\n- Always assess for ART failure in patients who develop TB after being on ART for 6 months or more.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 26,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and prevention services such as voluntary medical male circumcision (VMMC), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and other combination HIV prevention services. This initial step also creates opportunities for offering other interventions, including sexual and reproductive health services (SRH), TB screening and referral, and substance abuse screening and referral.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 26,\n",
       "  'section': '## Ethical Principles in HIV Testing\\n\\nHIV testing should be voluntary and conducted ethically, adhering to the six Cs principles: Consent, Confidentiality, Counseling, Correct results, Connection (linkage) to care, and creating an enabling environment. Targeted HIV testing is a strategic shift that involves index client listing of contacts, HIV self-testing, and using HIV screening tools to identify at-risk individuals for testing, aside from cases involving PMTCT (prevention of mother-to-child transmission) and key populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 26,\n",
       "  'section': '## Settings for HIV Testing\\n\\nIn Kenya, HTS is delivered in two primary settings: facility-based and community-based settings.\\n\\n### Facility-based Testing\\n\\n- The HTS screening tool should be used to prioritize testing for individuals at risk of HIV infection, including those diagnosed with sexually transmitted infections, those with multiple sexual partners, key populations, and individuals with known HIV exposures.\\n- Providers should perform thorough risk assessments using validated NASCOP screening tools (Annex 17) to identify clients at risk and those eligible for HIV tests.\\n- HTS should only be offered to clients who consent; those who are not eligible for testing should receive HIV prevention messages and be offered appropriate services.\\n- Clients who test HIV positive should be linked to care, while those who test negative should be connected to HIV prevention services.\\n- Patients starting HIV care should receive disclosure counseling and support and be offered testing for family, sexual, and needle-sharing partners.\\n\\nHIV testing services should be integrated into care pathways at all service delivery points, including adult and pediatric inpatient units, outpatient units, maternal and child health clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender-based violence (GBV) care units, and service delivery points for key and priority populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Key Recommendations for Prophylaxis and Screening\\n\\n- **PCP Prophylaxis**: Dapsone is recommended for patients in WHO Stage 4 and/or with an absolute CD4 count ≤ 200 cells/mm³ (or CD4% ≤ 25% for children ≤ 5 years old). It should be discontinued once viral suppression and a sustained CD4 count of > 200 cells/mm³ (or > 25% for children ≤ 5 years old) is achieved for at least 6 months.\\n  \\n- **TB Screening**: All People Living with HIV (PLHIV) should be screened for TB at every visit using the Intensified Case Finding (ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB.\\n\\n- **Cryptococcal Infection Screening**: All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm³ should be screened for cryptococcal infection using the serum CrAg test.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Reproductive Health Services\\n\\n- **STI Screening**: All PLHIV should be screened for sexually transmitted infections (STIs) at every clinic visit.\\n\\n- **Pregnancy Status**: Pregnancy status should be assessed for all women of reproductive age at each visit, along with their contraception needs.\\n\\n- **Cervical Cancer Screening**: HIV-positive women aged 18 - 65 years should be screened for cervical cancer with HPV testing every 2 years or annually if using VIA-VILI.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Screening for Non-Communicable Diseases\\n\\n- **Annual Screening**: All PLHIV should be screened annually for hypertension, diabetes mellitus, dyslipidemia, and renal disease.\\n\\n- **Cancer Screening**: Routine screening should be provided for the early detection of cervical cancer, breast cancer, bowel cancer, and prostate cancer.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Mental Health Screening and Management\\n\\n- **Depression and Anxiety Screening**: All PLHIV should undergo basic screening for depression and anxiety before initiating Antiretroviral Therapy (ART) and annually thereafter, or whenever there is a clinical suspicion.\\n\\n- **Support Structures**: PLHIV should be linked with support structures to maintain general well-being and address mental health issues.\\n\\n- **Substance Use Screening**: Adults and adolescents should be screened for alcohol and drug use before starting ART and regularly during follow-up.\\n\\n- **Caregiver Screening**: Caregivers should also receive baseline and follow-up screenings for depression and alcohol/drug use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Nutrition Services\\n\\n- **Nutritional Assessment**: All PLHIV should receive nutritional assessment, counseling, and support tailored to their individual needs.\\n\\n- **Breastfeeding Recommendations**: All infants, regardless of HIV status, should be exclusively breastfed for the first 6 months of life, with timely introduction of appropriate complementary foods after 6 months, and continued breastfeeding up to 24 months or beyond.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Prevention of Other Infections\\n\\n- **Vaccinations**: PLHIV (including children) should receive vaccinations as recommended by the National Vaccines and Immunization Program.\\n\\n- **COVID-19 Vaccination**: All PLHIV should receive the COVID-19 vaccine following national guidelines relevant to age and dosing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 24,\n",
       "  'section': '## HBV/HIV and HCV/HIV Co-infection Prevention and Management\\n\\n• All HIV positive adolescents and adults should be screened for HBV infection using serum HBsAg as part of initial evaluation; children who did not complete routine childhood immunizations should also be screened for HBV and vaccinated if negative.\\n\\n• People Living with HIV (PLHIV) without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against hepatitis B.\\n\\n• The recommended first-line ART for adults with HIV/HBV co-infection is TDF + 3TC + DTG.\\n\\n• HCV serology should be offered to individuals at risk of HCV infection.\\n\\n• Direct Acting Antiviral therapies (DAAs) for treatment of HCV have simplified the management of HIV/HCV co-infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 24,\n",
       "  'section': '## ARVs for Post-exposure Prophylaxis (PEP)\\n\\n• PEP should be offered as soon as possible (< 72 hours) after high-risk exposure.\\n\\n• The recommended ARV agents for PEP are:\\n  - For those < 15 years old:\\n    - < 30 kg: ABC + 3TC + DTG\\n    - ≥ 30 kg: TDF + 3TC + DTG\\n  - For those ≥ 15 years old:\\n    - TDF + 3TC + DTG'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 24,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV infection, including the seronegative partner in a discordant relationship.\\n\\n• PrEP works if taken as prescribed; however, it does not prevent other STIs or unintended pregnancies, therefore, additional protection should be offered.\\n\\n• PrEP should only be offered to clients ≥ 15 years of age who are sexually active after an eligibility assessment using the following parameters:\\n  - Laboratory: HIV negative\\n  - Medical (for oral PrEP): No contraindication to TDF, no severe renal diseases, weight ≥ 30 kg\\n  - Client readiness: Client must be willing to take PrEP as prescribed and adhere to associated follow-up and HIV testing (at enrollment, at month 1, and thereafter every 3 months).\\n\\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative TDF/3TC), available in two dosing strategies:\\n  - Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily.\\n  - Event-driven PrEP: Oral PrEP is used in men having sex with men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC taken between 2 and 24 hours (preferably closer to 24h) before the anticipated sexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth pill taken 24 hours after the third pill (“2+1+1”).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## HIV Testing and Counselling for PWID\\n\\nPeople Who Inject Drugs (PWID) should be offered regular HIV testing and counselling. This process is crucial for ensuring they are linked to comprehensive HIV treatment and prevention services, which includes harm reduction counselling and support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## Recommended ART for Adult PWID\\n\\nThe recommended first-line Antiretroviral Therapy (ART) for adult PWID is Tenofovir Disoproxil Fumarate (TDF) + Lamivudine (3TC) + Dolutegravir (DTG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## STI Screening and Treatment for PWID\\n\\nPWID should be offered screening, diagnosis, treatment, and prevention of sexually transmitted infections (STIs) as part of a comprehensive HIV prevention and care strategy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## TB Prevention and Services for PWID\\n\\nPWID should have the same access to tuberculosis (TB) prevention, screening, and treatment services as other populations that are at risk or living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## HBV and HCV Screening for PWID\\n\\nAt first contact, PWID should be screened for Hepatitis B Virus (HBV) using HBsAg tests and for Hepatitis C Virus (HCV) using HCV serology tests.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## Needle and Syringe Programs (NSP) for PWID\\n\\nAll PWID should be linked to Needle and Syringe Programs (NSP) to ensure access to sterile injecting equipment, which is essential for reducing the risk of HIV transmission.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## Medically Assisted Therapy (MAT) for PWID\\n\\nAll PWID should be linked to Medically Assisted Therapy (MAT) to support their addiction treatment and overall health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 22,\n",
       "  'section': '## Summary of Key Recommendations\\n\\n1 - 5  \\n• Persistent low-level viremia (pLLV) is defined as having VL 200 - 999 copies/ml on two or more consecutive measures. Patients with pLLV are at increased risk of progression to treatment failure, development of ARV resistance, and death. Therefore, they require a case management approach similar to patients with an initial VL ≥ 1,000 copies/ml.  \\n• All PLHIV with a detectable VL ≥ 200 copies/ml (unsuppressed): Assess for and address potential reasons for viremia, including intensifying adherence support, and repeat the VL after 3 months of excellent adherence.  \\n  - If the repeat VL is < 200 copies/ml (suppressed), continue routine monitoring.  \\n  - If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for a change to an effective regimen (Figure 5.2 and Table 6.10).  \\n  - If the repeat VL is 200 - 999 copies/ml (low-level viremia), reassess adherence and other causes of viremia, and repeat VL after another 3 months of excellent adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 22,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/HBV\\n\\n• Prevention of mother-to-child transmission (PMTCT) of HIV, Syphilis, and Hepatitis B (triple elimination) should be offered as part of a comprehensive package of fully integrated, routine antenatal care interventions.  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, Syphilis (using the HIV-Syphilis dual test), and HBV during their first ANC visit, and if negative, a repeat HIV-Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living with HIV, regardless of gestational age, WHO clinical stage, or CD4 count.  \\n• ART should be started as soon as possible, ideally on the same day the HIV diagnosis is made, with ongoing enhanced adherence support.  \\n• The preferred first-line ART regimen for pregnant and breastfeeding women is TDF + 3TC + DTG.  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after initiation, and then every 6 months until complete cessation of breastfeeding.  \\n• For HIV-positive women already on ART at the time of confirming pregnancy or breastfeeding, obtain a VL irrespective of when the prior VL was done, and then every 6 months until complete cessation of breastfeeding.  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/ml (unsuppressed): Assess for and address potential reasons for viremia, including intensifying adherence support, and repeat the VL after 3 months of excellent adherence.  \\n  - If the repeat VL is < 200 copies/ml (suppressed), continue routine monitoring.  \\n  - If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for a change to an effective regimen.  \\n  - If the repeat VL is 200 - 999 copies/ml (low-level viremia), reassess adherence and other causes of viremia and consult the Regional or National TWG.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 27,\n",
       "  'section': '## Community-Based Testing\\n\\nTargeted community-based HIV testing services (HTS) offer additional opportunities to identify and link people to HIV treatment and prevention. This approach is particularly crucial for testing children and partners of index clients through index testing and outreach to key and priority populations, orphans, vulnerable children (OVCs), adolescents, youth, and targeted testing in workplaces.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 27,\n",
       "  'section': '## HIV Testing Strategies\\n\\nThe major HTS strategies to identify individuals living with HIV who are unaware of their status include several methods:\\n\\n### HIV Self-Testing (HIVST)\\n\\n- **Self-Testing Process**: HIVST allows individuals to collect their own specimens, perform the test, and interpret the results independently, whether within a health facility, at home, or in any other convenient location.\\n- **Screening and Diagnosis**: HIVST serves as a screening test and is insufficient for making a definitive HIV-positive diagnosis. A reactive self-test result requires confirmation using the validated national testing algorithm by an HTS-trained service provider.\\n- **Test Kits**: HIVST should be conducted using MoH approved HIV rapid diagnostic test kits that are blood-based or oral fluid-based.\\n- **Target Populations**: This method may particularly benefit specific groups, such as partners of newly diagnosed individuals, pregnant women attending antenatal care (ANC), contacts of patients treated for STIs, and hard-to-reach populations like men, adolescents, young people, and key populations such as MSM and sex workers.\\n\\n### Index Testing\\n\\nIndex Testing, also referred to as partner testing or partner notification services, is an approach that encourages exposed contacts—such as sexual partners, biological children, and individuals with whom a needle was shared—of an HIV-positive person (index client) to access HIV testing services.\\n\\n### Voluntary Counselling and Testing (VCT)\\n\\nVCT involves providing targeted HIV testing to clients who voluntarily present to HTS facilities for testing due to various reasons, including self-assessed risk.\\n\\n### Social Network Strategy (SNS)\\n\\nSNS involves offering index clients self-guided options to informally reach out to a broader set of social, sexual, and injecting network members at elevated risk of HIV infection. The index client for SNS can be either a person living with HIV (PLHIV) or an HIV-negative person with an increased risk of HIV infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 27,\n",
       "  'section': '## Recommendations for HTS\\n\\nProviding targeted HTS for different populations and in various settings enhances opportunities for accessing knowledge of HIV status and a range of HIV treatment and prevention services. Key recommendations for HTS for different sub-populations are summarized in Table 2.1.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 16,\n",
       "  'section': '## Acronyms and Abbreviations for Antiretroviral Drugs\\n\\nThis section includes abbreviations and names of various antiretroviral drugs used in the treatment of HIV. \\n\\n- **3TC**: Lamivudine  \\n- **ABC**: Abacavir  \\n- **ATV**: Atazanavir  \\n- **ATV/r**: Atazanavir/ritonavir  \\n- **AZT**: Zidovudine  \\n- **DRV**: Darunavir  \\n- **DRV/r**: Darunavir/ritonavir  \\n- **DTG**: Dolutegravir  \\n- **EFV**: Efavirenz  \\n- **ETR**: Etravirine  \\n- **FTC**: Emtricitabine  \\n- **LPV**: Lopinavir  \\n- **LPV/r**: Lopinavir/ritonavir  \\n- **NVP**: Nevirapine  \\n- **RAL**: Raltegravir  \\n- **RTV**: Ritonavir  \\n- **TDF**: Tenofovir Disoproxil Fumarate'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 16,\n",
       "  'section': '## Other Acronyms and Abbreviations\\n\\nThis section covers additional acronyms relevant to healthcare, particularly in the context of HIV treatment and general health services.\\n\\n- **HTS**: HIV Testing Services  \\n- **ICF**: Intensified Case Finding  \\n- **IEC**: Information, Education and Communication  \\n- **INH**: Isoniazid  \\n- **INSTI**: Integrase Strand Transfer Inhibitor  \\n- **IPD**: In-Patient Department  \\n- **IPT**: Isoniazid Preventive Therapy  \\n- **IPV**: Intimate Partner Violence  \\n- **IRIS**: Immune Reconstitution Inflammatory Syndrome  \\n- **ITN**: Insecticide Treated Mosquito Nets  \\n- **IUD**: Intrauterine Device  \\n- **KEPI**: Kenya Expanded Program of Immunization  \\n- **KS**: Kaposi’s Sarcoma  \\n- **LEEP**: Loop Electrosurgical Excision Procedure  \\n- **L&D**: Labor And Delivery  \\n- **LIVES**: Listen, Inquiry, Validate, Enhance Safety and Support  \\n- **LLV**: Low Level Viremia  \\n- **LRF**: Laboratory Requisition Form  \\n- **LP**: Lumbar Puncture  \\n- **MAC**: Mycobacterium Avium Complex  \\n- **MAT**: Medically Assisted Therapy  \\n- **MCH**: Maternal Child Health  \\n- **MNCH/FP**: Maternal, Neonatal and Child Health/Family Planning  \\n- **MDT**: Multi-Disciplinary Team  \\n- **MEC**: Medical Eligibility Criteria  \\n- **MOH**: Ministry of Health  \\n- **MSM**: Men Who Have Sex with Men  \\n- **MUAC**: Mid-Upper Arm Circumference  \\n- **NACS**: Nutritional Assessment, Counselling and Support  \\n- **NCD**: Non-Communicable Diseases  \\n- **NHRL**: National HIV Reference Laboratory  \\n- **NNRTI**: Non-Nucleoside Reverse Transcriptase Inhibitor  \\n- **NRTI**: Nucleoside Reverse Transcriptase Inhibitor  \\n- **NSP**: Needle and Syringe Programmes'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 16,\n",
       "  'section': '## Laboratory and Clinical Indicators\\n\\nThis section lists various clinical indicators and lab tests relevant to HIV and other health conditions.\\n\\n- **ADR**: Adverse Drug Reaction  \\n- **AIDS**: Acquired Immunodeficiency Syndrome  \\n- **ALT**: Alanine Transaminase  \\n- **ALP**: Alkaline Phosphatase  \\n- **AHI**: Acute HIV Infection  \\n- **ANC**: Antenatal Care  \\n- **A&E**: Accident And Emergency  \\n- **ARB**: Angiotensin-Receptor Blocker  \\n- **ART**: Antiretroviral Therapy  \\n- **ARV**: Antiretroviral Drug(s)  \\n- **AST**: Aspartate Transaminase  \\n- **BD**: Twice Daily  \\n- **BF**: Breastfeeding  \\n- **BMI**: Body Mass Index  \\n- **BP**: Blood Pressure  \\n- **CAG**: Community Art Groups  \\n- **CCC**: Comprehensive Care Centre  \\n- **CrCl**: Creatinine Clearance  \\n- **OD**: Once Daily'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 30,\n",
       "  'section': '## HIV Testing for Key and Vulnerable Populations\\n\\n● Conduct HIV testing and counselling for all clients from key and vulnerable populations presenting to the health facility, irrespective of the reason for their visit, or through targeted outreach and testing at key and vulnerable population service delivery points (e.g., drop-in centers).  \\n● Key populations that test negative should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should include consistent and correct use of condoms and use of sterile needles and syringes. They should be screened for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the prevention benefits of Volume Male Circumcision (VMMC) and linked to VMMC services if they consent.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 30,\n",
       "  'section': '## Targeted HIV Testing and Counselling for Adults\\n\\n● All adults eligible for testing should be offered HIV Testing Services (HTS) and encouraged to know their HIV status and that of their partners.  \\n● For those that test negative, re-testing is recommended if there is a new risk exposure.  \\n● HIV positive adults should be counselled for immediate Antiretroviral Therapy (ART) initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention messages and be offered services as appropriate.  \\n● All males who test HIV negative should be counselled on the prevention benefits of VMMC and linked to VMMC services if they consent.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 30,\n",
       "  'section': '## Package of HIV Testing Services\\n\\nAn HIV testing and counselling session consists of:  \\n● A pre-test session  \\n● HIV testing  \\n● Assessment for other health-related conditions or needs (while HIV tests are running)  \\n● A post-test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post-test session)  \\n\\nThe HIV testing service package is summarized in Table 2.2.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 29,\n",
       "  'section': '## HIV Testing for Pregnant and Breastfeeding Women\\n\\n- During the first ANC visit, HIV testing of pregnant women should be conducted using a dual test for HIV and syphilis, unless the woman is already known to be living with HIV.\\n- Women who test negative for both HIV and syphilis should be offered a repeat HIV-syphilis dual test in the third trimester.\\n- Prevention services should be offered to all pregnant and breastfeeding women who test HIV negative; they should be screened for eligibility and willingness for PrEP.\\n- At labor and delivery, HIV testing is required for all women with unknown HIV status and those who previously tested negative (even if tested negative in the third trimester).\\n- All breastfeeding mothers (unless known to be HIV positive) should be counseled and tested at the 6-week infant immunization visit. The HIV test (if negative) should be repeated every 6 months until complete cessation of breastfeeding.\\n- For mothers considered to be at high risk of HIV infection, retesting postnatally should be conducted every 3 months; this includes mothers categorized as key populations, in an HIV discordant relationship, or engaging in ongoing behaviors that place them at risk.\\n- Mothers should be counseled on the schedule for repeat HIV testing during pregnancy and postnatal as part of routine ANC and postnatal education.\\n- All pregnant and breastfeeding women who are not tested, opt-out or decline HIV testing during the first contact should be offered HIV counseling and testing in subsequent visits, with appropriate referrals and linkage for prevention, care, and support services.\\n- All HIV positive pregnant and breastfeeding women enrolled in care should receive counseling and support (assisted disclosure), case management, and follow-up, including linkage to general care for ANC, delivery, and post-natal care.\\n- All spouses/partners and children of pregnant and breastfeeding women testing HIV positive should be offered HIV testing and counseling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 29,\n",
       "  'section': '## HIV Testing for Partners and Children of Index Clients\\n\\n- All people living with HIV (PLHIV) enrolled in HIV care should receive disclosure counseling and support to disclose their HIV status (assisted disclosure).\\n- HIV testing and counseling (facility-based or community-based) should be encouraged for all partners, including sexual partners, needle-sharing partners, and children of index clients, with appropriate linkage to treatment and prevention services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## HIV Testing Services and Linkage to Treatment and Prevention\\n\\nOverview of the importance of HIV testing services in linking individuals to treatment and prevention options.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## Birth Testing of Infants Born to Known HIV-Positive Mothers\\n\\n- **Recommendation:** Birth testing (HIV testing of infants at birth or within 2 weeks) is crucial where feasible. Results should be returned within 24 hours for immediate ART initiation.\\n- Infants must be tested again at the 6-week immunization visit regardless of the initial test result.\\n- Infants with a positive initial HIV DNA PCR result should be presumed HIV infected and started on ART, following national guidelines. Confirmatory HIV DNA PCR and baseline viral load samples should be taken upon ART initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## Testing Protocol for Infants and Children Under 18 Months\\n\\n- **HIV Exposure Status:** Establishing the HIV exposure status of all infants at first contact is vital.\\n- **Testing Procedure:** \\n  - Conduct HIV antibody testing for mothers with unknown status at the 6-week immunization visit or first contact.\\n  - If the mother is unavailable or declines testing, perform a rapid HIV antibody test for the child.\\n  - If confirmed as exposed, initiate ARV prophylaxis immediately.\\n- **Follow-up Testing:** \\n  - All exposed infants (HEIs) should undergo DNA PCR testing at the 6-week immunization visit or first contact.\\n  - Infants with positive initial tests require ART initiation, with follow-up PCR testing at 6 months, 12 months, and antibody testing at 18 months and during breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## Testing for Children Older Than 18 Months to Age 9 Years\\n\\n- **Testing Process:** Conduct HIV testing and counseling for all children of adults living with HIV as soon as the adult’s HIV-positive status is confirmed. Testing should occur in various health settings, including inpatient wards and nutrition clinics.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## Testing Services for Adolescents and Young People (Aged 10-24 Years)\\n\\n- **Targeted Services:**\\n  - Offer HIV testing services to adolescents and young people who are screened and eligible.\\n  - Provide prevention services for clients who test negative and link positive testers to HIV care.\\n- **Consent Requirements:** \\n  - Adolescents above 10 must obtain written consent from a parent/guardian and provide their own assent.\\n  - Emancipated minors can consent for themselves.\\n- **Counseling:** \\n  - All adolescents should receive counseling about the benefits and risks of disclosing their HIV status.\\n  - Support should be available for them to decide if, when, how, and to whom to disclose.\\n- **Partner Involvement:** Offer testing and counseling to partners and children of sexually active adolescents.\\n- **VMMC Counseling:** Uncircumcised adolescent males who test negative should be counseled about the prevention benefits of voluntary medical male circumcision (VMMC) and linked to such services if they agree.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nOverview of the guidelines and their purpose in addressing HIV prevention and treatment in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Age-Specific HIV Testing Algorithms\\n\\nExplanation of different testing algorithms based on age, focusing on infants and children.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Early Infant Diagnosis\\n\\nDetails on procedures and protocols for diagnosing HIV in infants.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Confirmation of HIV Infection in HIV Exposed Infants and Children < 18 Months Old\\n\\nInformation on the process for confirming HIV infection in infants exposed to the virus. Key points include:\\n\\n- **HIV Exposure**: Definition and potential timelines for transmission.\\n- **Testing Protocol**: Initial testing with DNA PCR within 6 weeks, followed by subsequent tests at 6 and 12 months if previous tests are negative.\\n- **Response to Symptoms**: Immediate DNA PCR testing if symptoms indicative of HIV occur.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Additional Testing Procedures for HIV Exposed Infants (HEI)\\n\\nOverview of ongoing testing requirements for HIV exposed infants:\\n\\n- **Antibody Testing**: Recommended at 18 months and every 6 months during breastfeeding.\\n- **Post-Breastfeeding Testing**: Conduct an antibody test 6 weeks after complete cessation of breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nThis section provides an overview of the HIV testing services and the linkage to treatment and prevention strategies, including the importance of testing and support services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Negative HIV Test Result\\n\\n- Explain test results.\\n- Review implications of being HIV negative.\\n- Support clients in developing a risk reduction plan (refer to HTS operational manual).\\n- Provide information on methods to prevent HIV acquisition.\\n- Distribute male and/or female condoms, lubricant, and guidance on their use.\\n- Emphasize the importance of knowing the HIV status of sexual partners and information about availability of partner and couples testing services.\\n- Make referrals and link clients to relevant HIV prevention services.\\n- Explain the need for repeat testing for individuals who test negative but report risky behavior within the prior 4 weeks (e.g., unprotected sex with a partner of unknown status or known HIV positive status). Advise them to return for testing every 3 months if they are at ongoing risk of HIV acquisition.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Positive HIV Test Result\\n\\n- Review implications of being HIV positive.\\n- Help the index client cope with emotions arising from the diagnosis.\\n- Discuss immediate concerns and identify support within the client’s social network.\\n- Discuss positive living and provide clear information on ART and its benefits.\\n- Provide guidance on how to access ART.\\n- Refer clients who test HIV positive to a Care and Treatment Center (CCC) for linkage to treatment.\\n- Revisit index testing and HIV self-testing (HIVST) to establish the partner notification plan/approach.\\n- Discuss the risks and benefits of disclosure to partners and offer couples counseling to support mutual disclosure.\\n- Encourage and offer HIV testing for sexual partners, injecting partners, biological children, and other family members through couples testing, family testing, and/or assisted partner notification service.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Assessment of Other Health Related Conditions\\n\\n- Assess risk for sexually transmitted infections (STIs) and opportunistic infections that may require management.\\n- Ensure referral and linkage to care is appropriately managed.\\n- Obtain accurate locator information from the index client (physical location, phone number).\\n- Physically escort the client for re-testing and linkage to ART.\\n- Document the outcomes of partner follow-up(s).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Post-Test Counseling in the Era of Test-and-Treat\\n\\n- Post-test counseling should include three key messages to help start the ART treatment preparation process for all people living with HIV (PLHIV):\\n  - ART (antiretroviral therapy) is available and recommended for everyone with HIV.\\n  - Starting treatment as soon as possible (preferably within two weeks of testing positive for HIV) reduces the chance of illness worsening or of transmitting HIV to others.\\n  - Adhering to ART properly and consistently can lead to a long and productive life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': \"## HIV Testing Services Overview\\n\\nKenya's HIV Prevention and Treatment Guidelines for 2022 outline the package of services related to HIV testing. This includes key components like pre-test counselling, testing procedures, and post-test counselling.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': \"## Pre-Test Counselling\\n\\nPre-test counselling may be provided to individuals or couples seeking HIV testing services (HTS). Group information sessions are also permissible. The objectives of pre-test counselling include:\\n\\n- **Information on Benefits**: Educating clients on the importance of knowing their HIV status, with emphasis on outcomes for those on ART and the concept of undetectable = Untransmittable (U=U).\\n- **Testing Process Explanation**: Clarifying the HIV testing process, including session duration, confidentiality, and how to interpret test results.\\n- **Informed Consent**: Obtaining consent for HIV testing.\\n- **Risk Exploration**: Discussing the client's risk of HIV infection.\\n- **Importance of Disclosure**: Highlighting the significance of disclosing results to partners and family.\\n- **Couple Testing Benefits**: Explaining the advantages of couple testing and partner services/index testing.\\n- **Post-Test Services Information**: Providing information about available post-test services and referrals for prevention or HIV care.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': '## HIV Testing Goals\\n\\nThe main goals of HIV testing are:\\n\\n- **Accurate Diagnosis**: Ensuring accurate HIV diagnosis according to the nationally approved testing algorithm.\\n- **Same-Day Results**: Providing clients with HIV test results on the same day.\\n\\nDuring the waiting period for test results (typically 15 minutes), clients should be engaged in discussions about:\\n\\n- **Combination Prevention**: Topics include PrEP, PEP, Risk Reduction, STI treatment, and condom information and demonstration.\\n- **Screening and Referrals**: Discussing intimate partner violence (IPV), STI and cancer screening, tuberculosis (TB), and family planning/contraceptive needs.\\n- **Data Collection**: Gathering information on the number of sexual contacts and biological children for index testing purposes.\\n- **Documentation**: Ensuring records in the HTS, Lab, referral, and linkage register (MOH 362).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': \"## Post-Test Counselling\\n\\nPost-test counselling involves several important steps:\\n\\n- **Result Readiness**: Checking if the client is ready to receive their results.\\n- **Understanding Interpretation**: Helping the client interpret their results.\\n- **Initial Reactions**: Allowing clients to express their initial reactions and feelings about their results.\\n- **Feelings and Concerns**: Exploring and acknowledging any immediate feelings and concerns of the client.\\n- **Support Offering**: Providing necessary support based on the client's emotional state and needs.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nThis section covers the procedures and protocols related to HIV testing services, including the interpretation of test results and necessary follow-up actions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## Initial HIV Test Results\\n\\nThis section outlines the initial outcomes of HIV testing, including possible results from tests A1, A2, and A3:\\n\\n- **Non-Reactive Result**: Indicates the absence of HIV.\\n- **Reactive Result**: Indicates the presence of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## Procedures for Reported Test Results\\n\\nThis section details the procedures based on the test results:\\n\\n- **Negative Result**: Report as negative and provide appropriate counseling.\\n- **Inconclusive Result**: \\n  - Report as inconclusive and advise retesting in 14 days.\\n- **Positive Result**:\\n  - Report as positive and refer the individual to the second tester at CCC/MCH.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## Follow-Up Actions for Inconclusive Results\\n\\nThis section specifies the actions to be taken if the test results remain inconclusive:\\n\\n- If reactivity remains the same after the 14-day retest, the individual should be reported as HIV-negative.\\n- Advise the individual to retest after 3 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## Supplemental Testing Guidelines\\n\\nThis section discusses the use of supplemental assays in HIV testing:\\n\\n- The use of DNA PCR as a supplemental assay is no longer recommended in the current guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## HIV Testing Services and Linkage to Treatment and Prevention\\n\\nThis section discusses the procedures for managing infants born to HIV-positive mothers, including testing and treatment protocols.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## Infant Testing and Treatment Protocol\\n\\n- **Collection of Samples**: For infants of known HIV-positive mothers, collect DBS for DNA PCR shortly after birth (or within 2 weeks).\\n- **ARV Prophylaxis Initiation**: Start infant ARV prophylaxis immediately after birth.\\n\\n### Outcomes of HIV DNA PCR Testing\\n\\n- **HIV DNA PCR Positive**:\\n  - Initiate ART (Antiretroviral Therapy) immediately.\\n  - Schedule follow-up at 2 weeks of age.\\n  - Provide comprehensive care for the HIV-infected child.\\n\\n- **HIV DNA PCR Negative**:\\n  - Continue infant ARV prophylaxis.\\n  - Follow up for HIV-exposed infants.\\n  - Repeat DNA PCR test at 6 weeks, adhering to the Early Infant Diagnosis (EID) algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## Confirmatory Testing and Management \\n\\n- **Confirmatory DNA PCR Positive / Detectable Viral Load**:\\n  - Continue ART.\\n  - Provide comprehensive care.\\n\\n- **Confirmatory DNA PCR Negative**:\\n  - Continue ART.\\n  - Collect DBS for repeat PCR at 6 weeks of age.\\n  - Manage according to EID algorithm and send new samples to the National Health Reference Laboratory (NHRL).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## Point-of-Care Testing for Children\\n\\nThis section covers the use of point-of-care testing for diagnosing HIV in children.\\n\\n- **Definition**: Point-of-care testing is performed at the health facility where care is provided, with results available on the same day as the sample collection.\\n- **Benefits**: Point-of-care DNA PCR testing for early infant diagnosis can significantly reduce the turnaround time for tests and help initiate ART promptly for infants.\\n- **Applications**: This testing method can be used for both diagnosing HIV infections and confirming positive results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 35,\n",
       "  'section': '## Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months\\n\\nChildren less than 18 months of age may present to hospitals with severe illness, and a rapid HIV antibody test may confirm HIV exposure. Due to the potential delay in obtaining HIV DNA PCR results for confirmation of HIV, initiating life-saving ART is critical. A presumptive diagnosis of HIV infection can be made using specific criteria.\\n\\n### Criteria for Presumptive Diagnosis\\n1. **HIV antibody test positive AND symptomatic with**:\\n   - 2 or more of the following:\\n     - Oral candidiasis/thrush\\n     - Severe pneumonia\\n     - Severe sepsis\\n2. **OR any of the following:**\\n   - Any WHO Clinical Stage 4 condition\\n   - Recent maternal death (if likely to have been HIV-related) or advanced HIV disease in the mother\\n   - Child’s CD4% < 25%'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 35,\n",
       "  'section': '## Birth Testing\\n\\nBirth testing is defined as HIV testing (using DNA PCR) at or around the time of birth for infants born to HIV-positive mothers. This practice is essential for improving survival rates for infants infected during pregnancy or around delivery.\\n\\n### Important Notes on Birth Testing\\n- **Do not use cord blood** for birth testing to avoid false positive results.\\n- A DNA PCR test should be offered at birth or soon after, where possible.\\n\\n### Follow-up Testing\\nAll children initially tested at birth should be re-tested at 6 weeks of age, following the Early Infant Diagnosis (EID) algorithm.\\n\\n### Considerations for Providing Birth Testing\\n- Prioritize newborns at high risk of HIV acquisition:\\n  - Mothers who seroconvert during pregnancy\\n  - Mothers with unsuppressed or unknown viral loads at delivery\\n  - Mothers diagnosed with HIV at or after 28 weeks gestation or during labor\\n  - Mothers on ART for less than 12 weeks prior to delivery\\n  \\n#### Conditions for Effective Birth Testing\\n- DNA PCR results should ideally be available the same day (e.g., on-site point of care).\\n- ART regimens recommended for neonates should be accessible for immediate initiation.\\n- Ensure follow-up of the newborn to prevent loss to follow-up.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 39,\n",
       "  'section': '## Results Interpretation\\n\\nInterpretation of HIV test results includes categorizing individuals as HIV-negative, HIV-positive, or HIV-inconclusive based on specific combinations of test results. The interpretations are as follows:\\n\\n- **HIV-NEGATIVE**: A1- \\n- **HIV-POSITIVE**: A1+; A2+; A3+ \\n- **HIV-INCONCLUSIVE**: \\n  - A1+; A2-; Retest after 14 days. If reactivity remains the same after 14 days, the individual should be reported as HIV-negative.\\n  - A1+; A2+; A3-; Retest after 14 days. If reactivity remains the same after 14 days, the individual should be reported as HIV-negative.\\n- **HIV-NEGATIVE**: A1+; A2-; Repeat A1-'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 39,\n",
       "  'section': '## HIV Testing for Pregnant Women\\n\\nFor pregnant women, the HIV/syphilis dual test should be utilized as the A1 test. Key guidelines include:\\n\\n- The dual test kit is recommended for:\\n  - Pregnant women during their first Antenatal Care (ANC) visit unless they are known to be living with HIV.\\n  - For women testing negative for both HIV and syphilis, repeat testing should occur in the third trimester using the HIV and syphilis dual test.\\n  - Partners accompanying pregnant women during their first ANC visit.\\n  \\n- Important note: The HIV/Syphilis dual test should not be used for:\\n  - Retesting women on Antiretroviral Therapy (ART) or those with a known positive HIV status.\\n  - Women diagnosed with syphilis during pregnancy. \\n\\nRefer to Figure 2.4 for the complete algorithm concerning the concurrent consideration of HIV and syphilis (TP) results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## HIV Testing Services for Infants and Children under 18 Months\\n\\nHIV testing protocols for infants and children under 18 months include procedures for establishing the HIV status of children, especially those born to mothers with known or unknown HIV status.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': \"## Establishing HIV Infection in Infants and Children\\n\\n1. If the mother is known to be HIV positive:\\n   - Conduct HIV Testing Services (HTS) for mothers.\\n   - Perform rapid antibody tests on the infant/child if the mother's HIV status cannot be obtained.\\n\\n2. If the child is HIV-exposed, initiate testing at 6 weeks or upon first contact, regardless of the negative DNA PCR result at birth:\\n   - Collect a dried blood spot (DBS) for an HIV DNA PCR test.\\n   - Start or continue antiretroviral (ARV) prophylaxis for the infant.\\n   - Initiate cotrimoxazole prophylaxis treatment (CPT) at various healthcare settings.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Response to Positive HIV DNA PCR Test in Children\\n\\n1. For children with a positive HIV DNA PCR test:\\n   - Discontinue infant ARV prophylaxis.\\n   - Begin antiretroviral therapy (ART).\\n   - Offer comprehensive care, including continuation of CPT.\\n   - Collect additional samples for confirmatory HIV DNA PCR, baseline viral load, and CD4%.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Confirmatory Testing and Follow-Up\\n\\n1. For children confirmed with HIV infection through a positive confirmatory HIV DNA PCR test:\\n   - Continue ART and comprehensive care, including routine under-5 care.\\n\\n2. For children who test negative on confirmatory testing:\\n   - Manage the child as presumed HIV infected and continue ART.\\n   - Collect and send a DBS to the National Health Reference Laboratory (NHRL) and follow up according to results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Continuous Monitoring and Testing Procedures\\n\\n1. For HIV-exposed children:\\n   - Conduct follow-up testing at 12 months or until 18 months of age, incorporating additional symptoms as per WHO staging criteria.\\n\\n2. If HIV antibody testing is negative at 18 months:\\n   - The child is considered HIV negative.\\n   - Stop CPT and document vital status at age 2, continuing routine under-5 care.\\n\\n3. If HIV antibody testing is positive:\\n   - The child is confirmed HIV infected.\\n   - Initiate comprehensive care, maintain CPT, and ensure routine under-5 care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Special Testing Procedures\\n\\n- Where Point of Care DNA PCR is available, it should be conducted using whole blood at the facility.\\n- For baseline viral load testing, utilize point-of-care machines if available; otherwise, collect plasma and send it to the viral load testing laboratory.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## HIV Testing Overview\\n\\nThis section covers the types of HIV tests included in the provided document, which primarily involves multiple test algorithms such as HIV Test A1, A2, and A3. Each test provides results that can be either reactive or non-reactive, indicating the presence or absence of an HIV infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Test Results and Interpretations\\n\\nThis section details the various outcomes from the testing process:\\n\\n- **NON-REACTIVE**: Indicates that there is no evidence of HIV infection.\\n- **REACTIVE**: Indicates a potential HIV infection, requiring confirmation through additional testing.\\n- **REPORT INCONCLUSIVE**: If the tests yield indeterminate results, a retest is necessary in 14 days.\\n- **REPORT POSITIVE**: If a positive result is confirmed, the individual should be referred for further treatment and testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Syphilis Testing\\n\\nThis section highlights the inclusion of syphilis testing alongside HIV testing. If a test result is reactive for syphilis, appropriate treatment should be initiated, alongside addressing the HIV status.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Recommendations for Inconclusive Results\\n\\nThis section outlines the procedure for individuals with inconclusive HIV test results. If reactivity remains the same after a 14-day retest, the person should be recorded as HIV-negative and advised to undergo another retest after 3 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Changes in Testing Guidelines\\n\\nThis section mentions a specific note regarding the use of DNA PCR as a supplemental assay. It states that its use is no longer recommended in the current testing protocols, emphasizing the need for adherence to updated guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 41,\n",
       "  'section': '## HIV Test Result Interpretation\\n\\nThis section outlines the interpretation of test results related to HIV and syphilis based on the guidelines set forth in the Kenya HIV Prevention and Treatment Guidelines, 2022. The results are categorized as follows:\\n\\n- **A1 HIV -, Syphilis Test (TP) -**: HIV negative, syphilis negative.\\n- **A1 HIV -, Syphilis Test (TP)+**: HIV negative, syphilis positive.\\n- **A1 HIV+, Syphilis Test (TP) -**: Syphilis negative; proceed with A2 for HIV.\\n- **A1 HIV+, Syphilis Test (TP)+**: Syphilis positive; proceed with A2 for HIV.\\n- **A1 (HIV+); A2+; A3+**: HIV-positive.\\n- **A1(HIV+); A2 -; Repeat A1+**: HIV-inconclusive (retest after 14 days). If reactivity remains the same after 14 days, report as HIV negative.\\n- **A1(HIV+); A2 -; Repeat A1 -**: HIV-negative.\\n- **A1(HIV+); A2+; A3 -**: HIV-inconclusive (retest after 14 days). If reactivity remains the same after 14 days, report as HIV negative.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 41,\n",
       "  'section': \"## Approaches to Improve Linkage to Treatment and Prevention Services \\n\\nThis section lists key actions aimed at enhancing the linkage of individuals to HIV treatment and prevention services.\\n\\n### Information\\n- Quality post-test counseling should include detailed information about additional HIV-related services, including treatment plans and follow-up schedules.\\n- Emphasize the benefits of immediate assessment and early initiation of ART (antiretroviral therapy).\\n- Involve the patient in decision-making regarding treatment and prevention, especially about the timing and location for starting ART.\\n\\n### Disclosure\\n- Encourage disclosure to a trusted ‘significant other’ to promote linkage and adherence to treatment.\\n- Support patients in discussing their HIV status with a trusted friend or close relative.\\n- Encourage adolescents to identify and invite a supportive adult or friend for support.\\n- For children, HIV status should ideally be disclosed by age 12, with the process starting as early as 7 years old. Health care providers or parents/guardians should disclose the child's status with appropriate guidance. The aim is to involve children in managing their own health and to reduce stigma associated with HIV.\\n\\n### Barriers to Linkage\\n- During post-test counseling, it is crucial to identify and address any barriers to linking patients with treatment and prevention services.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## Diagnosis of HIV Infection in Older Children, Adolescents, and Adults\\n\\n● Serial testing, using approved rapid HIV antibody testing kits, is employed to diagnose HIV infection in individuals aged 18 months and older, including adolescents and adults.\\n\\n● An HIV-positive diagnosis is established through three consecutive reactive assays. This three-test strategy, alongside retesting, aims to maintain at least a 99% Positive Predictive Value (PPV) and avoid false positive misdiagnoses.\\n\\n● Providing adequate information to clients and obtaining consent prior to the HIV test is crucial. Verbal consent is sufficient but should be documented by the healthcare worker in client records. For children under 14 who are not emancipated minors, written consent from a guardian is recommended.\\n\\n● Individuals aged 15 and older, as well as emancipated minors, have the ability to provide self-consent.\\n\\n● Clients testing positive should be linked to care and treatment, with counseling support and index and family testing offered.\\n\\n● Clients testing negative should be counseled on HIV risk reduction behaviors and linked to combination HIV prevention services, such as VMMC, RH/FP, condoms, and PrEP, based on their individual risk profiles. Recommendations for re-testing those who test HIV negative are detailed in Table 2.5.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## HIV Testing Algorithm\\n\\n**HIV Testing Algorithm for Children ≥ 18 Months, Adolescents, and Adults:**\\n\\nFigure 2.3 illustrates the serial testing algorithm. An HIV-positive diagnosis is reached through three consecutive reactive assays. The process is as follows:\\n\\n1. All individuals are first tested on Assay 1 (A1). Those with a non-reactive result (A1−) are reported HIV-negative.\\n\\n2. Individuals with a reactive result on Assay 1 (A1+) proceed to a separate and distinct Assay 2 (A2). \\n\\n3. Those reactive on both Assay 1 and Assay 2 (A1+; A2+) are then tested on a separate Assay 3 (A3). A positive diagnosis is confirmed when Assay 3 is reactive (A1+; A2+; A3+).\\n\\n4. If Assay 3 is non-reactive (A1+; A2+; A3−), the status is reported as HIV-inconclusive, and the individual is advised to return in 14 days for retesting.\\n\\n5. Individuals with a reactive Assay 1 but a non-reactive Assay 2 (A1+; A2−) should repeat Assay 1. If the repeat Assay 1 is non-reactive (A1+; A2−; repeat A1−), the status is reported as HIV-negative. If repeat Assay 1 is reactive (A1+; A2−; repeat A1+), the status is reported as HIV-inconclusive, with a recommendation to return in 14 days.\\n\\n6. All clients with HIV-positive results will be referred to a Comprehensive Care Clinic for retesting prior to the initiation of ART.\\n\\n**Note:** The three-test algorithm will be implemented after identifying the specific assay. The current algorithm remains in use until that time (Annex 7), and guidance will be provided before full implementation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## HIV Testing Services and Linkage to Treatment and Prevention\\n\\n### Systems to Facilitate Linkage  \\n- The HTS (HIV Testing Services) provider is responsible for linkage into care.  \\n- Same-day enrollment into care is expected.  \\n- Monitor linkage to treatment initiation within 14 days of diagnosis, allowing follow-up of clients up to 90 days post-HIV-positive diagnosis.  \\n- For HIV-negative clients, link to HIV prevention services based on assessed risk.  \\n- Linkage should be done to on-site treatment and prevention services through patient escorts. If on-site is not possible, the testing facility should book an appointment with the receiving facility. Follow-up to ensure patient registration at the receiving facility. Provide the patient with referral information, a referral form, and contact details.  \\n- Deploy retention and loss-to-follow-up tracking systems to ensure successful linkage. This includes enlisting peer or buddy systems, SMS reminders, phone calls, and community outreach workers to assist HIV-positive clients with enrollment.  \\n- Early preparation and assessment for ART (Antiretroviral Therapy), as well as early initiation of ART, strengthens engagement in care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## Care Coordination and Integration  \\n- Coordinate treatment for mother-baby pairs, partners, and families together.  \\n- Integrate common services offered to people living with HIV (PLHIV), such as TB (tuberculosis) diagnosis and treatment, sexual and reproductive health/family planning, cervical cancer screening, and nutrition.  \\n- If referrals are necessary, ensure that they are coordinated, including communication and documentation between referring and receiving service delivery points.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## Linkage Register  \\n- Maintain a linkage register at all testing points in the facility and community.  \\n- Track and report on linkage progress monthly.  \\n- Discuss linkage at multidisciplinary team (MDT) meetings.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## Retesting Recommendations for HIV Negative Persons  \\nRetesting refers to testing that occurs later after the initial test is negative. The purpose of retesting is:  \\n- To monitor the effectiveness of HIV prevention interventions.  \\n- To identify and treat new HIV infections early when prevention efforts fail.  \\n- The document mentions recommendations for HIV retesting in different populations and settings in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 46,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\nAll PLHIV (People Living with HIV) are eligible for ART (Antiretroviral Therapy) irrespective of CD4 cell count or percentage, WHO clinical stage, age, pregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, preferably within two weeks from the time of HIV diagnosis. \\n\\nDuring the initial evaluation, all PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting well. Patients with advanced disease require more intensive evaluation and management for opportunistic infections (OIs) and are at higher risk of developing immune reconstitution inflammatory syndrome (IRIS) after ART is started. \\n\\nAfter at least six months on ART, PLHIV should be categorized as either established or not established on ART (clinically, virologically, and psychosocially) to meet their specific treatment and follow-up needs. This approach improves patient outcomes through differentiated care, minimizing inconvenience and unnecessary frequent follow-ups, thus reducing costs and time related to clinic visits.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 46,\n",
       "  'section': '## Initial Clinical Evaluation of PLHIV\\n\\nAll patients enrolling in HIV care should have a complete medical history taken, a thorough physical examination, and appropriate laboratory investigations. Findings from this initial evaluation should be documented legibly in a retrievable health record management format (electronic or paper-based) to facilitate long-term follow-up of the patient. \\n\\nThe initial visit provides an opportunity to establish a meaningful patient-provider relationship; clinicians should elicit concerns and expectations with open, non-judgmental, and clear communication. \\n\\nTable 3.1 summarizes important aspects of the initial medical history and physical examination for PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': '## Overview of Kenya HIV Prevention and Treatment Guidelines\\n\\nThe guidelines focus on differential diagnosis and management plans for HIV-related problems, emphasizing investigations, treatment, referrals, and follow-up care. It highlights the importance of assigning and documenting the WHO Clinical Stage and managing presenting illnesses. Additionally, assessments of growth and developmental milestones in children are critical for appropriate WHO staging.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': '## Initial Laboratory Evaluation of PLHIV\\n\\nThe initial laboratory evaluation for People Living with HIV (PLHIV) is essential and should be tailored based on suspected concurrent illnesses. The guidelines recommend that ART initiation should not be delayed due to the unavailability of specific laboratory tests.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': '## Recommended Baseline Laboratory Investigations for PLHIV\\n\\nThe following are the recommended laboratory tests for all PLHIV, along with specific comments regarding each:\\n\\n- **HIV Confirmation Test**: Positive status needs reconfirmation prior to ART initiation.\\n  \\n- **CD4 Cell Count**: Should be conducted for all patients (CD4% for children ≤ 5 years old). For patients >5 years with CD4 ≤ 200 cells/mm³, reflex testing for cryptococcal infection through serum cryptococcal antigen (sCrAg) is required.\\n\\n- **Viral Load (HIV-1 RNA)**: Baseline viral load is recommended for infants after their first PCR test is positive. It is essential to ensure that obtaining a viral load does not delay ART initiation.\\n\\n- **Serum Cryptococcal Antigen (sCrAg)**: Obtain serum CrAg if CD4 ≤ 200 cells/mm³ in patients over 5 years as reflex testing. If the test is positive, patients should be managed according to the cryptococcal meningitis screening algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': \"## Additional Investigations\\n\\nFurther investigations should be guided by clinical indications, ensuring a comprehensive evaluation of each patient's health status.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': 'This format provides clearly defined sections on specific topics regarding HIV prevention and treatment guidelines, suitable for a Q&A system.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## HIV Testing Window Period\\n\\nThe window period is the time from exposure to HIV infection to when the body produces enough HIV antibodies to be detected by an HIV antibody test. This time can vary across different types of tests, with some tests capable of detecting antibodies earlier than others, potentially leading to discrepant test results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## Handling Inconclusive HIV Test Results\\n\\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. Receiving inconclusive results can be confusing and stressful for clients, making it important for providers to explain what an HIV inconclusive status means. It is neither HIV-positive nor HIV-negative, and retesting in 14 days is necessary for an accurate diagnosis. Because a definitive diagnosis cannot be made on the day of testing, immediate referral to HIV care or ART initiation is not appropriate. Providers should help clients make a follow-up plan and schedule an appointment for retesting. Additionally, clients should be informed about prevention options and how to remain HIV-negative, along with the availability and benefits of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## Acute HIV Infection Monitoring\\n\\nThose suspected of having an acute HIV infection — for example, if they report or present with symptoms associated with acute HIV infection — should be closely monitored. This phase is characterized by high infectiousness due to a high viral load, and clients need to be informed about how to protect their partners. Individuals at high ongoing risk of HIV should be informed about PrEP and encouraged to discuss their options depending on their final HIV status when they return for retesting.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## Managing Patients on ART with Discrepant HIV Test Results\\n\\nHIV testing should not be performed on patients who are already enrolled in HIV care and on ART. However, some patients may self-refer for HIV antibody testing without disclosing their known HIV-positive status and ART treatment. Recommendations for managing these patients, particularly those who receive a non-reactive antibody test while on ART, are outlined in Figure 2.5.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 43,\n",
       "  'section': '## Recommendations for Retesting HIV Negative Clients\\n\\n### General Population\\n- All general population to be screened every 2 years using the approved NASCOP HTS screening tool. Eligible individuals should get tested.\\n\\n### Key Populations\\n- High-risk groups including Female Sex Workers (FSW), Men who have Sex with Men (MsM), Transgender individuals (TG), and People Who Inject Drugs (PWID) should re-test every 3 months.\\n\\n### Discordant Couples\\n- For the HIV negative partner in discordant couples, retesting should occur:\\n  - At the initiation of ART for the HIV positive partner.\\n  - At 6 months and 12 months once viral suppression is achieved.\\n  - Annually if the positive partner remains virally suppressed.\\n\\n### Pregnant Women\\n- Pregnant women should be tested in the first trimester or at first contact, and re-tested during the third trimester and at the time of labor and delivery.\\n\\n### Breastfeeding Mothers\\n- Breastfeeding mothers should be re-tested 6 weeks after delivery, at 6 months, and then every 6 months until complete cessation of breastfeeding. For those at high risk of HIV infection, retesting postnatally should occur every 3 months.\\n\\n### Individuals with Recent High-Risk Exposure\\n- Individuals who had a recent high-risk exposure to HIV should be tested at initial presentation and re-tested at 4 weeks, after which national testing guidelines apply.\\n\\n### STI Symptomatic Patients\\n- Patients who are symptomatic for STIs or have symptoms suggestive of acute HIV should be tested at initial presentation and re-tested at 4 weeks, with subsequent adherence to national testing guidelines.\\n\\n### Individuals on PrEP\\n- Individuals on Pre-exposure prophylaxis (PrEP) should be tested at the initiation of PrEP, then re-tested at one month and every 3 months thereafter.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 43,\n",
       "  'section': '## Inconclusive HIV Status\\n\\nAn HIV-inconclusive test status indicates that individuals had discrepant results on the test (e.g., first test reactive, second test nonreactive, third test reactive) and therefore could not be definitively classified as HIV-positive or HIV-negative. \\n\\n### Causes of Inconclusive Results\\n- Inconclusive results are rare but may occur due to:\\n  i) Cross-reactivity between test kits or patient-related factors.\\n  ii) Errors made by the tester or test kit.\\n  iii) Individuals who are seroconverting and are in the window period, where infection cannot be definitively determined.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 47,\n",
       "  'section': '## Initial Clinical Evaluation for PLHIV (History and Physical Examination)\\n\\nThis section covers the comprehensive initial clinical evaluation for People Living with HIV (PLHIV) which includes gathering detailed medical history through various categories:\\n\\n### Current and Past Medical History\\n- Presenting complaints/current symptoms \\n  - Inquire about symptoms from co-existing HIV-related and non-HIV-related diseases and co-morbidities necessitating immediate intervention.\\n- History of TB and TB contacts\\n  - Utilize the Intensified Case Finding (ICF) tool.\\n- Date of first positive HIV test.\\n- Past and current co-morbidities (e.g., TB, cryptococcal meningitis, hypertension, diabetes, kidney, and liver disease).\\n  - Document history of TB.\\n- Current medications:\\n  - Establish current medications (prescription, non-prescription, and herbal) that may interact with ARVs.\\n  - Document ARV exposure history (including PMTCT, PEP, PrEP, and ART).\\n- Drug allergies, especially sulpha allergy.\\n- History of hospitalizations:\\n  - Establish reasons for hospitalizations.\\n- Family history of chronic disease or cancer.\\n- Establish nutritional history and adequacy of nutritional intake and household food security.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 47,\n",
       "  'section': '## Psychosocial History\\n\\nThis section addresses important psychosocial factors relevant to the health and treatment of PLHIV:\\n\\n- Education, employment, family, and marital status.\\n- Possible presence of mental health concerns:\\n  - Including past treatment for mental illnesses and current symptoms of depression.\\n- Disclosure and self-stigma considerations:\\n  - Encourage disclosure to trusted close relations and sexual partners.\\n- Substance use screening:\\n  - Include alcohol, tobacco, miraa (khat), marijuana, narcotics, injection drug use.\\n  - Use CRAFFT screening tool for adolescents and CAGE-AID screening tool for adults to assess alcohol and drug use disorders (consult Tables 4.15 and 4.16).\\n- Establish and document social support structures.\\n- Link to additional facility and community support resources:\\n  - Include psychosocial support groups, peer mentors, and harm reduction services for people who inject drugs (PWIDs).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 47,\n",
       "  'section': '## Barriers to Adherence\\n\\nThis section focuses on identifying and addressing potential barriers to adherence to treatment regimens among PLHIV. \\n\\n- Elicit possible barriers that may affect adherence to ART and other prescribed medications.\\n- Discuss strategies and resources to help overcome these barriers to ensure consistent treatment compliance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## Initial Evaluation and Follow-up\\n\\n### Sexual and Reproductive History\\n- **History of STIs**\\n- **Current Symptoms of STIs**\\n- **Sexual Practices**\\n  - Determine HIV status and disclosure to sexual partner(s)\\n  - ART status of sexual partner/s\\n- **Pregnancy History**\\n  - Age of all living children\\n- **Menstrual History**\\n  - Family planning and plans for pregnancy\\n- **History of Cervical Cancer Screening**\\n- **Vaccination History**\\n  - Including COVID-19 vaccine\\n\\n### Discussion Points\\n- Secondary prevention and avoidance of re-infection with STIs\\n- Pregnancy intention and contraception needs\\n\\n### Recommendations\\n- Encourage contact tracing and HIV testing for sexual partners and all children under 15 years of age of HIV-infected women or whose mothers’ HIV status is unknown.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## Vital Signs and Anthropometric Measurements\\n\\n- **Measurements to Record**\\n  - Weight, Height, MUAC (in children and pregnant women)\\n  - Temperature, Pulse Rate, Blood Pressure, Respiratory Rate, Pulse Oximetry\\n- **BMI Calculation**\\n  - Formula: Weight (kg) / Height² (m)\\n  - Use z-scores for children\\n- **Monitor Growth Trends for Children**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## General Examination\\n\\n### Areas to Examine\\n- **Conjunctiva and Palms**\\n  - Look for pallor or jaundice\\n- **Swollen Lymph Nodes**\\n  - Cervical, axillary, inguinal\\n- **Oral Examination**\\n  - Check for Kaposi’s sarcoma (KS) lesions, oral hairy leucoplakia, candidiasis, tooth decay\\n- **Skin Examination**\\n  - Check for drug eruptions, herpes zoster, dermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, molluscum, and KS\\n- **Developmental Milestones for Children**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## Systemic Examination\\n\\n### Areas to Assess\\n- **Central Nervous System**\\n- **Mental State Examination**\\n  - Evaluate mental status\\n- **Abdominal Examination**\\n- **Respiratory Examination**\\n- **Cardiovascular Examination**\\n- **Genitourinary/Anorectal System**\\n  - Check for ulcers, discharge, condylomata/warts\\n  - Prostate examination for men aged 45 years and older\\n  - Speculum examination with cervical cancer screening for females'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 52,\n",
       "  'section': '## Initial Evaluation and Follow-up\\n\\nThis section outlines the initial evaluation and follow-up procedures for adults, adolescents, and children aged 5 years and older who present with advanced HIV disease, specifically identifying those at WHO Stage 3 or 4 or a CD4 count of ≤ 200 cell/mm³. It also includes guidelines for all children younger than five years at enrollment into care.\\n\\n### Package of Care\\n- **Standard Package of Care (Chapter 4)**\\n- **Intensive management** of presenting illnesses and malnutrition.\\n- **Priority for identification, management, and prevention of Opportunistic Infections (OIs)**, including:\\n  - GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB.\\n  - TB-LAM for PLHIV with presumptive TB who meet specific criteria.\\n  - Cryptococcal antigen screening for vulnerable populations.\\n  - Cotrimoxazole Preventive Therapy (CPT).\\n  - TB Preventive Therapy (TPT).\\n\\n### ART Initiation and Monitoring\\n- Immediate ART initiation unless there are conditions suggesting TB or cryptococcal meningitis.\\n- Close monitoring for the development of immune reconstitution inflammatory syndrome.\\n\\n### Focus of ART Preparation\\n- **Counseling**:\\n  - Emphasis on immediate ART start to prevent further immune damage and reduce disease progression.\\n\\n### Frequency of Follow-up\\n- Weekly follow-ups until ART initiation, then at weeks 2 and 4, and monthly thereafter until confirmed viral suppression.\\n- More frequent visits or hospitalization may be necessary for acute conditions and psychosocial issues.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 52,\n",
       "  'section': '## Management of Opportunistic Infections in Patients with AHD\\n\\nThis section discusses the management of opportunistic infections in patients suffering from Advanced HIV Disease (AHD), with a particular focus on cryptococcal disease.\\n\\n### Cryptococcal Disease (CM)\\nCryptococcal disease is a significant opportunistic infection contributing to high mortality rates among those living with AHD. The following points are emphasized:\\n\\n- **Early Diagnosis and Treatment**: Critical for reducing mortality associated with cryptococcal meningitis. Healthcare professionals should maintain a low threshold for suspicion in advanced cases of HIV disease.\\n  \\n- **Screening, Prevention, and Treatment**: Detailed guidelines on these processes are provided in Section 4.33.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 50,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\nThis section outlines the recommended initial evaluations and follow-up tests for patients starting anti-retroviral therapy (ART), focusing on key laboratory tests.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 50,\n",
       "  'section': '## Laboratory Tests for HIV Patients\\n\\n### Hemoglobin (Hb)\\n- **Recommendation**: Preferably a full blood count if available.\\n- **Target Audience**: All patients, especially those on AZT.\\n\\n### Pregnancy Test\\n- **Recommendation**: Determine pregnancy status for all women of reproductive age.\\n- **Method**: Based on history of last menstrual period; if uncertain, perform a urine pregnancy test.\\n\\n### TB-LAM\\n- **Recommendation**: Conduct TB-LAM on a urine sample.\\n- **Criteria**: If CD4 ≤ 200 cells/mm³ in people living with HIV (PLHIV) over 5 years, or if CD4% ≤ 25% in children under 5 years. Also for seriously ill patients.\\n\\n### Urinalysis\\n- **Recommendation**: Perform urinalysis for protein and glucose.\\n- **Target Audience**: All patients.\\n\\n### Creatinine\\n- **Recommendation**: Obtain baseline creatinine levels.\\n- **Special Note**: Important for all patients, especially those starting TDF. Calculate Creatinine Clearance (CrCl) as per Annex 15.\\n\\n### Syphilis Serology\\n- **Tests**: VDRL, TPHA, or RPR.\\n- **Target Audience**: All patients with a history of being sexually active.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 50,\n",
       "  'section': '## Additional Recommended Tests\\n\\n### Glucose\\n- **Recommendation**: Conduct glucose testing for all patients.\\n\\n### Plasma Lipid Profile\\n- **Recommendation**: Perform lipid profile analysis for all patients.\\n\\n### HBsAg\\n- **Recommendation**: Test for HBsAg in all adolescent and adult patients, along with children who did not complete routine childhood immunizations.\\n\\n### HCV Antibody\\n- **Recommendation**: Test for HCV antibody in people who inject drugs (PWID) or patients with a history of injection drug use.\\n\\n### ALT\\n- **Recommendation**: Not recommended as baseline unless there is a specific clinical reason (e.g., history of hepatitis, liver disease symptoms, risk factors).\\n\\n### HPV Testing\\n- **Recommendation**: For women of reproductive age between 25-49 years, conducted at baseline and every two years, in accordance with cancer screening guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 50,\n",
       "  'section': '## Laboratory Capacity Limitations\\n\\n- **Note**: It is acknowledged that not all facilities providing ART can offer the recommended laboratory tests. If a facility lacks on-site capacity to perform any tests, transportation arrangements should be made to a local or regional reference laboratory for specimen analysis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 45,\n",
       "  'section': '## Education/Counseling for Patients on ART with a New Negative HIV Antibody Test\\n\\n- The new HIV antibody test may be a false negative; the patient may still be HIV-infected, but their antibody levels may be suppressed due to effective ART. This is more common for patients who start ART very soon after HIV infection.\\n- Patients with a prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost always truly HIV positive.\\n- Continue their ART until a special test (a new sample for DNA PCR) is performed at the National HIV Reference Laboratory (NHRL).\\n- Stopping ART before HIV status is confirmed could lead to a rapid rise in viral load, decline in CD4 count, and increased risk of developing an opportunistic infection or death.\\n- Draw a sample for DNA PCR and send it to the NHRL (preferably a whole blood EDTA sample following cold-chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible).\\n- Specify that this is a sample for confirming the HIV status of a patient on ART, and provide the dates and results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 45,\n",
       "  'section': '## If HIV DNA PCR Sample is Positive\\n\\n- A positive HIV DNA PCR sample confirms the patient is HIV positive.\\n- Provide additional counseling on why the antibody test may have been falsely negative and discourage the patient from any repeat antibody testing.\\n- Emphasize the importance of continued adherence to ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 45,\n",
       "  'section': '## If HIV DNA PCR Sample is Negative\\n\\n- A negative HIV DNA PCR sample may indicate that the patient is HIV negative, or they could still be HIV positive but have suppressed HIV DNA levels below the testing limit (this is more common if a DBS sample was used).\\n- Inform the patient that they may still be HIV positive and require close monitoring for an additional 6 months before confirming they are HIV negative.\\n- Inform the patient that ART should be stopped immediately.\\n- They should return for HIV viral load testing at 1 month, 3 months, and 6 months after stopping ART (samples for HIV viral load should be sent to the designated VL/EID network laboratory assigned to the requesting facility with all past details).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 53,\n",
       "  'section': '## Tuberculosis (TB) and Its Impact on PLHIV\\n\\nTB is the most frequent life-threatening opportunistic infection (OI) and a leading cause of death among people living with HIV (PLHIV). Despite substantial scale-up of antiretroviral therapy (ART), TB continues to be the leading cause of mortality among PLHIV, accounting for 30% of AIDS-related deaths reported. Screening, prevention, and treatment of TB are described in Chapter 8 of the guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 53,\n",
       "  'section': '## Management of Patients Presenting Well: WHO Stage 1 or 2 and CD4 Count > 200 cell/mm³\\n\\n### Adults, Adolescents, and Children ≥ 5 Years\\n\\n#### Focus of ART Preparation Counselling\\n- ART is crucial for maintaining good health and an active life.\\n- Starting ART early will decrease the risk of developing wasting and other infections.\\n- ART helps reduce the risk of transmitting HIV to others.\\n\\n#### Frequency of Follow-Up\\n- Weekly follow-ups until ART initiation.\\n- Follow-ups at 2 and 4 weeks after ART initiation.\\n- Monthly follow-ups thereafter until confirmed viral suppression.\\n- Additional visits are recommended to address medical or psychosocial concerns.\\n\\n#### Location of Services\\n- Management can occur at any ART service delivery point across all facility levels.\\n- Initial management and ART initiation should be conducted by trained and experienced healthcare workers (HCW).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 53,\n",
       "  'section': '## Follow-Up of PLHIV After ART Initiation\\n\\nFollow-up for patients on ART is based on the duration of treatment, the patient’s understanding of the treatment, and their response to ART. Follow-up activities include:\\n- Scheduled clinical appointments.\\n- Unscheduled clinical assessments for patients who have concerns or complaints.\\n- Routine and as-needed laboratory monitoring to assess patient health and treatment efficacy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Definition of Advanced HIV Disease (AHD)\\n\\nThe World Health Organization (WHO) defines Advanced HIV Disease (AHD) for adults, adolescents, and children five years and older as having a CD4 cell count of less than 200 cells/mm³ or WHO clinical stage III or IV disease. All children younger than five years living with HIV who are not already receiving ART and are not clinically stable are also considered to have AHD.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Settings Where AHD Occurs\\n\\nAdvanced HIV Disease can occur in various scenarios, including:\\n\\n- People Living with HIV (PLHIV) newly presenting to care\\n- Those returning to care after treatment interruption\\n- PLHIV on ART who have experienced treatment failure'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Risks Associated with AHD\\n\\nPLHIV with AHD face immune suppression, which reduces their ability to fight off opportunistic infections (OIs) and other diseases. This puts them at increased risk for morbidity and mortality. AHD is also linked to elevated healthcare costs and more extensive healthcare service usage, including more frequent monitoring. Leading causes of mortality among adults with AHD include:\\n\\n- Immune reconstitution inflammatory syndrome\\n- Tuberculosis (TB)\\n- Severe bacterial infections\\n- Cryptococcal disease\\n- Histoplasmosis\\n- Toxoplasmosis\\n- Pneumocystis Jirovecii pneumonia, among others'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## CD4 Testing Criteria for AHD\\n\\nTo diagnose AHD and determine eligibility for the care package, the following CD4 testing criteria should be applied:\\n\\n- **New clients initiating ART**: CD4 testing should be conducted as a baseline test for all PLHIV.\\n- **Patients who are treatment-experienced**:\\n  - PLHIV aged ≥5 years who had previously initiated ART and are reinitiating after more than three months.\\n  - Individuals with documented persistent unsuppressed viral load (two viral load tests >1,000 within 3-6 months).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Package of Care for AHD\\n\\nAll PLHIV presenting with Advanced HIV Disease (AHD) should be offered a comprehensive package of care that includes:\\n\\n- Timely initiation of ART\\n- Screening, diagnosis, prophylaxis, and management of opportunistic infections\\n\\nTable 3.3 provides a summary of the definitions of well versus advanced disease and the package of care for each at enrollment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 60,\n",
       "  'section': '## Initial Evaluation and Follow Up\\n\\nThis section introduces the process of initial evaluation and follow-up for individuals living with HIV (PLHIV). It emphasizes the importance of regular clinical appointments and support in the management of antiretroviral therapy (ART).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 60,\n",
       "  'section': '## Facility-Based ART Distribution Group\\n\\nFacility-based ART Distribution Groups are a model for ART distribution where a group of PLHIV gathers at a designated location within their health facility to receive drug refills. In these groups, peers support one another while ensuring treatment literacy. Key points include:\\n- ART refills are conducted every 3 months.\\n- Each client must attend a clinical review appointment every 6 months.\\n- This model may provide psychosocial support and is more convenient for urban clients who prefer not to join community-based groups.\\n- Groups can be led by peers or health care workers (HCWs).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 60,\n",
       "  'section': '## Community-Based ART Distribution Models\\n\\nCommunity-based ART distribution enables clients to receive their ART refills outside health facilities. It includes various distribution methods:\\n- Community-based ART distribution groups.\\n- Community ART distribution points.\\n- Community pharmacy distribution.\\n  \\nClients may also benefit from home visits for adherence monitoring on a case-by-case basis. Before implementing a community-based ART distribution program, health facilities need to collaborate with the County Health Management Team (CHMT) to ensure the program meets specific criteria and is approved by the County HIV Technical Working Group. For more detailed guidance, refer to the DSD operational manual.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Patient Eligibility for ART\\n\\nPatients established on ART must have achieved ALL the following:\\n- On their current ART regimen for ≥ 6 months\\n- Currently no active illness or in the previous 6 months (patients with well controlled chronic conditions should not be excluded)\\n- Adherent to scheduled clinic visits for the previous 6 months\\n- VL ≤200 copies/ml (LDL) within the last 6 months\\n\\n**Note:**\\n- This definition should be applied to all populations, including those receiving second- and third-line regimens, those with controlled comorbidities, children above 2 years, adolescents, pregnant and breastfeeding women, and key populations.\\n- The client’s category can change at any time, so there is a need for reassessment at each visit. Clients should be categorized at every visit and managed based on their status.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Package of Care\\n\\n- Standard Package of Care\\n- Re-assessment of criteria at every clinical visit'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Location of Services\\n\\n- Clinical review and ART prescription from any ART service delivery point; all facility levels\\n- Distribution of ART between clinical appointments, which can be facility-based or community-based'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Focus of Counselling\\n\\n- Encourage patients to continue with what is working\\n- Reminders that any significant life event or change in daily routine could interfere with adherence'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Frequency of Follow-up\\n\\n- Clinic appointments to be made at 6 months intervals\\n- ART should be offered as refills lasting 3 months (through fast-track pick-up at facility or through community-based distribution). Patients on injectable contraception should be provided FP through a fast-tracked process between clinic follow-up visits; oral contraceptives and condoms should be distributed with ART\\n- Additional visits as required to address any medical or psychosocial concerns\\n- Closer follow-up may be arranged based on patient preference\\n\\n**Note:** Children below 2 years are excluded as they require frequent dose adjustment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## Initial Evaluation and Follow-up\\n\\nThis section outlines the recommended minimum routine follow-up schedule for people living with HIV (PLHIV) on antiretroviral therapy (ART). Clinical and laboratory monitoring is crucial for managing health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## Summary of Clinical and Laboratory Monitoring for PLHIV\\n\\nTable 3.6 summarizes the follow-up schedule and specific assessments required for PLHIV on ART across different timeframes: initial visit, ART preparation, and subsequent months after starting ART. The monitoring is categorized as follows:\\n\\n- **Appointment Frequency:**\\n  - Initial visit and ART preparation: Every week\\n  - Months after ART initiation: Varies, from 2 to 6 weeks initially, and every 1–6 months thereafter depending on patient stability.\\n\\n- **Key Assessments:**\\n  - History and Physical Exam: Conducted at each clinical visit.\\n  - Adherence Assessment and Support: Conducted at each visit.\\n  - TB Screening: Mandatory at every visit using the ICF screening tool.\\n  \\n- **Laboratory Monitoring:**\\n  - **CD4 Count:**\\n    - Baseline assessment at the initiation of ART.\\n    - Follow-up only if treatment failure is suspected or if the patient has been off ART for over 6 months.\\n  \\n  - **HIV Viral Load:**\\n    - For patients aged 0–24 years: assessed at month 3 and every 6 months thereafter.\\n    - For patients aged ≥ 25 years: assessed at month 3, month 12, and then annually if viral load is suppressed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## Monitoring for Specific Populations\\n\\nThis section details the specific monitoring requirements for certain populations such as pregnant and breastfeeding individuals.\\n\\n- **HIV Viral Load for Pregnant/Breastfeeding Women:**\\n  - If on ART upon confirming pregnancy: Assess viral load at confirmation and every 6 months until cessation of breastfeeding.\\n  - If starting ART during pregnancy or breastfeeding: Assess viral load at 3 months after initiation and then every 6 months until breastfeeding ends.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## Conclusion\\n\\nRegular clinical and laboratory monitoring is essential for maintaining the health of PLHIV on ART, enabling early detection and intervention in case of treatment failure or other complications. These protocols help ensure effective management of HIV and related comorbidities.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': '## HIV Testing and Monitoring\\n\\n- **CrAg**: Baseline for adults and adolescents with CD4 ≤ 200 cells/mm³ (as reflex testing by laboratory), then only if there is clinical suspicion of cryptococcal meningitis (CM).\\n- **Hb**: Baseline, then symptom-directed; if on AZT, baseline then at weeks 2, 4, and 12.\\n- **Pregnancy Status**: At every visit for women of reproductive age (by history +/- urine pregnancy test).\\n- **Urinalysis (protein & glucose)**: Baseline, then annually if on TDF.\\n- **Creatinine**: Baseline, then annually if on TDF.\\n- **Glucose**: Baseline, then annually.\\n- **Plasma lipid profile**: Baseline, then annually.\\n- **HBsAg**: Baseline, followed by immunization for all patients who screen negative (after viral suppression is confirmed).\\n- **Syphilis serology (VDRL, TPHA, or RPR)**: Baseline, then annually in those at risk and as part of routine antenatal care (ANC) profile.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': '## Drug Resistance Testing\\n\\n- **Drug Resistance Testing (DRT)**: Recommended once treatment failure is confirmed on a Dolutegravir (DTG) or Protease Inhibitor (PI)-based first-line regimen, or confirmed treatment failure on second line or subsequent regimens.\\n- **ALT**: Not recommended for routine baseline or follow-up unless there is a specific clinical indication.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': \"## Cervical Cancer Screening\\n\\n- **Cervical Cancer**: All women should be screened for cervical cancer following national guidelines. HPV screening is conducted every two years for HIV-positive women in their reproductive age group (or annually if using Visual Inspection with Acetic Acid - VIA, or Visual Inspection with Lugol's Iodine - VILI).\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': '## Hepatitis C Monitoring\\n\\n- **Hepatitis C (HCV)**: Baseline screening for people who inject drugs (PWIDs) or have a history of injection drug use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 58,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\n1. Recommended investigations should not delay ART initiation.  \\n2. The recommended appointment schedule encourages clinicians and patients to schedule additional appointments as needed. Patients should return to the HIV clinic for unscheduled appointments whenever an acute issue arises instead of seeking care at another facility. Early after ART initiation and after any regimen modification, every appointment should include:  \\n   - Continued adherence counseling and support (started at the initial visit).  \\n   - Assessment of adherence and correct storage of medication.  \\n   - Assessment for and management of early side effects of the drugs, along with patient counseling on the same.  \\n3. Patients who are adherent and virally suppressed at month 3 may not need subsequent monthly appointments until month 6.  \\n4. All PLHIV qualify for ART and should be initiated as soon as possible, including same day and within 2 weeks. For patients who do not start ART on the same day as enrollment into HIV care, they should be followed up every week until ART initiation to address issues delaying it, for ongoing management of acute medical issues, and for treatment preparation and ART readiness assessment.  \\n5. Refer to Table 3.1 for detailed history and physical examinations.  \\n6. In children and adolescents, weight and height should be measured and recorded at every visit, with weight-based dosing of ARVs confirmed at every visit. In adults, weight and height should be measured at the initial visit to determine nutritional status and calculate BMI; thereafter, weight should be measured at every visit.  \\n7. The first 2-4 visits are critical for assessing and supporting adherence to ART, managing adverse drug reactions, and treating any acute illnesses, including IRIS. Adherence should be assessed at every contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring, and support procedures for each visit.  \\n8. Required laboratory tests are highly recommended for patient monitoring but are not a prerequisite for ART initiation. Targeted laboratory tests may be necessary to identify and manage inter-current diseases or adverse drug reactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 58,\n",
       "  'section': '## Differentiated Care for Children, Adolescents, and Pregnant/Breastfeeding Women\\n\\nChildren, adolescents, pregnant, and breastfeeding women, as well as key populations, face unique challenges in retention and viral suppression; hence, they may benefit more from differentiated service delivery models tailored to their needs.  \\n\\n### Children:  \\nChildren’s care is dependent on family and caregiver dynamics. A family-centered approach to care—where clinic visits for parents/caregivers and the child are synchronized—should be utilized. Assessment and categorization to determine establishment on ART should be conducted for pairs, with follow-ups tailored to their situations. Weight-based dose adjustments should be incorporated in both facility and community models (e.g., using portable weighing scales if outside the health facility) to determine optimal doses for ARVs at each review. Consideration should be given to align appointments with the school calendar to avoid disruptions in treatment and the child’s learning.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Initial Evaluation and Follow Up\\n\\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, identify and address barriers to adherence, and development of IRIS. A reasonable follow-up schedule for most patients is every 2 weeks and 4 weeks after ART initiation. When possible, follow-up for a particular patient should be provided by the same care provider or team of care providers (e.g., same clinician and same counselor) at every visit. This is particularly important during the first 6 months in care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## First 6 Months after ART Initiation\\n\\nThe care in the initial 6 months includes closely monitoring for adverse effects, adherence issues, and signs of IRIS. Key points include:\\n\\n- Follow-up schedule: 2 weeks and 4 weeks post-ART initiation.\\n- Consistency in care providers is emphasized for effective monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Differentiated Service Delivery for Patients Beyond the 1st 6 Months of ART\\n\\nFollow-up of patients beyond 6 months of ART involves fewer appointments and varies by the patient’s status regarding ART establishment. \\n\\nIn summary:\\n- Patients not established on ART require closer follow-up.\\n- Established patients can have follow-ups spaced up to six months apart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Criteria for Patients Not Established on ART\\n\\nThis section outlines the specific criteria for identifying patients who are not yet established on ART:\\n\\n- On treatment for less than 6 months.\\n- Any active opportunistic infections (OIs), including TB, within the previous 6 months.\\n- Poor or questionable adherence to clinic visits in the past 6 months.\\n- Most recent viral load (VL) of 200 copies/ml or higher.\\n- Children under 2 years.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Package of Care for Patients Not Established on ART\\n\\nThe care package for patients not established on ART includes:\\n\\n- Standard Package of Care.\\n- Case management focused on addressing reasons for not being established on ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Focus of Counseling for Patients Not Established on ART\\n\\nThe counseling focus for these patients includes:\\n\\n- ART is the most important treatment to maintain good health and an active life.\\n- ART will reduce the risk of transmitting HIV to others.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Frequency of Follow-Up for Patients Not Established on ART\\n\\nFrequency of follow-up for these patients includes:\\n\\n- Every 1-3 months, based on clinical judgment.\\n- Additional visits as needed for medical or psychosocial concerns.\\n- If VL is detectable at 3 months, patients require further assessments and management until viral suppression is achieved.\\n- Patients with confirmed viral suppression can be followed every 3-6 months, with additional unscheduled visits as concerns arise.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 62,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nAll PLHIV should receive a package of services that are known to promote health, improve the quality of life, prevent further HIV transmission, and prevent HIV disease progression and mortality. The standard package of care for PLHIV includes: \\n\\n- Antiretroviral therapy\\n- Positive Health, Dignity and Prevention (PHDP) services\\n- Screening and providing support in cases of gender-based violence (GBV) or intimate-partner violence (IPV)\\n- HIV education/counselling\\n- Screening and prevention of specific opportunistic infections\\n- Reproductive health services\\n- Screening for and management of non-communicable diseases\\n- Mental health screening and management\\n- Nutritional services\\n- Prevention of other infections\\n\\n(Note: A detailed table of services, referred to as Table 4.1, is part of this section but not included here.)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 62,\n",
       "  'section': '## Patient-Centered Care in PLHIV Management\\n\\nThe standard package of care should always be applied using a patient- and family-centered approach in PLHIV management. Patient-centered care includes:\\n\\n- Considering the individual patient’s health needs\\n- Eliciting and addressing the patient’s concerns and expectations\\n- Involving the patient’s (and their family and friends as appropriate) in decision-making \\n- Respecting the patient’s values and preferences'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 62,\n",
       "  'section': '## Family-Centered Care in HIV Management\\n\\nFamily-centered care identifies, engages, and provides care to all HIV-positive family members. It aims to:\\n\\n- Prevent new infections among family members at risk\\n- Promote family support and awareness concerning HIV'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Adolescents and Psychosocial Support\\n\\nAdolescents require psychosocial support, ongoing adherence assessments, and counseling, aligned with clinic visits, community follow-up, and the school calendar. Special considerations should be made during clinical encounters, particularly focusing on those facing adherence and viral suppression challenges. Adolescents and youth-friendly services should incorporate life skills and extracurricular activities where feasible.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Pregnant and Breastfeeding Women\\n\\nPregnant and breastfeeding women established on ART should have their HIV clinic appointments synchronized with antenatal care visits and follow-ups for the HIV-exposed infant. Women who are initiated on ART during pregnancy may need close follow-up to support adherence, retention, and achieving viral suppression. Clinical visits for breastfeeding women and their babies should align with the immunization clinic schedule. Psychosocial support groups, including peer-to-peer support, are encouraged for both pregnant and breastfeeding mothers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## ART Prescription, Dispensing, and Distribution\\n\\nPatients established on ART should be offered ART refills of up to 3 months. Other associated commodities such as cotrimoxazole, TPT, and condoms should align with the ART refill schedule. Clients established on ART should receive their medications through a distribution system that minimizes burdens, including travel costs and waiting times. This process must be voluntary, allowing clients the option to remain in standard care if preferred.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Health Facility Responsibilities\\n\\nThe health facility is responsible for ART prescription, dispensing, and distribution for all patients enrolled in care. ART distribution can occur either at the health facility or through a community distribution system, based on patient preference and available resources. The method of ART dispensing should allow easy client access to treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Models for ART Refills\\n\\nModels for ART refills include:\\n\\n- **Facility-based:**\\n  - Fast track facility-based refills\\n  - Facility-based ART distribution groups\\n  \\n- **Community-based:**\\n  - Community-based ART distribution groups\\n  - Community ART distribution points\\n  - Community pharmacy distribution'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Facility-based Fast Track System for ART Refills\\n\\nThe facility-based fast track system for ART refills is implemented at the health facility. Clients are required to visit the clinic every 3 months for ART refills, but these appointments should entail minimal or no waiting time. For detailed information on community models, refer to the DSD operational manual.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Kenya HIV Prevention Strategies\\n\\nThis section details the various strategies implemented in Kenya to prevent HIV transmission. It includes information on safe sex practices, pre-exposure prophylaxis (PrEP), and mother-to-child transmission prevention methods.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## HIV Treatment Protocols\\n\\nThis section outlines the treatment protocols for individuals diagnosed with HIV in Kenya. Key information includes antiretroviral therapy (ART) guidelines, adherence support, and management of drug resistance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Testing and Diagnosis\\n\\nHere, the guidelines for HIV testing and diagnosis are described. This encompasses the types of tests available, recommendations for routine testing, and specific testing for high-risk populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Monitoring and Support Services\\n\\nThis section discusses the necessary monitoring and support services for people living with HIV. It includes recommendations on routine health assessments, viral load monitoring, and psychosocial support mechanisms.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Key Populations and Tailored Interventions\\n\\nThis section focuses on key populations that are disproportionately affected by HIV. It highlights tailored interventions designed to address the unique needs of these groups, including men who have sex with men, sex workers, and intravenous drug users.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Community Engagement and Education\\n\\nThis section covers the importance of community engagement and education in HIV prevention. It discusses strategies for raising awareness, combating stigma, and promoting community-led health initiatives.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Legal and Ethical Considerations\\n\\nHere, the legal and ethical aspects surrounding HIV prevention and treatment in Kenya are presented. This includes patient rights, confidentiality, and the legal frameworks that govern HIV-related healthcare.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Research and Data Surveillance\\n\\nThis section highlights the role of research and data surveillance in informing HIV strategies. It discusses the necessity of ongoing research, monitoring epidemiological trends, and utilizing data to improve health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Conclusion and Future Directions\\n\\nThe final section outlines the conclusion of the guidelines and potential future directions for HIV prevention and treatment in Kenya. It emphasizes the need for continuous evaluation and adaptation of strategies based on emerging evidence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Components of the Standard Package of Care for PLHIV\\n\\nThis section outlines the key components of the Standard Package of Care for People Living with HIV (PLHIV) as per the Kenya HIV Prevention and Treatment Guidelines, 2022.\\n\\n1. **Antiretroviral therapy (ART)**\\n   - ART initiation\\n   - Adherence assessment, counselling, and support\\n   - Monitoring (clinical and laboratory)\\n\\n2. **Positive health, dignity and prevention (PHDP); gender-based violence (GBV) and intimate-partner violence (IPV) screening; and HIV education/counselling**\\n   - Disclosure\\n   - Index testing\\n   - Condom use\\n   - Family planning\\n   - STI screening, prevention, and treatment\\n   - Adherence counselling and support\\n   - Pre-exposure prophylaxis for HIV-negative sexual partners\\n   - GBV/IPV screening and support\\n   - HIV education/counselling\\n\\n3. **Specific opportunistic infection screening and prevention**\\n   - Cotrimoxazole preventive therapy\\n   - Tuberculosis (TB):\\n     - Intensified case finding\\n     - TB preventive therapy\\n     - ART for TB/HIV co-infected patients\\n   - Cryptococcal meningitis\\n\\n4. **Reproductive health services**\\n   - Sexually transmitted infections screening and management\\n   - Family planning and pre-conception services\\n   - Maternal healthcare\\n   - Cervical cancer screening\\n\\n5. **Non-communicable diseases (NCD) screening and management**\\n   - Hypertension\\n   - Diabetes mellitus\\n   - Dyslipidemia\\n   - Chronic kidney disease\\n   - Other NCDs\\n\\n6. **Mental health screening and management**\\n   - Depression\\n   - Anxiety\\n   - Stress\\n   - Trauma\\n   - Alcohol and drug use/addiction\\n   - Self-care and wellbeing\\n\\n7. **Nutritional services**\\n   - Assessment\\n   - Counselling and education\\n   - Management and support\\n\\n8. **Prevention of other infections**\\n   - Immunizations\\n   - Malaria\\n   - Safe water, sanitation, and hygiene'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 65,\n",
       "  'section': '## Standard Package of Care for Adolescents Living with HIV\\n\\n### Clinical Care\\n- Provide immediate linkage to HIV care\\n- Provide ART to all HIV-infected adolescents\\n- Perform clinical and laboratory assessments\\n- Conduct clinical assessments at every visit, treat infections early, and refer appropriately where specialized care is required\\n- Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)\\n- Provide nutritional assessment and counseling (NACS) and monitor growth and development\\n- Provide/refer for HPV vaccine\\n\\n### Adherence and Psychosocial Support\\n- Perform a baseline and regular subsequent psychosocial assessment\\n- Assess for and support disclosure of HIV status to the adolescent\\n- Enroll in age-appropriate psychosocial support groups\\n- Provide treatment literacy \\n- Provide life skills counseling\\n- Provide adherence counseling\\n- Support appropriate transition into adult HIV treatment and prevention\\n\\n### Prevention of HIV Transmission\\n- Encourage index testing and support for disclosure\\n- Assess for and manage drug and alcohol use\\n- Perform a sexual risk assessment and STI screening and treatment; link sexual partners to PrEP where applicable\\n- Assess for and manage Intimate Partner Violence (IPV)\\n- Provide reproductive health services, including pregnancy screening, pregnancy intention assessment, family planning, and linkage to PMTCT for pregnant adolescents\\n\\n### Referrals, Linkages, and Support for Continuum of Care\\n- Provide intra-facility and inter-facility referrals as needed for specialized care\\n- Link with youth community groups, targeting youth both in and out of school\\n\\n### Other Services\\n- Legal centers\\n- Paralegal services\\n- Gender-based violence recovery centers\\n- Educational institutions\\n- Bursary/scholarship programs\\n- Income-generating activities\\n- Constituency development funds\\n- Vocational training centers for skills development'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 65,\n",
       "  'section': '## Antiretroviral Therapy\\n\\nART is recommended for all People Living with HIV (PLHIV), regardless of WHO stage, CD4 count, age, pregnancy status, or comorbidities/co-infections. Once a diagnosis of HIV infection is confirmed, ART should be initiated as soon as possible (preferably within 2 weeks), once patient readiness has been determined. Other sections of these guidelines cover initial evaluation and monitoring, patient preparation and adherence support, and specific recommended ART regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 64,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the core components of care for people living with HIV (PLHIV). It includes the following elements that need to be addressed in their treatment and support plans.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 64,\n",
       "  'section': '## Standard Package of Care for HIV-Exposed and HIV-Infected Infants\\n\\nThis section details the essential care protocols for infants who are either exposed to or infected with HIV. Key elements include:\\n\\n- **HIV Status Determination**: Determine HIV status at first contact through HIV testing services (HTS) and Early Infant Diagnosis (EID), linking to HIV care.\\n  \\n- **ARV Prophylaxis and ART**: Provide Antiretroviral (ARV) prophylaxis for all HIV-exposed infants (HEIs) and ART for all HIV-infected children, ensuring correct weight-based dosing of ARVs at every visit. Perform clinical and laboratory assessments regularly.\\n  \\n- **Nutritional Support**: Conduct nutritional assessments, counseling, and support (NACS) and monitor growth and development of the child as indicated in Annex 3.\\n  \\n- **Immunization Protocols**: Ensure that all immunizations are provided in accordance with the national schedule.\\n  \\n- **Clinical Assessment and Infection Management**: Conduct clinical assessments at every visit, treat infections early, and manage and report adverse drug reactions aggressively. Refer to specialized care as necessary.\\n  \\n- **Screening for Opportunistic Infections**: Screen for opportunistic infections and provide prophylaxis, including cotrimoxazole, TB Preventive Therapy (TPT), and deworming every 6 months (starting at 1 year of age). Supplement with Vitamin A every 6 months starting at age 6 months.\\n  \\n- **Caregiver Education**: Educate the caregiver on all aspects of care, including infant feeding, immunizations, personal hygiene, HIV education/counseling, adherence to treatment, and follow-up requirements.\\n  \\n- **Adherence Support**: Assess adherence, provide counseling, and support for the family and child.\\n  \\n- **Psychosocial Support**: Offer age-appropriate psychosocial support for both family and child, making referrals to community-based support programs when necessary.\\n  \\n- **Caregiver and Family Support**: Ensure that caregivers and family members receive appropriate care, support, and treatment.\\n  \\n- **Intensive Case Management**: Provide intensive case management for mother/infant pairs until 2 years postpartum. Identify defaulters and prioritize tracking this population.\\n  \\n- **Enrollment in Support Programs**: Enroll families into the Orphans and Vulnerable Children (OVC) program for additional social protection and services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 66,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section introduces the standard package of care for people living with HIV (PLHIV), focusing on the framework of Positive Health, Dignity, and Prevention (PHDP). It highlights the importance of prioritizing health and rights while reducing the risk of onward transmission of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 66,\n",
       "  'section': '## PHDP Framework and Core Domains\\n\\nPHDP emphasizes providing comprehensive care for PLHIV and their caregivers. This section outlines the seven core domains of services to be provided at health facilities.\\n\\n### Core Domains and Components for PHDP Services\\n\\n1. **Disclosure of HIV Status**\\n   - Assessment of disclosure status, particularly to sexual partners.\\n   - Assisted disclosure.\\n   - Special considerations for children and adolescents regarding age-appropriate disclosure (see Annex 5).\\n\\n2. **Index Testing and Engagement**\\n   - HIV testing of sexual and drug-injecting partners.\\n   - HIV testing of other family members at risk.\\n   - Enrolment of positive family members into HIV care.\\n   - Engagement of negative partners and family members in care and support for the index patient, including PrEP as appropriate.\\n\\n3. **Condom Use**\\n   - Risk reduction counseling.\\n   - Correct and consistent condom use.\\n   - Provision of condoms at every visit.\\n\\n4. **Family Planning**\\n   - Assessment of pregnancy intention.\\n   - Pre-conception counseling.\\n   - Dual contraception until readiness for pregnancy (refer to Section 4.4.2 for clinical guidelines).\\n\\n5. **Sexually Transmitted Infections (STI)**\\n   - Screening for symptoms of STIs.\\n   - Prevention of STIs (refer to Section 4.4.1 for clinical guidelines).\\n\\n6. **Treatment Adherence**\\n   - Emphasizing the importance of adherence to clinical care and ART.\\n   - Messaging on Undetectable = Untransmissible (U=U) (see Chapter 5).\\n\\n7. **Pre-exposure Prophylaxis (PrEP)**\\n   - Assessing HIV-negative sexual partners for PrEP (see Chapter 11).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 66,\n",
       "  'section': '## Additional Services for PLHIV\\n\\nThis section emphasizes the importance of offering additional services to PLHIV beyond the core PHDP components. These services include screening for gender-based violence (GBV) and intimate partner violence (IPV) as well as HIV education and counseling services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 72,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the general care protocols for people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 72,\n",
       "  'section': '## Tuberculosis (TB) Prevention and Management for PLHIV\\n\\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool. All PLHIV older than 12 months who screen negative for TB should be provided with TB Preventive Therapy (TPT) unless they have a specific contraindication. Documentation of TPT is mandatory for all patients receiving a full course. For those with presumptive TB, GeneXpert ultra is the preferred testing platform for diagnosis confirmation, with TB-LAM as an adjunct bedside test. All PLHIV qualify for ART, including patients with HIV/TB co-infection. Further guidelines are provided in Chapter 8 regarding ICF, TPT, GeneXpert ultra, TB-LAM, and ART for TB/HIV co-infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 72,\n",
       "  'section': '## Cryptococcal Meningitis (CM) Screening and Treatment\\n\\nAdult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm³ should be screened for cryptococcal infection, which should be a reflex test by the laboratory. Symptomatic PLHIV of all ages should also undergo screening. For patients with meningitis symptoms but a negative serum CrAg, alternative diagnoses like TB meningitis should be considered. Management should occur at facilities capable of performing lumbar punctures. A CSF CrAg test should be performed for symptomatic meningitis patients, alongside a CSF GeneXpert ultra for TB and urine for TB-LAM.\\n\\nIn pregnant women screening positive for serum CrAg, a lumbar puncture should be offered regardless of symptoms. If positive for cryptococcal meningitis, treatment should consist of 2 weeks of amphotericin B for induction without fluconazole, and consolidation/maintenance should be discussed via the Uliza! hotline. Negative CSF CrAg results warrant immediate ART initiation without pre-emptive fluconazole, along with monitoring for CM symptoms. Detailed treatment guidance for symptomatic cryptococcal meningitis, including amphotericin, fluconazole, and flucytosine, can be found in Table 4.7.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 68,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the comprehensive care approach for people living with HIV (PLHIV), including aspects of healthcare, emotional support, and safety considerations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 68,\n",
       "  'section': '## Screening for GBV/IPV (LIVES)\\n\\n### Components of Screening:\\n1. **Listen**: Listen to the client closely, with empathy and without judging.\\n2. **Inquire**: Assess and respond to the client’s various needs and concerns.\\n3. **Validate**: Show the client that you understand and believe them. Assure the client that they are not to blame.\\n4. **Enhance safety**: Discuss a plan to protect the client from further harm if violence occurs again.\\n5. **Support**: Help the client access information, services, and social support.\\n\\n### Supportive Messages:\\n- “What happened to you is not your fault.”\\n- “Many women/men are in the same situation as you.”\\n- “You are not to blame.”\\n- “Everybody deserves to feel safe at home. If you feel like you are in immediate danger, we can involve the police or local administration.”\\n\\n### Vulnerable Populations:\\nMen, the elderly, and children may suffer different forms of violence and should be assessed if there is any clinical suspicion. Key populations, including MSM, transgender individuals, and prisoners, are particularly vulnerable to abuse. For children, art and play therapy may be used during history taking and psychological assessment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 68,\n",
       "  'section': '## HIV Education/Counseling \\n\\nThis section emphasizes the importance of education and psychosocial support for PLHIV and their caregivers.\\n\\n### Key Components of HIV Education:\\n- Focused education about HIV and its treatment.\\n- Empowerment for effective self-management of the infection.\\n\\n### Key Messages for Counseling:\\n- Mitigation of fear, anger, self-stigma, and discrimination.\\n- Alleviation of grief, bewilderment, and stress among partners and family members.\\n- Behavior changes to support healthy living and prevent further HIV transmission.\\n- Skills-building for a healthy and productive life.\\n- Identification and treatment of depression and substance abuse.\\n\\n### Delivery Settings:\\nHIV education and counseling can be offered in multiple settings, including:\\n- Facility-based individual, couples, family, or group counseling.\\n- Community-based counseling and peer support groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 67,\n",
       "  'section': '## Screening for Gender-Based Violence (GBV) and Intimate Partner Violence (IPV)\\n\\nNational data (KDHS 2014) shows that 45% of women and 44% of men aged 15-49 years have experienced physical violence since age 15. Additionally, 14% of women and 6% of men in this age group report having experienced sexual violence at least once in their lifetime. To identify survivors, screening is recommended.\\n\\n### Minimum Requirements for Screening\\nWHO recommends that facilities meet the following minimum requirements before starting routine screening:\\n\\n- A protocol or Standard Operating Procedure exists for providing post-GBV and Violence Against Children services.\\n- A questionnaire with standard questions where providers can document responses.\\n- Providers offer first-line support (LIVES).\\n- Providers have received training on how to ask about GBV and Violence Against Children.\\n- Private setting and confidentiality ensured.\\n- A system for referrals or linkages to other services within the facility is in place.\\n\\nIf any of these requirements are missing, GBV and Violence Against Children services are deemed inadequate, and providers must ensure these systems are in place before conducting routine inquiries.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 67,\n",
       "  'section': '## Screening Clients Accessing HIV Care Services\\n\\nAll clients accessing HIV care services should be screened for any form of violence, including IPV, as part of the standard package of care for People Living with HIV (PLHIV).\\n\\n### Suggested Screening Script\\nProviders can use the following script to screen clients:\\n\\n“Many people do not realize that violence can lead to various serious health problems. Many people have problems with their husbands, partners, or other people in their lives. Sometimes the people who love us can hurt us. Has this ever happened to you?”\\n\\n#### Screening Questions\\nHas your partner ever:\\n\\n1. Insulted you or made you feel bad about yourself?\\n2. Belittled or humiliated you in front of other people?\\n3. Did things to scare or intimidate you on purpose?\\n4. Threatened to hurt you or someone you care about?\\n5. Slapped you or thrown something at you that could hurt you?\\n6. Kicked, dragged, or beat you up?\\n7. Choked or burned you on purpose?\\n8. Threatened to use or actually used a gun, knife, or other weapon against you?\\n9. Physically forced you to have sexual intercourse when you did not want it?\\n10. Did you ever have sexual intercourse you did not want because you were afraid of what he might do?\\n11. Forced you to do something sexual that you found degrading or humiliating?\\n\\nIf a survivor answers yes to any of these questions, providers should offer LIVES and conduct a mental assessment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines Overview\\n\\nThis document outlines the Kenya HIV Prevention and Treatment Guidelines for 2022, focusing on specific recommendations for opportunistic infection screening and prevention.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Specific Opportunistic Infection Screening and Prevention\\n\\nThis section provides an overview of recommendations for the screening and prevention of specific opportunistic infections in individuals with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Cotrimoxazole Preventive Therapy (CPT)\\n\\nCPT is no longer recommended as lifelong prophylaxis and is only suggested for specific subpopulations, unless there is an allergy to sulfur drugs or toxicity from CPT. The subpopulations include:\\n\\n- **HIV exposed infants**\\n- **HIV infected children and adolescents under 15 years of age**\\n- **People Living with HIV (PLHIV) over 15 years of age** who are:\\n  - Living in malaria-endemic zones\\n  - Presenting with WHO stage 3 or 4 events or meeting the criteria for Advanced HIV Disease (AHD)\\n  - Suspected treatment failure\\n- **Pregnant and breastfeeding women**\\n\\nCPT is to be initiated at 6 weeks of age for HIV exposed and infected infants. Its effectiveness includes preventing specific opportunistic infections (PCP and toxoplasmosis) and reducing the risk of common bacterial infections, sepsis, diarrhea, and malaria.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Co-trimoxazole Preventive Therapy Guidelines\\n\\n### Sub-Population Recommendations\\n\\n#### HIV Exposed Infants\\n- **Starting Criteria**: All infants, starting 4-6 weeks after birth\\n- **Ending Criteria**: Child is confirmed HIV-negative\\n\\n#### HIV-Infected Children and Adolescents ≤ 15 years old\\n- **Starting Criteria**: All children\\n- **Ending Criteria**: Attains 15 years of age\\n\\n#### PLHIV > 15 Years Old\\n- **Starting Criteria**: Suspected treatment failure or WHO clinical stage 3 and 4\\n- **Ending Criteria**: Clinically stable, on ART for at least 12 months, showing no signs or symptoms of WHO clinical stage 2, 3, or 4\\n\\n#### HIV-Positive Pregnant and Breastfeeding Women\\n- **Starting Criteria**: All clinically stable individuals\\n- **Ending Criteria**: On ART for at least 12 months, showing no signs or symptoms of WHO clinical stage 2, 3, or 4, and not pregnant or breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 71,\n",
       "  'section': '## Cotrimoxazole Desensitization Protocols\\n\\n### Standard Cotrimoxazole Desensitization Regimen (8 days)\\n\\n- **Day 1**: 0.5 ml of TMP/SMX Suspension (40/200 mg per 5 ml)  \\n- **Day 2**: 1 ml  \\n- **Day 3**: 2 ml  \\n- **Day 4**: 3 ml  \\n- **Day 5**: 4 ml  \\n- **Day 6**: 5 ml  \\n- **Day 7**: 1 SS tablet  \\n- **Day 8**: 2 SS tablets or 1 DS tablet per day  \\n- **Note**: For children, continue up until they have reached their recommended weight-based dosage.\\n\\n### Rapid Cotrimoxazole Desensitization Regimen (6 hours)\\n\\n- **Hour 0**: 0.5 ml of TMP/SMX Suspension (40/200 mg per 5 ml)  \\n- **Hour 1**: 1 ml  \\n- **Hour 2**: 2 ml  \\n- **Hour 3**: 3 ml  \\n- **Hour 4**: 4 ml  \\n- **Hour 5**: 5 ml  \\n- **Hour 6**: 1 SS tablet  \\n- **Note**: This protocol should not be used for children due to the high cumulative dosage.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 71,\n",
       "  'section': '## Dapsone as a Substitute for Cotrimoxazole Prophylaxis (CPT)\\n\\n- **Usage**: In cases of severe allergy to cotrimoxazole or unsuccessful desensitization, dapsone may be used as a substitute for CPT. It primarily provides prophylaxis against PCP but lacks the additional prophylactic benefits of cotrimoxazole.\\n  \\n### Important Considerations\\n- Dapsone can lead to anemia in most patients and may cause hemolytic anemia in some. A baseline hemoglobin (Hb) level should be obtained before starting dapsone, with Hb monitored every 1-2 weeks for the first couple of months.\\n- Dapsone is only recommended for patients in WHO Stage 4 and/or those with an absolute CD4 count ≤ 200 cells/mm³ (or CD4 % ≤ 25% for children ≤ 5 years). It should be discontinued once the patient maintains a CD4 count of > 200 cells/mm³ (or > 25% for children ≤ 5 years) for at least 6 months.\\n- **Contraindication**: Dapsone is NOT recommended during breastfeeding.\\n\\n### Dapsone Dosage\\n- **Available Forms**: 25 mg and 100 mg tablets  \\n- **Children**: 2 mg/kg once daily (max dose: 100 mg) or 4 mg/kg once weekly (max dose: 200 mg)  \\n- **Adults**: 100 mg once daily'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 73,\n",
       "  'section': '## Treatment of Cryptococcal Meningitis in Adults\\n\\n### Target Population\\n- **Adults**\\n\\n### Regimen\\n- **Induction (2 weeks)**\\n  - **Preferred:** Amphotercin B 1.0 mg/kg/day + Fluconazole 1,200 mg/day\\n  - **Alternative:** Fluconazole 1,600 mg daily\\n\\n- **Consolidation (8 weeks)**\\n  - **Preferred:** Fluconazole 800 mg/day\\n  - **Alternative:** Fluconazole 800 mg daily\\n\\n- **Maintenance**\\n  - Fluconazole 200 mg/day for at least 1 year and until CD4 count is > 200 cells/mm³ for two measures 6 months apart AND viral load (VL) is undetectable\\n\\n### When to Start ART\\n- Defer ART until after completing 5 weeks of cryptococcal meningitis (CM) treatment and symptoms have resolved.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 73,\n",
       "  'section': '## Treatment of Cryptococcal Meningitis in Children and Adolescents\\n\\n### Target Population\\n- **Children and Adolescents**\\n\\n### Regimen\\n- **Induction (2 weeks)**\\n  - **Preferred:** Amphotercin B 1.0 mg/kg/day + Fluconazole 12 mg/kg/day (up to max 800 mg/day)\\n  - **Alternative:** Fluconazole 12 mg/kg/day (up to max 1,600 mg/day)\\n\\n- **Consolidation (8 weeks)**\\n  - **Preferred:** Fluconazole 6-12 mg/kg/day up to 800 mg/day\\n  - **Alternative:** Fluconazole 12 mg/kg/day up to 800 mg/day\\n\\n- **Maintenance**\\n  - Fluconazole 6 mg/kg/day up to 200 mg/day'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 73,\n",
       "  'section': '## Important Considerations for Fluconazole\\n\\n### Dosing Adjustments\\n1. **Renal Function:**\\n   - Fluconazole requires a dose adjustment for impaired renal function; when creatinine clearance (CrCl) ≤ 50 ml/min, use 50% of the standard recommended dose.\\n\\n2. **Drug Interactions:**\\n   - Fluconazole should not be used with rifabutin-based TB treatment.\\n\\n3. **Monitoring:**\\n   - When using high-dose fluconazole, check ALT after one week of treatment and based on symptoms thereafter.\\n\\n### Pregnancy Considerations\\n- Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used as an alternative. Consultation with an expert or the National or Regional Technical Working Group (TWG) is advised.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 73,\n",
       "  'section': '## Additional Notes on Amphotericin B\\n\\n- Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks of induction with amphotericin due to availability, toxicity, or monitoring, then use a shorter duration of amphotericin and complete the 14-day induction period with the alternative regimen.\\n- Once available, flucytosine may become part of the preferred and alternative induction regimens, given at 100 mg/kg per day divided into four doses per day.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section provides an overview of the standard package of care for people living with HIV (PLHIV), focusing on reproductive health services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '## Reproductive Health Services\\n\\nThis section outlines reproductive health services available to PLHIV, emphasizing the importance of screening and treatment for sexually transmitted infections (STIs), family planning, and pre-conception counselling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '### 4.4.1 Sexually Transmitted Infections\\n\\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation for all adolescent and adult PLHIV. Pregnant women should be screened for syphilis during the first ANC visit and third trimester. All PLHIV should be assessed for symptoms of STIs using the National Algorithms for Treating Common STI Syndromes (Kenya National guidelines for management and control of STIs, 2018). Sexual partners should be treated as well. Risk reduction counselling and provision of condoms are integral parts of STI treatment. Patients with persistent signs and symptoms of STIs after syndromic treatment should undergo diagnostic evaluation for definitive diagnosis and treatment. At the initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and chlamydia, with presumptive treatment every quarter.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '### 4.4.2 Family Planning and Pre-Conception Counselling\\n\\nPregnancy status should be determined for all women of reproductive age at every visit, based on the history of the last menstrual period, with a urine pregnancy test performed if uncertain or irregular. Pregnancy intention should be assessed for all women of reproductive age and their partners to provide appropriate family planning or pre-conception counselling. For patients who do not wish to become pregnant immediately, dual contraception (condoms plus another form of effective contraception) should be provided immediately, with follow-up appointments scheduled to ensure ongoing contraception provision. Table 4.8 outlines contraception options for PLHIV based on the antiretrovirals (ARVs) they are using.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the standard care recommendations for People Living with HIV (PLHIV), specifically focusing on Cotrimoxazole Preventive Therapy (CPT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Cotrimoxazole Dosage for Preventive Therapy\\n\\n### Daily Dose Recommendations\\n\\n| Weight (kg) | If using oral suspension (240mg per 5ml) | If using single strength tablet 480 mg (SS) | If using double strength tablet 960 mg (DS) |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '--|\\n| 1 – 4       | 2.5 ml                                   | ¼ SS tab                                   | --                                         |\\n| 5 – 8       | 5 ml                                     | ½ SS tab                                   | ¼ DS tab                                   |\\n| 9 – 16      | 10 ml                                    | 1 SS tab                                   | ½ DS tab                                   |\\n| 17 – 30     | 15 ml                                    | 2 SS tabs                                  | 1 DS tab                                   |\\n| > 30       | 20 ml                                    | 2 SS tabs                                  | 1 DS tab                                   |\\n| Adult (any weight) | --                              | 2 SS tabs                                  | 1 DS tab                                   |\\n\\n**Note:** If CrCl 15 -30 ml/min, use 50% of the normal recommended dose; if CrCl < 15 ml/min, then CPT should be avoided.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Cotrimoxazole During Pregnancy\\n\\nCPT should be initiated for women during pregnancy, irrespective of gestational age, and should continue throughout pregnancy and breastfeeding. Additional intermittent preventive therapy (sulfadoxine-pyrimethamine (SP)) for malaria is not required for women who are already on CPT.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Side Effects of Cotrimoxazole\\n\\nCotrimoxazole can cause anemia and neutropenia in some patients, as well as skin rash.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Management of Patients with Cotrimoxazole Allergy\\n\\n### Rash Development\\n\\nA rash may develop in patients, usually 7-14 days after initiating CPT, often presenting as a mild maculopapular rash, with or without pruritus. Infrequently, severe skin reactions such as Stevens-Johnson syndrome may occur. \\n\\n### Rash Severity and Management\\n\\n#### Table 4.5: Management of Drug-Associated Skin Rash\\n\\n| Severity | Characteristics                                        | Action                                                                                       |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '|\\n| Mild     | Dry, erythema +/- fine papules, pruritus; < 50% body | Continue CTX; close monitoring; symptomatic treatment with antihistamines +/- topical steroids (NOT oral steroids) |\\n| Moderate | Dry, erythema +/- fine papules, pruritus; ≥ 50% body | Stop CTX; symptomatic treatment with antihistamines +/- topical steroids (NOT oral steroids); trial of desensitization after symptoms completely resolved |\\n| Severe   | Mucosal involvement, blistering, fever; any % body    | Stop CTX; hospital admission for supportive management; patient should NEVER be re-challenged with CTX or other sulfa-containing drugs; document and report adverse event and issue patient alert card |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Desensitization Protocol\\n\\nDesensitization is effective in the majority of patients with mild to moderate rash. A rapid desensitization regimen can be used when treatment for Pneumocystis jirovecii pneumonia (PCP) is needed. \\n\\n### References for Desensitization\\n\\nSpecific tables outlining desensitization protocols are referenced (Table 4.6a and 4.6b), for those requiring further details on the management strategy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nOverview of care protocols for individuals living with HIV, focused on therapeutic and monitoring practices during Amphotericin B therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Managing and Monitoring for Amphotericin B Therapy\\n\\n### Adults\\n- Administer 1 L of normal saline with 20 mmol of KCl over 2-4 hours before each controlled infusion of Amphotericin B, which should be administered with 1 litre of 5% dextrose.\\n- Include one to two tablets of 8 mEq KCl orally twice daily. An additional 8 mEq KCl tablet may be added during the second week.\\n- Include magnesium supplementation at 250 mg of magnesium trisilicate tablets twice daily (or 4 mEq tablets of magnesium chloride twice daily).\\n\\n### Adolescents and Children\\n- Administer 1 L of normal saline with 20 mmol of KCl over 2-4 hours before each controlled infusion of Amphotericin B. Darrows or Ringer’s solutions can also be utilized.\\n- Note: Avoid KCl replacement in patients with pre-existing renal impairment or hyperkalemia.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Managing Hypokalaemia and Raised Creatinine Levels\\n\\n- Obtain routine baseline measurements for potassium and creatinine levels twice weekly.\\n  \\n  - If potassium (K) level is < 3.3 mmol/L:\\n    - Administer 1 L of normal saline with KCl 40 mmol in normal saline or 1-2 tablets of 8 mEq KCl every 8 hours. Additionally, give magnesium. Monitor potassium levels daily.\\n    \\n  - If the creatinine level increases > 2-fold from baseline:\\n    - Omit the dose of Amphotericin B and increase hydration to 1 L every 8 hours. If improvement is observed, restart Amphotericin B at 0.7 mg/kg/day on alternate days. If no improvement, discontinue Amphotericin B and administer fluconazole at 1,600 mg/day to complete induction. Monitor creatinine daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Therapeutic Lumbar Punctures\\n\\n- Therapeutic lumbar punctures are critical in the management of cryptococcal meningitis (CM) and should be standard practice.\\n\\n  - For all patients with symptomatic CM:\\n    - Perform daily therapeutic lumbar punctures.\\n      - If opening pressure is ≤ 40 cm: Draw off enough cerebrospinal fluid (CSF) to reduce pressure to 20 cm.\\n      - If opening pressure is > 40 cm: Draw off enough CSF to reduce pressure by 50%.\\n    - Continue daily lumbar punctures until pressure is normal for 3 consecutive days. Restart lumbar punctures if symptoms return.\\n  \\n- If measuring intracranial pressure is not feasible, perform daily therapeutic lumbar punctures until severe headache subsides, removing 10-20 ml of CSF each time.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nOverview of the 2022 guidelines for HIV prevention and treatment in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '## Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria\\n\\nDetails the various contraceptive methods appropriate for People Living with HIV (PLHIV), aligned with WHO guidelines.\\n\\n### Contraceptive Methods and ARVs Interaction\\n\\n- **IM Medroxyprogesterone (DMPA; Depo Provera)**:  \\n  ARVs: NRTI, NNRTI, PI/r, INSTI – All Categories 1.\\n\\n- **Norethisterone Enanthate (NET-EN; Norethindrone)**:  \\n  Interaction with ARVs has varying category ratings (1-2).\\n\\n- **Implants**:  \\n  Similar to NET-EN with ratings ranging from 1-2 based on ARVs.\\n\\n- **Combined Oral Contraceptive (Pill)**:  \\n  Interaction results in ratings of 1-3 depending on ARVs.\\n\\n- **Intrauterine Device (IUD)**:  \\n  - **Initiation**: Category 2 for asymptomatic or mild HIV disease; Category 3 for women with advanced HIV until stable.\\n  - **Continuation**: Category 2 for all women regardless of symptomatic HIV.\\n\\n### Other Contraceptive Options\\n\\n- **Condoms**:  \\n  No restrictions; recommended for dual protection against STI/HIV.\\n\\n- **Emergency Contraceptive Pill (ECP)**:  \\n  No restrictions; usable up to 5 days post-intercourse.\\n\\n- **Sterilization**:  \\n  Not to be denied; delayed if there is an acute HIV-related infection.\\n\\n- **Fertility Awareness-Based (FAB) Methods**:  \\n  Usable if menstrual cycles are regular; should be paired with condoms.\\n\\n- **Lactational Amenorrhea Method (LAM)**:  \\n  Effective for breastfeeding women; recommended combo with condoms.\\n\\n- **Spermicides and Diaphragm**:  \\n  Not recommended due to increased HIV transmission risk.\\n\\n### Categories of Contraceptive Methods\\n\\n- **Category 1**: No restriction for the use of the contraceptive.\\n- **Category 2**: Advantages generally outweigh risks.\\n- **Category 3**: Risks usually outweigh advantages.\\n\\n*Note: DTG interactions with hormonal contraception not identified even though not included in WHO 2018 MEC Guidelines.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '## Pre-Conception Messages and Services\\n\\nDetails on key pre-conception messages and services for patients intending to become pregnant, as documented in Table 4.9.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the essential elements included in the care approach for People Living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Smoking Cessation\\n\\nSmoking cessation has multiple short-term and long-term benefits, including:\\n\\n- Reduced premature aging/wrinkling of skin\\n- Improved fitness and quicker recovery from common infections\\n- Reduced risk of respiratory infections and chronic lung disease\\n- Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke\\n- Improved infant outcomes (for pregnant women)\\n- Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus\\n- Better response to ART (better viral suppression)\\n- Reduced risk of developing TB or dying from TB\\n\\nTobacco dependence treatment and cessation programs should combine behavioral/counseling support with pharmacotherapy treatment where necessary and available. For further details on cessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence Treatment. \\n\\nRefer to Table 4.18 for tips to assist a client to quit smoking.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Dietary Changes and Weight Loss\\n\\nThis section focuses on dietary modifications to promote weight management and overall health for PLHIV:\\n\\n- Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)\\n- Drink 8 glasses of water per day\\n- Reduce/abstain from alcohol\\n- Cut down sugar intake\\n- Cut down red meat intake\\n- Cut down consumption of fatty foods, fat for flavoring, and fried foods\\n- Increase intake of whole grains, vegetables, fruit, and beans\\n- Increase intake of fish\\n- Consume less than 5 g (just under a teaspoon) of salt per day'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Physical Activity\\n\\nEngaging in physical activity is crucial for maintaining health. This section recommends:\\n\\n- An active lifestyle with moderate-intensity physical activity\\n- At least 30 minutes of aerobic activity, such as brisk walking, on at least 5 days per week'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the essential care provided to People Living with HIV (PLHIV), emphasizing the importance of Antiretroviral Therapy (ART) and routine medical checks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Pre-Conception Counselling Messages for All Women/Couples\\n\\nThis section covers key counselling messages and pre-conception services for PLHIV who intend to conceive.\\n\\n- All PLHIV qualify for ART, which should ideally begin within 2 weeks of HIV diagnosis.\\n- Delaying pregnancy until there is confirmed viral suppression reduces risks to the baby and improves outcomes for both mother and infant.\\n- Unprotected sex should be limited to ovulation days, using methods like basal temperature monitoring or fertility calendars.\\n- Routine Antenatal Care (ANC) and delivery by qualified health providers are vital for better outcomes.\\n\\n### Pre-Conception Services Include:\\n- ART initiation for all PLHIV\\n- Baseline Investigations:\\n  - Hemoglobin assessment and management of anemia\\n  - Syphilis screening\\n  - Cervical cancer screening\\n- Screening for STI symptoms\\n- Nutritional assessment and counselling\\n- Folic acid supplementation\\n- Routine Viral Load (VL) monitoring\\n- Provision of PrEP for the HIV-negative partner'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Additional Counselling for Discordant Couples: Male Partner HIV Positive\\n\\nThis section focuses on counselling for discordant couples where the male partner is HIV positive.\\n\\n- Unprotected sex should be deferred until there is confirmed viral suppression in the HIV-positive partner.\\n- Discuss the option of PrEP for the HIV-negative partner.\\n- If viral suppression is difficult, consider specialist referral for sperm washing or artificial insemination.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Additional Counselling for Discordant Couples: Female Partner HIV Positive\\n\\nThis section provides guidance for discordant couples where the female partner is HIV positive.\\n\\n- Unprotected sex should also be deferred until the HIV-positive partner has confirmed viral suppression.\\n- Discuss the use of PrEP for the HIV-negative partner.\\n- Explore self-insemination options during the peri-ovulatory period, where appropriate.\\n- Consider specialist referral for artificial insemination if viral suppression is challenging.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 79,\n",
       "  'section': '## Maternal Healthcare\\n\\nMaternal healthcare begins with preconception counselling and continues throughout pregnancy and breastfeeding. The standard package of antenatal and postnatal services in the context of HIV is described in Chapter 7 of these guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 79,\n",
       "  'section': '## Non-communicable Diseases Screening and Management\\n\\n### Metabolic Disorders\\n\\nScreening, prevention, and management of specific non-communicable diseases (NCDs) are included in the standard package of care for people living with HIV (PLHIV) due to their associated high morbidity and mortality. PLHIV are at higher risk for cardiovascular, liver, and kidney diseases because of the chronic inflammatory state associated with HIV infection and as a side effect of some antiretroviral medications (ARVs).\\n\\n#### Modifiable Risk Factors\\n\\nThe modifiable risk factors for cardiovascular disease include:\\n- Tobacco use and exposure to tobacco smoke\\n- Unhealthy diets\\n- Overweight/obesity\\n- Physical inactivity\\n- Harmful use of alcohol\\n- Hypertension\\n- Diabetes\\n- Hyperlipidemia\\n- Infections such as rheumatic fever and HIV\\n\\n#### Non-modifiable Risk Factors\\n\\nAdvancing age, sex, race/ethnicity, and family history are non-modifiable risk factors associated with cardiovascular diseases.\\n\\n### Health Systems Support\\n\\nHIV and other chronic diseases require health systems that support chronic care and adherence. Their management should be integrated at the health facility, including at the primary care level.\\n\\n### Lifestyle Modifications\\n\\nLifestyle modifications are always the first line of prevention and management for hypertension, diabetes mellitus (DM), and dyslipidaemia. These recommendations are for all patients to prevent these NCDs and should be integrated into routine HIV treatment and prevention.\\n\\n#### Recommendations for Screening\\n\\nRecommendations for screening, diagnosis, and initial management of hypertension, type 2 diabetes mellitus, dyslipidaemia, and chronic kidney disease (CKD) are provided in the respective tables.\\n\\nFor comprehensive guidelines on the prevention, diagnosis, and management of diabetes and cardiovascular diseases, refer to:\\n- Kenya National Clinical Guidelines for the Management of Diabetes\\n- Kenya National Guidelines for Cardiovascular Diseases Management'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## HIV Diagnosis and Initial Management\\n\\nUpon diagnosis of an HIV-infected adult or adolescent with a CD4 count of 200 cells/mm³, automatic/reflex CrAg screening is initiated.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## CrAg Screening Results\\n\\n### Serum CrAg Positive\\n\\n- **Symptom Screen:**\\n  - Symptoms to check: Progressive headache, fever, malaise, neck pain, confusion.\\n  \\n- **Symptomatic Patients:**\\n  - Admit for lumbar puncture (LP) to obtain CSF for CrAg and GeneXpert.\\n  \\n- **Asymptomatic Patients:**\\n  - Offer presumptive treatment for possible early cryptococcal meningitis (CM) with:\\n    - Fluconazole 1,600 mg per day for 2 weeks,\\n    - Followed by fluconazole 800 mg per day for 8 weeks,\\n    - Followed by fluconazole 200 mg per day for at least 1 year, until:\\n      - CD4 count >200 cells/mm³ (two measures, 6 months apart) and\\n      - Viral Load (VL) is undetectable (LDL <200 copies/ml).\\n  - Defer antiretroviral therapy (ART) for 5 weeks.\\n  - Monitor closely and perform LP if symptoms develop.\\n\\n### Serum CrAg Negative\\n\\n- **Treatment:**\\n  - Offer pre-emptive therapy for non-meningeal disease with:\\n    - Fluconazole 800 mg per day for 2 weeks,\\n    - Followed by fluconazole 400 mg per day for 8 weeks,\\n    - Followed by fluconazole 200 mg for at least 1 year, until:\\n      - CD4 count >200 cells/mm³ (two measures, 6 months apart) and\\n      - VL is undetectable (LDL <200 copies/ml).\\n  - Defer ART until the completion of 5 weeks of treatment and resolution of symptoms.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Lumbar Puncture (LP) Recommendations\\n\\n- LP is strongly recommended for all serum CrAg positive patients irrespective of symptoms.\\n- If LP is not available to rule out meningeal disease, patients should be treated for possible CM, even if asymptomatic.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Management of Cryptococcal Meningitis\\n\\n- **CSF CrAg Positive:**\\n  - Treat for cryptococcal meningitis with amphotericin, fluconazole, and therapeutic LPs.\\n  - Defer ART until after completing 5 weeks of treatment and resolution of symptoms.\\n\\n- **Patients with cryptococcal meningitis** are at high risk of developing life-threatening immune reconstitution inflammatory syndrome (IRIS); deferring ART has shown to improve survival.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Special Considerations for Pregnant Women\\n\\n- All pregnant women who screen positive with serum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal meningitis.\\n- Fluconazole use during pregnancy increases the risk of birth defects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Additional Notes on Fluconazole Use\\n\\n- **Dose Adjustments:**\\n  - Requires dose adjustments for impaired renal function; when CrCl is ≤50 ml/min, use 50% of the standard recommended dose.\\n  \\n- **Drug Interactions:**\\n  - Fluconazole should not be used with rifabutin-based TB treatment.\\n\\n- **Monitoring:**\\n  - Check ALT after one week of high-dose fluconazole treatment and based on symptoms thereafter.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## ART Initiation Guidelines\\n\\n- No cryptococcal treatment is required for serum CrAg negative patients.\\n- Initiate ART within 2 weeks for these patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Hypertension Screening for Adults Living with HIV\\n\\n- BP should be measured and recorded for every adult at every visit.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Diagnosis of Hypertension\\n\\n- Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Additional Investigations for Patients with Hypertension\\n\\n- **Urinalysis**: Assesses for kidney disease and diabetes.\\n- **Creatinine, Na, K**: Assesses for kidney disease.\\n- **Blood Glucose**: Assesses for diabetes.\\n- **Full Blood Count**: Anaemia may indicate chronic kidney disease.\\n- **Lipid Profile**: Dyslipidemia is a cardiovascular risk factor.\\n- **ECG**: Assesses for cardiac pathology, including cardiomegaly, ventricular dysfunction, ischemic heart disease, etc.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Management of Hypertension in PLHIV\\n\\n### Treatment Target\\n- BP target is < 140/90 mmHg.\\n\\n### For Baseline BP 120-139/80-89 (Pre-Hypertension)\\n- Lifestyle modification, along with monthly BP monitoring.\\n\\n### For Baseline BP 140-159/90-99\\n- **Lifestyle Modification** (Table 4.9) for up to 6 months, along with monthly BP monitoring.\\n- If the treatment target is not met with lifestyle modifications, add drugs.\\n- First-line therapy for PLHIV without kidney disease or diabetes:\\n  - Thiazide diuretic (hydrochlorothiazide starting at 12.5 mg OD, max 25 mg OD) or\\n  - Calcium channel blocker (amlodipine starting at 2.5 mg OD, max 10 mg OD).\\n- For PLHIV with kidney disease or diabetes:\\n  - First antihypertensive should be an ACE-I or ARB (enalapril 2.5-10 mg OD, max 20 mg BD) or (losartan 50 mg OD, max 100 mg OD).\\n- Introduce one drug at a time; increase dosage if target BP is not reached within one month.\\n- If response is inadequate after titration, consider an additional agent (e.g., hydrochlorothiazide).\\n- Consult or refer to a physician if inadequate response to two agents.\\n- Caution with calcium-channel blockers due to drug interactions; ACE-I and thiazide diuretics have no significant interactions with ARVs.\\n\\n### For Baseline BP ≥ 160/100 mmHg\\n- Initiate lifestyle modifications and introduce anti-hypertensive medications concurrently.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 83,\n",
       "  'section': '## Screening for Dyslipidemia in PLHIV\\n\\nFasting lipid profile should be evaluated at baseline for all People Living with HIV (PLHIV), then annually if baseline screening is normal.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 83,\n",
       "  'section': '## Diagnosis of Dyslipidemia\\n\\nDyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L), or triglycerides (>2.2 mmol/L).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 83,\n",
       "  'section': '## Initial Management of Dyslipidemia\\n\\n### Lifestyle Modifications\\n- Implement lifestyle modification for 3-6 months (Refer to Table 4.10).\\n\\n### ARV Considerations\\n- If the patient is on an antiretroviral (ARV) known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV), consider a single-drug substitution to a more lipid-friendly drug (such as ATV/r or DTG) as the treatment of choice before adding a lipid-lowering drug. \\n- Rule out treatment failure before making single-drug substitutions (Refer to Figure 6.4).\\n\\n### Pharmacological Interventions\\n- If the patient does not meet treatment targets with lifestyle modifications, then add drugs:\\n  - **Atorvastatin**: Starting dose of 10 mg once daily (maximum dose 20 mg once daily if the patient is on a PI/r; maximum dose 80 mg once daily if not on a PI/r).\\n  - **Contraindications**: Simvastatin and lovastatin are contraindicated in the presence of PI/r.\\n  - Allow at least 3 months before repeating fasting lipids and titrating the dose.\\n\\n### Monitoring\\nOnce targets are achieved, lipids can be monitored every 6-12 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## PHQ-9 Depression Screening Tool\\n\\nThis section details the Patient Health Questionnaire-9 (PHQ-9) used for depression screening. The tool consists of 9 questions that assess the patient\\'s mental health over the last 2 weeks. Each question has a scoring system, where responses are categorized as \"Not at all,\" \"Several days,\" \"More than half the days,\" and \"Nearly every day,\" with corresponding points.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## Scoring and Interpretation\\n\\nIn this section, the total score from the PHQ-9 is calculated by adding the points from each response. The scores range from 0 to 27, and based on the total score, different provisional diagnoses and management recommendations are provided:\\n\\n- **0-4:** Depression unlikely\\n- **5-9:** Mild depression\\n- **10-14:** Moderate depression\\n- **15-19:** Moderate-severe depression\\n- **20-27:** Severe depression'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## Recommended Management\\n\\nThis section outlines the management recommendations based on the PHQ-9 scores:\\n\\n- **0-4:** Repeat screening in the future if concerns about developing depression arise.\\n- **5-9:** Provide counseling support, monitor the patient, and refer to a mental health team if available. If on EFV (Efavirenz), consider a different ARV after ruling out treatment failure.\\n- **10-14:** Provide supportive counseling, potentially refer to a psychologist, consider switching ARV if on EFV, and begin antidepressant medication or refer to a clinician experienced in prescribing them.\\n- **15-19 & 20-27:** Similar management as moderate depression, but severe depression may require immediate initiation of antidepressants.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## Special Considerations\\n\\nHere, we discuss the known adverse reactions related to EFV (Efavirenz) in patients, particularly noting that while depression is often mild and temporary, persistent symptoms should prompt a switch to an alternative ARV after ruling out treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nOverview of the recommended guidelines and protocols to ensure proper care and management of People Living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Screening for Type 2 Diabetes Mellitus in PLHIV\\n\\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if baseline screening is normal.  \\n● Urine dipstick for protein and glucose can be used if blood glucose testing is not available.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Diagnosis of Type 2 Diabetes Mellitus\\n\\n● Diabetes Mellitus is defined as:  \\n  - Fasting blood sugar ≥ 7.0 mmol/L  \\n  - Random blood sugar ≥ 11.1 mmol/L  \\n  - HbA1c > 6.5%  \\n  - Oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without symptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Management of Type 2 Diabetes Mellitus\\n\\n**Treatment Target:** HbA1c ≤ 7.0% or FBS 4 - 7 mmol/L  \\n\\n### For Patients with Pre-Diabetes\\n- Monitor FBS or HbA1c every 3 months.  \\n- Encourage lifestyle modifications (refer to Table 4.10).  \\n\\n### For Patients with Diabetes\\n- Monitor HbA1c (or FBS if HbA1c is not available) every 3 months.  \\n- Implement lifestyle modifications (weight loss, nutritional support) for 3 - 6 months.  \\n- If targets are not met with lifestyle modifications, add medication:  \\n  - **Metformin**:  \\n    - Obtain baseline Creatinine; do NOT use if creatinine clearance < 45 ml/min.  \\n    - Start with low dose (500 mg OD or BD) and titrate up every 1 - 2 weeks until reaching 1 g BD (or maximum tolerated dose).  \\n    - Note: DTG may increase metformin plasma levels; monitor blood glucose levels; dose reduction may be required.  \\n\\n### If Still Not Meeting Targets\\n- After 3 - 6 months on maximum tolerated metformin:  \\n  - Consider adding a drug from another class (e.g., sulphonylureas like gliclazide) and/or referral to a specialist.  \\n  - Some patients may require insulin.  \\n\\n### Routine Checks at Every Visit\\n- A thorough history for signs of hypoglycemia, cardiovascular risk factors, neuropathy, and diabetic foot ulcers.  \\n- Physical exam for blood pressure, neuropathy, and foot ulcers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Additional Routine Screening for Patients with Diabetes\\n\\n- Annual ophthalmology examination for diabetic retinopathy.  \\n- Annual urinalysis: start on an ACE-I/ARB if proteinuria develops (even if BP is normal).  \\n- Note: Patients with diabetes are at increased risk of developing TB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 84,\n",
       "  'section': '## Standard Package of Care for PLHIV: Chronic Kidney Disease\\n\\nThis section outlines the screening, diagnosis, and initial management of chronic kidney disease (CKD) for people living with HIV (PLHIV).\\n\\n### Screening\\n- Urinalysis (for protein) and serum creatinine evaluations should be done at baseline for all PLHIV and monitored annually.\\n\\n### Diagnosis\\n- Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1.\\n- Abnormal results should be confirmed by repeat testing.\\n- Chronic kidney disease is defined as evidence of kidney damage persisting for at least three months.\\n\\n### Management\\n- Management strategies depend on the cause of renal impairment; specialist consultation may be necessary.\\n- Prompt and aggressive treatment of dehydration is crucial.\\n- If on a TDF-containing regimen, substitute with another ARV if creatinine clearance (CrCl) < 50 ml/min, except for patients with HBV/HIV co-infection.\\n- Avoid nephrotoxic drugs (e.g., aminoglycosides, NSAIDs).\\n- Regular evaluation and treatment of hypertension is essential.\\n- Most NRTIs require dose adjustments for renal impairment, while NNRTIs, PIs, and INSTIs do not.\\n- Note: DTG may cause a small rise in serum creatinine levels but does not represent a decline in renal function; close monitoring is recommended.\\n\\n### High-Risk Patients\\nPatients at higher risk for kidney disease and TDF-associated renal toxicity include those with:\\n- Pre-existing renal disease\\n- Hypertension\\n- Diabetes mellitus\\n- Severe weight loss (below 60 kg in adults)\\n- Age > 45 years\\n- WHO stage 3 or 4\\n- CD4 < 200 cells/mm³\\n- High HIV viral load\\n- Concomitant use of nephrotoxic agents\\n\\n### HIV-Associated Nephropathy\\nGlomerular disease related to HIV infection, known as HIV-associated nephropathy (HIVAN), is a significant cause of CKD among PLHIV. Prevention, early identification, and management are crucial to reduce the burden of dialysis and other complications.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 84,\n",
       "  'section': '## Cancer Prevention, Early Detection, and Management among PLHIV\\n\\nThis section discusses the heightened cancer risk for PLHIV and the importance of preventive measures.\\n\\n### Cancer Risk\\n- PLHIV face a substantially higher risk for various cancers due to a weakened immune system that impairs control of oncogenic viral infections.\\n- Contributing factors to the elevated risk include:\\n  - High prevalence of oncogenic infections\\n  - Modifiable risk factors such as smoking, alcohol use, unhealthy diet, and physical inactivity.\\n  \\n### Common Cancers\\nPLHIV are significantly more likely than the general population to be diagnosed with:\\n- Kaposi Sarcoma\\n- Non-Hodgkin lymphoma\\n- Other cancers (e.g., cervical, anal, liver, lung, and oral/throat cancers).\\n\\n### Importance of Screening\\nThe elevated cancer risk in PLHIV underscores the importance of prioritizing screening and early diagnosis programs targeted at this group to enhance outcomes and manage potential health complications effectively.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the comprehensive care package for People Living with HIV (PLHIV), detailing the standard procedures and assessments involved in their care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## CAGE-AID Screening for Alcohol and Drug Use Disorders\\n\\nThis section introduces the CAGE-AID screening tool, which consists of four questions designed to assess alcohol and drug use disorders among adults. \\n\\n### Screening Questions\\nCandidates are asked the following four questions, requiring a yes/no response:\\n\\n1. Have you felt you should Cut down on your drinking or drug use?\\n2. Have people ever Annoyed you by criticizing your drinking or drug use?\\n3. Have you ever felt bad or Guilty about your drinking or drug use?\\n4. Have you ever had a drink or used drugs first thing in the morning to steady your nerves or to get rid of a hangover (Eye opener)?\\n\\n**Interpretation**: If a patient answers \"Yes\" to two or more questions, it indicates a potential alcohol or drug use problem that warrants further assessment and management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## Confidentiality and Patient Communication\\n\\nThis section emphasizes the importance of confidentiality and open communication with patients during the screening process. \\n\\n**Key Message**: Practitioners should encourage honesty by assuring patients that their answers will remain confidential and highlighting the routine nature of these questions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## Follow-Up for Positive Screenings\\n\\nThis section discusses the next steps for patients who screen positive for alcohol and drug use issues. \\n\\n**Key Actions**:\\n- If referral to a mental health team is not immediately possible, practitioners should assess the patient’s desire to quit.\\n- Provide targeted messages and support based on the patient’s stage of quitting.\\n\\n### Resource Reference\\nThe National Protocol for Treatment of Substance Use Disorders in Kenya offers additional resources for assessments and interventions needed in these cases.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 88,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThe standard care package for people living with HIV (PLHIV) focuses on supportive counselling and pharmacological management for associated mental health issues, particularly depression.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 88,\n",
       "  'section': \"## Supportive Counselling for Depression\\n\\nPatients with mild depression should receive supportive counselling, which includes:\\n\\n- **Psycho-education on the following key messages:**\\n  - Depression is common and can happen to anyone.\\n  - Depressed individuals often possess exaggerated negative opinions about themselves, their life, and their future.\\n  - Effective treatment is possible.\\n  \\n- **Counseling on self-management:**\\n  - Continuing ART as prescribed.\\n  - Engaging in activities that were previously enjoyable.\\n  - Maintaining a regular sleep cycle.\\n  - Keeping physically active.\\n  - Participating in community/social events.\\n  - Returning to the clinic if any thoughts of self-harm occur.\\n  \\n- **Addressing psychosocial stressors:**\\n  - Explore potential stressors in the patient's life.\\n  - Assist in problem-solving to reduce stressors.\\n  - Assess for and manage intimate partner violence.\\n  \\n- **Reactivation of or referral to social networks, including peer support groups.**\\n\\n- **Regular follow-up** until symptoms improve and are stable.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 88,\n",
       "  'section': '## Pharmacological Management of Depression\\n\\nPatients with moderate depression or worse should be treated with supportive counselling plus an antidepressant medication. \\n\\n- **Fluoxetine** is an antidepressant that does not have significant drug interactions with ARVs.\\n  \\n- **Starting dose for an adult:** \\n  - Usually 20 mg taken daily in the morning (consider starting with a lower dose for patients prone to side effects).\\n  - The dose can be titrated up by 20 mg every 2-4 weeks as needed, up to a maximum of 80 mg per day.\\n  \\n- **Common side-effects include:**\\n  - GI upset\\n  - Headaches\\n  - Insomnia\\n  - Disturbances of the menstrual cycle\\n  - These usually resolve after 1-2 weeks of continued use.\\n\\n- **Full effect:** \\n  - Not achieved until around 4 weeks of continued use.\\n  - Antidepressants should be continued for at least another 6 months once symptoms of depression resolve.\\n\\n- **Discontinuation of therapy:** \\n  - Should occur as a weekly taper (e.g., if the maintenance dose is 60mg, taper to 40mg, then 30mg, then 20mg, and then 10mg before stopping).\\n  - Close monitoring for recurrence of symptoms is essential.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Alcohol and Drug Use Among PLHIV\\n\\nAlcohol and other drug use are common among the general population and People Living with HIV (PLHIV). Substance use can significantly contribute to poor adherence to HIV treatment and treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Screening for Alcohol and Drug Use\\n\\nAll adults and adolescents should be screened for alcohol and drug use prior to starting Antiretroviral Therapy (ART) and annually thereafter. The following questions should be used for the screening:\\n\\n- During the past 12 months, did you drink any alcohol (more than a few sips)?\\n- During the past 12 months, did you smoke any marijuana?\\n- During the past 12 months, did you use anything else to get high?\\n\\nAnyone who answers \"yes\" to any of these questions should undergo a more thorough screening.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Follow-Up for Positive Screening Results\\n\\nPatients who have a detectable viral load after three or more months on ART, regardless of previous viral suppression, should also be screened thoroughly. \\n\\nFor adolescents, the CRAFFT screening tool is advised. For adults, the CAGE-AID screening tool should be used.\\n\\nAnyone screening positive on these tools should receive further assessment and management from clinical staff experienced in handling alcohol and drug use disorders.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## CRAFFT Screening Tool for Adolescents\\n\\nThe CRAFFT screening tool consists of six questions that require yes/no responses. A positive result — answering \"Yes\" to two or more questions — indicates a potential alcohol or drug use problem, necessitating further assessment and management.\\n\\n**Questions:**\\n1. Have you ever ridden in a car driven by someone (including yourself) who was “high” or had been using alcohol or drugs?\\n2. Do you ever use alcohol or drugs to relax, feel better about yourself, or fit in?\\n3. Do you ever use alcohol or drugs while you are alone?\\n4. Do you ever forget things you did while using alcohol or drugs?\\n5. Do your family or friends ever tell you that you should cut down on your drinking or drug use?\\n6. Have you ever gotten into trouble while you were using alcohol or drugs?\\n\\nEach question requires a yes/no response.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Management of Addictions\\n\\nFor individuals who screen positive for substance use disorders, further assessment and management should be conducted. It is ideal for this to be handled by clinical staff with experience in managing these disorders. General guidance on the management of addictions is provided in Table 4.1 8. Additionally, the National Protocol for Treatment of Substance Use Disorders in Kenya offers comprehensive guidelines for treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the general approach and care provided to persons living with HIV (PLHIV), emphasizing the importance of addressing both physical and mental health needs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': '## Understanding Anxiety\\n\\nAnxiety and anxiety-related disorders are mental health conditions characterized by feelings of nervousness, fear, and worry that can significantly affect daily functioning. Symptoms include:\\n\\n- Feelings of nervousness\\n- Fear or worry that interfere with sleep and functioning\\n- Lack of appetite\\n- Trembling or shakiness\\n- Sweating and clamminess of hands\\n- Additional symptoms such as rapid heartbeat, difficulty breathing, headaches, trouble sleeping, and difficulty concentrating'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': '## Addressing Anxiety in the Context of HIV\\n\\nConcerns regarding anxiety often arise during the evaluation of individuals living with HIV or those caring for them. It’s crucial to approach these concerns with sincerity and compassion. Many cases may simply need reassurance, support, or a listening ear.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': '## Screening for Anxiety\\n\\nA screening tool, such as the Generalized Anxiety Disorder Assessment (GAD-7), is recommended to evaluate the severity of anxiety symptoms in individuals. This instrument consists of seven items that help assess the severity of generalized anxiety disorder (GAD) by having individuals rate their symptoms over the past two weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 93,\n",
       "  'section': '## Generalized Anxiety Disorder Assessment (GAD-7)\\n\\nThe GAD-7 assessment consists of seven questions designed to evaluate the frequency of anxiety symptoms over the past two weeks. Respondents indicate how often they have been bothered by each issue on a scale of 0 (Not at all) to 3 (Nearly every day). The specific problems assessed include feelings of nervousness, inability to control worrying, excessive worry, trouble relaxing, restlessness, irritability, and feelings of fear about potential negative outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 93,\n",
       "  'section': '## Anxiety Severity Cut-offs\\n\\nThe following cut-offs correlate with levels of anxiety severity based on the GAD-7 scores:\\n- **Score 0 - 4**: Minimal Anxiety  \\n- **Score 5 - 9**: Mild Anxiety  \\n- **Score 10 - 14**: Moderate Anxiety  \\n- **Score greater than 15**: Severe Anxiety  \\n\\nDepending on the level of anxiety, treatment options including referrals to psychologists or psychiatrists for possible psychotherapy and medication should be explored.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 93,\n",
       "  'section': '## Stress and Stress Management\\n\\nStress is defined as a feeling of emotional or physical tension, and its symptoms may include aches and pains, palpitations, exhaustion, insomnia, headaches, dizziness, shaking, digestive problems, weak immune response, and tension in muscles or jaw. Symptoms may occur individually or in clusters, interfering with daily life. Common sources of stress for patients may include challenges in understanding HIV-related issues, personal concerns, and difficulties from significant others.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 95,\n",
       "  'section': \"## Psychosis\\n\\nPsychosis is a mental disorder characterized by a disconnection from reality. It may occur due to a psychiatric illness such as schizophrenia, or as a result of health conditions, medications, or drug use. \\n\\n### Signs and Symptoms of Psychosis\\n- Marked behavioral changes\\n- Neglecting usual responsibilities related to work, school, domestic, or social activities\\n- Agitated or aggressive behavior, with decreased or increased activity\\n- Fixed false beliefs not shared by others in the person’s culture\\n- Auditory or visual hallucinations (hearing voices or seeing things that are not there)\\n- Lack of awareness regarding one's mental health issues\\n\\n### Treatment\\nTreatment may include medication and talk therapy.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 95,\n",
       "  'section': '## Self-Care\\n\\nSelf-care strategies in the context of mental health can help individuals live more responsibly and satisfactorily, enhancing both physical and mental health.\\n\\n### Self-Care Strategies\\n- Getting regular exercise\\n- Eating healthy, regular meals, and staying well-hydrated\\n- Prioritizing sleep, including maintaining a consistent schedule for waking and sleeping\\n- Engaging in relaxing activities\\n- Setting realistic goals and priorities to manage expectations effectively\\n\\n### Additional Practices\\n- **Practicing Gratitude:** Regularly reminding oneself of things to be grateful for; specificity aids in clarity.\\n- **Focusing on Positivity:** Emphasizing the good and positive aspects of life, while identifying and challenging negative thoughts. Support from friends, counselors, and mental health professionals can be beneficial.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section covers the standard care practices for People Living with HIV (PLHIV), specifically focusing on tertiary prevention, including cancer management and the prevention of complications. It emphasizes the importance of adhering to national guidelines for screening, diagnosis, and management of cancers, and the necessity of referral to hospitals with comprehensive oncology services for individual patient management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Tertiary Prevention\\n\\nTertiary prevention involves cancer management, prevention of complications, and treatment of side effects and secondary cancers. It is essential for healthcare providers to refer to national guidelines for effective prevention and management of cancers and to ensure that patients are directed to appropriate healthcare facilities as needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Mental Health Screening and Management\\n\\nThis section discusses the heightened susceptibility of PLHIV to various psychological disturbances, including depression, anxiety, and post-traumatic stress disorder (PTSD). These mental health issues can significantly impact a patient’s well-being and adherence to HIV treatment. The section suggests that any suspected mental health disorders warrant formal screening and potential referral to specialists.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Depression\\n\\nDepression is highlighted as a prevalent psychiatric illness among PLHIV, who are 3-6 times more likely to suffer from it compared to the general population. This section outlines the importance of early detection and management, as untreated depression leads to significant disability and poorer treatment outcomes. \\n\\nPLHIV should be screened for depression at enrollment and annually thereafter using two specific questions. If patients respond affirmatively to either question or have a detectable viral load after 3 months on ART, a more comprehensive assessment using the PHQ-9 screening tool is recommended.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Screening for Depression\\n\\nThis subsection details the specific questions used to screen for depression, emphasizing the need for regular monitoring of mental health in PLHIV. The questions assess feelings of depression and loss of interest over the past two weeks, guiding further screening and management based on the PHQ-9 score.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## PHQ-9 Screening Tool\\n\\nThe PHQ-9 screening tool is utilized for a more thorough evaluation of depression in PLHIV who screen positively. Management of depression is guided by the score obtained from this tool, which assists healthcare providers in determining the appropriate level of care for each patient.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': 'This format allows for a structured understanding of the various topics relating to the care of PLHIV, facilitating a clearer and more effective Q&A system.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 91,\n",
       "  'section': '## Addiction Support Based on Stages of Change\\n\\nThis section divides the process of addiction recovery into distinct stages, outlining appropriate counselling approaches for each stage.\\n\\n### Pre-contemplation\\n- Not currently considering quitting, no immediate desire to quit\\n  - Acknowledge that not everyone is ready to think about quitting\\n  - Clarify that it is their decision\\n  - Listen to them describe the benefits they get from alcohol or drug use (motivation for continuing)\\n  - Explore why others might think quitting is a good idea\\n\\n### Contemplation\\n- Not sure if wanting to quit; thinking about quitting but no immediate plan\\n  - Acknowledge that not everyone is ready to quit immediately\\n  - Clarify that it is their decision\\n  - Listen to benefits from alcohol or drug use (motivation for continuing)\\n  - Listen to negative effects of use (motivation for considering quitting)\\n  - Discuss ideas on how to quit \\n\\n### Preparation\\n- Would like to quit within the next month\\n  - Congratulate them on their decision to quit\\n  - Listen to expected benefits from quitting\\n  - Discuss any plan they have to try quitting\\n  - Discuss potential challenges with quitting\\n  - Problem-solve overcoming challenges, including identifying support systems\\n  - Encourage small steps towards quitting (e.g., avoiding triggers)\\n  - Acknowledge their strength to succeed \\n\\n### Action\\n- Actively trying to quit or has recently quit (within past 6 months)\\n  - Listen to experiences with quitting\\n  - Congratulate them on progress made\\n  - Problem-solve overcoming challenges, identifying support systems\\n  - Review long-term benefits of quitting \\n\\n### Maintenance\\n- Has quit (more than 6 months ago) and wants to remain abstinent\\n  - Congratulate them on their success\\n  - Discuss potential for relapse and strategies to cope\\n  - Review long-term benefits of maintaining abstinence \\n\\n### Relapse\\n- Acknowledge that relapse is common\\n  - Evaluate triggers of relapse\\n  - Reassess motivation to quit and barriers\\n  - Problem-solve on overcoming challenges and explore additional support strategies'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 91,\n",
       "  'section': '## Mental Health Concerns\\n\\nThis section highlights critical areas of concern in mental health, emphasizing the need for vigilance in identifying debilitating conditions.\\n\\n- High index of suspicion is necessary to identify mental health issues that negatively affect daily living tasks.\\n- The last two items within this section contribute towards building resilience, which positively impacts mental health:\\n  - Enables individuals to connect positively with their environments \\n  - Supports living more meaningful lives'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section introduces the comprehensive care approach designed for people living with HIV (PLHIV). It highlights the importance of addressing various non-medical issues such as social, financial, and environmental concerns that may adversely affect their lives. The impact of stress on PLHIV is discussed, emphasizing the need for healthcare workers to remain calm and assured while addressing patient concerns.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Assessing Stress in PLHIV\\n\\nThis section focuses on the effects of stress experienced by PLHIV, which can be severe enough to be observed by others. It underscores the importance of utilizing screening tools to assess the need for referrals to specialized mental health professionals, ensuring that patients receive appropriate support for stress-related issues.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': \"## Experiences of Trauma in PLHIV\\n\\nThis section defines trauma and its impact on individuals, particularly PLHIV. It explains how exposure to emotionally disturbing or life-threatening events can have lasting adverse effects on an individual's mental, physical, social, emotional, and spiritual well-being. It emphasizes the necessity of addressing past traumatic experiences for the overall well-being of PLHIV.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Trauma Assessment using PC-PTSD-5\\n\\nHere, the document introduces the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) as a tool for identifying individuals with probable PTSD. It outlines criteria for a \"positive\" screening result, which indicates that further assessment by a mental health professional is needed. This section also lists specific types of traumatic events that can trigger PTSD.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Screening Questions for PTSD\\n\\nThis section provides a series of questions to assess recent experiences of the respondent related to potential traumatic events. The questions are designed to gauge symptomatology indicative of PTSD, including nightmares, avoidance behaviors, hypervigilance, emotional detachment, and feelings of guilt or blame.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 97,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nThis document focuses on the nutritional services related to the management of HIV, highlighting the importance of good nutrition for people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 97,\n",
       "  'section': '## 4.7 Nutritional Services\\n\\nGood nutrition is crucial for the management of HIV, contributing to various health benefits including reducing infection risk, delaying progression to AIDS, and enhancing overall health and energy levels while minimizing ART side effects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 97,\n",
       "  'section': '## 4.7.1 Nutritional Assessment, Counselling, and Support (NACS)\\n\\nAll PLHIV should receive tailored nutritional assessment, counselling, and support. This includes:\\n\\n### Nutritional Assessment and Diagnosis\\n- **Timing**: Regular assessments during routine clinic visits.\\n  - Monthly for the first year of life.\\n  - Quarterly up to 14 years old.\\n  - Every 3-6 months thereafter.\\n- **Components of Assessment**:\\n  - **Anthropometric**: Utilization of Tables 4.1, 4.20, and 4.21 for interpretation of results.\\n  - **Biochemical**: Follow-up investigations as listed in Tables 3.2 and 3.5.\\n  - **Clinical**: Physical examinations as described in Table 3.1 for initial evaluation.\\n  - **Dietary**: 24-hour food recall and household food security assessment.\\n  - **Environmental and Psychosocial Factors**.\\n  - **Functional Status**: Evaluate the individual’s ability to care for themselves.\\n\\n### Counselling and Education\\n- Educate clients on maintaining good nutritional status and its benefits for PLHIV.\\n- Discuss Mother Infant and Young Child Nutrition (MIYCN), emphasizing exclusive breastfeeding.\\n- Reassure clients about achieving and maintaining good nutritional status and overall health.\\n- Identify locally accessible foods and address food safety and preparation.\\n- Assist clients in meal planning for balanced dietary needs aligned with treatment plans.\\n- Explore and address clients’ constraints regarding nutrition.\\n- Discuss potential side effects of medications and food interactions.\\n- Identify the causes of poor appetite and suggest appropriate interventions.\\n\\n### Messages: Critical Nutrition Practices (CNPs)\\n1. Conduct periodic nutritional status assessments.\\n2. Increase energy intake through a balanced diet.\\n3. Maintain high levels of sanitation and food hygiene.\\n4. Practice positive living behaviors.\\n5. Engage in physical activities or exercises.\\n6. Drink plenty of clean, safe water.\\n7. Seek prompt treatment for opportunistic infections and manage diet-related symptoms.\\n8. Manage drug-food interactions and side effects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Screening for Severe Acute Malnutrition (SAM)\\n\\nMeasure anthropometry and check for bilateral pitting oedema. \\n\\n### Key Components:\\n- **Medical History and Physical Examination:**\\n  - Evaluate nutritional status and health condition\\n  - Check for medical complications\\n  - Perform appetite test'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Admission Criteria for SAM \\n\\n- **If SAM without Medical Complications:**\\n  - If appetite test passed: Admission to Outpatient care\\n \\n- **If SAM with Medical Complications or Failed Appetite Test:**\\n  - Medical complications developed, decreased appetite, weight loss or stagnant weight, increased oedema or no decrease.\\n  - Admission to Inpatient care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Referral for Continuing Treatment\\n\\nCriteria for referral back to outpatient care include:\\n- Appetite returning (passed appetite test)\\n- Oedema decreasing\\n- Medical complications resolving\\n\\n### Discharge Criteria:\\nOnce SAM treatment is completed based on discharge criteria:\\n- Discharge to home or refer for supplementary feeding and other services that address underlying causes of malnutrition.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Medical Complications Necessitating Hospitalization\\n\\nAdditional medical complications that necessitate inpatient care include:\\n- Intractable vomiting\\n- Convulsions\\n- Lethargy\\n- Unconsciousness\\n- Lower respiratory tract infection\\n- High fever\\n- Severe dehydration\\n- Severe anaemia\\n- Hypoglycaemia\\n- Hypothermia\\n- Eye signs of vitamin A deficiency\\n- Skin lesions'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Referral for Medical Evaluation\\n\\nThe following complications require referral of the patient for further medical evaluation:\\n- No appetite (failed appetite test)\\n- IMCI danger signs\\n- Increased or newly developed bilateral pitting oedema\\n- Weight loss due to diarrhoea (re-feeding or other origins)\\n- Weight loss for three consecutive weeks\\n- Static weight (no weight gain) for five consecutive weeks\\n- Other signs of failure to respond to treatment'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section introduces the overall framework for care and support for people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Staying Connected\\n\\nStaying connected is crucial for both physical and mental health. This section emphasizes the importance of maintaining relationships with family, friends, and spiritual support systems as a means to manage life effectively and enhance mental well-being.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Wellbeing\\n\\nAccording to the World Health Organization (WHO), mental health is defined as a state of well-being where an individual recognizes their own abilities, copes with normal stresses, works productively, and contributes to their community.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Support Structures for Wellbeing\\n\\nThis section lists the various support structures available for enhancing wellbeing, which include:\\n- Individual counseling\\n- Group therapy\\n- Networks of organizations that offer support to different population categories, including adolescents, men, and women.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Role of Health Workers\\n\\nHealth workers at facilities should take the initiative to establish and maintain these support structures. They should also set up referral systems for clients requiring additional services targeted at addressing issues that can impact the mental health of PLHIV, including social and financial challenges.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThe individual and population benefits of ART are dependent on high levels of adherence to prescribed medication, accompanying medical advice, and follow-up plans. Adherence-enhancing strategies should be implemented beginning at the point of HIV diagnosis, as part of post-test counseling and linkage, and continued during initial evaluation and throughout the follow-up period for ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Importance of Early Adherence Strategies\\n\\nTo avoid treatment failure and the need for switching patients to 2nd or 3rd line ART, it is crucial to have an adherence support strategy in place before ART initiation. This strategy should anticipate common and individual barriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis, especially with the current recommendation that all PLHIV qualify for ART and ART should be initiated within 2 weeks of diagnosis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Timing of Adherence Preparation\\n\\nAdherence preparation must begin at the time of HIV testing, and close follow-up is required after ART initiation. The adherence preparation, monitoring, and support that a patient requires should be tailored to their level of adherence, the stage of ART initiation, and the follow-up stage they are at.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Importance of Consistent Care Providers\\n\\nWhenever possible, follow-up should be provided by the same care provider or team of care providers (e.g., same clinician and same counselor) at each visit. This continuity of care is particularly important during the first few months of HIV care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 85,\n",
       "  'section': '## Cancer Control Interventions for PLHIV\\n\\nFour interventions are important for cancer control among People Living with HIV (PLHIV):\\n\\n1. **Achieve viral suppression**: Uncontrolled viral replication is a major risk factor for cancer. All PLHIV should initiate Antiretroviral Therapy (ART) and be supported and monitored to achieve long-term viral suppression to reduce the risk of cancer and improve treatment outcomes for many cancers.\\n\\n2. **Primary prevention through avoidance of modifiable risk factors**:\\n   - Smoking cessation\\n   - Avoidance of harmful use of alcohol\\n   - Regular physical activity\\n   - Healthy diets\\n   - Vaccination: \\n     - Vaccination against Human Papillomavirus (HPV) for girls aged 9-14 years old.\\n     - Hepatitis B vaccine for newborns and high-risk groups.\\n\\n3. **Secondary prevention through screening and early diagnosis**:\\n   - **Screening**: Application of simple tests to detect cancer in asymptomatic individuals.\\n     - **Cervical cancer**: All women living with HIV who have been sexually active up to 49 years old (25 -49 years in the general population) should have screening through either visual inspection with acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years.\\n     - **Breast cancer**: Mammogram annually from age 40-55; every two years from age 56-74. Screening for younger women can be performed on an individual basis based on family history or other risk factors. Clinical breast exams can be used where mammograms are not available.\\n     - **Prostate cancer**: Serum prostate-specific antigen (PSA) annually for men aged 40 years and above; digital rectal examination can be used if PSA is not available, and for all men with urinary symptoms.\\n     - **Colorectal cancer**: Fecal occult blood testing of stool (guaiac or FIT) annually for everyone aged 45-75 years, or colonoscopy every 10 years.\\n     - **Oral cancer**: Visual examination for everyone above 40 years with a history of tobacco use, known HPV infection, or immunosuppression.\\n\\n   - **Early diagnosis**: Prompt diagnosis of cancer in symptomatic individuals:\\n     - **Breast**: Lump, asymmetry, skin changes, nipple changes, blood-stained discharge.\\n     - **Cervix**: Post-coital bleeding, excessive vaginal discharge.\\n     - **Colon and rectum**: Change in bowel habits, unexplained weight loss, anemia, blood in stool.\\n     - **Oral**: White or red lesions, growth, ulceration.\\n     - **Naso-pharynx**: Nosebleed, permanent blocked nose, deafness, lymph nodes in the upper neck.\\n     - **Larynx**: Persistent hoarseness of voice.\\n     - **Stomach**: Upper abdominal pain, indigestion, weight loss.\\n     - **Skin**: Irregular growths, lesions, or non-healing sores.\\n     - **Bladder**: Painful or frequent urination, blood in urine.\\n     - **Prostate**: Difficulty in urination, frequent nocturnal urination.\\n     - **Retinoblastoma**: White spot in the pupil, convergent strabismus (in a child).\\n     - **Testis**: Swelling of one testicle.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the various components of care for People Living with HIV (PLHIV), focusing on nutritional support and food security.\\n\\n- **Therapeutic and Supplementary Foods**: Usage of food by prescription, therapeutic feeds, and fortified blended flour for treating clinical malnutrition. Recommendations for malnutrition management in adults and children.\\n- **Exclusive Breastfeeding**: Emphasis on exclusive breastfeeding for the first 6 months of life, followed by complementary foods for children aged 6-24 months to prevent malnutrition.\\n- **Micronutrient Supplements**: Importance of providing micronutrient supplements to prevent vitamin and mineral deficiencies.\\n- **Food Security**: Linkage to HIV-sensitive social protection measures such as household food support, home-based care, agricultural extension services, and livelihood support.\\n- **Community Support**: The necessity of nutrition support being promoted at the community level, even as certain aspects are administered by trained healthcare professionals.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': '## Nutrition Support for Children and Pregnant/Lactating Women\\n\\nFocus on the interpretation of Mid-Upper Arm Circumference (MUAC) results and nutritional support for children and pregnant/lactating women.\\n\\n### MUAC Level Interpretation\\n#### Classification and Actions\\n- **Severe Acute Malnutrition**: \\n  - MUAC < 11.5 cm for children aged 6-59 months, < 13.5 cm for 5-9 years, < 14.5 cm for 10-17 years.\\n  - Action: Admission for stabilization/therapeutic rehabilitation.\\n  \\n- **Moderate Acute Malnutrition**: \\n  - MUAC 11.5-12.5 cm for children 6-59 months, 13.5-14.5 cm for 5-9 years, 14.5-18.5 cm for 10-17 years.\\n  - Action: Admission for supplementary feeding recommended.\\n\\n- **Mild Acute Malnutrition**: \\n  - MUAC 12.6-13.5 cm for children 6-59 months, 14.5-18.5 cm for 10-17 years.\\n  - Action: Nutritional education and counselling.\\n  \\n- **Normal Nutrition**: \\n  - MUAC > 13.5 cm for children aged 6-59 months, > 23 for pregnant and lactating women.\\n  - Action: Education and counselling for caregivers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': \"## Interpretation of Z-scores for Children\\n\\nThis section details the interpretation of Z-scores related to children's nutritional status, including underweight, stunting, and wasting.\\n\\n### Z-score Indicators and Severity\\n- **Weight/Age (Underweight)**: \\n  - Z-score < -3: Severe\\n- **Height/Age (Stunting)**: \\n  - Z-score between -3 to -2: Moderate\\n- **Weight/Height (Wasting)**: \\n  - Z-score > -2 to -1: Mild\\n  - Z-score < -2: Support with therapeutic/supplementary foods.\\n- **Normal Nutrition**: \\n  - Z-score > -1: Indicates normal nutritional status. \\n\\nThis section emphasizes the importance of monitoring children's nutritional health through Z-score assessments to guide interventions.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Adherence Challenges in Early Treatment\\n\\nAdherence is particularly challenging during the first few months of treatment. Patients may not yet have the habit of taking their medications daily, may be unfamiliar with common side effects, and may face stigma and disclosure challenges. These factors can significantly interfere with adherence. Moreover, poor adherence in the initial months is critical, as this is the riskiest period for the development of resistance mutations, especially when the viral load remains high.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Importance of Adherence Preparation and Support\\n\\nGiven the critical nature of early treatment, adherence preparation, monitoring, and support should be emphasized during the first months of Antiretroviral Therapy (ART). This support continues until the patient achieves full virological suppression, after which it can be reduced in intensity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Collaborative Patient Preparation and Counseling\\n\\nPatient preparation and counseling should be a collaborative process between healthcare providers and the patient or caregiver. This approach is essential to help the patient initiate and sustain lifelong treatment. It is most effective when the same adherence counselor works with the same patient throughout the preparation, initiation, and early ART period.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Timing of ART Initiation\\n\\nART can be initiated concurrently with the first adherence counseling session, including during the initial enrollment visit. This is particularly relevant for infants, pregnant women, or patients who have a good understanding of HIV and ART and demonstrate strong motivation for immediate treatment initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Multidisciplinary Team Training and Support\\n\\nEvery team member involved in patient care should have adequate training to provide treatment education and address potential barriers to adherence. Support should be seamlessly integrated into various healthcare settings, such as triage, consultation, pharmacy, or other clinic stations that ensure confidentiality and privacy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Conducting Effective Counseling Sessions\\n\\nBefore beginning a counseling session, counselors should ensure they have an adequate and private space to conduct the session. They should also have access to essential tools, such as psychosocial assessment forms, treatment literacy flip charts, PHDP flip charts, and documentation tools for recording the counseling sessions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## HTS Post-Test Counselling\\n\\nKey treatment preparation messages for all patients who test positive:\\n- Treatment is available and recommended for everyone with HIV.\\n- Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s).\\n- With good adherence, you can live a long and productive life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Enrolment Visit\\n\\n- HIV education and adherence preparation for all patients/caregivers (refer to Table 5.1).\\n- ART Readiness Assessment for all patients/caregivers (refer to Table 5.4), along with an individualized adherence support plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Patients Ready to Start ART\\n\\nFor patients who are ready to start ART:\\n- Initiate ART.\\n- Conduct baseline investigations if not already completed.\\n- Provide a standard package of care and differentiated care based on initial presentation (advanced disease vs. well).\\n- Book follow-up appointments for week 2 and 4 to review adherence and side effects.\\n- Continue adherence support plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Patients Not Ready to Start ART\\n\\nFor patients who are not ready to start ART:\\n- Schedule weekly appointments to review clinical status, barriers to ART initiation, and provide ongoing HIV education and counselling.\\n- Provide a standard package of care.\\n- Re-assess ART readiness at every visit, targeting readiness within 2 weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Follow-Up and Adherence Monitoring\\n\\nFollow-up with adherence monitoring at every visit (refer to Table 5.10) and counselling based on level of adherence (refer to Table 5.14) until the first Viral Load (VL) at 3 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Viral Load Undetectable\\n\\nFor patients with undetectable VL (LDL < 200 copies/ml):\\n- Conduct ongoing adherence assessment and counselling (refer to Table 5.16).\\n- Continue routine VL monitoring as per the population group.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Suspected Poor Adherence\\n\\nIn cases of suspected poor adherence:\\n- Assess for barriers to adherence (refer to Table 5.15).\\n- Follow the VL algorithm with enhanced adherence assessment and interventions, and assessment for other causes of viremia (refer to Figure 6.6).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 103,\n",
       "  'section': '## Antiretroviral Drugs and Malaria Interaction\\n\\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with advanced HIV disease. Further, people with advanced immunosuppression are at risk of failure of anti-malarial treatment. In pregnancy, there is increased risk of placental malaria, severe anaemia, premature delivery, and perinatal mortality. Drug interactions between ARVs and antimalarial drugs may further complicate management. \\n\\n### Recommendations for Malaria Prevention for PLHIV\\n- Offer cotrimoxazole preventive therapy (CPT) for protection against malaria infection.\\n- In areas of stable malaria transmission, PLHIV should have access to insecticide treated mosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bites and therefore malaria transmission.\\n- PLHIV travelling from non-malarious zones to malaria endemic areas should sleep under ITNs.\\n- Pregnant women with HIV living in areas of stable malaria transmission who are not able to take CPT should be given at least three doses of sulfadoxine-pyrimethamine (SP) intermittent preventive treatment for malaria as part of routine antenatal care. Note: SP should not be given to women who are taking CPT.\\n- PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive diagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to initiation of anti-malarial therapy.\\n- PLHIV with malaria should receive standard antimalarial therapy according to national guidelines. Those on CPT should not be given sulfa-containing anti-malarial drugs. Patients on ART receiving anti-malarial therapy should be monitored closely for adverse drug reactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 103,\n",
       "  'section': '## Safe Water, Sanitation, and Hygiene for PLHIV\\n\\nDiarrheal illnesses are common causes of morbidity and mortality among PLHIV. These diseases are often due to lack of access to safe drinking water, improper disposal of human and animal waste, and poor personal hygiene, leading to contamination of food and water. \\n\\n### Recommendations for Prevention of Faecal-Orally Spread Illnesses\\n- Offer CPT for protection against some gastrointestinal infections.\\n- Encourage hand washing with soap and water after handling human or animal faeces, after using the toilet, and before food preparation or eating.\\n- Establish facilities for proper disposal of human waste.\\n- Provide training on household-based water treatment methods and water storage containers that prevent direct hand contact with drinking water.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Weight Loss Score\\n\\nThe weight loss score categorizes individuals based on unplanned percentage weight loss over the last 1-3 months:\\n- **<5%** – Low Risk\\n- **5-10%** – Moderate Risk\\n- **>10%** – High Risk'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Opportunistic Infections Score\\n\\nThis score assesses the presence of opportunistic infections:\\n- **No opportunistic infection** – Low Risk\\n- **Sub acute OI** – Moderate Risk\\n- **Acute OI** – High Risk'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Food Intake Score\\n\\nThe food intake score evaluates the adequacy of dietary consumption:\\n- **Adequate Intake** – Low Risk\\n- **Low intake** – Moderate Risk\\n- **Nausea/Vomiting** or **Fasted for >5 days** – High Risk'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Food Security Score\\n\\nThe food security score measures household hunger:\\n- **Little or No Household Hunger** = 0 - 1 (Low Risk)\\n- **Moderate Household Hunger** = 2 - 3 (High Risk)\\n- **Severe Household Hunger** = 4 - 6 (High Risk)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Assessment for Pregnant & Postpartum Women\\n\\nThe assessment uses Mid-Upper Arm Circumference (MUAC) measurements:\\n- **MUAC <19 cm** – SAM (Severe Acute Malnutrition)\\n- **19.0 - 20.9 cm** – MAM (Moderate Acute Malnutrition)\\n- **21.0 - 23.1 cm** – High Risk\\n- **>23.1 cm** – Normal\\n\\nAdditionally, nutritional anemia and deficiencies related to specific vitamins are evaluated.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Assessment for Other Adults\\n\\nFor adults, Body Mass Index (BMI) categories apply:\\n- **BMI < 16** – SAM\\n- **BMI 16 – 18.5** – MAM\\n- **BMI 18.6 - 21.9** – High Risk\\n- **BMI 22 – 24** – Normal'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Management of Severe Malnutrition (SAM)\\n\\nActions for individuals with Severe Acute Malnutrition include:\\n1. Initiate Phase I therapeutic feeding until stable (Inpatient – rescue phase feeding)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Management of Moderate Malnutrition (MAM)\\n\\nActions include:\\n1. Nutrition counselling & education\\n2. Repeat nutrition screening every 2-3 months'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Management of Normal/Low Risk\\n\\nFor individuals categorized as normal or low risk, actions involve:\\n1. Nutrition counselling & education\\n2. Multiple micronutrient supplementation\\n3. Review nutrition status and risk factors every 2-4 weeks until stable\\n4. Repeat nutrition screening every 2-3 months once stable\\n\\nFor pregnant or postpartum mothers, enrollment in additional programs is recommended.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Interventions\\n\\nGeneral nutritional interventions involve:\\n- Nutrition counselling and education\\n- Multiple micronutrient supplementation\\n- Regular review of nutrition status and adjustments based on assessments'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Referral Protocols\\n\\nNon-responders or those facing challenges are referred for further clinical assessment and management. For food insecure clients, refer to livelihood assistance programs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the care provided to people living with HIV (PLHIV), particularly regarding immunizations and recommendations for vaccination schedules.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '## Immunization Response in PLHIV\\n\\nPLHIV may have an inadequate response to immunizations, especially before achieving full viral suppression. Guidance for revaccination will be provided by the National Vaccines and Immunization Program and NASCOP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '## Recommended Vaccinations for Adolescents and Adults Living with HIV\\n\\nThis section lists the recommended vaccinations specifically for adolescents and adults living with HIV.\\n\\n### Table of Vaccinations\\n\\n| Infection                    | Vaccine               | Live (Y/N) | Course                             | Comments                                                                                       |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '--|\\n| COVID-19                     | Various              | N          | Variable                          | Follow national guidelines on dosing for the specific vaccine available                       |\\n| Hepatitis B                  | Subunit              | N          | 4 doses (at 0, 1, 2 and 6 months)| Use double dose if non-adjuvanted; use standard dose if adjuvanted                          |\\n| Pneumococcus                 | Conjugate            | N          | 1 dose (PCV 13)                  | Preferable to polysaccharide                                                                   |\\n| Polysaccharide               | N                    | 1 dose     | Use if >65 years and with co-morbidity other than HIV                                     |\\n| Human Papillomavirus (HPV)   | Virus-like particles  | N          | 3 doses (at 0, 1-2, and 6 months) | All girls at 9-14 years old                                                                    |\\n| Influenza                    | Inactivated          | N          | 1 dose                            | Annually                                                                                       |\\n| Hepatitis A                  | Inactivated          | N          | 2 - 3 doses                       | 3 doses if CD4 count < 350 cells/mm³ at 0, 1, and 6 months; if CD4 count > 350, give 2 doses at 0 and 6 months. Booster every 10 years for those at continued risk. |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '## Additional Vaccines for Special Circumstances\\n\\nThis section details additional vaccines that may be recommended for specific health circumstances in PLHIV.\\n\\n| Vaccine       | Type                    | Live (Y/N) | Course | Comments                                                    |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '-|\\n| Yellow fever  | Live attenuated         | Y          | 1 dose | Use only in patients <60 years of age and CD4 > 200 cells/mm³ |\\n| Typhoid       | Polysaccharide          | N          | 1 dose | Give the ViCPS parenteral; repeat every 3 years              |\\n| Cholera       | Subunit                 | N          | 2 doses| Administered as indicated (usually during epidemics). 2 oral doses given 1-6 weeks apart with a booster at 2 years from the primary vaccination.|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '## Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya\\n\\nThis section provides an overview of the guidelines related to the usage of antiretroviral drugs in the context of HIV infection management in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '## Interpretation of BMI Results for Adults\\n\\n### BMI Level Classification and Actions to Take\\n\\n| BMI Level          | Classification            | Action to Take                                                                                           |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '-|\\n| < 16              | Severe malnutrition       | • Refer for facility-based therapeutic intervention; rehabilitation with therapeutic foods; counselling on intake issues and possible metabolic issues<br>• Screen for TB |\\n| 16.0 – 18.4       | Mild/moderate malnutrition| • Nutritional counselling and supplementary feeding<br>• Screen for TB                                   |\\n| 18.5 – 25.0       | Normal/recommended        | • Nutritional counselling, consistent exercise to build muscles                                          |\\n| 25.1 – 30         | Overweight                | • Nutritional counselling to reduce energy intake; aerobic physical activity to reduce weight            |\\n| >30               | Obese                     | • Counselling to change lifestyle and reduce energy intake; aerobic physical activity to reduce weight   |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '## Prevention of Other Infections\\n\\n### Immunizations\\n\\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, with exceptions for infants with severe immunosuppression. For infants living with HIV and HIV Exposed Infants (HEIs), an earlier dose of measles vaccines should be given at 6 months of age.\\n\\n### Kenya Expanded Program on Immunizations 2016 Schedule\\n\\n| Age          | Vaccines                                                                                             |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '--|\\n| Birth        | OPV1, BCG2                                                                                          |\\n| 6 weeks      | OPV3, Pentavalent (DPT-HepB-HiB), Pneumococcal (PCV10), Rotavirus                                   |\\n| 10 weeks     | OPV3, Pentavalent (DPT-HepB-HiB), Pneumococcal (PCV10), Rotavirus                                   |\\n| 14 weeks     | IPV, Pentavalent (DPT-HepB-HiB), Pneumococcal (PCV10)                                              |\\n| 6 months     | Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A                              |\\n| 9 months     | Measles/Rubella (MR); Vitamin A; Yellow Fever4                                                     |\\n| 18 months    | Measles/Rubella (MR); Vitamin A                                                                     |\\n| 10 years     | HPV (2 doses at 6 months apart in the general population; 3 doses for PLHIV, at month 0, 1-2, and 6)|\\n| 11-12 years  | Tdap (tetanus, diphtheria, and pertussis)                                                          |\\n\\n### Additional Guidelines for Vaccination\\n\\n1. **OPV and BCG Administration**:  \\n   - Give OPV to all infants at birth or within the first two weeks. If missed and the child has symptoms of advanced HIV disease (WHO Stage 3 or 4), defer BCG until viral suppression is achieved through ART.\\n\\n2. **Administering BCG**:  \\n   - BCG should be given within the first two weeks of birth unless the infant shows advanced HIV disease or comes from a smear-positive mother. In such cases, perform a TB investigation, administer TPT, and vaccinate two weeks after TPT completion.\\n\\n3. **IPV Usage**:  \\n   - If HIV+ with symptoms of advanced HIV disease, use IPV instead of OPV.\\n\\n4. **Yellow Fever Vaccine**:  \\n   - The yellow fever vaccine is routinely used in specified counties; defer vaccination if the child shows symptoms of advanced HIV disease until they are virally suppressed on ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 109,\n",
       "  'section': '## U=U: Understanding and Discussion\\n\\nCounsel patients to share information about the research on U=U as follows:  \\n- In recent research studies involving thousands of couples, no one who was on HIV treatment and whose HIV was durably undetectable passed HIV to their HIV-negative sex partner.  \\n- Advise patients that they can share personal information with current or potential sex partners about when they last had a viral load test and if their viral load was undetectable.  \\n- Individuals should disclose their undetectable HIV status only if they have consistently taken HIV medicines since their last test with an undetectable viral load.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 109,\n",
       "  'section': \"## Other Prevention Combination Interventions\\n\\n### PrEP (Pre-Exposure Prophylaxis)\\n- PrEP is a safe and effective daily pill that prevents HIV infection. The partner without HIV may consider taking PrEP if they:\\n  - Are unsure if their partner’s HIV viral load is undetectable, especially if their partner has recently started ART.\\n  - Have more than one sexual partner.\\n  - Feel more secure with the added perception of protection provided by PrEP.\\n\\n### PEP (Post-Exposure Prophylaxis)\\n- After a possible HIV exposure (e.g., occupational exposure or if a sex partner with HIV has not consistently taken ART and is not virally suppressed), the immediate initiation of emergency PEP can prevent HIV infection.\\n\\n### Condom Use\\n- Condoms protect against other STIs (such as gonorrhea, chlamydia, and syphilis) and help prevent pregnancy.  \\n- Counsel patients to identify a prevention strategy that works for them. If an individual who does not have HIV is unsure of their partner's viral load status or anxious about acquiring HIV, care providers should recommend choosing a prevention strategy, which may include PrEP, emergency PEP, condoms, or a combination of these methods.\\n\\nNote: Care providers should emphasize that no one should ever be compelled to have sex without condoms.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 109,\n",
       "  'section': '## Application of U=U in Other Settings\\n\\n### Breastfeeding\\n- Studies demonstrate that ART greatly reduces the risk of transmission through breast milk. However, research has not established that people whose HIV is undetectable do not transmit the virus during breastfeeding. Prophylaxis should be provided to HIV-exposed infants during breastfeeding as per the guidelines, regardless of viral load status.\\n\\n### Injection Drug Use\\n- Studies show that ART significantly reduces the risk of transmission through shared injection drug use. However, it has not been confirmed that people with an undetectable viral load do not transmit the virus through needle sharing. All individuals who inject drugs should only use their own needles and refrain from sharing needles or other paraphernalia.\\n\\n### Needle Stick Injuries\\n- Research has not established that individuals with an undetectable viral load do not transmit HIV to those stuck by needles containing their blood. HIV PEP should be provided as per the guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Introduction to Peer Support in HIV Care\\n\\nPersons living with HIV (PLHIV), including adolescent and adult peer educators, should be engaged to support patient education. These individuals can share personal experiences to enhance the educational process concerning HIV prevention and treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Operational Guidance: Meaningful Involvement of People Living with HIV\\n\\nFor optimal patient outcomes, PLHIV should lead facility-based and community-based HIV education and support systems. They may be referred to as \"peer educators,\" \"mentor mothers,\" or \"lay health workers.\" Their involvement has shown significant contributions in:\\n- Identifying individuals at risk for or infected with HIV\\n- Increasing linkage from testing to treatment\\n- Reducing onward transmission of HIV\\n- Providing psychosocial support\\n- Improving adherence and retention to care and ART'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Identifying PLHIV for Peer-led Patient Support\\n\\nTo effectively engage PLHIV in patient support roles, the following criteria can be used to identify suitable candidates:\\n- Must be on ART for at least one year\\n- Must demonstrate good adherence and have an undetectable viral load (VL)\\n- Must possess a positive attitude and a genuine interest in supporting peers'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Preparing PLHIV for Roles in Patient Support Systems\\n\\nTo enable effective participation of PLHIV in support roles, the following preparations are essential:\\n- Training for the specific roles they are expected to provide\\n- Access to job aids and information, education, and communication (IEC) materials suitable for their roles\\n- Supervision by healthcare professionals to ensure quality support'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Potential Roles for PLHIV in Patient Support\\n\\nPLHIV can take on various roles within patient support systems, including:\\n- Supporting HIV self-testing\\n- Providing HIV testing services\\n- Acting as peer linkage supporters\\n- Leading or contributing to facility-based or community-based support groups\\n- Providing individual or group HIV education\\n- Offering individual or group adherence counseling\\n- Distributing ART refills for stable patients'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Compensation for PLHIV in Patient Support Roles\\n\\nCompensation for PLHIV who contribute to patient support systems can include:\\n- Recognition through ID badges, certificates of service, or acknowledgments at community forums\\n- Training opportunities that come with certification\\n- Financial compensation such as salaries, stipends, or transportation allowances\\n- Priority consideration for employment opportunities within health care settings'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section covers the significance of adherence to antiretroviral therapy (ART) in achieving viral suppression for individuals living with HIV (PLHIV). It emphasizes the role of sustained adherence in eliminating the risk of sexual transmission of HIV and its importance in HIV epidemic control.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Undetectable = Untransmittable (U=U)\\n\\nDetails the concept of U=U, where achieving durable viral suppression of less than 50 copies/ml eliminates the risk of sexual transmission of HIV. This section highlights the importance of U=U in reducing stigma and enhancing the role of ART.\\n\\n### Definitions\\n- **Durably Undetectable**: Defined as having two consecutive viral load results of less than 50 copies/ml.\\n- **Untransmittable**: Established through clinical trials, indicating that individuals with an undetectable viral load have effectively no risk of transmitting HIV through sexual contact.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Benefits of U=U\\n\\nHighlights the positive outcomes associated with the U=U campaign, including:\\n- Diminishing HIV-related stigma\\n- Lowering barriers to testing and treatment\\n- Increasing interest in ART\\n- Enhancing self-esteem by reducing fears of contagion\\n- Supporting healthy sexuality for all, regardless of HIV status\\n- Alleviating concerns of sexual partners'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Considerations for Implementation of U=U in Clinical Settings\\n\\nOutlines critical considerations for adopting U=U in clinical practice, such as:\\n- Regular viral load monitoring as recommended for different populations\\n- Continuous monitoring and support for adherence at all clinical visits\\n- Routine STI screening\\n- Providing U=U messaging as part of treatment literacy for all PLHIV'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Messaging to Patients on U=U\\n\\nDetails key messages to communicate to patients regarding U=U, including:\\n- The importance of keeping HIV undetectable for long and healthy living\\n- Adherence to ART to achieve and maintain undetectable levels\\n- The timeframe for viral load reduction (up to 6 months)\\n- Assurance that durably suppressed individuals cannot transmit HIV through sexual intercourse\\n- Risks associated with discontinuing ART, including potential viral rebound and transmission risks\\n- Benefits of maintaining a durably suppressed viral load for safe conception'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the importance of preparing for antiretroviral therapy (ART) adherence and the ongoing support needed for individuals diagnosed with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## ART Adherence Preparation and Support\\n\\nPreparation for ART begins at the time of HIV diagnosis and continues until initiation of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## Treatment Preparation as Part of HIV Testing Services\\n\\nThis subsection discusses the crucial messages that should be integrated into post-test counseling for all people living with HIV (PLHIV), highlighting the importance of starting treatment promptly.\\n\\n- Treatment (called antiretroviral therapy (ART)) is available and is recommended for everyone with HIV.\\n- Starting treatment as soon as possible (preferably within two weeks of testing positive for HIV) reduces the chance of your illness getting worse or of passing HIV to others.\\n- If you take your ART properly and do not miss pills, you can expect to live a long and productive life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## ART Treatment Preparation\\n\\nThis subsection focuses on the detailed components of ART treatment preparation, which includes education, counseling, and the development of an adherence plan tailored to the individual’s needs.\\n\\nART treatment preparation involves HIV education and counseling, identifying likely barriers to adherence, discussing strategies to overcome barriers, and creating an individualized adherence plan, as summarized in Table 5.1. The education and counseling sessions should be documented in patient charts.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': \"## HIV Education\\n\\nThis section details specific educational topics to be covered during ART preparation.\\n\\n- Ask the patient what they know about HIV.\\n- Ask the patient what they know about treatment for HIV.\\n- Correct/clarify as needed, ensuring coverage of the following key points:\\n  - Modes of transmission and the importance of testing partners/children.\\n  - HIV's effect on the immune system and health.\\n  - HIV viral load and its relationship to health and transmission.\\n  - Goals of ART.\\n  - Relationship between adherence and viral suppression, treatment failure, and drug resistance.\\n  - Consequences of drug resistance.\\n- Ensure the patient understands by asking them to explain it back.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## Barriers to Adherence\\n\\nThis section focuses on exploring potential barriers to ART adherence and strategies for overcoming them.\\n\\n- Ask the patient what they think will be most difficult about taking ART every day.\\n- Ask the patient what they think will be most difficult about attending all clinic appointments.\\n- Discuss common reasons patients encounter difficulties with adherence and identify which may be most relevant for them, including various identified barriers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': \"## Patient Factors Affecting Adherence\\n\\n- Stigma and non-disclosure (having to hide their ARV pill-taking)  \\n- Lack of support systems  \\n- Alcohol or drug use  \\n- Depression or other psychiatric illness  \\n- Loss or grief  \\n- Cognitive disorders  \\n- Change in daily routine  \\n- Chaotic lifestyle; no consistent daily routine  \\n- Forgetting to take pills  \\n- Feeling better and thinking ART is no longer necessary  \\n- Feeling too sick to take ART  \\n- Age factors (adolescents' impulsivity and susceptibility to social pressure; children’s dependency on caregivers)\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': '## Provider/System Factors Affecting Adherence\\n\\n- Side effects from ART (nausea, headaches, difficulty sleeping, which typically resolve with continued use)  \\n- Pill burden  \\n- Poor patient-provider relationship  \\n- Inadequate HIV education  \\n- Cost of care (both direct and indirect)  \\n- ARV supply-chain limitations (stock-outs or low stock levels leading to small refill quantities)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': '## Individualized Adherence Plan\\n\\n- Engage the patient in discussions about ensuring excellent adherence  \\n- Incorporate specifics of the patient’s ART regimen, including:\\n  - Number of pills\\n  - Frequency of taking pills\\n  - Food requirements/restrictions\\n  - Common side effects\\n  - Important drug interactions  \\n\\n- Collaborate on creating an individualized adherence plan that may include:\\n  - Disclosing HIV status to a close friend or family member for support\\n  - Bringing a treatment buddy to clinic visits or counseling sessions  \\n  - Informing household members to avoid hiding pill-taking  \\n  - Integrating pill-taking with a consistent daily activity  \\n  - Keeping ARVs in a visible, daily-accessible location  \\n  - Setting a daily alarm on devices to remind of pill-taking  \\n  - Connecting with support groups for additional counseling and education  \\n  - Seeking treatment for any substance use issues  \\n  - Addressing mental health concerns like depression'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': '## Managing Challenges in Adherence\\n\\n- Discuss steps to take if:\\n  - Side effects develop: Talk about common and serious adverse events related to their specific regimen and encourage a clinic visit rather than stopping ART  \\n  - A dose is forgotten: Advise to take it late instead of skipping completely  \\n  - Traveling without ART: Recommend going to the nearest health facility or calling the clinic for guidance  \\n- Request the patient to summarize their individualized adherence plan to ensure understanding and commitment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 112,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThis section outlines the key activities involved in supporting adherence to antiretroviral therapy (ART) during patient visits. The following steps are recommended for ongoing support:\\n\\n- Review the patient’s HIV knowledge.\\n- Assess the patient’s motivation to take ART.\\n- Address any concerns the patient may have regarding their ART, including side effects and visit schedules.\\n- Review the ART dosing schedule and inquire about any missed doses.\\n- Explore previously identified or newly developed barriers to adherence.\\n- Discuss any recent or anticipated changes in the patient’s life or daily routine that may impact adherence.\\n- Revisit the individualized adherence plan to determine if any changes are necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 112,\n",
       "  'section': '## HIV Education and Counselling\\n\\nThis section emphasizes the importance of HIV education as a critical component of the enrolment process for patients beginning ART. Key points include:\\n\\n- All patients and their caregivers must receive adequate information to make informed decisions about ART initiation and adherence.\\n- This education and counselling should occur prior to ART initiation, including for those starting ART during the enrolment visit.\\n- A detailed content guide for HIV education and adherence counselling can be found in Annex 8.\\n- The ART Readiness Assessment and management plan should be completed for each patient individually, as shown in Table 5.4.\\n- The education can be delivered through group or individual counselling settings.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 114,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThis section outlines the key components and strategies for supporting patient adherence to treatment, particularly for those undergoing antiretroviral therapy (ART) for HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 114,\n",
       "  'section': '## Standard Adherence Support Interventions\\n\\n### Structural Interventions\\n- Conduct a baseline psychosocial assessment to explore various aspects of the client’s life that may influence adherence to treatment and prevention, along with general well-being. Issues to be explored include:\\n  - Disclosure\\n  - Family planning\\n  - Living circumstances\\n- Use a multidisciplinary team approach to develop and implement individualized treatment plans.\\n- Engage peer educators to lead HIV education and support services.\\n- Prepare and assess the patient’s readiness to initiate and continue ART.\\n- Implement a system for identifying and addressing missed appointments.\\n- Formalize a system for providing health talks and treatment literacy classes for patients.\\n- Establish connections to community-based resources, such as:\\n  - Community support groups\\n  - Religious groups\\n  - Organizations providing food support\\n  - CBOs (Community-Based Organizations)\\n  - Child welfare societies'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 114,\n",
       "  'section': '## HIV Education and Counseling\\n\\n### Key Educational Components\\n- Remind patients about:\\n  - The nature of HIV disease and its health implications.\\n  - How ART works and the significance of adherence.\\n  - The connection between adherence and key health indicators (viral load, CD4 count).\\n  - The potential side effects of medications and strategies for management.\\n- Address and clarify misconceptions regarding HIV and ART.\\n  \\n### Treatment Planning\\n- Collaborate with the patient to discuss and agree upon a treatment plan, fostering their commitment to adhere.\\n- Address substance use (alcohol and drugs) and its potential impact on treatment efficacy.\\n\\n### Building Trust\\n- Maintain a non-judgmental attitude to establish trust, especially with parents and caregivers.\\n- Involve children in discussions as they mature, ensuring they understand their treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 118,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the strategies for preparing and supporting children and adolescents with HIV in adherence to their treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 118,\n",
       "  'section': '## Age-Appropriate Involvement in HIV Education and Adherence Counselling\\n\\n### < 6 years old\\nThe counselling sessions will focus on engaging all of the child’s caregivers.\\n\\n### 6-12 years old\\nBoth the caregiver and the child will be involved. The counselling will focus on the caregiver. Younger children can be given a paper and pen to draw their family, school, etc., and talk about their experiences. Disclosure of HIV status to the child should commence by 5 years of age and be completed by 10-12 years of age.\\n\\n### > 12 years old with caregiver present\\nMost of the counselling can focus on the adolescent, who is often fully responsible for medication administration. However, it is necessary to keep the caregiver involved in supporting the adolescent. A recommended approach is to initially meet with the caregiver alone, then conduct sessions with both the caregiver and adolescent together, and finally see the adolescent alone. Use the HEADSSS tool* to facilitate discussion.\\n\\n### > 12 years old without caregiver present\\nUtilize the HEADSSS tool* to facilitate discussion. Negotiate the involvement of a treatment supporter.\\n\\n*HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; Suicide/depression/self-image; Safety'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 118,\n",
       "  'section': '## Unique Issues in HIV Education and Adherence Counselling\\n\\nIn addition to the standard HIV education and adherence counselling topics, there are specific issues that need to be addressed for caregivers, children, and adolescents.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': \"## Adherence Preparation, Monitoring and Support\\n\\nThis section highlights the importance of customizing treatment preparation based on the patient's age, gender, needs, and clinical status. It emphasizes different focuses for patients based on their health status, whether they are symptomatic or clinically well.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': '## Age-Specific Treatment Preparation and Support\\n\\nTreatment preparation must be tailored to the specific demographics of patients, including children, adolescents, caregivers, pregnant and breastfeeding women, and men. The emphasis is on a personalized approach to ensure that all unique requirements are met.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': \"## HIV Education and Counselling\\n\\nEvery visit should include HIV education and counselling until the patient is ready to start ART, as assessed via the ART Readiness Assessment Form. It’s crucial to address prior knowledge and concerns by reviewing the patient's previous session notes.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': '## Duration of ART Preparation\\n\\nART preparation should ideally take 1-2 weeks unless special circumstances are present, such as uncontrolled mental health issues or untreated drug addictions. Continued education and adherence support remain crucial after initiating ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': \"## Role of Counsellors and Support Staff\\n\\nCounselling should ideally be conducted by the same certified professional to establish rapport and continuity. They are responsible for providing quality counselling tailored to the patient's needs, particularly for children and adolescents where specialized training is necessary.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': \"## ART Readiness Assessment Form\\n\\nThis section includes a checklist for assessing a patient's readiness to start ART. Criteria include understanding HIV, screening for substance use and mental health disorders, willingness to disclose HIV status, and preparedness for medication adherence.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': '## Barriers to Adherence\\n\\nPotential barriers to medication adherence should be identified and addressed, such as travel commitment or clinic accessibility. This proactive approach helps ensure that patients have a plan for any challenges that may arise.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': '## Patient and Caregiver Responsibilities\\n\\nPatients and caregivers are expected to provide accurate locator information and demonstrate a willingness to start ART. The commitment of caregivers to support patients in their treatment journey is crucial for long-term success.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Support Systems Criteria for HIV Patients and Caregivers\\n\\n1. Has identified convenient time/s of day for taking ART, and/or associated dose/s with daily event/s?  \\n2. Treatment supporter has been identified and engaged in HIV education, or will attend next counselling session?  \\n3. Is aware of support group meeting time/s?  \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?  \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Medical Criteria for ART Initiation\\n\\n1. Newly diagnosed with TB: defer ART until the patient tolerates anti-TB medication; initiate ART as soon as possible preferably within 2 weeks; for TB meningitis delay ART for 4 to 8 weeks; monitor closely for IRIS.  \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM (progressive headache, fever, malaise, neck pain, confusion): defer ART until completed 5 weeks of CM treatment, or until ruling out CM as the cause of symptoms; monitor closely for IRIS.  \\n   \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a strategy to address the issue as quickly as possible and consider assigning a case manager. ART may be initiated with adequate adherence support while the criteria is being addressed, on a case-by-case basis.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Patient Readiness Assessment for ART\\n\\nAt each visit up until ART initiation, every patient should be assessed for readiness to start ART (Table 5.4), with the patient/caregiver allowed to make the final decision on whether and when to start ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Special Considerations When Counselling Children and Adolescents\\n\\nChildren and adolescents depend on caregivers to support their adherence, so there are special considerations for adherence preparation and support. All topics covered in the HIV Education and Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the caregiver, with involvement of the child/adolescent as appropriate based on the stage of disclosure and their developmental stage (Table 5.5).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Disclosure and Stigma\\n\\n- Respect patient privacy and confidentiality.\\n- Discuss with the patient the role of disclosure to close family members/trusted friends in promoting adherence.\\n- Offer to facilitate disclosure.\\n- For children/adolescents, discuss age-appropriate disclosure with the caregiver and offer support in the process (see Annex 5).\\n- Conduct stigma assessment and provide appropriate support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Treatment Supporter\\n\\n- Encourage the patient to identify a treatment supporter/buddy who can provide encouragement, social support, and reminders for medication adherence.\\n- Invite the treatment supporter to at least one adherence counseling session.\\n- Obtain consent from the patient to contact the treatment supporter if needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Support Group\\n\\n- Link the patient to psychosocial support groups and other community-based support mechanisms (ideally through direct introduction).\\n  - Support groups provide confidence and encouragement, promote a positive attitude towards HIV status, and may aid in disclosure.\\n  - They offer opportunities for additional counseling, experience sharing, and developing/strengthening life skills.\\n  - Some support groups engage in economic empowerment activities.\\n  - Support groups may serve as venues for ART distribution to enhance patient convenience.\\n- Develop population-specific support groups when possible (e.g., youth groups with peer educators for adolescents, children’s clubs, caregiver support groups).\\n- MDT members should act as patrons to the support groups to guide activities in alignment with intended objectives.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## SMS Reminder System\\n\\n- Enroll patients into an automated SMS reminder system with their consent.\\n- Review the type of messages the patient will receive, the frequency of these messages, and any actions required when receiving them.\\n- Ensure that the system and messages uphold patient privacy and confidentiality.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Other Reminder Strategies\\n\\n- Encourage patients/caregivers to set a specific time of day for taking ART and associate this time with specific events in their daily schedule.\\n- Suggest that patients/caregivers set an alarm on their phones as a reminder.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## HIV Education\\n\\n### Component Questions to be Covered\\n- What is HIV?\\n- How is HIV transmitted?\\n- Why should partners and family members be tested for HIV?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Viral Load\\n\\n### Component Questions to be Covered\\n- What is viral load?\\n- How often is viral load measured?\\n- What do viral load measurements mean, including the goal of achieving viral suppression?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## CD4 Cells\\n\\n### Component Questions to be Covered\\n- What are CD4 cells?\\n- How are CD4 cells affected by HIV?\\n- What happens when CD4 cells decrease?\\n- How often is CD4 cell count measured?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Antiretroviral Therapy (ART)\\n\\n### Component Questions to be Covered\\n- What is ART?\\n- What are the benefits of ART?\\n- When is ART started?\\n- Does ART cure HIV?\\n- Can you still give HIV to others while taking ART?\\n- How long is ART taken?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Treatment Failure\\n\\n### Component Questions to be Covered\\n- What happens if you stop taking ART?\\n- What happens if you do not take ART regularly?\\n- What happens if the viral load increases?\\n- What happens in treatment failure?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## ART Side Effects\\n\\n### Component Questions to be Covered\\n- What are the side effects of ART?\\n- What should you do if you notice any side effects?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Adherence\\n\\n### Component Questions to be Covered\\n- What is adherence?\\n- How should ART be taken?\\n- What usually interferes with good adherence?\\n- What might make it difficult for you to take your ART as prescribed?\\n- What can help you take ART as prescribed?\\n- What happens if you miss an appointment?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Other Medications\\n\\n### Component Questions to be Covered\\n- What other medications will you take, in addition to ART (e.g., CPT, TPT)?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Nutrition\\n\\n### Component Questions to be Covered\\n- Why is nutrition important?\\n- What can you do to improve your nutrition?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Follow-up\\n\\n### Component Questions to be Covered\\n- How often will you need to come for clinic visits?\\n- What will we be checking for during your clinic visits?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Adherence Support\\n\\n### Overview\\nPsychosocial support for PLHIV (People Living with HIV) and their families is essential for well-being and good health outcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. PLHIV need psychological and social support to deal with various issues that are common to chronic illness and those that are unique to HIV, such as stigma, bereavement, self-image, loss of earning capacity, life skills, and chronic illness. Providing psychosocial support involves identifying and addressing their needs, sometimes even before they arise.\\n\\n### Implementation\\nThe individualized patient management plan should include establishing appropriate adherence support interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Caregiver Barriers to Adherence\\n\\n- Frequently changing or multiple simultaneous caregivers  \\n- Loss or grief  \\n- Absent or sick caregiver  \\n- Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate caregiver  \\n- Depression, alcohol and other drug use  \\n- Living far from the health facility  \\n- Economically unstable  \\n- Lack of affection between caregiver and child  \\n- Lack of support systems for the caregiver'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Child/Adolescent Barriers to Adherence\\n\\n- Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n- Lack of understanding of disease/treatment  \\n- Developmental stage and emotional state  \\n- Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should be stopped for the child until the dose is swallowed)  \\n- Stigmatization and discrimination  \\n- Low self-esteem  \\n- Depression  \\n- Defiance related to a troublesome caregiver-child relationship  \\n- Inadequate structures at school (day or boarding) to support adherence  \\n- Lack of support systems for the child/adolescent'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Treatment Barriers to Adherence\\n\\n- Large volumes of syrups  \\n- Bad taste of syrups  \\n- Pill burden  \\n- Confusing regimens combining syrups and tablets  \\n- Side effects  \\n- Dose adjustment requirements as the child grows'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Disclosure and Management Strategies\\n\\nFor all children/adolescents, the level of disclosure should be assessed at the first visit. The management plan should include a plan for age-appropriate disclosure (Annex 5). Treatment preparation and support sessions should be customized to the patient’s age (Tables 5.7 - 5.9).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 123,\n",
       "  'section': '## ART Follow-Up Sessions\\n\\nTwo weeks after ART initiation:  \\n- Review and reinforce the messages delivered at enrolment; confirm the patient’s understanding of key messages.  \\n- Review ART dosing, timing, and reminders.  \\n- Explore any barriers to adherence.  \\n- Review support systems.  \\n- Revisit benefits of disclosure, the disclosure plan, and progress in aPNS.  \\n- Document the session in the patient’s chart.  \\n\\nFour weeks after ART initiation, and further follow-up visits:  \\n- Review and reinforce the messages delivered in previous sessions; confirm the patient’s understanding of key messages.  \\n- Review ART dosing, timing, and reminders.  \\n- Explore any barriers to adherence.  \\n- Review support systems.  \\n- Revisit benefits of disclosure, the disclosure plan, and progress in aPNS.  \\n- Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 123,\n",
       "  'section': '## Adherence Monitoring, Counselling, and Support\\n\\n### 5.3 Adherence Monitoring\\n\\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained provider during each visit. The objectives of this assessment are to evaluate and reinforce the patient’s adherence to ART, elicit any barriers to adherence, and develop a plan to address identified barriers.  \\n\\nBarriers may include:  \\n- Incorrect knowledge of HIV infection and ART.  \\n- Unsupportive psychosocial factors.  \\n- Difficult home or school environment.  \\n- Substance use.  \\n- Poor motivation for taking medication.  \\n\\nPatients/caregivers need to be counselled on the importance of being honest about their adherence for the healthcare team to assist them effectively.  \\n\\nAdherence monitoring requires a combination of interventions. At every clinical visit:  \\n- The MMAS-4 should be administered, along with pill counts.  \\n- The MMAS-8 should be administered any time a healthcare worker suspects an adherence problem (e.g., patients with suspected or confirmed treatment failure; patient who misses an appointment).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 124,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines various strategies for monitoring adherence to medication, detailing the different techniques used based on subjective and objective assessments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 124,\n",
       "  'section': '## Subjective Adherence Monitoring Strategies\\n\\n### Morisky Medication Adherence Scale - 4\\n- **Technique:** Use Table 5.11 to assess adherence with a standardized questionnaire.\\n- **Frequency:** Every patient, every visit.\\n\\n### Morisky Medication Adherence Scale - 8\\n- **Technique:** Use Table 5.12 to assess adherence with a standardized questionnaire.\\n- **Frequency:** Anytime a healthcare worker suspects adherence problems, such as in cases of suspected or confirmed treatment failure or missed appointments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 124,\n",
       "  'section': '## Objective Adherence Monitoring Strategies\\n\\n### Pill Counts\\n- **Technique:** Ask the patient to bring all their pills during follow-up visits. Calculate the expected number of remaining pills versus actual pills remaining.\\n- **Frequency:** At every visit until confirmed viral suppression and anytime a healthcare worker suspects adherence problems.\\n\\n### Pharmacy Refill Records\\n- **Technique:** Compare the actual drug pick-up date with the expected date, based on the number of pills dispensed.\\n- **Frequency:** At every drug pick-up and anytime a healthcare worker suspects adherence problems.\\n\\n### Viral Load Monitoring\\n- **Technique:** Follow the viral load monitoring algorithm (Figure 6.6) to check for adequate adherence.\\n- **Frequency:** \\n  - **Age 0-24 years:** At 3 months after ART initiation, then every 6 months.\\n  - **Age ≥ 25 years:** At 3 months after ART initiation, then at month 12, and subsequently annually.\\n  - **Pregnant and breastfeeding women:** At first ANC visit if already on ART, or 3 months after ART initiation if starting ART during pregnancy, followed by every 6 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 125,\n",
       "  'section': '## Home Visits in HIV Care\\n\\nHome visits are crucial for understanding how patients store and take their medications. They allow healthcare providers to assess whether patients have extra medications from missed doses and gain insights into the patient’s living situation and barriers to adherence. Unscheduled home visits can be more revealing but must be conducted with patient consent, ideally obtained during enrollment or initiation. These visits are particularly important for patients with suspected or confirmed treatment failure, those who default from care, or whenever the Multi-Disciplinary Team (MDT) feels it will aid in patient management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 125,\n",
       "  'section': '## Assessing Adherence\\n\\nAccurate adherence assessment requires clinicians to establish a collaborative, non-judgmental relationship with patients. This is best achieved when a single provider follows an individual patient longitudinally. The effectiveness of adherence inquiries lies not in the specific methods used, but in conducting regular, open discussions about adherence. Many patients may provide socially desirable responses, such as claiming perfect adherence, if they feel judged.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 125,\n",
       "  'section': '## Training and Support for Providers\\n\\nEvery provider within ART service delivery points should be adequately trained and confident in assessing adherence and providing support for patients with minimal barriers. Patients facing significant adherence challenges or multiple barriers should be referred to specialized providers with additional training and resources for enhanced support and counseling. Early involvement of experienced colleagues should occur as soon as issues are identified, and the patient’s case should be discussed within the MDT to explore various solutions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 125,\n",
       "  'section': '## Involving Mental Health Teams\\n\\nFor complex adherence situations, consultation with Mental Health Teams or regional/national mentors may be necessary. This team-based approach ensures that patients receive comprehensive support that addresses both medical and psychosocial challenges, ultimately aiming to improve adherence and health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '## Adherence Preparation at Enrolment into Care\\n\\n- **Use the 5As (Assess, Assist, Advice, Agree, Arrange)**  \\n  - Perform a psychosocial assessment to evaluate psychological, emotional, and social adherence boosters and barriers.  \\n  - Assess growth and developmental milestones to rule out challenges such as growth retardation, autism, deafness, and other physical issues. Refer children with developmental challenges for appropriate care.  \\n  - Identify the primary caregiver post-HIV diagnosis. In the absence of a caregiver, link the child to a community health volunteer or peer educator.  \\n  - Ensure that both the child and their caregiver are enrolled in the same clinic and schedule appointments on the same clinic day for family-centered care.  \\n  - Provide HIV education and counseling to caregivers and, as appropriate, to the child.  \\n  - Identify and establish appropriate adherence support interventions and linkage to pediatric and caregiver support groups.  \\n  - Discuss the benefits of disclosure of HIV status and formulate a disclosure plan for children aged 5 years and above.  \\n  - Conduct a readiness assessment to initiate ART; ART should be initiated on the same day or an agreed date.  \\n  - Review ART dosing and timing, ensuring the caregiver demonstrates how to measure and administer the ART.  \\n  - Conclude the session with an agreed treatment and follow-up plan.  \\n  - Book a return visit within two weeks for children initiated on ART; those unwilling to initiate should return weekly for further counseling.  \\n  - Identify referral needs and link as appropriate.  \\n  - Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '## Follow-Up Two Weeks After ART Initiation \\n\\n- **Review and Reinforce Messages**  \\n  - Confirm the caregiver’s understanding of key messages delivered at enrolment.  \\n  - Review ART dosing, timing, and reminders, ensuring the caregiver can demonstrate measurement and administration of ART.  \\n  - Explore any barriers to adherence.  \\n  - Revisit the benefits of disclosure and the individualized disclosure plan.  \\n  - Identify referral needs and link as appropriate.  \\n  - Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '## Follow-Up Four Weeks After ART Initiation and Further Visits\\n\\n- **Ongoing Review and Reinforcement**  \\n  - Review previous messages and confirm caregiver understanding.  \\n  - Continue reviewing ART dosing, timing, and reminders; ensure the caregiver can demonstrate the administration process.  \\n  - Explore barriers to adherence.  \\n  - Revisit the benefits of disclosure and the individualized disclosure plan.  \\n  - Identify referral needs and provide appropriate links.  \\n  - Document each session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 126,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the importance of preparing, monitoring, and providing support for medication adherence among patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 126,\n",
       "  'section': '## Morisky Medication Adherence Scale (MMAS -4)\\n\\nThe MMAS -4 is a tool to assess patient adherence to medication. It consists of four questions to evaluate the patient\\'s behavior regarding medication intake.\\n\\n### MMAS -4 Questions\\n\\n1. Do you ever forget to take your medicine?  \\n2. Are you careless at times about taking your medicine?  \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  \\n4. When you feel better do you sometimes stop taking your medicine?  \\n\\nEach question is responded to with a \"Yes\" (1 point) or \"No\" (0 points). The total score is the sum of the points from all items.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 126,\n",
       "  'section': '## Interpretation of MMAS -4 Score\\n\\nThe total score from the MMAS -4 indicates the level of medication adherence and the necessary actions to improve it.\\n\\n### Adherence Ratings and Actions\\n\\n- **Score: 0 (Good)**\\n  - Action Required: Continue with routine monitoring, counseling, and support.\\n\\n- **Score: 1-2 (Inadequate)**\\n  - Actions Required:\\n    - Discuss as a Multi-Disciplinary Team (MDT).\\n    - Assign a case manager.\\n    - Assess for and address barriers to adherence.\\n    - Engage treatment supporter in adherence counseling sessions.\\n    - Follow up in 2-4 weeks.\\n\\n- **Score: 3-4 (Poor)**\\n  - Actions Required:\\n    - Discuss as a Multi-Disciplinary Team (MDT).\\n    - Assign a case manager.\\n    - Assess for and address barriers to adherence.\\n    - Engage treatment supporter in adherence counseling sessions.\\n    - Implement Directly Observed Treatment (DOTs).\\n    - Follow up in 1-2 weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 129,\n",
       "  'section': '## Adherence Counselling and Support During the First 3 Months of ART\\n\\nThis section outlines the guidelines for adherence counselling based on the assessment of a patient’s adherence during the initial months of antiretroviral therapy (ART).\\n\\n### No Adherence Concerns\\n- **Counselling**: Group or Individual sessions at every visit (can be conducted by any healthcare team member).\\n  - Review patient/caregiver HIV knowledge and address any gaps.\\n  - Review understanding of ART administration (dosing, timing, frequency) and address any gaps.\\n  - Address concerns from the patient/caregiver regarding ART, other medications, visit schedules, or health.\\n  - Explore major recent or expected changes in the patient’s/caregiver’s life that could disrupt adherence.\\n  - Update patient locator and contact information.\\n  \\n- **Support**:\\n  - Encourage ongoing support systems discussed previously.\\n  - Introduce additional standard support systems, including supporting disclosure as needed (refer to Table 5.3).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 129,\n",
       "  'section': '## Inadequate or Poor Adherence\\n\\nThis section details the approach for counselling and support for patients who display inadequate or poor adherence to ART.\\n\\n- **Counselling**: Individual sessions at every visit until adherence improves (preferably with someone trained in adherence counselling).\\n  - Assess and address potential barriers to adherence.\\n  - Review patient/caregiver HIV knowledge and address any gaps.\\n  - Review understanding of ART administration and address any gaps.\\n  - Address concerns from the patient/caregiver regarding ART, other medications, visit schedules, or health.\\n  - Explore major recent or expected changes in the patient’s/caregiver’s life that could disrupt adherence.\\n  - Update patient locator and contact information.\\n\\n- **Support**:\\n  - Review the effectiveness of existing support systems.\\n  - Encourage the introduction of additional standard and enhanced support systems, including support for disclosure, assigning a case manager, and considering directly observed therapy (DOT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Treatment Preparation and Support for Adolescents\\n\\nThis section outlines the standard of care for adolescents (ages 10-19) enrolled in HIV treatment. It emphasizes the use of the 5As (Assess, Assist, Advice, Agree, Arrange) as a framework for initial visits.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Psychosocial Assessment at Enrolment\\n\\nHealth providers are advised to conduct a psychosocial assessment to evaluate psychological, emotional, and social factors that may impact adherence to treatment. This includes assessing growth and developmental milestones to rule out potential challenges.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': \"## Caregiver Identification and Role\\n\\nThe importance of identifying a primary caregiver soon after an adolescent's HIV diagnosis is discussed. For adolescents over 15 years and emancipated minors, alternatives to caregiver involvement are suggested, including mentors, peer educators, and community health volunteers.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Sexual and Reproductive Health (SRH) Counseling\\n\\nThis section details the approach for introducing Sexual and Reproductive Health counseling for adolescents, emphasizing the need for a private one-on-one session to facilitate open discussion.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Family-Centered Care\\n\\nIt is recommended for both the adolescent and their caregiver (if also HIV-positive) to be enrolled in the same clinic and scheduled for appointments on the same day to promote family-centered care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## HIV Education and Counseling\\n\\nThe guidelines suggest providing HIV education and counseling to caregivers and adolescents in accordance with their age and during consultations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Adherence Support Interventions\\n\\nThis section discusses the importance of identifying appropriate adherence support interventions, including connecting adolescents and caregivers to support groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Disclosure Planning\\n\\nA discussion on the benefits of disclosure of HIV status to the adolescent is included, along with the formulation of a disclosure plan tailored to the adolescent’s readiness.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## ART Readiness Assessment and Initiation\\n\\nGuidelines for conducting a readiness assessment for starting Antiretroviral Therapy (ART) are provided, and it is recommended that ART initiation should happen on the same day or on an agreed-upon date.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Review of ART Dosing and Administration\\n\\nHealth providers should review the ART dosing and timing, ensuring that adolescents and/or caregivers can demonstrate how to measure and administer the medication.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Follow-Up Plan\\n\\nThe requirements for concluding the initial visit with a clear treatment and follow-up plan are emphasized. Adolescents who are unwilling to start treatment should return weekly for counseling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Referral Needs and Documentation\\n\\nIt is crucial to identify any referral needs and link patients as appropriate. Documentation of the session in the patient’s chart is also necessary for maintaining comprehensive records.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 122,\n",
       "  'section': '## Adherence Preparation for Adolescents\\n\\nTwo weeks after ART initiation:  \\n- Review and reinforce the messages delivered at enrolment; confirm the adolescent’s and/or caregiver’s understanding of key messages.  \\n- Review ART dosing, timing, and reminders (including having the adolescent and/or caregiver demonstrate how they measure and administer the ART).  \\n- Explore any barriers to adherence, including issues related to the school environment.  \\n- Review support systems (including adolescent support groups).  \\n- Revisit benefits of disclosure and the individualized age-appropriate disclosure plan.  \\n- Review sexual and reproductive health (SRH) needs.  \\n- Identify referral needs and link as appropriate.  \\n- Document the session in the patient’s chart.\\n\\nFour weeks after ART initiation and further follow-up visits:  \\n- Review and reinforce the messages delivered in previous sessions; confirm the adolescent’s and/or caregiver’s understanding of key messages.  \\n- Review ART dosing, timing, and reminders (including having the adolescent and/or caregiver demonstrate how they measure and administer the ART).  \\n- Explore any barriers to adherence, including issues related to the school environment.  \\n- Review support systems (including adolescent support groups).  \\n- Revisit benefits of disclosure and the individualized age-appropriate disclosure plan.  \\n- Review SRH needs.  \\n- Link to psychosocial support group.  \\n- Identify referral needs and link as appropriate.  \\n- Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 122,\n",
       "  'section': '## Treatment Preparation and Support for Adults\\n\\nAt enrolment into HIV care:  \\n- Use the 5As (Assess, Assist, Advice, Agree, Arrange).  \\n- Perform a psychosocial assessment to evaluate adherence boosters and barriers (e.g., mental, emotional, and social status assessments; refer for appropriate care if a mental disorder is diagnosed).  \\n- Identify a treatment buddy (family member, friend, peer educator, community health volunteer, etc.) and involve them in HIV education and adherence counselling.  \\n- Provide HIV education and counselling to the patient.  \\n- Identify and establish appropriate adherence support interventions (Table 5.3), including linkage to a support group.  \\n- Discuss the benefits of disclosing HIV status to a trusted family member or friend; how to disclose; and establish a disclosure plan.  \\n- Discuss the importance of child and sexual partner testing as well as assisted partner notification services (aPNS).  \\n- Discuss prevention methods such as condoms, PrEP, PEP, STI screening, and treatment.  \\n- Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated the same day or an agreed date for initiation.  \\n- Review ART dosing and timing.  \\n- Conclude the session by agreeing on a treatment and follow-up plan.  \\n- Where ART is initiated, book the patient to return within two weeks. Those unwilling to initiate should return weekly for further counselling on barriers to initiation.  \\n- Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 130,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the importance of preparing and monitoring adherence to ART (Antiretroviral Therapy) and providing support to patients and caregivers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 130,\n",
       "  'section': '## Assessment for Barriers to Adherence\\n\\n### Awareness of HIV Status\\n- Has the patient/caregiver accepted HIV status?\\n- For children/adolescents: is age-appropriate disclosure underway/complete?\\n\\n### Understanding of HIV Infection and ART\\n- How HIV affects the body and the risk of transmission to sexual partners and children during pregnancy and breastfeeding.\\n- ART and how it works.\\n- Understanding of side effects and actions to take in case of side effects:\\n  - “Have you experienced any side effects since your last visit? Has this affected the way you take your medicine?”\\n- Benefits of adherence.\\n- Consequences of non-adherence, including drug resistance and treatment failure.\\n\\n### Daily Routine\\n- Review the patient’s/caregiver’s daily routine: “Tell me about your typical day.”\\n- Review how the patient takes medicine or how the caregiver administers it:\\n  - “Please tell me how you take each of your medicines?”\\n  - “How does taking your medicine fit into your daily routine?”\\n- If the daily routine conflicts with the medication schedule, work with the patient/caregiver to establish a new, appropriate medication schedule.\\n- Remind the patient/caregiver to take/give missed or delayed doses as soon as they remember (up to 12 hours late for once-daily regimens or up to 6 hours late for twice-daily regimens). The next dose should be taken at the usual time.\\n- “What do you do in case of visits or travel?”\\n- Remind the patient/caregiver to plan travel well, pack sufficient medicine, and if medication runs out before return, visit the nearest ART center with their appointment card to get a refill.\\n- For orphans, assess the primary caregiver’s identity and their commitment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 128,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the importance of adherence monitoring and support for patients, particularly during the initiation of Antiretroviral Therapy (ART). It provides a framework for assessing adherence based on missed doses and offers guidance on the actions required depending on adherence ratings.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 128,\n",
       "  'section': '## Adherence Rate Based on Pill Counts\\n\\nThis section includes a table (Table 5.13) that categorizes adherence based on the number of missed doses per month. It specifies adherence ratings and required actions based on adherence levels for both once-daily and BD regimens.\\n\\n- **Missed Doses per Month and Corresponding Actions:**\\n  - **1 dose (1-3 doses):** ≥ 95% adherence rated as Good. Action: Continue with routine monitoring, counselling, and support.\\n  - **2-4 doses (4-8 doses):** 85-94% adherence rated as Inadequate. Actions include discussing with the MDT, assigning a case manager, assessing barriers to adherence, engaging a treatment supporter, and following up in 2-4 weeks.\\n  - **≥ 5 doses (≥ 9 doses):** < 85% adherence rated as Poor. Similar actions to inadequate adherence, with the addition of implementing Directly Observed Therapy (DOTs) and following up in 1-2 weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 128,\n",
       "  'section': '## Adherence Counselling and Support During the First 3 Months of ART\\n\\nThis section emphasizes the necessity of adherence monitoring and support for patients newly initiated on ART. It stresses that achieving virological suppression is crucial and that adherence support intensity should vary depending on the patient’s assessed adherence levels.\\n\\n- **Timeframe:** From the initiation of ART until the 3-month viral load results are available.\\n- **Counselling Guidelines:** Methods for monitoring adherence are outlined in section 5.2.1, with further details on assessing barriers to adherence provided in Table 5.15 for patients with inadequate or poor adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section provides a comprehensive overview of the protocols for adherence preparation, monitoring, and support for patients undergoing Antiretroviral Therapy (ART).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Adherence Monitoring for Patients with Suppressed Viral Load\\n\\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower Detection Limit (LDL)), this is an indication of adequate adherence to ART. It is important to continue monitoring adherence, counseling, and support even after viral suppression, though at a reduced intensity and frequency unless concerns arise.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Strategies for Supporting Stable Patients\\n\\nPatients who have achieved viral suppression should be educated on qualifying for “stable patient” services. These may include less frequent facility visits and faster community-based ART distribution.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Adherence Counselling: No Concerns\\n\\nFor patients with no adherence concerns (as assessed by the healthcare team), the recommendation includes:\\n- Counseling should be conducted at every visit, which can be done by any team member.\\n- Key activities include:\\n  - Addressing any patient or caregiver concerns regarding ART or overall health.\\n  - Exploring life changes that may disrupt adherence.\\n  - Updating patient locator and contact information.\\n- Support systems already in place should be encouraged.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Adherence Counselling: Inadequate or Poor Adherence\\n\\nFor patients with identified inadequate adherence, individualized counseling at each visit is required until adherence improves. This counseling includes:\\n- Assessing and addressing potential barriers to adherence.\\n- Reviewing HIV knowledge and addressing any knowledge gaps.\\n- Ensuring understanding of ART administration (dosing, timing, frequency).\\n- Eliciting and addressing any concerns regarding ART or health.\\n- Checking for major life changes that could disrupt adherence.\\n- Updating patient locator and contact information.\\n- Reviewing existing support systems and encouraging enhanced support options, which may include case management and Directly Observed Therapy (DOT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 131,\n",
       "  'section': '## Psychosocial Circumstances\\n\\n- **Home Environment**\\n  - Questions to ask:\\n    - “Who do you live with?”\\n    - “Who is aware of your HIV status? Are there people in your life with whom you’ve discussed your HIV status and ART use?”\\n  - Discuss the usefulness of enlisting support from family members, friends, or a treatment supporter/buddy for medication reminders (for children/adolescents, include teachers and supportive peers at school). Offer assisted disclosure.\\n  - Encourage the patient to identify and bring a treatment supporter during the next visit.\\n\\n- **Support System**\\n  - Include treatment buddies and psychosocial support groups.\\n  - Evaluate any recent losses or grief.\\n  - Discuss changes in relationships with family members or friends.\\n  - Screen the patient/caregiver for alcohol and substance abuse:\\n    - Discuss the impact on medication adherence.\\n    - Explore motivation to stop and offer support/referral.\\n    - Encourage planning ahead to avoid missing medication.\\n\\n- **Intimate Partner Violence Screening**\\n  - Refer to Section 4.2.1 for guidelines.\\n\\n- **Stigma and Discrimination**\\n  - Ask:\\n    - “Does it bother you that people might find out about your HIV status?”\\n    - “Do you feel that people treat you differently when they know your HIV status?”\\n  - Discuss how stigma may interfere with medication adherence or keeping clinic appointments.\\n\\n- **Beliefs**\\n  - Inquire if the patient has tried faith healing or stopped medication due to religious beliefs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 131,\n",
       "  'section': '## Mental Health Screening\\n\\n- **Depression Screening**\\n  - Use the PHQ-9 (Table 4.14) to screen patients/caregivers for depression and manage/refer as required.\\n\\n- **Other Psychiatric Conditions**\\n  - Screen for conditions such as anxiety, post-traumatic stress disorder, or psychosis, and refer to a mental health worker for assessment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 131,\n",
       "  'section': '## Referrals\\n\\n- **Existing Referrals**\\n  - Determine if the patient has been referred to other services, including nutrition, psychosocial support services, or substance use treatment.\\n  - Check if the patient attended those appointments and their experiences.\\n  - Assess whether the referrals need to be re-organized.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 133,\n",
       "  'section': '## Viral Load Monitoring Cut-Offs\\n\\nThis section discusses the clinical definitions related to viral load monitoring, including specific categories, lab values, interpretations, and guidance for treatment:\\n\\n- **Suppressed (Low Risk)**\\n  - **LLV:** <50 Copies/ml\\n    - **Interpretation:** Treatment Goal\\n    - **Guidance:** Continue management, remind client of treatment goal, enroll in DSD.\\n\\n- **Stable Client, Untransmissible**\\n  - **LLV:** 50 – 199 Copies/ml\\n    - **Interpretation:** Treatment Goal\\n    - **Guidance:** Continue management, remind client of treatment goal, enroll in DSD.\\n\\n- **Unsuppressed (High Risk)**\\n  - **LLV:** 200 - 999 Copies/ml\\n    - **Interpretation:** Increased risk of progression to treatment failure.\\n    - **Guidance:** Step down from DSD, institute EAC, repeat VL after 3 months of excellent adherence.\\n\\n- **Suspected Treatment Failure**\\n  - **VL:** ≥1000 Copies/ml\\n    - **Interpretation:** Client at increased risk of morbidity and mortality.\\n    - **Guidance:** Enroll client in specialized clinic if available, conduct EAC, refer to VL algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 133,\n",
       "  'section': '## Adherence Monitoring, Counseling, and Support\\n\\nThis section outlines the procedures and considerations for adherence monitoring and support for patients with an unsuppressed viral load (≥ 200 copies/ml):\\n\\n- **Criteria for Treatment Failure:**\\n  - Treatment failure should be suspected if a patient has been on ART for at least 3 months with:\\n    - Viral load ≥ 200 copies/ml.\\n    - Decline in CD4 count.\\n    - Any new or worsening clinical condition.\\n\\n- **Confirming Treatment Failure:**\\n  - Treatment failure is confirmed as per the viral load monitoring algorithm.\\n\\n- **Adherence Assessment:**\\n  - Poor adherence is often the primary factor leading to treatment failure.\\n  - All issues regarding adherence must be thoroughly assessed and addressed before switching patients to the next line of ART.\\n  - Do not change regimens until the reasons for treatment failure are identified and addressed.\\n\\n- **Next Steps for High-Risk Patients:**\\n  - For patients with high-risk persistent low-level viremia (VL 200-999 copies/ml after additional assessment and intervention):\\n    - Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 127,\n",
       "  'section': '## Morisky Medication Adherence Scale (MMAS -8)\\n\\nThe MMAS -8 is a tool used to assess patient adherence to medication. It consists of a series of questions that patients answer with either \"Yes\" or \"No.\" After answering all the questions, the points circled for each response are totaled to determine the overall score.\\n\\n### Questions:\\n1. Do you ever forget to take your medicine?  \\n   - Yes: 1, No: 0\\n2. Are you careless at times about taking your medicine?  \\n   - Yes: 1, No: 0\\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  \\n   - Yes: 1, No: 0\\n4. When you feel better do you sometimes stop taking your medicine?  \\n   - Yes: 1, No: 0\\n5. Did you take your medicine yesterday?  \\n   - Yes: 0, No: 1\\n6. When you feel like your symptoms are under control, do you sometimes stop taking your medicine?  \\n   - Yes: 1, No: 0\\n7. Taking medication every day is a real inconvenience for some people. Do you ever feel under pressure about sticking to your treatment plan?  \\n   - Yes: 1, No: 0\\n8. How often do you have difficulty remembering to take all your medications?  \\n   - Options: A. Never/Rarely (0), B. Once in a while (¼), C. Sometimes (½), D. Usually (¾), E. All the time (1)\\n\\n### Total Score\\nPatients should sum all the points from their responses to get their total score.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 127,\n",
       "  'section': '## Interpretation of MMAS -8 Score\\n\\nOnce the total score is obtained, the interpretation is as follows:\\n\\n### Scores and Actions:\\n- **Score 0: Good**\\n  - Continue with routine monitoring, counselling, and support.\\n  \\n- **Scores 1-2: Inadequate**\\n  - Discuss as a Multi-Disciplinary Team (MDT).\\n  - Assign a case manager.\\n  - Assess for and address barriers to adherence.\\n  - Engage treatment supporter in adherence counselling sessions.\\n  - Follow up in 2-4 weeks.\\n  \\n- **Scores 3-8: Poor**\\n  - Discuss as an MDT.\\n  - Assign a case manager.\\n  - Assess for and address barriers to adherence.\\n  - Engage treatment supporter in adherence counselling sessions.\\n  - Implement Directly Observed Therapy (DOTs).\\n  - Follow up in 1-2 weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 134,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the process for preparing, monitoring, and providing support for patients in adherence to treatment protocols. It emphasizes the importance of a multi-disciplinary team approach to care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 134,\n",
       "  'section': '## Enhanced Adherence Assessments\\n\\nAs soon as treatment failure is suspected, a discussion involving the patient/caregiver and the facility multi-disciplinary team is crucial. The team should develop a plan to assess barriers to adherence, such as scheduling home visits and evaluating other potential causes of treatment failure, including inadequate dosing, drug-drug interactions, drug-food interactions, and impaired absorption due to factors like chronic severe diarrhea.\\n\\nAll patients with suspected or confirmed treatment failures should undergo thorough assessments of potential barriers to adherence, as outlined in Table 5.15. If the patient has a caregiver or treatment buddy enrolled in HIV care, their files should be reviewed to confirm recent viral load results and adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 134,\n",
       "  'section': '## Enhanced Adherence Counselling\\n\\nEnhanced adherence counselling should be initiated as soon as a detectable viral load (≥ 200 copies/ml) is recorded, preferably within two weeks. The primary goal is to identify possible barriers to adherence in a non-judgmental manner, helping the patient construct a concrete adherence plan.\\n\\nThis counselling process should also take into account psychological, emotional, and socio-economic factors contributing to poor adherence. Exploring the patient’s motivation for medication can further illuminate reasons for any adherence issues.\\n\\nA minimum of three counselling sessions, spaced 2-4 weeks apart, is recommended to establish a solid foundation for adherence. If adherence is deemed adequate, a repeat viral load test is scheduled after three months of excellent adherence, followed by a session to discuss the results. A detailed content guide for Enhanced Adherence Counselling is available in Annex 9.\\n\\nTo ensure consistency and continuity, it is preferable for the patient to work with the same counsellor for all sessions, with documentation maintained for follow-up on identified issues. If adequate adherence is not achieved, consultation with a senior clinician or discussion within the multi-disciplinary team, or consultation with the Regional or National TWG, is advised.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 140,\n",
       "  'section': \"## Antiretroviral Therapy Overview\\n\\nAntiretroviral Therapy (ART) is very effective in managing HIV disease but does not cure HIV infection. The primary goal of ART is to suppress viral replication to reduce the patient's viral load (VL) to undetectable levels. Maintaining uninterrupted ART with strict adherence helps preserve the immune system, reduce AIDS-related morbidity and mortality, and minimize the risk of sexual and vertical transmission of HIV.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 140,\n",
       "  'section': '## Eligibility for ART\\n\\nAll individuals with confirmed HIV infection are eligible for ART regardless of their CD4 count, WHO clinical stage, age, pregnancy or breastfeeding status, co-infection status, risk group, or any other criteria.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 140,\n",
       "  'section': '## Timing of ART Initiation\\n\\nART should be initiated as soon as possible for all patients, preferably within 2 weeks of confirming HIV status. Initiating ART on the same day as testing positive for HIV is encouraged if the patient is ready. Using ART Readiness Criteria can help identify any concerns that need addressing prior to initiation. Same-day ART initiation can enhance HIV prevention efforts, particularly for pregnant or breastfeeding women and HIV-positive partners in discordant relationships. It has been associated with better retention, viral suppression, and improved survival outcomes. Special considerations regarding timing are outlined in Table 6.1.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': '## Enhanced Adherence Counselling Sessions: Overview\\n\\nThis section provides an overview of the components involved in Enhanced Adherence Counselling Sessions, which are designed to support patients in adhering to HIV treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': '## Session 1: Initial Assessment and Planning\\n\\n- **Objectives:**\\n  - Review understanding of viral load (VL) and discuss reasons for high VL.\\n  - Discuss common barriers to adherence: \\n    - Stigma and non-disclosure\\n    - Loss or grief\\n    - Treatment literacy\\n    - Medications: dosage, timing, storage\\n    - Side effects\\n    - Risk reduction (e.g., for substance abuse)\\n    - Motivation\\n    - Mental health screening (using PHQ-9)\\n    - Support systems\\n- **Outcome:**\\n  - Assist the patient in developing an adherence plan to address the identified issues.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': '## Session 2: Follow-Up and Modification\\n\\n- **Objectives:**\\n  - Review the adherence plan from Session 1 and discuss any challenges faced.\\n  - Identify additional gaps or emerging issues.\\n- **Outcome:**\\n  - Modify the adherence plan to better address the identified challenges.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': '## Session 3: Continued Assessment and VL Decisions\\n\\n- **Objectives:**\\n  - Review the adherence plan from Sessions 1 and 2 and discuss persistent challenges.\\n  - Identify further gaps or issues following the previous sessions.\\n- **Outcome:**\\n  - Make a decision on the need for repeat VL testing based on current adherence:\\n    - If adherence is good: Plan a repeat VL test after three months and explain the role of the patient and health facility.\\n    - If challenges persist: Consult with a senior clinician or the Regional/National TWG before repeating the VL.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': '## Session to Discuss Repeat Viral Load Results\\n\\n- **Objectives:**\\n  - Discuss the results of the second VL test.\\n- **Plan Forward:**\\n  - If VL < 200 copies/ml: Continue the current regimen with ongoing enhanced adherence; repeat VL after 6 months.\\n  - If VL ≥ 1,000 copies/ml: Prepare the patient for a change of regimen.\\n  - If VL is between 200 - 999 copies/ml: Conduct another assessment for causes of viremia, address identified issues, and repeat VL after an additional 3 months of excellent adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Introduction to Kenya HIV Prevention and Treatment Guidelines\\n\\nThis section provides an overview of the purpose and importance of the Kenya HIV Prevention and Treatment Guidelines, emphasizing the need for effective strategies to combat HIV in the country.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## HIV Prevention Strategies\\n\\nDiscussion on various methods and approaches used for HIV prevention in Kenya, including education, condom distribution, pre-exposure prophylaxis (PrEP), and harm reduction programs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## HIV Testing and Diagnosis\\n\\nDetailed information on the recommended procedures for HIV testing, including types of tests available, counseling protocols, and the importance of early diagnosis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Treatment Protocols\\n\\nAn overview of the antiretroviral therapy (ART) recommended for individuals living with HIV, including drug regimens, adherence strategies, and monitoring of treatment effectiveness.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Care and Support Services\\n\\nInformation on the supplementary services that support individuals living with HIV, including mental health support, nutrition, and community resources available for patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nGuidelines on the monitoring and evaluation of HIV programs and treatment outcomes, focusing on data collection, indicators for success, and improving service delivery.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Special Populations\\n\\nDiscussion addressing specific considerations and strategies for vulnerable populations, such as children, adolescents, key populations, and pregnant women in relation to HIV prevention and treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Policy Framework and Legal Considerations\\n\\nAn overview of the policies and legal context surrounding HIV prevention and treatment in Kenya, including rights of individuals and the role of government and NGOs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Conclusion and Future Directions\\n\\nThis section summarizes the key points of the guidelines and discusses potential future directions for HIV prevention and treatment efforts in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThis section covers the importance of having a functional system in place at service delivery points providing antiretroviral therapy (ART), post-exposure prophylaxis (PEP), or pre-exposure prophylaxis (PrEP) to monitor patient adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Identifying Patients who Default from Care\\n\\nEvery service delivery point must implement procedures for identifying patients who miss appointments. Actions must be taken within 24 hours of a missed appointment, including:\\n\\n- Entering the date of the next appointment in the appointment diary.\\n- Checking off patients’ names as they arrive.\\n- Recording patients who did not attend in a follow-up register.\\n- Calling the patient or caregiver within 24 hours to follow up on the missed appointment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Tracing Patients After Missed Appointments\\n\\nIf initial calls do not reach the patient, the following tracing methods should be employed:\\n\\n- Contact the treatment buddy if there’s no response.\\n- Make several attempts to reach the patient through phone calls.\\n- Update the patient follow-up register with findings from the calls.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Handling Patients Who Return to Clinic\\n\\nWhen a patient returns to the clinic within a week or on a date agreed during the phone call, the following actions should be taken:\\n\\n- Assess and address barriers to adherence as per Table 5.14.\\n- Review the patient/caregiver’s HIV knowledge and fill any gaps.\\n- Address any concerns regarding ART, medications, or health with the patient/caregiver.\\n- Explore any life changes that might disrupt adherence.\\n- Review the existing support systems and encourage the introduction of additional support, as outlined in Table 5.2.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Returning to Care and Home Visits\\n\\nFor prioritized home visits based on patient type, such as pregnant women or children, take the following steps:\\n\\n- Complete a home visit form.\\n- Update the patient follow-up register with findings from the visit.\\n- If the patient agrees to return, update the appointment diary accordingly.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Managing Patients Not Returning to Clinic\\n\\nIf a patient is unable to be traced or does not return to their scheduled appointment, discussions should be held as a multi-disciplinary team (MDT) to develop a follow-up or management plan, ensuring that patient records are updated with the outcome.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Summary of Follow-up Actions\\n\\nKey actions following missed appointments include:\\n\\n- Continuous monitoring of patient engagement.\\n- Regular updates to patient records.\\n- Implementing and assessing support strategies for adherence.\\n- Collaboration among care team members for comprehensive patient support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Adherence Support Systems\\n\\nAdherence support systems need to be tailored to the specific needs of patients within their contextual environments. Special consideration should be given to groups such as children, adolescents, pregnant and breastfeeding women, patients with mental health disorders, and substance users.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': \"## Treatment Preparation for 2nd Line or 3rd Line ART\\n\\nUpon confirming treatment failure and deciding to initiate 2nd line or 3rd line ART, a Multi-Disciplinary Team (MDT) should consult with the Regional or National HIV Clinical Technical Working Group (TWG). The patient will require targeted counseling and education for preparedness in managing the new regimen and sustaining adherence.\\n\\n### Key Steps in Treatment Preparation\\n\\n1. **Review Patient File**  \\n   Ensure all previous treatments and adherence issues are documented.\\n\\n2. **Assess Patient’s Knowledge and Understanding**  \\n   Evaluate the patient's grasp of their prior ART and expectations of the new regimen.\\n\\n3. **Provide Patient Education**  \\n   Educate on the new treatment plan, including drug regimen, dosing schedule, dietary restrictions, potential side effects, and actions in case of missed doses.\\n\\n4. **Construct Adherence Plan**  \\n   Develop a tailored adherence plan in collaboration with the patient.\\n\\n5. **Monthly Counselling Follow-Up Sessions**  \\n   Schedule monthly sessions during clinic visits for the first 6 months to:\\n   - Follow up on issues identified previously.\\n   - Assess adherence and tackle any identified barriers.\\n\\n6. **Viral Load Monitoring**  \\n   Perform viral load (VL) tests after 3 months on the new regimen:\\n   - If VL is undetectable: Continue with adherence counseling every 3 months.\\n   - If VL is detectable: Discuss management strategies with MDT and consult TWG.\\n\\n### Counseling Focus Areas\\n\\n- Prepare for potential barriers to adherence and encourage open discussion about difficulties.\\n- Plan collaborative sessions with pharmacists and nutritionists to address medication adherence and nutritional support.\\n- Reinforce key messages around HIV, viral load, and the essential nature of adherence.\\n\\n### Educational Materials\\n\\nProvide simple take-home informational materials covering:\\n- The significance of adherence.\\n- The complexities associated with 2nd/3rd line ART.\\n- Reasons for switching to these regimens due to treatment failure and high VL.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Enhanced Adherence Counseling\\n\\nReview all patient files and address problems identified during counseling sessions. Confirm that any identified barriers to adherence are actively addressed before considering any changes in treatment regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nThis section provides a brief introduction to Antiretroviral Therapy (ART) for different populations, focusing on infants, children, adolescents, and adults, including pregnant and breastfeeding women.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## First-Line ART Recommendations\\n\\nThis section outlines the recommendations for patients starting ART for the first time. It includes details on preferred and alternative first-line regimens, and emphasizes the importance of weight documentation and correct weight-based dosing for children and adolescents.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Importance of Caregiver Involvement\\n\\nThis section discusses the critical role of caregivers in administering ART to infants and children. It highlights the need for caregiver preparation, addressing challenges such as drug palatability, and the importance of having multiple caregivers informed about the child’s HIV status.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Administration Instructions for Caregivers\\n\\nHere, the document details the procedures for caregivers during the ART administration process. It emphasizes the need for caregivers to be shown how to measure and administer ARVs, and the requirement for consistency in caregiver attendance during clinical visits.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Preferred First-Line ART Regimens for Various Age Groups\\n\\nThis section outlines specific preferred first-line ART regimens and dosing based on age and weight, as presented in Table 6.2. It includes guidance for infants, children, adolescents, and adults, specifying regimens for different weight brackets.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Special Considerations for Infants and Adolescents\\n\\nThis section provides specific recommendations for infants initiating ART and adolescents transitioning therapies. It includes considerations for pre-term infants and discussions on the potential transition to TAF or dual therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Additional Notes on Regimen Optimization\\n\\nThis section directs clinicians to consider regimen optimization for patients currently on first-line regimens not included in the preferred or alternative regimens mentioned earlier, as per Section 6.5.1.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## Timing of ART Initiation for Special Populations\\n\\n### Pregnant and Breastfeeding Women\\n- Support ART initiation on the same day as testing positive for HIV.\\n- Intensive adherence counselling, support, and close follow-up required due to limited time for patient preparation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '### Infants (< 12 months old)\\n- Support ART initiation on the same day as testing positive for HIV.\\n- Treatment should commence following a first positive PCR test.\\n- Always take a sample for a confirmatory PCR test as soon as the first positive PCR result is received, but do not delay ART initiation for the second PCR result.\\n- Intensive adherence counselling, support, and close follow-up required due to limited time for caregiver preparation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '### Patients with Strong Motivation\\n- Support ART initiation as soon as the patient feels ready, preferably on the same day as testing positive for HIV.\\n- Intensive adherence counselling, support, and close follow-up required due to limited time for patient preparation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '### Patients with Newly Diagnosed TB\\n- Start anti-TB treatment immediately and initiate ART as soon as anti-TB medications are tolerated, preferably within 2 weeks.\\n- For TB meningitis, delay ART for 4 to 8 weeks.\\n- Monitor closely for Immune Reconstitution Inflammatory Syndrome (IRIS).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '### Patients with Cryptococcal Meningitis\\n- Defer ART until after completing 5 weeks of cryptococcal meningitis treatment.\\n- Monitor closely for IRIS.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '### Patients with Adherence Challenges\\n- Start ART as soon as possible while implementing additional support systems (e.g., optional enrolment of a person who injects drugs (PWID) into a medication-assisted therapy (MAT) program; psychiatric treatment for a patient with mental illness; enrolment into an orphaned and vulnerable child (OVC) program).\\n- A case manager should be assigned to all patients with complex adherence challenges.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '### All Other Patients\\n- Start ART as soon as possible, preferably within 2 weeks and even on the same day as testing positive for HIV if they are ready.\\n- Continued adherence monitoring and support is recommended after ART initiation for all patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThis section outlines the various interventions and strategies designed to support patient adherence to treatment, particularly for those at high risk of failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Case Management\\n\\n• Assign a case manager to all children and adolescents (those not achieving optimum treatment outcomes); pregnant women, orphans, patients with alcohol and substance abuse, patients with mental illness, patients with suspected or confirmed treatment failure, and any patients who the healthcare team feels has poor adherence or is at high risk of defaulting from care.\\n\\n• The case manager acts as the link between the patient and the multidisciplinary team (MDT).\\n\\n**Roles of the Case Managers Include:**\\n\\n- Coordinating multidisciplinary management for patients under case management.\\n- Following up on appointment-keeping for their patients.\\n- Organizing patient reminders (SMS, calling the day before) and other support systems.\\n- Ensuring appropriate defaulter tracing.\\n- Coordinating home visits to their patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Directly Observed Therapy (DOT)\\n\\n• For patients with suspected treatment failure, DOTs should be implemented to ensure good adherence before a viral load is retested to confirm treatment failure.\\n\\n• DOTs involve a healthcare provider, a family member, a treatment supporter, or any trained peer observing the patient take their prescribed ART daily.\\n\\n• DOTs can be tapered off once the patient develops consistent adherence-enhancing behaviors and overcomes barriers to adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Home Visits\\n\\n• Home visits allow for observation of how and where a patient stores and takes their medications, and to assess if they have extra medications due to missed doses.\\n\\n• These visits can provide insights into the patient’s living situation and specific barriers to adherence.\\n\\n• Unscheduled home visits may yield more revealing insights but should only occur if the patient has consented to home visits previously (preferably at the time of enrollment or initiation).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Monthly \"High Viral Load\" Clinics\\n\\n• Patients with suspected treatment failure should be scheduled for dedicated monthly high viral load clinics.\\n\\n• Children and adolescents in school who are unable to attend the clinics monthly may attend dedicated monthly clinics during mid-terms and school holidays (at least every 6 weeks).\\n\\n• A comprehensive clinical and psychosocial evaluation should be conducted at each visit, with appropriate investigations and treatment for any opportunistic infections.\\n\\n• Enhanced adherence counseling sessions should occur at each visit.\\n\\n• Support groups for patients with viremia can be scheduled to coincide with \"high viral load\" clinic days.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Special Support Groups\\n\\n• For health facilities with multiple patients failing treatment or on 2nd line ART, special support groups can be established so these patients can collaboratively address their adherence challenges.\\n\\n• Additionally, community support groups can be engaged and linked to the facility to assist patients facing adherence issues.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 143,\n",
       "  'section': '## Alternative ARVs for Infants (Birth to 4 Weeks)\\n\\nFor infants under 4 weeks of age experiencing hypersensitivity reactions to NVP or notable anemia indicated by Hb < 9.5 g/dL, the following alternative ARVs should be used:\\n- **NVP Hypersensitivity Reaction**: Use RAL granules or LPV/r granules (if over 2 weeks of age) or defer ART until 4 weeks of age, then start ABC+3TC+DTG.  \\n- **AZT with Hb < 9.5 g/dL**: Defer ART until 4 weeks of age, then start ABC+3TC+DTG.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 143,\n",
       "  'section': '## Alternative ARVs for Children (4 Weeks to 15 Years, < 30 kg)\\n\\nFor children between 4 weeks and less than 15 years weighing less than 30 kg, the following alternative ARVs should be considered:\\n- **ABC Hypersensitivity Reaction**: Use AZT (if Hb ≥ 9.5 g/dL), consulting the Regional or National HIV Clinical TWG if Hb < 9.5 g/dL.\\n- **DTG Tolerance**: If unable to tolerate DTG, use LPV/r at standard weight-based BD dosing. Preferably use a 4-in-1 combination if available.\\n- **DTG on Rifampicin**: Increase the dosing frequency to twice daily during the duration of rifampicin-containing TB treatment and for an additional 2 weeks after completing TB treatment, then revert to once daily dosing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 143,\n",
       "  'section': '## Alternative ARVs for Older Children and Adults (≥ 30 kg and ≥ 15 Years)\\n\\nFor individuals aged 15 years and older or weighing 30 kg or more, the following guidelines apply:\\n- **TDF with Impaired Renal Function (CrCl ≤ 50 ml/min)**: Use ABC or TAF (once available).\\n- **DTG Tolerance**: If unable to tolerate DTG, use EFV (for people who inject drugs, use ATV/r).\\n- **DTG on Rifampicin**: Administer TDF/3TC/DTG FDC in the morning and DTG 50mg in the evening for the duration of rifampicin-containing TB treatment and for an additional 2 weeks afterward before reverting to TDF/3TC/DTG FDC once daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 145,\n",
       "  'section': '## Pregnancy Safety of DTG\\n\\nDTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all women initiating ART regardless of regimen. Women who do not wish to become pregnant should be offered appropriate family planning counseling and methods.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 145,\n",
       "  'section': '## Important Drug Interactions with DTG\\n\\n### Rifampicin\\n\\n- Rifampicin lowers DTG levels: For patients on rifampicin who are > 20 kg in body weight, increase DTG to 50 mg twice daily. Children <20 kg taking DTG who require rifampicin should have their weight-appropriate DTG dose increased to twice daily.\\n- There are no significant drug interactions between DTG and other currently used anti-TB medications (including for MDR-TB).\\n\\n### Mineral Supplements\\n\\n- Supplements including antacids containing calcium, zinc, magnesium, or aluminum; iron supplements; and prenatal vitamins (which contain iron and calcium) decrease the absorption of DTG. \\n- Administer DTG at least 2 hours before or 6 hours after taking any of these supplements. \\n- Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if DTG is taken with a meal. \\n- It is critical to educate patients about this important drug interaction since many obtain these supplements and antacids over-the-counter without informing their healthcare provider.\\n\\n### Anticonvulsants (Carbamazepine, Phenobarbital, Phenytoin)\\n\\n- These anticonvulsants decrease DTG levels: it is advisable to use a different anticonvulsant if available. \\n- If DTG must be co-administered with these drugs, increase the DTG dosage to twice daily, although there is little data to guide this recommendation. \\n- If valproic acid is available, this can be used with DTG without the need for dose adjustment.\\n\\n### Metformin\\n\\n- DTG increases the levels of metformin; however, the levels of DTG are not affected. \\n- A lower dose of metformin (often 50% of the usual dose) should be used, and glycemic control should be monitored. The maximum daily dose of metformin should be 1 g.\\n\\n### Other Drug-Drug Interactions\\n\\n- For additional drug-drug interactions with DTG, refer to Annex 13C.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## ART Regimens for Children Weighing < 30 kg\\n\\nChildren weighing less than 30 kg on first-line ART regimens other than ABC/3TC + DTG should be monitored for viral load (VL) levels within the last 6 months to ensure effective treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Viral Load Monitoring\\n\\n1. **Viral Load Levels**:\\n   - VL < 200 copies/ml (LDL)\\n   - No VL result within the last 6 months\\n   - VL ≥ 200 copies/ml\\n\\n2. **Actions Based on VL Results**:\\n   - **VL < 200 copies/ml**: Continue monitoring.\\n   - **VL ≥ 200 copies/ml**: Collect sample for VL testing; schedule a clinical appointment for adherence and side effect review.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Regimen Modification Guidelines\\n\\n1. **If switching from a regimen containing ABC**:\\n   - Switch to AZT/3TC + DTG.\\n\\n2. **If switching from a regimen containing AZT**:\\n   - Switch to ABC/3TC + DTG.\\n\\n3. **Weight-Based Dosing**:\\n   - Use the weight-based dosing from Annex 10A-B for all modifications.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Enhanced Adherence Counselling\\n\\n- Schedule a clinical appointment 2 weeks after any regimen change to review adherence, side effects, and any other concerns.\\n- If VL remains ≥ 200 copies/ml after 3 months, consult the regional or national Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Summary of Cases for TWG\\n\\nFor all patients on PI/r or DTG-containing regimens:\\n- Summarize the case for the TWG.\\n- Collect a sample for Drug Resistance Testing (DRT); do not wait for DRT results before modifying the regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Routine Viral Load Monitoring\\n\\n- After modifying a regimen, repeat VL testing 3 months post-modification.\\n- If VL < 200 copies/ml, continue with routine viral load monitoring.\\n- If VL remains ≥ 200 copies/ml, proceed with further consultation as necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral therapy (ART) is critical for infants, children, adolescents, and adults living with HIV. This section serves as an introduction to the goals of ART, including the suppression of viral load and the promotion of overall health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Monitoring and Changing ART\\n\\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat intercurrent illnesses, manage adverse drug reactions, and evaluate treatment response. Routine laboratory monitoring recommendations are described in Table 3.5, but additional investigations may be needed based on clinical suspicion.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Indications for Changing ART\\n\\nChanging ART is necessary in certain situations, including:\\n- Optimizing therapy for patients with undetectable viral loads.\\n- Managing adverse drug reactions or toxicity.\\n- Addressing drug-drug interactions.\\n- Taking co-morbidities into account.\\n- Responding to treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Optimizing Therapy for Patients with Suppressed Viral Load\\n\\nPatients who achieve viral suppression on first-line ART may benefit from regimen optimization, even if they tolerate their current regimen well. Optimization may involve age/weight transitions for children and adolescents under 15 years, simplifying regimens, preventing long-term toxicity, and improving cost-effectiveness. Dolutegravir is preferred due to its superior tolerability and efficacy compared to efavirenz and lopinavir.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Pediatric Considerations in ART\\n\\nChildren and adolescents with suppressed viral load not on the recommended regimen should be evaluated for optimization based on growth and transition to different weight bands. This optimization applies particularly to those who have recently initiated non-standard therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Discussing Changes in ART Regimen\\n\\nWhen considering a regimen change, it’s essential to discuss the potential new side effects, including common side effects associated with all ARVs (such as headache, nausea, and diarrhea) as well as those specific to the new ARV. Patients should be reassured that most side effects are temporary and tend to resolve within 1-2 weeks of continued use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral therapy is critical for infants, children, adolescents, and adults living with HIV. For specific scenarios not outlined in current guidelines, it is recommended to consult the Regional or National HIV Clinical Technical Working Group (TWG) through the Uliza Hotline or the provided online resources.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## ABC Hypersensitivity Reaction (AHR)\\n\\nABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Detailed definitions and management strategies for AHR are outlined in Table 6.9, which should be referenced for clinical guidance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## Dolutegravir (DTG) in Antiretroviral Therapy\\n\\n### Dosing and Administration of DTG\\n\\nDTG is the preferred first-line antiretroviral therapy (ART) for children, adolescents, and adults due to its efficacy and better tolerability. Key dosing recommendations include:\\n\\n- **Weight-based dosing for children < 20 kg:** Dispersible 10 mg DTG tablets.\\n- **For patients ≥ 20 kg:** 50 mg film-coated DTG tablet once daily, preferably in the morning. Available as part of fixed-dose combinations.\\n- During rifampicin treatment: Increase to twice daily dosing and continue for 2 weeks post-treatment to counteract liver enzyme induction.\\n- In cases of confirmed INSTI resistance, use DTG twice daily.\\n- DTG can be consumed with or without food.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## Common Side Effects of DTG\\n\\nPatients may experience several common side effects from DTG, including:\\n\\n- **Headache, nausea, diarrhea:** Generally resolve within 1-2 weeks. Patients should be informed about these temporary effects and encouraged to continue ART.\\n- **Insomnia:** Can be minimized by taking DTG in the morning or with low-fat meals.\\n- **Increased serum creatinine levels:** Indicates no true decline in renal function.\\n- **Weight gain:** Associated with integrase inhibitors, including DTG. Patients should be counseled on maintaining healthy eating habits and physical activity.\\n- All adverse events should be reported via the national pharmacovigilance mechanism.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## Future Considerations\\n\\n- TAF (Tenofovir alafenamide) may become the preferred NRTI upon the availability of fixed-dose combinations.\\n- DTG/3TC dual therapy may be considered for HBV-negative patients once fixed-dose combinations become available.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Antiretroviral Therapy Overview \\n\\nThis section discusses the importance of evaluating alternative explanations for toxicity before concluding a reaction is secondary to an antiretroviral (ARV) therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Evaluating Adverse Drug Reactions \\n\\nThis section emphasizes the need to assess concurrent medications and any pre-existing conditions to determine the cause of adverse reactions, including drug-drug interactions, other medical conditions, and inter-current illnesses such as IRIS.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Assessing Seriousness of Adverse Events \\n\\nIn this section, the seriousness of adverse events is graded as follows: \\n\\n- Life-threatening (Grade 4)  \\n- Severe (Grade 3)  \\n- Moderate (Grade 2)  \\n- Mild (Grade 1)  \\n\\nManagement strategies for each grade are described.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Management Strategies for Adverse Events \\n\\nThis section outlines the management steps depending on the seriousness level of the adverse event, including:\\n- Immediate discontinuation of all drugs for life-threatening cases.\\n- Reintroduction of ARVs using modified regimens after stabilization.\\n- Continued monitoring and symptomatic relief in moderate and mild cases.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Monitoring and Reporting Adverse Drug Reactions \\n\\nThis section highlights the importance of monitoring patients on ART for toxicities during clinical visits, including soliciting specific histories of symptoms and conducting relevant physical and lab assessments. It also discusses the need to report suspected or confirmed adverse drug events.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Clinical Evaluation at Each Visit  \\n\\nThis section underscores the requirement for clinical evaluation at every clinic visit. It includes the need to monitor for toxicity through patient history, physical examinations, and laboratory assessments, ensuring thorough investigation into the potential causes of adverse reactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Algorithm for Single-Drug Substitution \\n\\nThis final section refers to the single-drug substitution algorithm for managing adverse drug reactions effectively, highlighting the considerations needed for substitutions and adjustments to treatment regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral Therapy (ART) is critical for managing HIV in infants, children, adolescents, and adults. The document outlines the initial ART regimen choices and considerations based on viral load (VL) results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## ART for Children and Adolescents\\n\\nChildren and adolescents weighing ≥ 30 kg or ≥ 15 years old should follow specific guidelines on ART regimens. If their viral load is less than 200 copies/ml (LDL) within the last six months, treatment management varies depending on recent VL results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Management of Viral Load Results\\n\\n- **VL < 200 copies/ml (LDL) within the last 6 months**: Continue current regimen.\\n  \\n- **No VL result in the last 6 months**: Collect sample for VL testing.\\n\\n- **VL 200 copies/ml**: Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once daily and schedule a clinical appointment at 2 weeks post-regimen change to assess adherence and side effects.\\n\\n- **For patients on PI/r or DTG regimens**: Summarize the case for the Technical Working Group (TWG) and prepare for a drug resistance testing (DRT) sample, but do not wait for the DRT results before modifying the regimen.\\n\\n- **Follow-up after regimen changes**: Repeat VL testing 3 months after the regimen modification.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Addressing Viremia\\n\\nIf viremia persists (VL still > 200 copies/ml post-regimen change), consult the regional or national TWG. If VL falls below 200 copies/ml, continue routine viral load monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Changing ARVs Due to Adverse Drug Reactions (ADRs)\\n\\nPatients starting ART must be educated on possible side effects. Recognizing and managing ADRs early is vital for patient adherence. All ADRs should be reported through appropriate pharmacovigilance channels.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Importance of Pharmacovigilance\\n\\nPharmacovigilance is crucial for tracking ADRs, especially for newly introduced ARVs that might exhibit rare side effects not seen in clinical trials. The most common ADRs that may necessitate drug substitution are summarized in specific sections of the document.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## General Principles for Managing ADRs\\n\\nOutlined principles for managing ADRs guide healthcare providers in addressing patient reactions to ART. Specific ADR management strategies are detailed in accompanying tables.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Overview of ARV Management\\n\\nThis section outlines general guidelines for patients on antiretroviral therapy (ART) regarding viral load (VL) monitoring and drug substitution protocols.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Criteria for Stopping ARV\\n\\nPatients with specific reasons for stopping an ART regimen should be monitored closely based on their recent viral load results:\\n\\n- **VL within last 6 months < 200 copies/ml**: Follow current treatment\\n- **No VL result within last 6 months**: Continue existing regimen\\n- **VL within last 6 months ≥ 200 copies/ml**: Collect sample for VL testing and reassess treatment'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Single Drug Substitution Protocol\\n\\nIf a viral load test indicates that a patient has ≥ 200 copies/ml, practitioners should:\\n\\n- Proceed with single drug substitution.\\n- Schedule a clinical appointment 2 weeks after the regimen change to review adherence, side effects, and any other concerns.\\n- Repeat viral load testing 3 months after the regimen modification followed by routine monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Guidelines for Emergencies\\n\\nIf an ART must be changed for clinical reasons (such as adverse drug reactions, drug-drug interactions, or co-morbidity) before VL results are available, practitioners must urgently consult the Uliza Hotline (0726 460 000) or the Regional or National Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Follow-Up and Monitoring\\n\\nFor patients on ART:\\n\\n- **On ART for < 3 months**: Follow standard monitoring procedures.\\n- **For all patients**, adhere to the viral load monitoring algorithm (Figure 6.6) to ensure appropriate response measures are taken based on test results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Conclusion\\n\\nProper management of ART regimens, including consistent viral load monitoring and timely decision-making regarding drug substitutions, is essential to achieving optimal patient health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 153,\n",
       "  'section': '## ARV Adjustments in Renal and Hepatic Impairment\\n\\nThis section outlines the adjustments to antiretroviral (ARV) drugs, Cotrimoxazole (CTX), and Fluconazole based on renal and hepatic impairment levels.\\n\\n- **ABC**: No change; Reduce adult dose to 200 mg BD for moderate to severe liver impairment; AVOID in severe hepatic impairment.\\n- **AZT**: No change; 300 mg/day; Reduce dose by 50% or double interval in moderate to severe impairment.\\n- **TDF**: AVOID unless HBV+; 300 mg every 7 days; No change in mild or moderate impairment.\\n- **TAF**: No change; AVOID unless HBV+; Administer after dialysis.\\n- **3TC**: 150 mg OD; No change in mild to moderate impairment.\\n- **LPV**: No change; Use with caution in moderate to severe impairment.\\n- **DTG, EFV, RAL**: No change; use cautiously in severe impairment.\\n- **NVP**: AVOID in severe impairment.\\n- **CTX**: Adjust according to CrCl levels; caution in liver impairment.\\n- **Fluconazole**: Adjust doses based on CrCl levels; use with caution.\\n\\nA note advises patients with renal or hepatic impairment should have regular monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 153,\n",
       "  'section': '## TDF and Renal Impairment\\n\\nThis section provides specific guidance regarding TDF in the context of renal impairment.\\n\\n- **Acute Kidney Injury (AKI)**: Interrupt TDF administration until the cause of AKI is addressed.\\n- **CrCl < 50 ml/min**: Avoid TDF unless in HIV/HBV co-infection; in such cases, TAF or TDF may be used as the benefits often outweigh the risks.\\n- **For HBV-negative patients on first-line ART**: Substitute TDF with ABC, TAF, or DTG + 3TC following a substitution algorithm.\\n- **For treatment failure or other scenarios**: Consult the Regional or National HIV Clinical Technical Working Group (TWG) for guidance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 153,\n",
       "  'section': '## Consultation Resources\\n\\nThis section lists resources available for clinicians regarding patient management and treatment adjustments.\\n\\n- **Uliza Hotline**: 0726 460 000\\n- **NASCOP Clinical Form**: [NASCOP Clinical Form Link](https://nhcsc.nascop.org/clinicalform)\\n\\nThese resources are recommended for clinicians managing patients with complex treatment needs or those requiring substitution strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 154,\n",
       "  'section': '## Management of AZT-Associated Bone Marrow Suppression\\n\\nThis section outlines the management protocols for patients experiencing bone marrow suppression while on AZT (Zidovudine). \\n\\n### Hemoglobin (Hb) Management\\n- **Test Result**: Hb > 8.5 g/dL (and decrease from pre-AZT baseline)\\n  - **Action**: Retain AZT, repeat Hb at week 1, 2, 4, and 12. Consider substituting to an alternative ARV if follow-up Hb access is difficult.\\n  \\n- **Test Result**: Hb ≤ 8.5 g/dL\\n  - **Action**: Switch from AZT to an alternative ARV.\\n\\n### Neutrophils Management\\n- **Test Result**: Neutrophils 1.0 – 1.5 x 10⁹/L (and decrease from pre-AZT baseline)\\n  - **Action**: If receiving cotrimoxazole, consider withholding unless essential. Retain AZT; repeat at week 1, 2, 4, and 12. Consider switching to an alternative ARV if follow-up neutrophil access is difficult.\\n\\n- **Test Result**: Neutrophils ≤ 1.0 x 10⁹/L\\n  - **Action**: Switch from AZT to an alternative ARV.\\n\\n### Additional Notes\\n- Patients with a baseline Hb < 9.5 g/dL should not be initiated on AZT.\\n- Patients developing anemia while on AZT should be managed according to this protocol.\\n- AZT-associated bone marrow suppression typically occurs within 3 months of initiating ART.\\n- All patients with anemia and/or neutropenia should be evaluated for other causes and managed appropriately.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 154,\n",
       "  'section': '## Management of Drug-Related Hepatotoxicity\\n\\nThis section describes the management of patients who experience hepatotoxicity while on antiretroviral therapy.\\n\\n### ALT (Alanine Aminotransferase) Management\\n- **Test Result**: ALT < 2.5 x Upper Limit of Normal (ULN)\\n  - **Action**: Retain the regimen, repeat testing in 2 weeks.\\n\\n- **Test Result**: ALT 2.5 – 5 x ULN\\n  - **Action**: Retain the regimen, repeat testing in 1 week.\\n\\n- **Test Result**: ALT > 5 x ULN\\n  - **Action**: Discontinue the offending drug(s) and consult a senior clinician for next steps.\\n\\n### Additional Notes\\n- All patients with an acute increase in liver enzymes should be evaluated for other possible causes of hepatitis/hepatotoxicity and managed accordingly.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nThis section provides an overview of considerations for administering antiretroviral therapy (ART) to various age groups, including infants, children, adolescents, and adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Kidney Disease Risk Assessment\\n\\nAssessing the risk of kidney disease is crucial at every clinic visit. The following factors should be considered:\\n\\n- Age > 60 years\\n- Concurrent HIV-associated diseases (e.g., TB and other opportunistic infections)\\n- Concurrent conditions like diabetes, hypertension, or viral hepatitis\\n- Use of nephrotoxic drugs (e.g., aminoglycosides, amphotericin, boosted protease inhibitors)\\n- Presence of wasting or low BMI\\n- CD4 count < 200 cells/mm³\\n\\nIf any risk factor is present, proceed with further assessment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Diagnostic Procedures\\n\\nFor patients identified at risk of kidney disease, the following diagnostic steps should be taken:\\n\\n1. Obtain a dipstick urinalysis.\\n2. Measure serum creatinine and calculate creatinine clearance (CrCl in ml/min).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': \"## TDF Administration Guidelines\\n\\nWhen prescribing Tenofovir Disoproxil Fumarate (TDF), the following recommendations apply based on the patient's CrCl levels:\\n\\n- **CrCl < 30 ml/min**: Avoid TDF unless no suitable alternative exists. Administer TDF 300 mg every 48 hours; monitor CrCl monthly for the first year and then quarterly if stable.\\n  \\n- **CrCl 30-49 ml/min**: Avoid TDF unless no suitable alternative exists. Administer TDF 300 mg every 48 hours; monitor closely with monthly CrCl for the first year and quarterly thereafter if stable.\\n\\n- **CrCl 50-89 ml/min**: Administer TDF 300 mg once daily and monitor closely for a decline in renal function (monthly for the first year and every three months thereafter if stable).\\n\\n- **CrCl > 90 ml/min**: Administer TDF 300 mg once daily, re-assess creatinine and CrCl at 1 month, 3 months, and bi-annually thereafter if normal.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Special Considerations for Renal Function\\n\\nThis section outlines specific considerations for renal function in ART prescriptions:\\n\\n1. DTG may cause a slight rise in serum creatinine levels without indicating true renal function decline.\\n2. Patients at risk of renal disease should undergo biannual serum creatinine and CrCl assessments.\\n3. For patients with CrCl < 50 ml/min, consider alternative ART options such as ABC, TAF, or DTG + 3TC dual therapy.\\n4. If on first-line ART and HBV negative, substitute TDF.\\n5. Reference the Regional or National HIV Clinical Technical Working Group for consultation in case of treatment failure or other scenarios.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Follow-Up and Monitoring\\n\\nFor patients with decreased renal function, assess other causes of renal impairment and refer to a physician for management review. Regular monitoring and adjustments to ART are essential to ensure patient safety and effective treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 155,\n",
       "  'section': '## Diagnosis and Management of Abacavir Hypersensitivity Reaction\\n\\n**Diagnosis**  \\nWithin 3 weeks of initiating an ABC-containing regimen, a patient develops any 2 of the following symptom groups concurrently:  \\n- Fever  \\n- Erythematous and/or pruritic rash  \\n- Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n- GI symptoms: nausea and/or vomiting and/or diarrhea  \\n- Extreme fatigue and/or body pain preventing normal activities  \\nAND there is not a more likely alternative explanation for the symptoms.  \\n\\n**Management**  \\n- Stop ABC immediately and substitute with an alternative ARV.  \\n- The patient must NEVER be re-challenged with ABC; a single dose could result in a fatal hypersensitivity reaction.  \\n- Clearly mark the file and educate the patient about avoiding ABC in the future.  \\n- Issue an Adverse Event alert card.  \\n\\n**Note:**  \\n- ABC hypersensitivity reaction is rare in our population; always consider other more likely possible diagnoses.  \\n- Symptoms generally worsen within hours after each dose of ABC.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 155,\n",
       "  'section': '## Changing ARVs Due to Drug-Drug Interactions\\n\\nPatients must be asked about other medications (including non-prescription and herbal medicine) they are taking at every visit. Some common drugs have specific drug-drug interactions that may require dose adjustment or substitution of the ARV or the other interacting drugs.  \\n\\n**Common medications that interact with specific ARVs include:**  \\n- Rifampicin  \\n- Rifabutin  \\n- Antacids  \\n- Multivitamin/mineral supplements  \\n- Methadone  \\n- Several anti-fungal medications  \\n- Anti-convulsants  \\n- Calcium-channel blockers  \\n- Some anti-depressants  \\n- Some statins  \\n- Some anti-malarials  \\n\\nAnnex 13 provides common drug-drug interactions and management recommendations. It is recommended practice to check for interactions whenever a new medicine is started.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Adverse Drug Reactions for NRTIs\\n\\nThis section covers significant adverse drug reactions associated with NRTIs (Nucleoside Reverse Transcriptase Inhibitors) along with high-risk situations.\\n\\n- **ABC**: ABC hypersensitivity reaction. Avoid re-challenge.\\n  \\n- **AZT**:\\n  - **Adverse Reactions**: Anemia, neutropenia.\\n  - **Risk Factors**: CD4 count < 200 cells/mm3, BMI < 18.5 (or body weight < 50 kg), baseline anemia, concurrent use of other drugs with similar ADR (cotrimoxazole, gancyclovir, ribavirin).\\n  - **Other Risks**: Lactic acidosis (Risk factors: pregnancy, obesity; Lipoatrophy (Risk factors: low CD4 count).\\n  \\n- **TDF**:\\n  - **Adverse Reaction**: Renal dysfunction.\\n  - **Risk Factors**: Underlying renal disease, age > 60 years, BMI < 18.5 (or body weight < 50 kg), diabetes, hypertension, concomitant PI use or nephrotoxic drug.\\n  - **Management**: Avoid in patients with CrCl < 50 ml/min unless no alternative.\\n\\n- **TAF**:\\n  - **Adverse Reaction**: Weight gain.\\n  - **Risk Factors**: Women, concomitant use of INSTIs.\\n  - **Advice**: Provide guidance on healthy eating and physical activity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Adverse Drug Reactions for NNRTIs\\n\\nThis section focuses on adverse drug reactions associated with NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors).\\n\\n- **All NNRTIs**:\\n  - **Adverse Reaction**: Rash (NVP >> EFV > ETR).\\n\\n- **EFV**:\\n  - **Adverse Reactions**: CNS side-effects, gynaecomastia.\\n  - **Recommendation**: Switch to an alternative if gynaecomastia does not improve.\\n\\n- **NVP**:\\n  - **Adverse Reaction**: Hepatotoxicity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Adverse Drug Reactions for PIs\\n\\nThis section discusses adverse drug reactions related to Protease Inhibitors (PIs).\\n\\n- **All PIs boosted with RTV**:\\n  - **Adverse Reactions**: GI intolerance (LPV/r > DRV/r > ATV/r), dyslipidaemia (LPV/r > DRV/r > ATV/r).\\n  - **Management**: Consult for alternative regimen recommendations.\\n\\n- **ATV/r**:\\n  - **Adverse Reaction**: Hyperbilirubinemia. Substitution is only necessary if jaundice affects adherence.\\n\\n- **DRV/r**:\\n  - **Adverse Reaction**: Rash/hypersensitivity. Risk factors include sulfa allergy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Adverse Drug Reactions for INSTIs\\n\\nThis section examines adverse drug reactions associated with Integrase Strand Transfer Inhibitors (INSTIs).\\n\\n- **All INSTIs**:\\n  - **Adverse Reaction**: Weight gain.\\n  - **Risk Factors**: Women, concomitant use of TAF.\\n  - **Advice**: Provide guidance on healthy eating and physical activity.\\n\\n- **DTG**:\\n  - **Adverse Reaction**: Insomnia.\\n  - **Management**: Administer in the morning; consider taking with low-fat meal or on an empty stomach if needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Contact Information for Management\\n\\nFor issues related to adverse drug reactions or alternative regimens, patients can contact:\\n- **R-TWG** or **Uliza Hotline**: 0726 460 000 \\n- **Website**: [NASCOP Clinical Form](https://nhcsc.nascop.org/clinicalform)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 160,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral therapy (ART) is crucial for managing HIV in different populations, including infants, children, adolescents, and adults. The choice of ART regimen may vary based on age and specific health considerations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 160,\n",
       "  'section': '## Possible Third-Line ART Regimens for Children\\n\\n- **DTG + 3TC + DRV/r**: The selection for third-line ART is based on drug resistance testing (DRT) results.\\n- **DTG + AZT + 3TC + DRV/r**: An alternative regimen option.\\n- **DTG + ABC (or TDF) + 3TC + DRV/r**: Another possible combination.\\n- **ETV + 3TC + DRV/r**: An option that includes etravirine.\\n\\n**Note**: Recommendations from the Regional or National HIV Clinical Technical Working Group (TWG) may allow for reusing some antiretrovirals the patient has previously failed, even if resistance is present.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 160,\n",
       "  'section': '## Possible Third-Line ART Regimens for Adults\\n\\n- **DTG + 3TC + DRV/r**: A standard third-line regimen.\\n- **DTG + AZT + 3TC + DRV/r**: Another combination widely used.\\n- **DTG + TDF + 3TC + DRV/r**: An alternative adult regimen.\\n- **DTG + TDF (or AZT) + 3TC**: Flexibility with TDF or AZT.\\n- **ETV + 3TC + DRV/r**: Similar to the options for children.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral therapy (ART) is crucial for managing HIV in infants, children, adolescents, and adults. The primary goal is to achieve sustained viral suppression to ensure better health outcomes in people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Monitoring Viral Load\\n\\nViral load (VL) is the recommended method for monitoring the response to ART and identifying treatment failure.\\n\\n- **First VL Testing:** Conducted 3 months after ART initiation for all PLHIV.\\n- **Indicators of Treatment Failure:** Development of a new or recurrent HIV-associated condition indicating severe immunodeficiency (WHO stage III or IV) after at least 6 months on ART.\\n- **Confirming Treatment Failure:** Always verify with VL testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Frequency of Routine VL Monitoring\\n\\nThe frequency of VL monitoring varies by age and status:\\n\\n- **Ages 0-24 years:** \\n  - At 3 months after ART initiation and then every 6 months.\\n  \\n- **Ages ≥ 25 years:** \\n  - At 3 months after ART initiation, then at month 12, and then annually.\\n  \\n- **Pregnant or Breastfeeding:** \\n  - At confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if initiated during pregnancy/breastfeeding), then every 6 months until cessation of breastfeeding.\\n\\n- **Drug Substitution:** \\n  - Before making any drug substitutions (if no VL results from the prior 6 months) and three months after any regimen modification.\\n\\n- **Detectable VL Patients:** \\n  - Follow the viral load monitoring algorithm for those with detectable VL.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Interpreting Viral Load Results\\n\\nThe goal of ART is to achieve sustained viral suppression, defined as below the Lower Detection Limit (LDL), with < 50 copies/ml considered as suppressed.\\n\\n- **Persistent Low-Level Viremia (PLLV):** \\n  - Defined as having 200-999 copies/ml on two consecutive measures. Patients with PLLV are at increased risk of progression to treatment failure and require a case management approach similar to those with VL ≥ 1,000 copies/ml.\\n\\n- **Defining Treatment Failure:** \\n  - Treatment failure is suspected with a high VL ≥ 1,000 copies/ml after at least 3 months on ART. \\n  - Confirmation of treatment failure occurs when VL remains ≥ 1,000 copies/ml after assessing and addressing poor adherence or other reasons for high VL, followed by repeat VL testing after at least 3 months of enhanced adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Consultation and Support Resources\\n\\nFor further guidance, consultation should be made with the Regional or National HIV Clinical Technical Working Group (TWG). Contact details include the Uliza Hotline at 0726 460 000 and the website [NASCOP Clinical Guidelines](https://nhcsc.nascop.org/clinicalform).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Kenya HIV Prevention Guidelines, 2022\\n\\nThis section outlines the guidelines for HIV prevention in Kenya, including strategies such as condom distribution, pre-exposure prophylaxis (PrEP), and community engagement initiatives aimed at reducing transmission rates.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Kenya HIV Treatment Guidelines, 2022\\n\\nThis section provides details about the treatment protocols for managing HIV in Kenya, including antiretroviral therapy (ART) regimens, adherence strategies, and monitoring of viral loads to ensure effective treatment outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Target Populations for HIV Programs\\n\\nThis section describes the specific populations targeted by the HIV prevention and treatment programs in Kenya, such as key populations at higher risk (e.g., men who have sex with men, sex workers) and vulnerable groups (e.g., adolescents, pregnant women).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Integration of HIV Services\\n\\nThis section discusses the integration of HIV prevention and treatment services with other health services, highlighting the importance of a holistic approach to healthcare that addresses co-infections, sexual and reproductive health, and mental health support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Community Engagement and Education\\n\\nThis section focuses on the role of community engagement in HIV prevention and treatment efforts, including public awareness campaigns, educational outreach, and the involvement of local organizations in combating stigma and promoting health-seeking behavior.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Monitoring and Evaluation of HIV Programs\\n\\nThis section covers the frameworks for monitoring and evaluating the effectiveness of HIV prevention and treatment programs, including data collection methods, performance indicators, and feedback mechanisms to improve program delivery.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Policy and Legal Frameworks\\n\\nThis section outlines the relevant policies and legal frameworks that govern HIV prevention and treatment efforts in Kenya, emphasizing the importance of supportive laws and policies for achieving desired health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Viral Load Testing Schedule\\n\\nThe schedule for routine viral load (VL) testing is as follows:\\n- **Age 0 - 24 years old**: At month 3, then every 6 months.\\n- **Age X and older**: At month 3, then month 12, and then annually.\\n- **Pregnant or breastfeeding patients**: At confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiated during pregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding.\\n- Before any drug substitution (if no VL result available from the prior 6 months).\\n- Three months after any regimen modification (including single-drug substitutions).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Interpretation of Viral Load Results\\n\\n### VL < 200 copies/ml\\n- Indicates successful treatment; routine adherence counseling and monitoring continue.\\n\\n### VL 200 – 999 copies/ml\\n- Indicates increased risk of progression to treatment failure; patient should be discussed in a Multi-Disciplinary Team (MDT).\\n\\n### VL ≥ 1000 copies/ml\\n- Indicates suspected treatment failure; enhanced adherence support and possible regimen changes may be necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Treatment Failure Management\\n\\n1. Discuss the patient in a Multi-Disciplinary Team (MDT).\\n2. Assign a case manager.\\n3. Assess for and address likely causes of non-adherence, and provide enhanced adherence support/interventions as appropriate.\\n4. Assess for other causes of viremia and manage as needed, including supporting daily witnessed ingestion by a treatment buddy or healthcare worker.\\n5. After 3 months of excellent adherence, perform repeat VL testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Actions for VL Results\\n\\n- **VL < 200 copies/ml (Low Level Detection)**: Continue ART regimen, maintain routine adherence counseling and monitoring, and repeat VL after another 3 months of excellent adherence.\\n  \\n- **VL 200 – 999 copies/ml**: Continue enhanced adherence support, and schedule clinical appointment at 2 weeks after any regimen change to review adherence, side effects, and concerns.\\n\\n- **Confirmed Treatment Failure**: \\n   - Begin treatment preparation for a new regimen and continue the failing regimen until adherence preparation is completed.\\n   - Take sample for CD4 count and manage any opportunistic infections (OIs).\\n   - If failing a Dolutegravir (DTG) or Protease Inhibitor (PI) based regimen, a Drug Resistance Testing (DRT) is recommended in consultation with a Regional or National HIV Clinical Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Common Causes of Poor Adherence\\n\\n1. Stigma.\\n2. Non-disclosure.\\n3. Travel.\\n4. Toxicities.\\n5. Alcohol or drug use.\\n6. Mental health disorders.\\n7. Religious beliefs.\\n8. Inadequate treatment preparation.\\n9. Chaotic lifestyle.\\n10. Lack of support systems.\\n11. Poor patient-provider relationship.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Other Causes of Treatment Failure\\n\\n1. Inadequate dosing or dose adjustments.\\n2. Drug-drug interactions.\\n3. Drug-food interactions.\\n4. Impaired absorption (e.g., chronic severe diarrhea).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 162,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nRoutine antenatal care (ANC) offers an important opportunity to provide high-quality combined HIV prevention through targeted health education and counselling; HIV testing for the woman, partners, and family members; linkage to HIV prevention and treatment; and discussions and planning for future conception and contraception needs. Prevention of mother-to-child transmission of HIV (PMTCT), syphilis, and hepatitis B should be offered as part of a comprehensive package of fully integrated routine antenatal care interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 162,\n",
       "  'section': '## Essential Package of Antenatal Care\\n\\n**Intervention**: Group & Individual Education  \\n**Recommendation/Description**: Include information on the importance of at least 8 ANC visits, details of ANC services (including health checks and treatment of any illness, medical tests including HIV, syphilis testing, and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), nutrition, personal care, recognizing and responding to danger signs during pregnancy, birth preparedness including skilled birth attendance, post-natal care including immunization, family planning and maternal and infant nutrition, HIV prevention and treatment (HTS, preventing new infections during pregnancy including PrEP where appropriate, ART for those who are HIV positive, monitoring of ART and ARV prophylaxis and follow-up for HEIs), and triple elimination (preventing HIV, syphilis, and hepatitis B transmission from mother to child).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 162,\n",
       "  'section': '## Counselling\\n\\n### Pre-conception\\nWomen in reproductive age who are known to be HIV positive should have a pregnancy intention assessment visit at every visit. If they desire to become pregnant, pregnancy should be planned, i.e., attain viral load suppression, immune reconstitution, and have Iron and Folic Acid Supplementation (IFAS) administered prior to conception.\\n\\n### Newly Diagnosed Women\\nWomen who are newly diagnosed with HIV and/or newly initiating ART require more intensive adherence counseling and HIV education, which may include a case manager and/or mentor mother.\\n\\n### Birth Preparedness\\nSupport the pregnant woman and her partner to develop an individual birth plan that includes place of delivery with skilled attendants, emergency transport, birth companionship, and readiness for infant care.\\n\\n### Pregnancy Danger Signs\\nOffer information on returning to ANC as soon as possible in case they develop fever, lower abdominal pain, severe headache, swollen feet, convulsions, and per vaginal bleeding.\\n\\n### Maternal, Infant, and Young Child Nutrition (MIYCN)\\nAll pregnant women should receive information on proper nutrition during pregnancy and breastfeeding, safe infant feeding, and optimal nutrition practices. Promote exclusive breastfeeding for the first 6 months irrespective of HIV status, followed by complementary feeding. During pregnancy, provide iron, folate, and multivitamins; monitor for anemia, and advise on adequate caloric intake (HIV positive women require an additional 10% of the recommended daily allowance (RDA)).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Antiretroviral Therapy and Treatment Failure\\n\\nNon-adherence is the most frequent cause of treatment failure in patients undergoing antiretroviral therapy (ART). Adherence issues must be addressed before confirming treatment failure as per the viral load monitoring algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': \"## Adherence Confirmation Strategies\\n\\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to ensure excellent adherence before repeating the viral load (VL) test. It's critical to resolve any adherence issues before switching to a new regimen to avoid rapid treatment failure again. One exception is when the regimen is the primary cause of poor adherence, such as severe side effects from one of the antiretrovirals (ARVs).\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Modifying a Regimen\\n\\nIf side effects are unmanageable and result in poor adherence, the regimen may need to be modified. This modification should be done in consultation with the Regional or National HIV Clinical Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Adherence Preparation and Support\\n\\nDetailed guidance on adherence preparation, assessment, and support can be found in Chapter 5 of the document.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Recommended Second-line ART Regimens\\n\\n### Infants, Children, and Adolescents (Weight/Scenario: < 30 kg)\\n\\n- **First-line ART:** \\n  - ABC (or AZT) + 3TC + DTG \\n  - ABC + 3TC + LPV/r \\n  - AZT + 3TC + LPV/r \\n  - ABC + 3TC + EFV \\n  - AZT + 3TC + EFV \\n- **Second-line ART:** \\n  - DRT-based second-line for all options; modifications based on DRT results if indicated.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '### Adults (Weight/Scenario: ≥ 30 kg or ≥ 15 years old)\\n\\n- **First-line ART:**\\n  - TDF (or ABC) + 3TC + DTG (or PI/r)\\n  - TDF (or ABC) + 3TC + EFV \\n  - AZT + 3TC + EFV \\n- **Second-line ART:**\\n  - DRT-based second-line, with modifications based on DRT results if required.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '### Pregnant and Breastfeeding Women\\n\\n- **First-line ART:**\\n  - TDF (or ABC) + 3TC + DTG \\n  - TDF (or ABC) + 3TC + PI/r \\n  - TDF (or ABC) + 3TC + EFV \\n  - AZT + 3TC + EFV \\n- **Second-line ART:**\\n  - Changes to TDF + 3TC + ATV/r or TDF + 3TC + DTG while awaiting DRT results; modifications based on results if indicated.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Special Considerations for Co-infections\\n\\n### HIV/HBV Co-infection\\n\\nIt is essential to maintain TDF to treat both HIV and HBV effectively.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '### TB/HIV Co-infection\\n\\nRefer to additional guidelines in Table 8.8 for recommended ART regimens for patients who develop TB while failing first-line ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## Second-Line Regimen Considerations\\n\\n1. If any drug in the recommended second-line regimen is contraindicated or previously not tolerated, consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform). Such patients may require a Drug Resistance Test (DRT) to select agents for the second-line ART. Additional drugs may be recommended on a case-by-case basis, including DRV/r, ATV/r, RAL, or ETR.\\n\\n2. Patients failing DTG-based or PI-based first-line regimens should have a Drug Resistance Test (DRT) ordered as soon as treatment failure is confirmed. The patient summary and DRT results should be sent to the Regional or National HIV Clinical TWG or call Uliza Hotline (0726 460 000) to determine the most suitable second-line regimen for the patient. The DRT results will be used to determine if there is true DTG or PI failure or if there is an underlying problem with non-adherence. Daily witnessed ingestion is recommended prior to performing DRT.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## Important Considerations for First-Line Treatment Failure in Children\\n\\n- Second-line ART in infants and children is more complex to manage. These children and their caregivers should undergo thorough clinical and psychosocial assessment to rule out inter-current illness or non-adherence as the reason for a high viral load.\\n  \\n- All children failing first-line should be discussed in the MDT and preferably with an experienced ART provider prior to the change of ART to second-line. However, this should not cause undue delay in switching a failing regimen.\\n\\n- The choices for infants and children failing an alternative first-line regimen are limited and may need to be discussed with the Regional or National HIV Clinical TWG. Some of these children will require HIV DRT to determine the most suitable second-line regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## Important Considerations for Second-Line ART Treatment Failure\\n\\n- Patients failing second-line ART have limited options. ARVs used to construct a third-line regimen are often more expensive, will have increased pill burden, and more side effects. These factors will exacerbate pre-existing poor adherence.\\n\\n- Second-line treatment failure should be confirmed by viral load testing following the viral load monitoring algorithm:\\n  - After the first detectable VL (≥ 50 copies/ml), assess for and address all causes of poor adherence, and assess for all other possible causes of viremia.\\n  - These patients should be discussed at an MDT session. Repeat the VL after 3 months of excellent adherence (preferably with daily witnessed ingestion of the ARVs by a treatment buddy, relative, CHV, etc.).\\n  - If the second VL is still ≥ 50 copies/ml, then continue the failing second-line regimen while reassessing adherence and other causes of viremia, implementing adherence support systems as needed, and then repeat the VL after another 3 months.\\n  - If viremia continues, then consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform) using the national case summary form (Annex 9B). These patients will likely require DRT in order for the TWG to design the most suitable third-line regimen.\\n\\n- Patients failing second-line ART require thorough assessment for barriers to adherence and ongoing enhanced adherence support including:\\n  - Assigning a case manager.\\n  - More frequent adherence counselling by a trained counsellor.\\n  - Assessment and treatment of mental health and substance use disorders.\\n  - Provision of adherence support such as modified directly observed therapy, a treatment supporter, home visits, etc.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 164,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nThis section introduces the overarching goal of preventing the transmission of HIV, syphilis, and Hepatitis B from mother to child.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 164,\n",
       "  'section': '## Antiretroviral Therapy for HIV-positive Pregnant and Breastfeeding Women\\n\\nThe goal of Antiretroviral Therapy (ART) for HIV-positive pregnant women is two-fold: to restore and maintain the mother’s immune function and prevent HIV transmission during pregnancy, labor, and breastfeeding. Effective ART must be initiated to achieve viral suppression.\\n\\n### Recommendations for Use of ART\\n\\n#### Overall Recommendations\\nART should be initiated in all pregnant and breastfeeding women living with HIV regardless of gestation, WHO clinical stage, or CD4 cell count, and should continue lifelong. Ideally, ART should start on the same day as HIV diagnosis, following a readiness assessment and with ongoing adherence support.\\n\\n#### What to Start With (First-line ART)\\nThe recommended first-line ART regimen includes TDF/3TC/DTG. \\n\\n#### Infant Prophylaxis\\nInfant prophylaxis involves administering AZT+NVP for 6 weeks, with NVP continuing until 6 weeks after complete cessation of breastfeeding.\\n\\nRefer to Table 7.3 for more comprehensive information.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 164,\n",
       "  'section': '## Monitoring\\n\\n### Viral Load Monitoring\\nMonitoring viral load during pregnancy and breastfeeding is critical.\\n\\n- Whenever possible, use same-day point-of-care methods for viral load testing to expedite decision-making. If not available, prioritize viral load specimens and results for pregnant and breastfeeding women across lab referrals.\\n- For newly initiated ART users, obtain viral load (VL) testing 3 months after initiation and every 6 months until breastfeeding cessation.\\n- For women already on ART at the time of confirming pregnancy or breastfeeding, obtain a VL regardless of prior results, and then every 6 months until complete cessation of breastfeeding.\\n\\n### Addressing Viremia\\nFor pregnant or breastfeeding women with a VL ≥ 50 copies/ml:\\n- Assess reasons for viremia and enhance adherence support.\\n- Repeat VL after 3 months of excellent adherence.\\n  - If the repeat VL is 200 - 999 copies/ml, consult the Regional or National HIV Clinical TWG.\\n  - If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen (Refer to Table 6.10).\\n  - If the repeat VL is < 200 copies/ml (LDL), continue routine monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 166,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nThis section introduces the overarching goal of eliminating HIV, syphilis, and hepatitis B transmission from mothers to their children.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 166,\n",
       "  'section': '## Syphilis Elimination for Pregnant and Breastfeeding Women and Infant Treatment\\n\\nThe country has adopted a triple elimination approach for HIV, syphilis, and hepatitis B among pregnant and breastfeeding women. It is crucial that:\\n\\n- All pregnant women attending Antenatal Care (ANC) and are unaware of their HIV status undergo dual HIV and syphilis testing during their first trimester.\\n- A second HIV and syphilis test is recommended in the third trimester if the initial test was negative.\\n- Women who test positive for syphilis during pregnancy or breastfeeding should receive the appropriate treatment regimen as outlined in Table 7.3.\\n- Babies born to mothers who test positive for syphilis are presumed exposed and should receive the correct treatment regimen.\\n- Contact tracing should be performed for all sexual contacts to ensure they are treated for syphilis.\\n- Symptoms of congenital syphilis may not appear for several weeks or months after birth.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 166,\n",
       "  'section': '## Hepatitis B Elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis\\n\\nThis section outlines the steps for routine testing and prevention of hepatitis B transmission:\\n\\n- Routine testing of pregnant women is necessary to identify those in need of antiviral treatment for their health and to reduce the risk of mother-to-child transmission of hepatitis B.\\n- Incorporate viral hepatitis screening as part of the ANC profile, focusing on the risks posed by hepatitis B and C to both mother and fetus.\\n- Pregnant and breastfeeding women positive for HBsAg should be offered appropriate treatment options, such as ARVs containing TDF/3TC or FTC. This treatment also serves as prophylaxis for HBV transmission from mother to child.\\n- All pregnant and breastfeeding women without evidence of hepatitis B infection (HBsAg negative) should receive hepatitis B vaccination, as well as HIV-positive infants without evidence of infection.\\n- Infants born to mothers who test positive for HBsAg should receive treatment with Hepatitis B Immunoglobulin, as specified in Table 7.3.\\n- Refer to Chapter 9 for management strategies concerning HIV/HBV coinfection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## HIV Testing Services for Pregnant Women\\n\\n- All pregnant women (unless known HIV positive) should be counselled and tested for HIV, syphilis, and Hepatitis B during their first ANC visit. If negative, repeat HIV and syphilis testing in the third trimester.\\n  \\n- Pregnant and breastfeeding mothers with continued HIV risk (key populations) should be counselled and tested for HIV every 3 months until cessation of breastfeeding.\\n\\n- Pregnant and breastfeeding mothers should be educated and offered a self-test kit for their sexual partner(s).\\n\\n- At labour and delivery, HIV testing should be done for all women with unknown HIV status or those who previously tested negative, even if tested during the third trimester.\\n\\n- All breastfeeding mothers (unless known HIV positive) should be counselled and tested at the 6-week infant immunization visit. The HIV test (if negative) should be repeated every 6 months until complete cessation of breastfeeding.\\n\\n- Key population mothers (FSWs and PWIDs) should get retested every 3 months.\\n\\n- Women should be counselled about the schedule for repeat HIV testing in pregnancy and postnatally as part of routine ANC and postnatal education.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Follow-up for Unscreened Pregnant and Breastfeeding Women\\n\\n- All pregnant and breastfeeding women who are not tested, opt-out, or decline HIV, syphilis, or Hepatitis testing during the first contact should be offered counselling and testing in subsequent visits, with appropriate linkage and referral for prevention, care, and support services.\\n\\n- Daily Witnessed Ingestion (DWI) is advised to support viral suppression for newly initiated clients and those whose regimens are being switched, particularly among women with high viral load.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Support for HIV Positive Pregnant and Breastfeeding Women\\n\\n- All HIV positive pregnant and breastfeeding women enrolled into care should receive counselling and support (including assisted disclosure), case management linkage, and follow-up for comprehensive treatment and prevention, including lifelong ART.\\n\\n- All syphilis and Hepatitis B positive clients should be given appropriate care as defined in Table 7.3 “triple elimination”.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Partner and Child Testing\\n\\n- All partners of pregnant and breastfeeding women should be offered HIV testing and counselling, as well as all biological children if the mother is HIV positive.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Risk Reduction and Contraception\\n\\n- All pregnant and breastfeeding women should receive information on risk reduction, including PrEP where appropriate.\\n\\n- For postpartum contraception, counselling on contraception methods should be provided to help patients develop a plan for effective contraception from 6 weeks postpartum to avoid unplanned pregnancies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## Pre-conception Planning for Women on ART\\n\\nMaintain ART for women who are already on antiretroviral therapy (ART) and not yet pregnant.  \\n- Carry out a viral load (VL) test if not done in the prior six months to confirm viral suppression.  \\n- Refer to Table 4.8 for pre-conception care including laboratory screening, tetanus immunization, and folate supplementation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## Management During Pregnancy and Breastfeeding\\n\\n### On ART at Time of Pregnancy Confirmation\\n- Maintain ART throughout the pregnancy.  \\n- Conduct a VL test upon first identification of pregnancy to confirm viral suppression.  \\n- Manage the newborn as a HIV-exposed infant (HEI).\\n\\n### Not on ART at Time of Pregnancy Confirmation\\n- Prepare the patient and start ART as soon as possible, preferably on the same day HIV infection is confirmed.  \\n- Perform VL testing three months after ART initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## Patients with Treatment Interruption\\n\\nPregnant and breastfeeding women with a history of treatment interruption returning to care should:\\n- Assess the reasons for interruption.  \\n- Preferentially restart on a dolutegravir (DTG) containing regimen unless the interruption was due to DTG intolerance or failure.  \\n- Monitor viral load after 3 months of ART initiation and every 6 months thereafter until cessation of breastfeeding.  \\n- Provide additional adherence support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## ART Administration During Labor and Delivery\\n\\n### Not on ART During Labor and Delivery\\n- Start ART during labor.  \\n- Continue treatment preparation and adherence support after delivery.\\n\\n### Postpartum and Breastfeeding Management\\n- Prepare and start ART as soon as possible, preferably on the same day HIV infection is confirmed if the mother was not on ART.  \\n- Manage the baby as HEI and provide adherence support for both mother and child, possibly including daily witnessed ingestion (DWI) support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## Managing Labor and Delivery\\n\\nTo ensure safe labor and delivery:\\n- Minimize vaginal examinations.  \\n- Use aseptic techniques for delivery.  \\n- Avoid artificial rupture of membranes.  \\n- Monitor labor progression using a partograph and avoid prolonged labor.  \\n- Avoid unnecessary genital tract trauma.\\n\\n### Special Considerations\\nCertain patient groups may require additional adherence and psychosocial support, including:\\n- Recent HIV infections.  \\n- Pregnant adolescent girls and young women.  \\n- Women with previous children with HIV infection.  \\n- Patients with high viral load at the time of pregnancy confirmation.  \\n- Patients with poor social support systems or a history of defaulting from care.  \\n- Those with active comorbidities.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nThis section likely covers strategies and guidelines aimed at preventing the transmission of HIV, syphilis, and hepatitis B from mothers to their children during pregnancy, childbirth, or breastfeeding. Specific intervention measures may include prenatal care, testing, treatment, and safe delivery practices.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '## Table 7.7: Complementary Foods for Children 6 - 24 Months Old\\n\\nThis section presents a table outlining the appropriate complementary foods for children aged 6 to 24 months, addressing texture, frequency, and amount of food per meal across different age ranges.\\n\\n### Foods to Offer\\n\\n- **6 months**: Start with thick porridge or well mashed foods; frequency: 2 times per day; amount: 2 tablespoons each feed, increasing to 3 tablespoons in the 3rd to 4th week.\\n\\n- **7-8 months**: Offer mashed/pureed family foods, begin finger foods by 8 months; frequency: 3 meals per day, plus frequent breastfeeds; amount: gradually increase to ½ of a 250 ml cup, use a separate plate/bowl.\\n\\n- **9-11 months**: Provide finely chopped or mashed foods, and foods the baby can pick up; frequency: 3 meals and 1 snack, plus frequent breastfeeds; amount: ¾ of a 250 ml cup/bowl, use a separate plate/bowl.\\n\\n- **12-23 months**: Cut food into small, soft pieces that the child can pick up, chew, and swallow comfortably; frequency: 3 meals and 2 snacks, plus breastfeeds; amount: one 250 ml cup/bowl, use a separate plate/bowl.\\n\\n- **24-59 months**: Continue cutting food into small, soft pieces; frequency: 3 meals and 2 snacks, plus breastfeeds if still breastfeeding; amount: 1 ½ - 2 cups of 250 ml cup/bowl, use a separate plate/bowl.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 173,\n",
       "  'section': '## Intensified Case Finding Screening Questions\\n\\nThe document outlines specific screening questions aimed at intensified case finding for TB in patients. If a patient answers \"Yes\" to any of the questions, a detailed history should be taken, a physical examination should be performed, and sputum examination (either sputum smear or GeneXpert) is recommended.\\n\\n- Cough of any duration (Y/N)\\n- Fever (Y/N)\\n- Noticeable weight loss/Failure to thrive/Poor weight gain (Y/N)\\n- Night sweats (Y/N)\\n- Reduced playfulness/Lethargy/Irritability (Y/N)\\n- Contact with a TB case (Y/N)\\n\\nIf all responses to questions 1-5 are \"No,\" consider the patient\\'s eligibility for TB Preventive Therapy (TPT) and plan for follow-up screenings on subsequent visits. Notably, questions 5 and 6 do not apply to adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 173,\n",
       "  'section': '## Follow-up Actions Based on Screening Responses\\n\\nDepending on the answers to the screening questions, the document suggests the following actions:\\n\\n- If there is a \"Yes\" response to any question:  \\n  - Take detailed medical history.  \\n  - Conduct a physical examination.  \\n  - Perform sputum examination.  \\n\\n- If there is a \"No\" response to questions 1-5:  \\n  - Evaluate eligibility for TB Preventive Therapy.  \\n  - Schedule repeat screening during future visits.  \\n\\nThis approach ensures timely identification and treatment of potential TB cases, thereby enhancing patient care and management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Breastfeeding Guidelines\\n\\nAll infants, irrespective of HIV status, should be exclusively breastfed for the first 6 months of life. After 6 months, appropriate complementary foods should be introduced, and breastfeeding should continue up to 24 months or beyond.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Support for Working Mothers\\n\\nIf mothers need to be physically separated from their infants due to work, they should be supported to sustain lactation and exclusively breastfeed, including mentorship on expressing breast milk, in accordance with the current MIYCN Policy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Recommendations for All Mothers\\n\\nAll mothers, regardless of their HIV status, should be encouraged and supported to exclusively breastfeed for the first six months and continue with appropriate complementary feeding after that for a period of 24 months or longer. Breastfeeding should only cease once a nutritionally adequate and safe diet without breast milk can be maintained.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## ART for HIV Positive Mothers and Infants\\n\\nHIV positive mothers and infants should always be on Antiretroviral Therapy (ART) and receive extra attention for adherence support, viral load (VL) monitoring, and optimal retention in care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## HIV Testing for Breastfeeding Mothers\\n\\nBreastfeeding mothers who are unaware of their HIV status or who have previously tested negative should be encouraged to retest for HIV at the 6-week immunization visit, then every 6 months until they completely cease breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Access to HIV Testing for Partners\\n\\nAccess for HIV testing and STI/HIV prevention interventions should be reinforced for partners of pregnant and breastfeeding women.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Management of Newly Diagnosed HIV Patients\\n\\nMothers diagnosed with HIV while breastfeeding should start appropriate ART immediately, focusing on adherence support, VL monitoring, and retention in care. The infant should also start ARV prophylaxis and receive PCR testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Gradual Cessation of Breastfeeding\\n\\nMothers who choose to stop breastfeeding should do so gradually over one month, provided that a nutritionally adequate and safe diet can be sustained. HIV positive mothers and infants should continue on ART. Continued breastfeeding is recommended for HIV positive infants for as long as possible.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Special Medical Circumstances\\n\\nIn special medical circumstances where an infant cannot breastfeed, refer to the current MIYCN Policy and the Breast Milk Substitute (BMS) Regulation and Control Act, 2012.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': \"## Complementary Feeding\\n\\nComplementary feeding means providing additional foods after six months of exclusive breastfeeding. It helps meet the child's growing nutritional needs and allows them to adapt to family foods while continuing to benefit from breastfeeding. A balance of all seven food groups for children should be emphasized:\\n\\n- Cereal/tubers and roots\\n- Beans, pulses, and nuts\\n- Dairy and dairy products\\n- Eggs and flesh (meat, poultry, insects, organ meat)\\n- Vitamin A-rich foods (orange/yellow fruits) and green vegetables\\n- Fats and high-sugar foods\\n- Other fruits and vegetables\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nTB is a leading cause of morbidity and mortality among people living with HIV (PLHIV). Reducing this burden of illness requires early identification of TB, providing pre-emptive treatment for TB, and ensuring optimal treatment for both HIV and TB. Timely initiation of antiretroviral therapy (ART) combined with TB Preventive Therapy is effective in minimizing the burden of TB in PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## Counseling for PLHIV\\n\\nAll PLHIV should receive counseling on the following topics:\\n- The risk of acquiring TB\\n- Strategies for reducing exposure to TB\\n- Recognizing clinical manifestations of TB and seeking care promptly\\n- The risk of TB transmission to others\\n- TB preventive therapy to prevent TB disease'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## TB Transmission in Healthcare Settings\\n\\nHealthcare settings can facilitate the transmission of TB, particularly among vulnerable individuals like PLHIV. Therefore, all healthcare facilities should develop and implement TB infection control guidelines to minimize the risk of TB transmission between patients, visitors, and staff.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## TB Screening for PLHIV: Intensified Case Finding (ICF)\\n\\nTB screening and prevention services should be conducted at every clinical visit. Symptom-based TB screening using the Intensified Case Finding (ICF) tool must be performed to rule out active TB. Patients who screen positive (presumptive TB cases) must complete definitive diagnostic pathways, while those who screen negative should be evaluated for TB Preventive Therapy (TPT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## Active Case Finding (ACF) vs. Intensified Case Finding (ICF)\\n\\nActive Case Finding (ACF) differs from ICF. While ICF refers to TB screening conducted among PLHIV, ACF involves special efforts made by the National Tuberculosis Program (NTP) or other partners. ACF extends beyond passive TB case finding at health facilities and actively reaches underserved or higher-risk communities to provide access to care, including screening and testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nThis section outlines the strategies employed to prevent the transmission of HIV, syphilis, and hepatitis B from mothers to their infants.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age\\n\\nThis section provides specific dosing guidelines for antiretroviral drugs for infants based on age and weight.\\n\\n### Age/Weight Dosing Guidelines:\\n- **Birth to 6 weeks**\\n  - Birth weight < 2,000 g: NVP 2 mg/kg per dose (OD), AZT 4 mg/kg per dose (BD)\\n  - Birth weight 2,000 - 2,499 g: NVP 10 mg (1 ml) (OD), AZT 10 mg (1 ml) (BD)\\n  - Birth weight ≥ 2,500 g: NVP 15 mg (1.5 ml) (OD), AZT 15 mg (1.5 ml) (BD)\\n\\n- **> 6 weeks to 12 weeks of age**\\n  - Any weight: NVP 20 mg (2 ml) (OD), AZT 60 mg (6 ml) (BD)\\n\\n*Note: Dose adjustment is required once the child reaches 6 weeks of age. Older infants beyond 6 weeks identified as HIV-exposed should receive AZT+NVP for 6 weeks, continued NVP + cotrimoxazole until 6 weeks after complete cessation of breastfeeding.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Dosing of NVP for Infant Prophylaxis beyond 12 Weeks of Age\\n\\nThis section specifies the dosing of NVP for infants based on their age beyond 12 weeks.\\n\\n### Dosing Guidelines:\\n- **12 weeks – 6 months:** NVP 25 mg (2.5 ml) (OD)\\n- **7 months – 9 months:** NVP 30 mg (3 ml) (OD)\\n- **10 months – 12 months:** NVP 40 mg (4 ml) (OD)\\n- **> 12 months:** Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform)\\n\\n*Note: If a child presents late and needs AZT and NVP beyond 12 weeks of age, follow the above dosing guidelines.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Dosing of AZT for Infant Prophylaxis beyond 12 Weeks of Age\\n\\nThis section outlines the dosing for AZT syrup for infants exceeding 12 weeks of age, categorized by weight.\\n\\n### Dosing Guidelines:\\n- **3.0-5.9 kg:** AZT 6 ml (BD)\\n- **6.0-9.9 kg:** AZT 9 ml (BD)\\n- **10.0 -13.9 kg:** AZT 12 ml (BD)\\n- **14.0 -19.9 kg:** AZT 15 ml (BD)\\n\\n*Note: Similar to NVP, if a child presents late and requires AZT and NVP beyond 12 weeks of age, follow the above dosing instructions.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Infant and Young Child Nutrition in the Context of HIV\\n\\nThis section discusses recommended nutritional practices for infants in the context of HIV management.\\n\\n### Key Points:\\n- **Exclusive breastfeeding:** It is recommended to give the baby only breast milk with no other liquids (including water) or solids for the first six months. Vitamins and mineral supplements are permitted if prescribed.\\n  \\n- **Mixed feeding:** This practice involves providing other liquids and/or foods along with breast milk to infants under 6 months and is not recommended. Mixed feeding during this period increases the risk of mother-to-child HIV transmission and other health issues, such as diarrheal and respiratory illnesses, and should be avoided.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nThis section covers the interaction between tuberculosis (TB) and HIV, highlighting the relevance of co-infection in treatment and prevention strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Drug Susceptible TB Treatment Regimen\\n\\n### Recommended Regimen for Different TB Disease Categories\\n\\n**Intensive Phase:**\\n- All forms of TB except TB meningitis, bone, and joint TB (osteoarticular TB): 2 RHZE\\n- TB meningitis: 2 RHZE\\n- Osteoarticular TB: 2 RHZE\\n- Drug-resistant TB: Refer to a DRTB Clinical Team\\n\\n**Continuation Phase:**\\n- All forms of TB except TB meningitis, bone, and joint TB: 4 RH\\n- TB meningitis: 10 RH\\n- Osteoarticular TB: 10 RH'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Monitoring and Follow-Up\\n\\n### Follow-Up Smears\\n- Follow-up smears should be conducted for all bacteriologically confirmed pulmonary TB cases at the end of month 2, 5, and 6 of TB treatment using smear microscopy.\\n- Monitoring for RR TB and DR TB should follow PMDT guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Additional Treatment Considerations\\n\\n### Pyridoxine (Vitamin B6) Supplementation\\n- Patients taking a regimen containing isoniazid should receive Pyridoxine (Vitamin B6) daily throughout treatment to mitigate the risk of developing peripheral neuropathy (refer to Annex 10 for dosing guidelines).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Treatment Adherence\\n\\n### Importance of Completing TB Treatment\\n- Once TB treatment is initiated, it is crucial to complete the regimen unless another definitive diagnosis, such as lung cancer, is confirmed and TB is excluded.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nThis section provides a general understanding of TB/HIV co-infection and its implications for patient management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Clinical Review Process\\n\\nIf a patient presents with any signs and symptoms indicative of TB, they require a clinical review. If no symptoms are present, the following steps should be taken:\\n\\n1. Take a comprehensive history and conduct a thorough examination.\\n2. Decide on classification as a presumptive TB case.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Presumptive TB Case Assessment\\n\\nThis section focuses on evaluating if the client/patient is classified as a presumptive TB case. \\n\\n- **Is a sample available for TB testing?**\\n  - If yes, consider evaluating and managing for other conditions.\\n  - Consider TB preventive therapy (TPT) per LTBI guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Testing Facilities Assessment\\n\\nThis section outlines the steps based on the availability of testing facilities.\\n\\n1. **GeneXpert Availability**\\n   - If available, consider a chest X-ray (CXR).\\n   - Consider clinical diagnosis of TB.\\n   \\n2. **Smear Microscopy Availability**\\n   - If available, collect a sample for GeneXpert.\\n   - Evaluate TB LAM testing for eligible PLHIV.\\n     - If positive, initiate DS TB treatment and review once GeneXpert results are received.\\n     - Note: A negative TB LAM test does not rule out TB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Sample Collection Protocols\\n\\nDetails on sample collection procedures based on the availability of testing facilities.\\n\\n- If smear microscopy is positive, initiate DS TB treatment and review the patient with GeneXpert results.\\n- If GeneXpert is not available, collect and refer a sample for GeneXpert.\\n- Evaluate TB LAM for eligible PLHIV accordingly.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## GeneXpert and TB LAM Testing\\n\\nFocused on interpreting the results from GeneXpert and TB LAM tests.\\n\\n- Recognize and evaluate symptoms such as:\\n  1. Unintended weight loss\\n  2. Chest pain\\n  3. BMI less than 18.5 or Z score -21\\n  4. Cough of any duration\\n  5. Hotness of body\\n  6. Drenching night sweats\\n\\n- Guidelines on interpreting initial tests:\\n  - Positive TB LAM test: Initiate DS TB treatment.\\n  - Negative TB LAM test: Does not rule out TB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## TB-LAM Overview\\n\\nTB-LAM is a rapid point-of-care urine dip-stick test that can be performed at the bedside. LAM stands for lipoarabinomannan, which can be detected in urine when it sheds off of the TB cell wall. GeneXpert is the recommended initial diagnostic test for people with presumptive TB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Use of TB-LAM in Diagnosis\\n\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert but can be performed to help diagnose TB while waiting for GeneXpert test results. TB-LAM cannot detect resistance to rifampicin.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Indications for Use of TB-LAM\\n\\nTB-LAM is indicated for use as an adjunct test to GeneXpert in the following scenarios:\\n- PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count < 350 cells/mm3 for adults or < 500 cells/mm3 for children).\\n- PLHIV presenting any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, heart rate >120 beats per minute, or unable to walk unaided.\\n- Currently admitted to the hospital.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Interpretation of TB-LAM Results\\n\\n### LF-LAM Negative\\n\\n- TB is not ruled out.\\n- Evaluate the clinical response after 3–5 days of antibiotic treatment while awaiting GeneXpert results: \\n  - TB is likely: Initiate TB treatment and conduct additional investigations for TB and other HIV-related diseases.\\n  - Clinical improvement: Continue TB treatment even if GeneXpert results come back negative.\\n  - Clinical worsening or no improvement: TB is unlikely. Conduct additional investigations for TB and other opportunistic illnesses and complete the course of parenteral antibiotics.\\n\\n### LF-LAM Positive\\n\\n- TB is likely: \\n  - Initiate TB treatment.\\n  - Conduct additional investigations for TB and other HIV-related diseases.\\n  - Complete the course of parenteral antibiotics.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Response to GeneXpert Results\\n\\n- If GeneXpert results are positive for TB, initiate TB treatment irrespective of TB-LAM results or clinical improvement.\\n- If GeneXpert results are negative for TB, consider TB preventive therapy (TPT).\\n- Start TB treatment if the patient is seriously ill or if GeneXpert results come back positive, irrespective of TB-LAM results.\\n- Conduct additional investigations for TB and other HIV-related diseases, and complete the course of parenteral antibiotics.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Introduction to Guidelines\\n\\nOverview of the Kenya HIV Prevention and Treatment Guidelines for 2022, focusing on the management of drug-resistant tuberculosis (DR TB) and evaluation protocols.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## GeneXpert Test Results\\n\\nDetails on interpreting GeneXpert results, including:\\n- MTB Detected\\n- Rifampicin Resistance Detected (RR)\\n- Rifampicin Resistance not Detected (TR)\\n- MTB Not Detected (N)\\n- Indeterminate Results (TI)\\n- Trace/Invalid/Error Results'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Protocol for Rifampicin Resistance Detected \\n\\nSteps to follow when Rifampicin resistance is detected in the test results:\\n1. Collect a sample for FL & SL LPA, culture, and 1st and 2nd line DST.\\n2. Conduct baseline workup for DR TB treatment.\\n3. Comprehensive review by a DR TB clinical review team.\\n4. Start DR TB treatment as per guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Protocol for Patients at High Risk of DR TB\\n\\nManagement for patients identified at high risk for DR TB:\\n1. Collect sample for FL & SL LPA, culture, and 1st and 2nd line DST.\\n2. Initiate DS TB treatment while awaiting DST results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Protocol for Patients at Low Risk of DR TB\\n\\nGuidelines for managing patients at low risk for DR TB:\\n1. Start DS TB treatments.\\n2. If already under treatment (smear positive), continue until further test results are reviewed.\\n3. Evaluate potential NTM if smear positive but MTB not detected.\\n4. Conduct patient assessment for other respiratory illnesses and necessary imaging tests.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Management of Indeterminate and Positive MTB Results\\n\\nGuidance for handling indeterminate results or where MTB is detected:\\n1. Treat as DS TB.\\n2. Collect another sample for repeat GeneXpert (Ultra) test.\\n3. Send samples for FL & SL LPA, culture, and 1st and 2nd line DST.\\n4. Adjust treatment regimen based on DST results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Follow-Up Protocols\\n\\nFollow-up actions mandated during DR TB treatment:\\n1. Clinical improvement assessment.\\n2. Regular smear microscopy at months 2/3, 5, and 6.\\n3. If drug resistance is detected, transition to DR TB treatment per guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Revise Treatment Based on DST Results\\n\\nProcess for revising treatment plans based on Drug Susceptibility Testing (DST) results, including team-based adjustments to regimens as necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Conclusion and Further Evaluations \\n\\nEncouragement for continuous clinical evaluations and adjustments based on patient responses and ongoing assessments throughout the treatment period. Ensured follow-up meetings and requisite evaluations for optimal patient management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## Introduction to HIV Prevention and Treatment in Kenya\\n\\nThis document outlines the Kenya HIV Prevention and Treatment Guidelines published in 2022, focusing on the necessary protocols for managing HIV in infants and mothers, specifically regarding antiretroviral (ARV) prophylaxis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': \"## ARV Prophylaxis for HIV-Exposed Infants\\n\\n### Infant Prophylaxis Protocol \\n- HIV exposed infants should receive:\\n  - AZT + NVP for 6 weeks\\n  - NVP + cotrimoxazole should continue until 6 weeks after complete cessation of breastfeeding\\n  - Discontinuation of infant prophylaxis can occur after a minimum of 12 weeks on NVP if the child is not breastfeeding (due to mother's death or separation).\\n  \\n### Testing Recommendations\\n- Perform DBS or whole blood for PCR at 6 weeks or first contact, following the EID algorithm (Figure 2.1).\\n- Birth testing may be conducted in medically indicated cases where point of care has been implemented (Figure 2.2).\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## Maternal Scenarios for HIV Management\\n\\n### If the Mother is Not on ART\\n- Initiate ART as soon as possible, preferably on the same day.\\n\\n### If the Mother is on ART\\n- For mothers on ART for ≥ 3 months with a viral load (VL) of ≥ 50 copies/ml:\\n  - Intensify adherence measures and repeat the VL.\\n- If VL < 50 copies/ml, continue the current regimen.\\n- Follow the Viral load algorithm (Figure 6.6).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## Triple Elimination Conditions Management\\n\\n### Syphilis Management\\n- Administer crystalline penicillin for suspected congenital syphilis.\\n  - 50,000 IU/kg BD if <7 days old, or TDS if >7 days old for a total of 10 days.\\n  - Alternatives include Penicillin G (2.4 MU IM Stat) or Ceftriaxone (1 gm IM daily for 8-10 days in case of penicillin allergy).\\n\\n### Hepatitis B Management\\n- Perform HbsAg test.\\n- Administer Hepatitis B immunoglobulin (0.5ml IM) within 12 hours after birth, followed by three doses of Hepatitis B vaccine at birth, 1 month, and 6 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## Management of Infants with Specific Conditions\\n\\n### Contraindications for HIV Prophylaxis\\n- If the infant cannot tolerate NVP or AZT, administer an alternative tolerated drug until breastfeeding ceases.\\n- For infants on AZT prophylaxis, continue for a minimum of 12 weeks or until the maternal viral load is suppressed.\\n- If neither AZT nor NVP are tolerated, consider 3TC as a third option if available.\\n\\n### TB Infection Protocol\\n- For HIV-exposed infants with TB infection, use AZT plus 3TC fixed dose (60/30 mg) for 12 weeks or until maternal VL is suppressed.\\n- After TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding.\\n- Monitor HB in all HIV-exposed infants on AZT prophylaxis (Table 6.7 management recommendations).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## High-Risk Groups for Mother-to-Child Transmission\\n\\n### Identifying High-Risk Mothers\\n- Higher risk groups include:\\n  - All new HIV positives regardless of detection time.\\n  - HIV positive adolescent girls and young women (AGYW) <19 years, including orphaned and vulnerable children (OVC).\\n  - Mothers with VL >200 copies/ml.\\n  - Clients facing stigma, poor adherence, and declining treatment.\\n  - Mothers with prior HIV infected infants and active comorbidities (e.g., diabetes, opportunistic infections, malnutrition, mental health issues).\\n  - Those who sero-convert during ANC/PNC follow-up.\\n  - Individuals facing poor socio-economic and family support.\\n  - Key populations such as female sex workers (FSW) and persons who inject drugs (PWID).\\n  \\n### Additional Support Requirements\\n- These groups may require extra adherence and psychological support due to their circumstances, such as alcohol use or involvement in risky activities.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 181,\n",
       "  'section': '## Contraindications to TPT\\n\\nPatients with the following conditions should not receive Tuberculosis Preventive Therapy (TPT) until the underlying issues are addressed:\\n- Active tuberculosis disease\\n- Active hepatitis (acute or chronic)\\n- Chronic alcohol abuse\\n- Symptoms of peripheral neuropathy'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 181,\n",
       "  'section': '## Dose and Duration of TPT\\n\\n### Recommended TPT Regimens for PLHIV\\n\\n**Target populations and corresponding TPT Regimens:**\\n- **Adult PLHIV excluding patients on PI/r-based ARV regimens:**  \\n  Rifapentine and Isoniazid (3HP)  \\n  Dosage: Once weekly for three months (12 doses)\\n\\n- **Adult PLHIV on PI/r-based ARV regimens, all CALHIV aged below 15 years, any patient with intolerance or contraindication to 3HP, and pregnant women:**  \\n  Isoniazid (6H)  \\n  Dosage: Once daily for 6 months\\n\\n### Important Notes\\n- The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due to drug-drug interactions. 3RH is used in HIV-negative populations.\\n- All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to reduce the risk of developing peripheral neuropathy.\\n- Comprehensive health education and adherence counseling should be conducted prior to initiation of TPT.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 181,\n",
       "  'section': '## Dosing Guidelines\\n\\n- Children should be weighed at each visit, and correct weight-based dosing must be confirmed.\\n- Clients on 3HP should receive a weekly dose of pyridoxine; those on the Rifapentine and Isoniazid regimen should be given pyridoxine once a week.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## TB Diagnosis in Children Under 10 Years Old\\n\\nThis section outlines the algorithm for diagnosing pulmonary TB in children. It includes the initial assessment, clinical evaluation, and the necessary investigations.\\n\\n### History of Presenting Illness\\nFor all children presenting to a health facility, ask for the following suggestive symptoms:\\n- Cough\\n- Fever\\n- Poor weight gain\\n- Lethargy or reduced playfulness\\n\\n**Suspect TB** if the child has two or more of these suggestive symptoms and has a history of contact with an adult/adolescent with chronic cough or TB within the last 2 years.\\n\\n### Clinical Evaluation\\nExamine the child and check for:\\n- Temperature > 37.5°C (fever)\\n- Weight (to confirm poor weight gain or weight loss using the growth monitoring curve)\\n- Respiratory rate (fast breathing)\\n- Respiratory system examination for abnormalities\\n- Other systems for abnormal signs suggestive of extra-pulmonary TB\\n\\n### Investigations\\nObtain specimens for:\\n- Xpert MTB/RIF (and culture when indicated)\\n- Chest X-ray (where available)\\n- Mantoux test (where available)\\n- HIV test\\n- Other tests to diagnose extra-pulmonary TB where suspected'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## Diagnosis of Tuberculosis\\n\\nThis section describes how to diagnose TB in children based on bacteriological confirmation and clinical signs.\\n\\n### Bacteriologically Confirmed TB\\nDiagnosis is established if the specimen is positive for MTB.\\n\\n### Clinical Diagnosis of Pulmonary TB\\nDiagnosis can also be made if:\\n- The child has two or more suggestive symptoms (persistent cough, fever, poor weight gain, lethargy)  \\nAND  \\n- Two or more of the following: positive contact, abnormal respiratory signs, abnormal positive Mantoux.\\n\\n**Note:** If clinical signs suggest extra-pulmonary TB (EPTB), refer to the EPTB diagnostic table.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## TB Treatment Guidelines\\n\\nThis section outlines the treatment protocols for TB in children based on the diagnosis.\\n\\n### Treatment for TB\\n- Treat all children with bacteriologically confirmed TB.\\n- Treat all children with a clinical diagnosis of TB.\\n\\n**Important Note:** In children who do not have an Xpert result or whose Xpert result is negative but have clinical signs and symptoms suggestive of TB, they should still be treated for TB.\\n\\n### Treatment Duration\\n- **All forms of TB (except TB meningitis, bone, and joint TB):** Treat for 6 months (2 RH ZE/ 4 RH).\\n- **TB meningitis and bone and joint TB:** Treat for 12 months (2 RHZE/ 10 RH).\\n\\n**Specimen Collection:** Attempt to obtain specimens from every child, which may include expectorated sputum (for children > 5 years), induced sputum, nasopharyngeal aspirate, and gastric aspirate.\\n\\n### Culture and Drug Susceptibility Testing (DST)\\nPerform a culture and DST for:\\n1. Rifampicin resistance detected by the Xpert test.\\n2. Refugees and children in contact with anyone who has Drug Resistant TB.\\n3. Those not responding to TB treatment.\\n4. Those with indeterminate Xpert results.\\n\\n***Note:** This may include IGRA in facilities where it is available.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## Classification of TB Severity\\n\\nUse the Integrated Management of Childhood Illness (IMCI) guidelines to classify the severity of TB disease in pediatric patients. This classification will help guide treatment decisions and resource allocation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Overview of Kenya HIV Prevention and Treatment Guidelines\\n\\nThe Kenya HIV Prevention and Treatment Guidelines, 2022, provide a comprehensive framework for the prevention, diagnosis, and management of HIV in the country. These guidelines are designed to ensure a consistent and effective response to the HIV epidemic and cater to diverse populations and age groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## HIV Prevention Strategies\\n\\nThis section outlines the various strategies employed to prevent the transmission of HIV. Key methods include:\\n\\n1. **Condom Distribution**: Promotion and distribution of male and female condoms.\\n2. **Pre-Exposure Prophylaxis (PrEP)**: Use of antiretroviral medications by HIV-negative individuals to reduce their risk of infection.\\n3. **Behavioral Interventions**: Programs aimed at changing high-risk behaviors.\\n4. **Needle and Syringe Programs**: Providing sterile injection equipment to people who inject drugs.\\n5. **Education and Awareness**: Community outreach and education to reduce stigma and increase knowledge of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Treatment Protocols\\n\\nThis section details the protocols for the treatment of individuals living with HIV:\\n\\n1. **Antiretroviral Therapy (ART)**: Guidelines on initiating and maintaining ART, including first-line and second-line treatment regimens.\\n2. **Monitoring and Adherence**: Strategies for ensuring adherence to treatment, including regular check-ups and support systems.\\n3. **Managing Co-infections**: Approaches to treat co-infections, such as tuberculosis (TB) and hepatitis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Special Populations\\n\\nThe guidelines address the unique needs of specific populations, including:\\n\\n1. **Pregnant and Breastfeeding Women**: Prevention of mother-to-child transmission (PMTCT) strategies.\\n2. **Key Populations**: Tailored interventions for populations at higher risk, including sex workers, men who have sex with men (MSM), and people who inject drugs (PWID).\\n3. **Children and Adolescents**: Pediatric care considerations and adolescent-specific interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nThis section emphasizes the importance of monitoring and evaluating HIV prevention and treatment efforts:\\n\\n1. **Data Collection**: Guidelines for collecting data on HIV prevalence, treatment uptake, and health outcomes.\\n2. **Impact Assessment**: Measuring the effectiveness of programs to ensure they meet community needs.\\n3. **Quality of Care**: Strategies to maintain high standards in service delivery.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Community Engagement\\n\\nThe guidelines highlight the role of community involvement in HIV response:\\n\\n1. **Community-Based Interventions**: Engaging local organizations in the implementation of prevention and treatment programs.\\n2. **Advocacy and Support**: Promoting the involvement of people living with HIV in leadership and decision-making processes.\\n3. **Reducing Stigma**: Initiatives aimed at addressing stigma and discrimination against those affected by HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Conclusion\\n\\nThe guidelines represent a critical step in the fight against HIV in Kenya, providing an evidence-based approach to prevention, treatment, and care. Stakeholders are encouraged to adopt these recommendations to enhance the efficacy of HIV interventions and improve overall health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nThis section provides an overview of TB (Tuberculosis) and HIV co-infection, including the importance of proper management and prevention strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Diagnostic Tests and Techniques\\n\\nThis segment discusses various tests for TB diagnosis, including GeneXpert, chest X-rays, and additional diagnostic procedures. It highlights the samples recommended for use in TB diagnostics.\\n\\n- **Footnote 1**: Samples for GeneXpert include sputum, CSF, pleural aspirate, peritoneal fluid, synovial fluid, gastric aspirate, nasopharyngeal aspirate, FNA, lymph node biopsy, pus, stool.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## TB-LAM Indications\\n\\nThis section outlines the indications for using the TB-LAM test as an adjunct to GeneXpert in patients living with HIV (PLHIV).\\n\\n- **Indications**:\\n  - PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count <200 cells/mm³).\\n  - PLHIV showing severe illness signs (e.g., high respiratory rate, temperature, heart rate, inability to walk).\\n  - Those currently admitted to the hospital.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## High-Risk and Low-Risk Groups for Drug-Resistant TB\\n\\nThis segment identifies the criteria for high-risk and low-risk classifications for drug-resistant TB (DR TB).\\n\\n- **High Risk for DR TB**:\\n  1. Previously treated TB patients.\\n  2. Contacts of drug-resistant TB patients.\\n  3. TB patients with a positive smear result at month 2 or 5 of treatment.\\n  4. Symptoms while on IPT (isoniazid preventive therapy).\\n  5. Healthcare workers with TB symptoms.\\n  6. Prisoners with TB symptoms.\\n  7. Refugees with TB symptoms.\\n  \\n- **Low Risk for DR TB**:\\n  - All presumptive TB cases not in the high-risk category.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Management of Positive Smear Results\\n\\nThis section details the actions to take for patients with positive smear results at various treatment stages.\\n\\n- **Month 2/3 Actions**:\\n  - Evaluate adherence and request drug susceptibility tests.\\n  - Continue with RHZE (rifampicin, isoniazid, pyrazinamide, ethambutol) for one more month.\\n  \\n- **Month 5 or 6 Actions**:\\n  - Declare treatment failure and stop anti-TB treatment.\\n  - Request necessary diagnostic tests and review results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Follow-up Protocol for Drug Susceptibility Testing (DST)\\n\\nThis segment discusses the follow-up procedures for smear-positive or culture-positive patients and their treatment management.\\n\\n- **Actions for Smear Positive or Culture Positive at Months 3 or Later**:\\n  - Evaluate adherence and request DST.\\n  - Do not proceed to the continuation phase without a DST confirming susceptibility.\\n  - Declare treatment failure if necessary and send case summaries to the national clinical team.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Key Terminology and Abbreviations\\n\\nThis section provides definitions and explanations for key terms and acronyms used throughout the document.\\n\\n- CBR - Chest X-ray\\n- DR TB - Drug Resistant TB\\n- DS TB - Drug Susceptible TB\\n- DST - Drug Susceptibility Testing\\n- EPTB - Extra Pulmonary TB\\n- FL - First Line\\n- LPA - Line Probe Assay\\n- MTB - Mycobacteria Tuberculosis\\n- NTM - Non-Tuberculous Mycobacteria\\n- TST - Tuberculin Skin Test\\n- SL - Second Line'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Conclusion\\n\\nThis section summarizes the critical aspects of TB/HIV co-infection management, highlights the importance of timely diagnosis, and emphasizes the need for adherence to treatment protocols.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## TB/HIV Co-infection: Prevention and Management\\n\\nThis section addresses the strategies for preventing and managing TB in patients co-infected with HIV, focusing on the importance of TPT (TB preventive treatment).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## Follow-up of Patients on TPT\\n\\nPatients on TPT should be followed up on a monthly basis and their return-to-clinic dates harmonized with any other routine schedules. During each clinic visit, conduct the following:\\n\\n- Symptom screening for active TB disease and update status.\\n- Assess and reinforce adherence to treatment.\\n- If a patient screens positive for TB while on TPT, stop TPT and manage according to National TB guidelines.\\n- Assess for any adverse drug reactions at each visit and intervene appropriately.\\n- Provide/update TPT appointment card.\\n- Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, Contact Management/TPT register.\\n- Document outcome of TPT use e.g., completion in the relevant tools and/or EMR.\\n\\n*Baseline liver function tests are not mandatory for patients initiating TPT. However, these may be considered on an individual basis, especially for patients taking other medications for chronic medical conditions or those suspected of having active hepatitis.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## Identifying and Managing Drug Toxicities from TPT\\n\\nThe management of drug toxicities should be based on severity, with appropriate grading of individual patients. The most common adverse drug reactions associated with TPT are peripheral neuropathy, drug-induced liver injury (DILI), and rash.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## Peripheral Neuropathy - Suspected Drug: INH\\n\\n### Diagnosis of Peripheral Neuropathy\\n\\n- Symptoms include burning sensation, numbness, or tingling, usually starting at the feet on both sides.\\n- May have decreased sensation on examination.\\n- May develop weakness in severe cases.\\n- Symptoms may be potentiated by other neurotoxic drugs, alcoholism, metabolic diseases (e.g., diabetes), malnutrition, and infections.\\n- Rarely severe enough to require drug withdrawal.\\n\\n### Management of INH-induced Peripheral Neuropathy\\n\\n- Increase the dose of pyridoxine to 100 mg per day.\\n- For children, give double the standard weight-based dose.\\n- Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 deficiency, syphilis, etc.).\\n- Relief of symptoms can be achieved with analgesics, tricyclic antidepressants (amitriptyline, nortriptyline), and anticonvulsants (carbamazepine, phenytoin).\\n- If symptoms do not improve, or there is any worsening, then discontinue TPT. Symptoms may persist even after discontinuing TPT.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Kenya HIV Prevention Guidelines\\n\\nThis section outlines the strategies and recommendations for preventing HIV transmission in Kenya. It includes information on safe sex practices, the use of condoms, pre-exposure prophylaxis (PrEP), and education initiatives aimed at high-risk populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Kenya HIV Treatment Guidelines\\n\\nThis section details the treatment protocols for individuals diagnosed with HIV in Kenya. It covers antiretroviral therapy (ART), treatment initiation criteria, adherence strategies, and regular monitoring for viral load and CD4 counts.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## HIV Testing and Counseling\\n\\nThis section provides information on the guidelines for HIV testing and counseling in Kenya. It discusses the types of tests available, the importance of confidentiality, informed consent, and post-test counseling for individuals.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Special Populations\\n\\nThis section addresses the unique considerations for specific populations affected by HIV in Kenya, such as men who have sex with men (MSM), sex workers, and adolescents. It details tailored interventions and support mechanisms for these groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Stigma and Discrimination\\n\\nThis section highlights the challenges of stigma and discrimination faced by people living with HIV in Kenya. It discusses strategies for community engagement, awareness campaigns, and the importance of supportive legal frameworks to reduce stigma.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nThis section covers the protocols for monitoring and evaluating HIV prevention and treatment programs in Kenya. It includes indicators for success, reporting mechanisms, and the importance of data collection for policy-making.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': \"## Drug-Induced Liver Injury (DILI) Overview\\n\\nDrug-Induced Liver Injury (DILI) is a potential adverse effect associated with certain medications, with suspected drugs including Isoniazid (H), Rifapentine (P), and Rifampicin (R). It's important to recognize the symptoms and manage liver health in patients undergoing treatment.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Monitoring Liver Function\\n\\n- **Elevations in Liver Enzymes**: These may occur in the initial weeks of treatment.\\n- **Routine Monitoring**: In asymptomatic patients, serum liver enzyme levels do not require routine monitoring.\\n- **Assessment for Symptoms**: Clients presenting with gastrointestinal symptoms such as nausea, vomiting, liver tenderness, hepatomegaly, or jaundice should undergo liver function assessments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Diagnosis of DILI\\n\\nDiagnosis can be established through clinical symptoms and laboratory findings:\\n- **Symptoms**: Jaundice, abdominal pain, nausea, vomiting, anorexia, etc.\\n- **Laboratory Testing**: The presence of abnormal liver enzymes is indicative of potential DILI.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Grading and Management of DILI\\n\\n### Table 8.4: Grading of Liver Injury\\n\\n| Grade | ALT (SGPT) Levels      | AST (SGOT) Levels      | Recommended Actions                                                                                                                                           |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '--|\\n| 1     | 1.25 – 2.5 x ULN     | 1.25 – 2.5 x ULN     | Continue treatment regimen; weekly follow-up until resolution or stabilization of AST/ALT elevation.                                                         |\\n| 2     | 2.6 – 5.0 x ULN      | 2.6 – 5.0 x ULN      | Continue treatment regimen; weekly follow-up until resolution or stabilization of AST/ALT elevation.                                                         |\\n| 3     | 5.1 – 10.0 x ULN     | 5.1 – 10.0 x ULN     | Stop all drugs, including TPT drugs; measure liver function tests (LFTs) weekly; TPT should not be reintroduced after severe DILI.                       |\\n| 4     | > 10.0 x ULN         | > 10.0 x ULN         | Stop all drugs, including TPT drugs; measure LFTs weekly; TPT should not be reintroduced after life-threatening DILI.                                      |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Reintroduction of Medications\\n\\nPatients living with HIV (PLHIV) who experience DILI during active tuberculosis (TB) treatment may have anti-TB medications reintroduced after toxicity is resolved, and this should be done in consultation with a senior clinician.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 187,\n",
       "  'section': '## Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART\\n\\nThis section outlines the recommended antiretroviral therapy (ART) regimens for patients with HIV who develop tuberculosis (TB) while on first-line ART.\\n\\n**1. Patients Under 30 kg Body Weight**  \\n- First-line ART: LPV/r-based\\n- Immediate Action: Start anti-TB treatment.\\n- Change to DTG-based second-line treatment immediately.\\n- Increase DTG dosing frequency to twice daily during rifampicin-containing TB treatment and for an additional 2 weeks after TB treatment is completed, then revert to once daily dosing.\\n- Collect a sample for drug resistance testing (DRT).\\n- Assess and address reasons for treatment failure.\\n- If unable to switch to DTG, use super-boosted LPV/r.\\n\\n**2. Patients 30 kg or Older or 15 Years and Older**  \\n- First-line ART: TDF (or ABC or AZT) + 3TC + DTG\\n- Immediate Action: Start anti-TB treatment.\\n- Administer TDF/3TC/DTG FDC in the morning and DTG 50 mg in the evening during rifampicin-containing TB treatment and for an additional 2 weeks after TB treatment. Revert to TDF/3TC/DTG FDC once daily.\\n- Follow viral load monitoring algorithm and assess treatment failure reasons.\\n- Consult the Regional or National Technical Working Group (TWG) for a second-line regimen based on DRT results.\\n\\n**3. Alternative First-Line Regimens**  \\n- TDF (or ABC or AZT) + 3TC + EFV\\n  - Start anti-TB immediately.\\n  - Continue current regimen, following the viral load monitoring algorithm.\\n  - Once treatment failure is confirmed, switch to TDF + 3TC + DTG, maintaining TDF and increasing DTG dose to twice daily for the duration of rifampicin-based TB therapy.\\n\\n- PI/r-based First-Line\\n  - Start anti-TB immediately.\\n  - Switch to TDF+3TC+DTG immediately, maintaining a similar dosing schedule as stated above.\\n  - Collect a sample for DRT and assess treatment failure reasons.\\n\\n**4. Special Considerations**  \\n- **Pregnant or Breastfeeding**: Follow the same recommendations as for patients ≥ 30 kg or ≥ 15 years old.\\n- **HIV/HBV Co-infection**: Always maintain TDF or TAF in the second-line treatment instead of switching to a different NRTI.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 185,\n",
       "  'section': '## Introduction to HIV and TB Co-infection Management\\n\\nThis section outlines the basic considerations for managing patients who are co-infected with HIV and tuberculosis (TB), emphasizing the need for immediate and coordinated treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 185,\n",
       "  'section': '## Immediate Actions for Patients on ART\\n\\nPatients who are already on antiretroviral therapy (ART) and diagnosed with TB should take the following immediate actions:\\n\\n- Start TB treatment immediately.\\n- Continue ART while assessing for treatment failure and adjusting the ART regimen based on drug-drug interactions (see Table 8.7).\\n- Closely monitor for Immune Reconstitution Inflammatory Syndrome (IRIS) as outlined in Annex 16.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 185,\n",
       "  'section': '## Monitoring Requirements for TB and HIV Treatment\\n\\nPatients being treated concurrently for TB and HIV need careful monitoring for potential toxicity. This management is especially critical for those with multi-drug resistant (MDR) TB, which should be managed in settings with experienced clinicians or multidisciplinary teams.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 185,\n",
       "  'section': '## Preferred ART Regimens for TB/HIV Co-infection\\n\\nThis section summarizes the preferred ART regimens for patients with TB/HIV co-infection, detailing specific recommendations based on age and weight categories.\\n\\n### Recommended Regimens for Various Age and Weight Groups\\n\\n- **Birth to 4 weeks**:\\n  - Start anti-TB treatment immediately.\\n  - Begin ART after 4 weeks of age, assuming toleration of anti-TB drugs.\\n  \\n- **Ages over 4 weeks to under 15 years**:\\n  - **Weight < 30 kg**: \\n    - ABC + 3TC + DTG; increase DTG dosing to twice daily during rifampicin-containing TB treatment and for an additional 2 weeks thereafter.\\n\\n  - **Weight ≥ 30 kg**: \\n    - TDF/3TC/DTG FDC in the morning + DTG 50mg in the evening for the duration of rifampicin-containing TB treatment and for an additional 2 weeks thereafter.\\n\\n- **Ages 15 years and older**:\\n  - Regardless of weight: \\n    - TDF/3TC/DTG FDC in the morning + DTG 50mg in the evening for the duration of rifampicin-containing TB treatment and for two weeks thereafter.\\n\\nNote: Refer to Annex 10 for weight-based ARV dosing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '## TB/HIV Co-infection, Prevention and Management\\n\\nOverview of TB/HIV co-infection management and prevention strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '## HBV/HIV and HCV/HIV Co-infection Prevention and Management\\n\\nInformation about the co-infection of Hepatitis B (HBV) and Hepatitis C (HCV) with HIV, including their implications for health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '## Hepatitis B/HIV Co-infection\\n\\nDetails on the relationship between HIV and Hepatitis B virus (HBV), including transmission routes and complications associated with co-infection.\\n\\n### Implications of HIV/HBV Co-infection\\n\\n- Increased risk of chronicity in acute HBV infection for HIV positive individuals.\\n- Reduced chances of spontaneous HBV clearance.\\n- Higher rates of replication and reactivation of HBV.\\n- Increased incidence of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).\\n- Association with rapid HIV disease progression and poorer treatment outcomes.\\n- Other complications: drug-related hepatotoxicity, drug-drug interactions, ART-related immune reconstitution hepatitis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '## Screening for HBV in HIV Patients\\n\\nGuidelines for screening HIV positive individuals for HBV infection.\\n\\n### Recommendations\\n\\n- All adolescents and adults living with HIV should be screened for HBV infection using HBsAg.\\n- Routine screening should include children who did not complete childhood immunizations.\\n- Population-wide prevention should integrate hepatitis B prevention into HIV care programs.\\n\\n### Specific Indications for HBsAg Screening\\n\\n- Household and sexual contacts of HBsAg positive individuals.\\n- Pregnant women.\\n- Persons who inject drugs (PWID).\\n- Men who have sex with men.\\n- Sex workers.\\n- Individuals with multiple sexual partners.\\n- Prisoners.\\n- Blood donors.\\n- Unvaccinated healthcare providers.\\n\\n### Additional Screening Criteria \\n\\nPLHIV presenting with signs of liver disease or unexplained persistent ALT elevation should also be screened for HBV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '## Prevention of HBV in HIV Patients\\n\\nStrategies for preventing HBV infection in HIV positive individuals.\\n\\n### Vaccination Recommendations\\n\\n- HBV vaccination is crucial for reducing new HBV infections in PLHIV.\\n- Vaccination is recommended for:\\n  - HIV positive infants, children, adolescents, and adults without evidence of hepatitis B infection (HBsAg negative).\\n  - HIV exposed infants (HEI) as part of childhood immunization.\\n- It is essential to integrate HBV prevention through vaccination in HIV care settings to reduce population-level burden of HBV infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## TB/HIV Co-Infection Overview\\n\\nThis section provides a general understanding of co-infection between tuberculosis (TB) and HIV, highlighting the importance of managing both conditions simultaneously due to their interactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## Preferred ART Regimens for TB Patients\\n\\nThis section outlines the preferred Antiretroviral Therapy (ART) regimens for patients who develop TB while virally suppressed on first-line ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## PI/r-Based Regimens\\n\\nThis section describes the recommended substitutions for patients on PI/r-based ART who develop TB, including guidance on dosage and recommendations for children and adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## RAL-Based Regimens\\n\\nThis section explains the recommended approach for patients on RAL-based ART, detailing the necessary adjustments during and after TB treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## DTG-Based Regimens\\n\\nThis section covers the guidelines for patients on DTG-based ART, providing instructions for dosing adjustments during TB treatment and reverting to standard dosing afterward.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## Considerations During ART for TB Patients\\n\\nThis section emphasizes the need to assess for HIV treatment failure in patients developing TB while on ART for six months or longer, along with referral guidelines for second-line regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## Drug Interaction Management\\n\\nThis section addresses the management of drug interactions, particularly focusing on the use of “super-boosted” LPV/r in conjunction with rifampicin-based TB therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## Additional Resources and Support\\n\\nThis section provides contact information for further guidance, including hotlines and web resources for clinical support concerning HIV and TB co-infection management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 188,\n",
       "  'section': '## TB/HIV Co-infection Management\\n\\nFor patients on 2nd line ART who require a regimen change due to TB treatment, consult the Regional or National HIV Clinical Technical Working Group (TWG) using the Uliza Hotline: 0726 460 000 or through the provided link: [NASCOP Clinical Form](https://nhcsc.nascop.org/clinicalform).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 188,\n",
       "  'section': '## Drug Interaction Guidance\\n\\nIn cases of drug intolerance or nonstandard drugs requiring a regimen change because of TB treatment, immediate contact with the Regional or National HIV Clinical TWG is advised to ensure proper guidance and management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 188,\n",
       "  'section': '## Urgent DRT Sample Collection\\n\\nFor urgent collection of DRT samples in patients co-infected with TB and HIV, reach out to the Regional or National HIV Clinical TWG via the Uliza Hotline: 0726 460 000 or the provided link: [NASCOP Clinical Form](https://nhcsc.nascop.org/clinicalform).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 188,\n",
       "  'section': '## Managing Drug Interactions with LPV/r\\n\\nTo manage the drug interaction between LPV/r and rifampicin, use “super-boosted” LPV/r by adding additional ritonavir. Refer to Annex 10 for specific dosing recommendations. It is important that two weeks after TB treatment is completed, the child should return to standard LPV/r dosing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '## Hepatitis B Vaccination Recommendations\\n\\n### Target Groups for Vaccination\\n- Babies and young children (through EPI and catch-up immunization for missed vaccinations)\\n- Household contacts of HBsAg positive individuals\\n- Sexual contacts of HBsAg positive individuals\\n- People on haemodialysis\\n- People who Inject Drugs (PWID)\\n- Individuals with chronic liver disease and/or hepatitis C\\n- Inmates and prison personnel\\n- Healthcare workers\\n\\n### Vaccination Schedule\\n**Table 9.1: Hepatitis B Vaccination Schedule for HIV-positive Adolescents and Adults**\\n\\n| Vaccine                    | Dose (intramuscular)     | Schedule                     |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '|\\n| Non-adjuvanted formulation | Double the standard dose  | 0, 1, 2, and 6 months         |\\n| Adjuvanted formulation     | Standard dose            | See above                    |\\n\\n*Booster vaccination is not required for persons who have completed the full vaccination schedule.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '## General Preventive Measures\\n\\nGeneral measures for infection prevention adopted by People Living with HIV (PLHIV) and in healthcare settings include:\\n\\n- Hand hygiene\\n- Use of personal protective equipment\\n- Medical waste management, including safe disposal of used sharps\\n- Disinfection and sterilization\\n- General health advice against sharing personal effects like towels, toothbrushes, razors, combs, and other grooming equipment\\n- Harm reduction counselling and services for PWID as outlined in Chapter 12\\n- Safer sex practices'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '## Treatment Recommendations for Co-infection\\n\\n### When to Start Antiretroviral Therapy (ART)\\nAll HIV-infected patients who are co-infected with hepatitis B should start ART irrespective of CD4 cell count, WHO clinical stage, or stage of liver disease.\\n\\n### Monitoring and Support\\n- General recommendations for treatment preparation, adherence counselling, and therapy monitoring for PLHIV apply.\\n- However, because HBV-positive patients are at higher risk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised.\\n\\n**Table 9.2: Initial Evaluation Focus Areas for HIV/HBV Co-infected Patients Initiating Therapy**\\n- Summary of areas of focus during initial evaluation for patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nThis section introduces TB/HIV co-infection, highlighting its significance and the need for comprehensive management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## Recommended First-Line ART for HIV/HBV Co-infection\\n\\nThe recommended first-line ART in adolescents and adults with HIV/HBV co-infection is TDF + 3TC + DTG. This includes women and adolescent girls of childbearing potential. \\n\\nTreatment with both TDF (or TAF) and 3TC is necessary, as 3TC alone risks rapid emergence of resistance. In cases of renal impairment (assessed by creatinine clearance), the doses of TDF and 3TC should be adjusted accordingly.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## Initial Clinical and Laboratory Evaluation in HIV/HBV Co-infection\\n\\n### Findings and Actions\\n\\n1. **History**  \\n   Key risk factors include alcohol use, cigarette smoking, intravenous drug use, risky sexual practices, anorexia, right upper quadrant pain, jaundice, early satiety, haematemesis, dark stool, bleeding, and pruritus.  \\n   **Action:** Assess, counsel, and support to stop alcohol and smoking; provide harm reduction interventions; consider referring for additional evaluation.\\n\\n2. **Physical Examination**  \\n   Look for signs like an enlarged liver, enlarged spleen, ascites, and scratch marks.  \\n   **Action:** Evidence of established chronic liver disease requires closer follow-up due to increased risk of hepatotoxicity. Refer for additional evaluation if necessary.\\n\\n3. **ALT Levels**  \\n   Elevated ALT may indicate active liver disease.  \\n   **Action:** Exclude other causes of elevation and assess liver function (albumin and INR), especially in symptomatic patients, without delaying ART initiation.\\n\\n4. **Creatinine Levels**  \\n   Calculate creatinine clearance.  \\n   **Action:** TDF is indicated in HIV/HBV co-infection even with CrCl < 50 ml/min; avoid fixed-dose combinations (FDCs) in these patients to allow for dosage adjustments.\\n\\n5. **Comorbidities**  \\n   Include testing for HCV antibody, random blood sugar, lipid profile, alcoholic and non-alcoholic liver disease, and family history of hepatocellular carcinoma.  \\n   **Action:** Refer for additional investigations when these conditions are suspected.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '## Management of TPT-Associated Rash\\n\\n### Overview\\n- TPT (Tuberculosis Preventive Therapy) may occasionally cause a rash, typically within a few days of initiation.\\n- The rash is often mild and may present as a maculopapular rash with or without itching (pruritus).\\n- Systemic hypersensitivity reactions in children are rare; adults may experience mild and self-limiting reactions.\\n- Severe cases may lead to skin exfoliation and conditions such as Stevens-Johnson syndrome.\\n\\n### Severity Assessment and Management\\nSeverity of rash should be assessed and managed as outlined below:\\n\\n#### Table 8.5: Management of TPT-Associated Skin Rash\\n\\n| Severity  | Characteristics                                     | Action                                                                                     |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '-|\\n| Mild      | Dry; erythema +/- fine papules; pruritus; affecting < 50% of body surface area | Continue TPT; close monitoring; symptomatic treatment with antihistamines +/- topical steroids (NOT oral steroids) |\\n| Moderate  | Dry; erythema +/- fine papules; pruritus; affecting ≥ 50% of body surface area   | Stop TPT; symptomatic treatment with antihistamines +/- topical steroids (NOT oral steroids); trial of desensitization after symptoms completely resolved |\\n| Severe    | Mucosal involvement; blistering; associated fever; any % of body surface area     | Stop TPT; hospital admission for supportive management (IV fluids, wound care, pain control, infection control, monitoring for super-infection); patient should NEVER be re-challenged; document and report adverse event and issue patient alert card |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '## ART for TB/HIV Co-infection\\n\\n### Overview\\n- Individuals living with HIV (PLHIV) diagnosed with TB/HIV co-infection should be on Antiretroviral Therapy (ART) and Cotrimoxazole Preventive Therapy (CPT) as part of their comprehensive care package.\\n\\n### Timing of ART for TB/HIV Co-infection\\n1. **For Patients Not on ART:**\\n   - Initiate TB treatment immediately.\\n   - Begin ART as soon as anti-TB medications are tolerated, preferably within 2 weeks.\\n   - For TB meningitis, delay ART commencement for 4 to 8 weeks.\\n   - Monitor closely for Immune Reconstitution Inflammatory Syndrome (IRIS).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 194,\n",
       "  'section': '## TB/HIV Co-infection: Prevention and Management\\n\\nThis section discusses the management of patients co-infected with TB and HIV. For patients switching from TDF-based therapy who are HIV/HBV co-infected, it is essential to maintain TDF + 3TC in their ART regimen. For instance, if a patient fails TDF/3TC/EFV in first-line therapy, the recommendation is to switch to TDF/3TC/DTG in the second line. Patients failing second-line ART should have their cases discussed in the multi-disciplinary team (MDT) and with the Regional or National HIV Clinical Technical Working Group, with the contact number being Uliza Hotline 0726 460 000.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 194,\n",
       "  'section': '## Hepatitis C/HIV Co-infection\\n\\nThis section covers the prevalence and implications of Hepatitis C Virus (HCV) infection among HIV-positive individuals, particularly within Kenya. It notes that while HCV prevalence is high in people who inject drugs (PWID), it is generally low in the overall population and among people living with HIV (PLHIV) at less than 3%. Co-infection with HIV and HCV is associated with several risks including rapid progression of liver fibrosis, a higher risk of deteriorating liver disease even with controlled HIV, and worsened hepatotoxicity from ART and other medications. It is recommended that HIV-positive individuals at risk of HCV co-infection be identified and offered HCV treatment. The introduction of direct acting antiviral therapies (DAAs) has simplified the management of HIV/HCV co-infection, allowing for safe management even in primary care settings. Providers are encouraged to stay updated on HCV treatment developments and to consult experienced providers when uncertain.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 194,\n",
       "  'section': \"## Screening for HCV\\n\\nThis section provides guidelines for screening individuals at risk for Hepatitis C Virus (HCV) infection. HCV serology should be offered to the following groups:\\n- People who inject or use intranasal drugs\\n- Persons who have had tattoos, body piercing, or scarification from places with questionable infection prevention measures\\n- Children born to HCV positive mothers\\n\\nIt's highlighted that up to 30% of individuals infected with HCV may spontaneously clear the infection. To confirm chronic HCV infection, those who test positive should undergo nucleic acid HCV RNA testing to confirm the presence of chronic infection.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## TB/HIV Co-infection: Overview\\n\\nThis section provides a general understanding of the intersection between TB (Tuberculosis) and HIV (Human Immunodeficiency Virus) co-infection, highlighting the significance of managing both conditions together for improved patient outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## TB Preventive Therapy (TPT)\\n\\nThis section summarizes the current national recommendations for the treatment of latent TB infections (LTBI) in the PLHIV population, in line with updated World Health Organization guidelines. It includes the use of shorter, safer LTBI treatment options for an expanded at-risk population.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## Indications for TPT\\n\\nTPT should be provided to patients in whom TB is excluded (using the ICF tool) and meet the eligibility criteria to initiate TPT. The eligible client categories include:\\n\\n- All PLHIV above 12 months of age (children, adolescents, and adults including pregnant and breastfeeding women)\\n- All household contacts of persons with bacteriologically confirmed pulmonary TB\\n- Prisoners and staff working in a prison setting\\n- Health care workers and other staff in health care settings\\n- Other clinical risk groups as defined in LTBI guidelines\\n\\n*Note: Neonates born to mothers with TB, or exposed to close contacts with TB, should be given TPT once TB disease has been ruled out. BCG should be administered 2 weeks after completion of TPT or anti-TB treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## Summary of Recommendations for TPT among PLHIV\\n\\n- PLHIV are at a much higher risk of developing TB compared to the general population.\\n- TB preventive therapy should be administered to all PLHIV over 12 months of age without active TB disease, irrespective of immune status, ART status, previous history of TB, and pregnancy status.\\n- Children under 12 months living with HIV who are household contacts of a person with bacteriologically confirmed pulmonary TB, and in whom active TB has been ruled out, should receive TB preventive therapy.\\n- TPT may be initiated immediately following successful completion of TB treatment among PLHIV.\\n- Repeat TPT is not recommended for PLHIV except if they become a household contact of someone with bacteriologically confirmed pulmonary TB.\\n- PLHIV aged 15 years and above should receive 3 months of weekly Rifapentine and Isoniazid (3HP), while those under 15 years are given 6 months of daily INH (6H).\\n- For PLHIV on PI/r-based ART, pregnant women, and those intolerant to 3HP, 6 months of daily INH (6H) should be provided.\\n- Eligible patients who have been previously treated for TB should initiate TPT upon completion of their TB treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 196,\n",
       "  'section': '## TB/HIV Co-Infection Overview\\n\\nThis section discusses the co-infection of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV), highlighting the complexities and considerations in managing patients who are infected with both diseases.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 196,\n",
       "  'section': '## Recommended Direct-Acting Antiviral (DAA) Regimens for HCV Treatment\\n\\nThis section presents the recommended DAA regimens for the treatment of Hepatitis C Virus (HCV) among people living with HIV (PLHIV). \\n\\n### Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV\\n\\n- **Genotype 1 and 4**\\n  - **DAA Regimen:** Sofosbuvir + Ledipasvir (Harvoni)\\n  - **Duration of treatment:** 12 weeks\\n\\n- **All Genotypes**\\n  - **DAA Regimen:** Sofosbuvir + Velpatasvir (Epclusa)\\n  - **Duration of treatment:** 12 weeks\\n\\n*Note: DAA regimen availability continues to evolve; this table illustrates the most readily available regimens at the time of publication. Always initiate DAA HCV therapy and review the most recent drug-drug interactions with antiretroviral (ARV) medications.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 196,\n",
       "  'section': '## Considerations in DAA Therapy\\n\\nThis section emphasizes the importance of regularly reviewing drug-drug interactions when initiating DAA therapies in patients who are also receiving antiretroviral treatments for HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': \"## HIV Prevention Strategies\\n\\nKenya's guidelines outline various strategies for the prevention of HIV transmission, particularly in different settings and populations. Key measures include:\\n\\n### General Prevention Measures\\n- Effective practices in healthcare settings can significantly minimize the risk of blood-borne infections, including HIV.\\n  \\n### Recommendations for Healthcare Settings\\n- **Training for Healthcare Providers:** \\n  - Hand hygiene practices, including surgical hand preparation, hand-washing, and appropriate use of gloves.\\n  - Safe handling and disposal of sharps and waste materials.\\n  - Effective disinfection and sterilization techniques.\\n  - Provision of safe blood and blood products.\\n\\n### Recommendations for People Who Inject Drugs (PWID)\\n- **Harm Reduction Counseling and Support** (See Table 12.1).\\n\\n### Recommendations for Prevention of Sexual Transmission\\n- **Condom Use:** Correct and consistent use of condoms.\\n- **Access to Prevention Services:** Focused on sex workers and individuals at increased risk, including screening and treatment for STIs and routine testing for HIV and HCV.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': '## Treatment of HIV/HCV Co-infection\\n\\nThe guidelines provide a structured approach for the clinical and laboratory evaluation of patients with HIV/HCV co-infection.\\n\\n### Initial Clinical and Laboratory Evaluation\\n| Findings | Action |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': '--|\\n| **History**: Alcohol use, smoking, intravenous drug use, risky sexual practices, anorexia, right upper quadrant pain, jaundice, early satiety, hematemesis, dark stool, bleeding, pruritus | Assess, counsel, and support cessation of alcohol and smoking; refer for harm reduction interventions. |\\n| **Physical Examination**: Enlarged liver, spleen, ascites, scratch marks | Indicates chronic liver disease; necessitates closer follow-up and possible referral to a specialist. |\\n| **HCV RNA PCR** | Used for confirmation of chronic HCV infection; priority testing at baseline if available. |\\n| **HCV Genotype** | Important for selecting appropriate DAA regimen; current regimens are pan-genotypic, reducing the need for genotype testing. |\\n| **ALT** | Elevated levels may indicate active liver disease; assess liver function (albumin and INR) without delaying ART initiation. |\\n| **Comorbidities**: Consideration of HBV, blood sugar levels, lipid profiles, and family history of liver disease | Recommend additional investigations to rule out underlying conditions. |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 193,\n",
       "  'section': '## TDF and 3TC Dose Adjustments in Impaired Renal Function\\n\\nThis section provides dosing guidelines for Tenofovir Disoproxil Fumarate (TDF) and Lamivudine (3TC) in patients with varying levels of renal function. The dosing recommendations vary based on creatinine clearance and whether the patient is on hemodialysis. \\n\\n- **TDF Granules (33 mg/g)**:\\n  - Creatinine clearance 50 - 80 ml/min: 245 mg (7.5 scoops) once daily\\n  - 30 - 49 ml/min: 132 mg (4 scoops) once daily\\n  - 10 - 29 ml/min: 65 mg (2 scoops) once daily\\n  - Hemodialysis: 16.5 mg (0.5 scoop) after each 4-hour session\\n\\n- **TDF 300 mg**:\\n  - Unchanged: 300 mg once daily \\n  - 30 - 49 ml/min: 300 mg every 48 hours \\n  - 10 - 29 ml/min: 300 mg every 72 to 96 hours (twice weekly)\\n  - Hemodialysis: 300 mg once weekly after completion of dialysis\\n\\n- **3TC 300 mg**:\\n  - Unchanged: 300 mg once daily or 150 mg twice daily\\n  - 30 - 49 ml/min: 150 mg once daily\\n  - 10 - 29 ml/min: 50 mg first dose, then 25 mg once daily\\n  \\nNote: Special consideration should be given when benefits of TDF usage outweigh risks, especially in the management of HIV/HBV co-infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 193,\n",
       "  'section': '## Follow-up and Monitoring for HIV/HBV Co-infected Patients\\n\\nThis section outlines the follow-up and monitoring protocols for HIV/HBV co-infected patients on Antiretroviral Therapy (ART). \\n\\n- **Monitoring Frequency**: Follow-up should be similar to patients on ART but requires more frequent monitoring (using ALT) for those with active liver disease (e.g., jaundice, liver cirrhosis).\\n\\n- **Increased Risk**: Co-infection increases the risk of drug-related hepatotoxicity from all classes of ARVs by 3 - 5 times, particularly when anti-TB therapy is concurrently administered.\\n\\n- **ALT Elevations**: ALT elevations of 5 - 10 times normal can be tolerated in the first 3 months of ART if the patient is stable and asymptomatic, with no signs of synthetic dysfunction.\\n\\n- **Specialist Referral**: Patients with persistently elevated ALT levels should be referred to a specialist.\\n\\n- **Laboratory Monitoring**: Subsequent laboratory tests should be conducted every 6 months. Patients should also receive counselling to abstain from alcohol.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 193,\n",
       "  'section': '## Treatment Stopping and Interruptions for Patients with HIV/HBV Co-infection\\n\\nThis section discusses the implications of stopping ART that includes TDF in patients with HIV/HBV co-infection.\\n\\n- **Do Not Stop TDF**: TDF-containing ART should not be halted to avoid a hepatitis flare-up.\\n\\n- **Monitoring Upon Stopping**: If stopping the regimen is necessary and there are no alternatives for hepatitis B suppression, liver enzymes must be monitored carefully.\\n\\n- **Reinstatement**: Treatment should be reinstated as soon as possible if liver enzyme elevations are observed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 199,\n",
       "  'section': '## Eligibility For PEP\\n\\nPEP should be offered as soon as possible, preferably within 72 hours, after an exposure. Persons who present after 72 hours should receive other appropriate services including counseling and support. Eligibility assessment for PEP is based on the type of exposure, HIV status of the source (where possible), and the timing of seeking care. The following criteria determine eligibility for PEP:\\n\\n- The exposed individual is HIV negative at baseline.\\n- Exposure must have occurred within the past 72 hours.\\n- Exposure to bodily fluids poses a significant risk (exposure and/or material):\\n  - **Type of exposure:** mucous membrane (i.e., sexual exposure; splashes to eye, nose, or oral cavity), non-intact skin, percutaneous injury, or parenteral exposures.\\n  - **Material:** blood, blood-stained body fluids, breast milk; semen; vaginal secretions; synovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories.\\n\\nExposures that do not require HIV PEP include:\\n\\n- When the exposed individual is already HIV positive.\\n- Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non-blood-stained saliva, urine, and sweat.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 199,\n",
       "  'section': '## Management and Follow Up\\n\\nPatients should be counseled and encouraged to complete the full course of PEP once a decision has been made to initiate PEP. For occupational exposure, immediate care of the exposure site includes washing the site with soap and water and allowing the wound to bleed freely for several minutes. \\n\\n**NOTE:** Do not do anything that will increase tissue damage, such as squeezing, scrubbing, or cutting the site further.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 201,\n",
       "  'section': '## Risk Reduction Counselling\\n\\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual partners and the children of breastfeeding mothers. Risk reduction counselling should form part of each consultation with the individual. Measures to reduce transmission to another person may include:\\n\\n- The use of condoms and safe injecting practices to prevent secondary transmission.\\n- Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 201,\n",
       "  'section': '## Considerations for Special Circumstances\\n\\n### Breastfeeding Women\\n- Breastfeeding is not a contraindication for Post-Exposure Prophylaxis (PEP).\\n- The risks and benefits of continuing breastfeeding while HIV transmission risk is unknown should be discussed with the mother.\\n\\n### Children\\n- HIV testing approaches for children should align with national guidelines and be age-appropriate.\\n- Informed consent from the caregiver is needed.\\n\\n### Adolescents\\n- Requiring parental consent for adolescents can be a barrier to HIV testing, particularly in cases of sexual assault.\\n- HIV testing should be performed in accordance with national guidelines and consenting requirements.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 201,\n",
       "  'section': '## Preventing HIV Exposure\\n\\nTo avoid or minimize the risk of exposure to HIV, the following infection prevention control (IPC) measures are recommended:\\n\\n- Precautions should be taken when handling contaminated body fluids, including the use of appropriate barriers such as gloves, gowns, and goggles.\\n- Care with sharps, including minimizing blind surgical procedures and proper handling and disposal of sharps.\\n- Safe disposal of contaminated waste.\\n- Safe handling of soiled linen.\\n- Adequate disinfection procedures.\\n- Universal Hepatitis B vaccination of non-immune at-risk groups, including healthcare workers (HCWs), police, prison staff, and rescue workers.\\n\\nIn cases that do not require PEP, the exposed person should be counselled about limiting future exposure risk.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Introduction to Kenya HIV Prevention and Treatment Guidelines\\n\\nThe Kenya HIV Prevention and Treatment Guidelines, 2022 provide comprehensive strategies for preventing and treating HIV among populations at risk. These guidelines are designed to enhance the delivery of services and improve health outcomes for individuals living with or at risk of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Key Population Groups\\n\\nThis section outlines the specific populations that are prioritized in the guidelines. These groups may include men who have sex with men, sex workers, and people who inject drugs, as well as women and adolescents at increased risk for HIV. Understanding the needs of these populations is crucial for effective intervention.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## HIV Prevention Strategies\\n\\nHere, various evidence-based HIV prevention methods are discussed, including:\\n- Use of antiretroviral pre-exposure prophylaxis (PrEP)\\n- Safe sex practices and education\\n- Behavioral interventions\\nThese strategies aim to reduce the transmission of HIV and provide individuals with tools to protect themselves.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Antiretroviral Therapy (ART)\\n\\nThis section covers the guidelines for antiretroviral therapy, including treatment protocols, medication options, and the importance of adherence. It emphasizes the need for timely initiation of ART to improve health outcomes for people living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nMonitoring and evaluation are essential components of the guidelines. This section details the frameworks for assessing the effectiveness of HIV prevention and treatment efforts, including data collection tools and performance indicators.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Community Engagement and Support\\n\\nThis section discusses the role of community-based organizations and peer support in the implementation of HIV services. It highlights the importance of community involvement in enhancing outreach and providing support to those affected by HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Addressing Stigma and Discrimination\\n\\nThe guidelines also address the impact of stigma and discrimination on HIV prevention and treatment. This section provides strategies for reducing stigma, fostering an inclusive environment for people living with HIV, and promoting respectful healthcare practices.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Conclusion\\n\\nThe Kenya HIV Prevention and Treatment Guidelines, 2022, are designed to provide a structured and evidence-based approach to tackle the HIV epidemic in the country. These guidelines serve as a vital resource for healthcare providers, policymakers, and community organizations working towards better health outcomes for all those affected by HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '## ARVs for Post-exposure Prophylaxis\\n\\nAn ARV regimen, with preferably three drugs, should be offered as post-exposure prophylaxis as soon as possible (preferably within 72 hours) after an exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '## What is PEP?\\n\\nPost-exposure prophylaxis (PEP) is short-term use of antiretroviral treatment to reduce the likelihood of HIV infection after potential exposure. People can be accidentally exposed to HIV through healthcare work or due to exposures outside the healthcare setting, such as unprotected sex or sexual assault among adults and children. Healthcare workers are at increased risk of exposure to HIV through contact with contaminated blood and other body fluids containing HIV, through needle stick injuries and injuries by other sharp objects, or through non-intact skin and mucous membranes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '## Recommended ARVs for PEP\\n\\nThree-drug regimens are preferred for PEP. However, if the person is unable to tolerate the third drug (usually the PI/r), two drugs can be used.\\n\\n### Table 10.1: Recommended ARVs for PEP\\n\\n| Age             | Weight     | Preferred                          | Alternate                                    |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '-|\\n| <15 years      | < 30kg    | ABC + 3TC + DTG                    | AZT + 3TC + DTG<br>AZT + 3TC and LPV/r may be used as the third drug |\\n| ≥ 30 kg        |            | TDF + 3TC/FTC + DTG                | TDF + 3TC/FTC and ATV/r may be used as an alternative third drug |\\n| ≥ 15 years     | Any weight | TDF + 3TC/FTC + DTG                | TDF + 3TC/FTC and ATV/r may be used as an alternative third drug |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nPre-Exposure Prophylaxis (PrEP) is a preventive strategy for individuals at high risk of HIV infection. It is not intended for use solely with HIV self-testing (HIVST) for confirming eligibility or monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## HIV Testing and PrEP Initiation\\n\\nHIV self-testing should not be used as a definitive test for initiating or monitoring PrEP. Proper HIV testing is essential to determine eligibility for PrEP treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Package of PrEP Service\\n\\nThe PrEP service package includes a comprehensive approach that integrates behavioral, biomedical, and structural components. \\n\\n### Key Components:\\n- Integration of PrEP services within various service delivery points.\\n- Recommended locations include community health centers, antenatal care (ANC), and family planning (FP) clinics.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Service Access for Clients\\n\\nClients seeking services related to PrEP should be screened for ongoing risk of HIV and tested for HIV. \\n\\n### Screening and Referral Process:\\n- **Screen for ongoing risk for HIV**\\n- **Test for HIV**\\n  - If HIV positive, link or refer the individual to appropriate services.\\n- Additional screenings may include assessments for gender-based violence (GBV) and HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Integration of PrEP Services\\n\\nPrEP services should be effectively integrated into existing health service frameworks to enhance accessibility and uptake among those at risk for HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## ARVs for Post-Exposure Prophylaxis\\n\\nAntiretroviral medications (ARVs) are used for post-exposure prophylaxis (PEP) to prevent HIV infection following high-risk exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Recommendations for PEP Management and Follow-Up\\n\\n### Management at Initial Contact\\n\\n- Counsel on risks and benefits of PEP and obtain verbal consent for HIV testing.\\n- Voluntary testing for both exposed and source individuals.\\n- Offer PEP as soon as high-risk exposure is established and the exposed individual tests HIV-negative at baseline (if HIV testing is not feasible, offer 1-2 days of PEP until HIV test is performed).\\n- Provide first aid in case of broken skin or other types of wounds.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Time of Initiation and Duration of PEP\\n\\n- **Time of Initiation**: As soon as possible after exposure, but no later than 72 hours.\\n- **Duration of PEP**: 28 days (dispense all 28 days of treatment at the first visit if tested HIV-negative).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Dose of PEP\\n\\n- Use the same dose indicated for treatment; employ weight-based dosing for children.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Laboratory Investigations at Baseline\\n\\n- Conduct creatinine testing (if TDF-containing regimen) and Hb testing (if AZT-containing regimen); however, PEP should be offered even when lab tests are not available. Do not delay administration of PEP while waiting for lab results.\\n- HBsAg testing is recommended; do not delay PEP while waiting for results. If negative, provide HBV vaccination.\\n- Pregnancy testing for women of childbearing potential in cases of sexual assault.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Follow-Up Care\\n\\n- Follow up with the client at 7 days, 14 days, 28 days, and 12 weeks after starting PEP.\\n- Assess for and manage side effects due to PEP.\\n- Follow-up HIV testing should be conducted at the completion of PEP and, if negative, test again at 12 weeks.\\n- Link to HIV treatment if positive.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Counselling Services\\n\\nCounselling at baseline should include:\\n\\n- Adherence counselling.\\n- Information on side effects.\\n- Risk reduction counselling.\\n- Trauma and mental health counselling.\\n- Specific support for sexual assault.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Additional Services for Sexual Assault Survivors\\n\\n- STI prophylactic treatment for all (treat for vaginal/urethral discharge syndrome following national STI algorithms).\\n- Emergency contraception for non-pregnant women.\\n- Tetanus toxoid for any physical injury of skin or mucous membranes.\\n- Documentation of clinic evidence of assault and collection of forensic evidence.\\n- Refer to post-rape care guidelines for additional details.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 205,\n",
       "  'section': '## Pre-Initiation Checklist for PrEP\\n\\nThis checklist is intended to help the service provider ensure that all necessary screenings and assessments are completed prior to the initiation of pre-exposure prophylaxis (PrEP).\\n\\n### Assessment Checklist Items\\n\\n1. **Screening and Support for Gender-Based Violence (GBV)**\\n2. **HIV Testing**\\n3. **Check Symptoms of Acute Viral Infection in Last 6 Weeks**\\n4. **Behavior Risk Assessment**\\n5. **Substance Use and Mental Health Screening**\\n6. **Partner Information**\\n7. **Pre-Initiation Education and Understanding of PrEP**\\n8. **Client Readiness and Willingness to Adhere to Prescribed PrEP and Follow-Up Schedule**\\n9. **STI Screening and Treatment**\\n\\n### Specific Assessments for Women\\n\\n- **Pregnancy Test**: Assessment of pregnancy intentions and/or breastfeeding.\\n- **Contraceptive Use Screening**: Utilizing appropriate tools to assess contraception use.\\n- **Condom Use**: Emphasizing the need for consistent condom use.\\n- **PrEP Access Plans**: Discussion on continuous access to PrEP.\\n\\n### Laboratory Tests\\n\\n- Additional laboratory tests should not delay PrEP initiation:\\n  - **Serum Creatinine and Creatinine Clearance**\\n  - **HBsAg**\\n  - **HCV Serology**\\n  \\n### Medication History\\n\\n- Review of medication history and potential drug interactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 205,\n",
       "  'section': '## Important Notes\\n\\n- The absence of specific laboratory tests should not hinder the initiation of PrEP.\\n- Client readiness and willingness to adhere to the prescribed regimen is critical for successful PrEP usage.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 202,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition of HIV infection by an uninfected person at ongoing risk of acquiring HIV infection. PrEP is recommended for use as follows:  \\n- **Daily Oral PrEP**: For all individuals, irrespective of gender or sexual orientation, who are at risk of HIV infection.  \\n- **Event-Driven (ED) PrEP**: Currently recommended for all people born male who are not taking exogenous estradiol-based gender-affirming hormones.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 202,\n",
       "  'section': '## Indications for PrEP and Criteria for Eligibility\\n\\n### Indications for PrEP\\n\\nPrEP is indicated for:  \\n- **HIV uninfected persons** at ongoing risk of HIV acquisition.  \\n- Some risk situations that place one at ongoing risk include individuals or sexual partners who are:  \\n  - HIV positive and: not on ART, or on ART < 6 months, on ART with viral non-suppression, or on ART with suspected poor adherence.  \\n  - In sero-discordant relationships trying to conceive.  \\n  - Of unknown HIV status and at high risk of HIV infection.  \\n  - Engaging in transactional sex or sex work.  \\n  - With a history of recent or current sexually transmitted infections.  \\n  - With recurrent use of Post-Exposure Prophylaxis.  \\n  - With a history of sex while under the influence of alcohol or recreational drugs.  \\n  - Inconsistent or no condom use or unable to negotiate condom use during intercourse with persons of unknown HIV status.  \\n  - Using injection drugs where needles and/or syringes are shared.  \\n\\n### HIV Risk Assessment\\n\\nClients accessing health services should be screened for HIV risk and additionally provided with information on HIV prevention options available, including the availability of PrEP. This is in addition to the use of HIV testing services (HTS), as clients are assessed for HIV risk before testing.  \\n\\nThe risk assessment questions are inquiries into behavioral practices that may expose an individual to HIV. A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a conversation about HIV risk. Screening for HIV risk should be integrated within other service delivery points.  \\n\\nHIV negative individuals who answer “yes” to any of the screening questions should be engaged in a discussion about the risks and benefits of PrEP. The client then is evaluated for eligibility to receive PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 203,\n",
       "  'section': '## HIV Screening Questions\\n\\nThe HIV screening questions refer to the past 6 months and include the following:\\n\\n- Have you had sex with more than one person?\\n- Have you had sex without a condom?\\n- Have you had sex with anyone whose HIV status you do not know?\\n- Are any of your partners at risk of HIV?\\n- Have you had sex with a person who has HIV?\\n- Have you received a new diagnosis of a sexually transmitted infection?\\n- Do you desire pregnancy?\\n- Have you used or wanted to use PEP or PrEP for sexual exposure to HIV?\\n- Have you injected drugs that were not prescribed by a healthcare provider? If yes, did you use syringes, needles, or other drug preparation equipment that had already been used by another person?\\n- Have you received money, housing, food, or gifts in exchange for sex?\\n- Have you been forced to have sex against your will?\\n- Have you been physically assaulted, including assault by a sexual partner?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 203,\n",
       "  'section': '## Criteria for PrEP Eligibility\\n\\nTo be eligible for PrEP, individuals identified as at risk of HIV infection must meet ALL the following criteria prior to initiating PrEP:\\n\\n- Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.\\n- Willingness to take PrEP as prescribed, assessed through adherence education and counseling on the PrEP regimen.\\n- No current or recent illness consistent with acute HIV infection (e.g., fever, sore throat, muscle or joint pains, swollen glands, diarrhea, or headache) in combination with a preceding high-risk exposure for HIV.\\n- No contraindication to the use of any of the ARVs recommended for PrEP (e.g., TDF +/- FTC or 3TC for those who choose oral PrEP).\\n- No renal or liver disease. Clients with these conditions should receive further clinical and laboratory tests to determine renal/liver function and the extent of disease.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 203,\n",
       "  'section': '## Important Factors for Screening\\n\\n1. **Gender-Based Violence (GBV) Screening**: All clients accessing PrEP must be screened for gender-based violence, especially intimate partner violence (IPV). Appropriate interventions should be offered or clients linked to appropriate resources.\\n\\n2. **Mental Status Assessment**: Psychological issues that may influence adherence should be assessed and addressed. Basic mental health evaluations should be carried out, with appropriate referrals made as necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': '## Event-Driven PrEP Overview\\n\\nEvent-driven PrEP is a preventive strategy particularly suited for specific groups, especially men who have infrequent sexual encounters. It is ideal for those who have sex less than twice a week, can plan for sex at least two hours in advance, or find this method more convenient.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': '## Ideal Candidates for Event-Driven PrEP\\n\\nEvent-driven PrEP is most appropriate for men who:\\n- Have infrequent sex (for example, sex less than 2 times per week on average).\\n- Can plan for sexual activity at least 2 hours in advance or can delay sexual encounters by at least 2 hours.\\n- Would find the event-driven PrEP more convenient for their lifestyle.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': \"## Follow-Up Requirements for Event-Driven PrEP\\n\\nClients on event-driven PrEP require careful follow-up. The follow-up process includes:\\n- A follow-up visit one month after initiation and every three months thereafter.\\n- Providing HIV testing and screening for STIs.\\n- Offering counseling that discusses adherence to the dosing strategy, especially if transitioning between daily dosing and event-driven PrEP.\\n- Assessing the client's HIV risk for the upcoming weeks and months.\\n- Providing more active support for continued use of PrEP, regardless of the chosen dosing strategy.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': '## Dosing Options for PrEP\\n\\nWhen discussing dosing options for PrEP, consider the following:\\n- Daily dosing is recommended if a client has a higher risk and has sex more frequently than 2 times per week, or if sex cannot be predicted or delayed by at least 2 hours.\\n- Men who have sex with men and are on PrEP can switch from daily dosing to event-driven PrEP and vice versa, depending on their sexual activity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 206,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nOverview of PrEP and its role as part of combination HIV prevention. Discusses the significance of client education before initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 206,\n",
       "  'section': '## Pre-Initiation Client Education\\n\\nThe following components should be discussed prior to PrEP initiation:\\n\\n### Client Education Checklist\\n\\n- Explain how PrEP works as part of combination HIV prevention.\\n- Explain the need for baseline and follow-up tests including regular HIV testing.\\n- Explain PrEP use, including:\\n  - The medications used (show the client the pills or other PrEP options).\\n  - How the medications are used (frequency of dosing for the various options).\\n  - Number of doses required to achieve efficacy (7 doses for daily oral PrEP, loading dose for event-driven oral PrEP).\\n  - What to do when doses are missed (continue for daily doses).\\n  - Discontinuation of PrEP, how and when it can be discontinued.\\n  - Side effects and what to do in case they are experienced (including when to consult the clinician).\\n- Discuss what to do if the client experiences symptoms of seroconversion (acute HIV infection).\\n- Discuss the limitations of PrEP:\\n  - PrEP reduces but does not eliminate the risk of acquiring HIV.\\n  - PrEP does not prevent pregnancies and STIs.\\n- Risk reduction counseling and support education covering:\\n  - Managing mental health needs.\\n  - Couple counseling.\\n  - Access to, and consistent use of condoms and lubricants.\\n  - Access to and need for frequent HIV testing.\\n  - Early access to ART.\\n  - VMMC (Voluntary Medical Male Circumcision).\\n  - STI screening and treatment.\\n  - Harm reduction for PWID (People Who Inject Drugs).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 206,\n",
       "  'section': '## Recommended ARVs for PrEP\\n\\nThe preferred ARV regimen for PrEP is Tenofovir 300mg/Emtricitabine 200mg (TDF/FTC), administered as one fixed-dose combination (FDC) tablet orally daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 212,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nOverview of what PrEP is and its purpose.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 212,\n",
       "  'section': '## Initial Assessment Visit\\n\\nDetails regarding the first screening visit for PrEP, including actions needed:\\n\\n- HIV testing and counseling.\\n- Evaluation for eligibility and readiness to take PrEP.\\n- Education about risks, benefits, and limitations of PrEP options.\\n- Recognizing symptoms of Acute HIV Infection (AHI).\\n- Behavior risk assessment.\\n- STI screening and treatment.\\n- Pregnancy counseling and tests (if pregnancy suspected).\\n- Adherence counseling.\\n- Discussing combination prevention.\\n- Laboratory tests (serum creatinine, HBsAg, Hepatitis C).\\n\\nIf no contraindications exist, prescribe TDF/FTC or alternatives for 30 days with a follow-up date set.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 212,\n",
       "  'section': '## Month 1 Follow-Up Visit\\n\\nActions taken during the first month follow-up visit:\\n\\n- Assess for side effects and adverse effects.\\n- Review lab results and conduct an HIV test.\\n- Behavioral risk assessment.\\n- Review for continuation or discontinuation of PrEP.\\n- Adherence and risk reduction counseling.\\n- Prescription for PrEP for 2 months.\\n- Offer HBV vaccination if available and HBsAg negative.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 212,\n",
       "  'section': '## Subsequent Follow-Up Visits\\n\\nOutline of what to expect during follow-up visits every 3, 6, 12, and 15 months:\\n\\n- HIV testing and counseling.\\n- HIV risk assessment.\\n- Review for PrEP continuation or discontinuation.\\n- Assess for side effects and adverse effects.\\n- Safety monitoring clinical assessment and lab review.\\n- Adherence and risk reduction counseling.\\n- Provide a prescription for PrEP for 3 months.\\n- Refill PrEP prescription.\\n- Serum creatinine and creatinine clearance tests.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 207,\n",
       "  'section': '## PrEP Dosing Strategies\\n\\nThis section outlines the preferred and alternative dosing strategies for Pre-Exposure Prophylaxis (PrEP) using specific antiretrovirals.\\n\\n**Preferred Dosing Strategies:**\\n- **Daily Oral PrEP:**  \\n  - TDF/FTC (300 mg/200 mg) as FDC once daily.\\n- **Event Driven Oral PrEP:**  \\n  - TDF/FTC (300 mg/200 mg) as FDC – two pills taken between 2 and 24 hours before anticipated sex; then a third pill 24 hours after the first two pills and a fourth pill 48 hours after the first two pills (2-1-1 dosing).\\n\\n**Alternative Dosing Strategies:**\\n- **Daily Oral PrEP:**  \\n  - TDF/3TC (300 mg/300 mg) as FDC once daily.\\n- **Event Driven Oral PrEP:**  \\n  - TDF/3TC (300 mg/300 mg) as FDC – two pills taken between 2 and 24 hours before anticipated sex; then a third pill 24 hours after the first two pills and a fourth pill 48 hours after the first two pills (2-1-1 dosing).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 207,\n",
       "  'section': '## Long-Acting Products\\n\\nThis section describes recommended long-acting products for PrEP that are at different stages of approval and availability in Kenya.\\n\\n- **Cabotegravir Injection:**  \\n  - **Initiation injections:** 600 mg Intramuscular (IM) x 2 doses given 1 month apart (the second initiation injection can be given up to 7 days before or after scheduled date).  \\n  - **Continuation injections:** 600 mg IM every 2 months.\\n\\n- **Dapivirine Vaginal Ring:**  \\n  - Dapivirine vaginal ring, 25 mg, inserted vaginally every 28 days. \\n\\nNote: The Ministry of Health will issue specific implementation guidelines for these long-acting products as they become available.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 207,\n",
       "  'section': '## Prescription Intervals for Daily Oral PrEP\\n\\nThis section provides guidelines on the prescription intervals and follow-up for daily oral PrEP.\\n\\n- **Initial Prescription:**  \\n  - The first prescription should be for 30 days to allow for the first follow-up visit, during which a repeat HIV test should be conducted. Adherence, tolerability, and adverse effects will be assessed at this visit.\\n\\n- **Follow-up Prescriptions:**  \\n  - If no major concerns are noted during the one-month visit, PrEP should be prescribed for 2 months.  \\n  - Following this, a 3-month prescription can be given.  \\n  - Clients with sub-optimal adherence or other major concerns should have monthly follow-up visits.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 207,\n",
       "  'section': '## Efficacy and Safety Considerations\\n\\nThis section highlights important considerations regarding the efficacy and safety of PrEP use.\\n\\n- **Dosage Efficacy Timing:**  \\n  - Individuals using daily oral PrEP need to understand that it takes 7 doses (equivalent to 7 days) of continuous PrEP use to achieve adequate levels of the antiretrovirals in tissues. \\n\\n- **Safer Sex Practices:**  \\n  - During the initial 7-day period, safer sex practices, including abstinence and condom use, should be encouraged for individuals born female.  \\n  - Those born male may achieve protective levels as soon as 2 hours before sex but ideally 24 hours prior to sexual activity. \\n\\nThese efficacy considerations apply even to those intending to take daily oral PrEP for ongoing exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 208,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP) Overview\\n\\nPre-Exposure Prophylaxis (PrEP) is a preventive strategy for individuals at high risk of HIV infection. It involves taking specific medications to reduce the risk of contracting HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 208,\n",
       "  'section': '## Initial Visit/First Contact for PrEP\\n\\n### Risk Assessment\\n- Perform a risk assessment to determine if PrEP is indicated.\\n- Discuss effective PrEP use and clarify misinformation.\\n\\n### Clinical and Laboratory Assessment\\n- Conduct a baseline HIV test and rule out symptoms of acute HIV infection.\\n- Screen for STIs and assess risk of renal disease/Hepatitis B/C infection.\\n\\n### If Eligible for PrEP\\n- Offer adherence counseling and support.\\n- Prescribe a 30-day supply of PrEP (TDF 300 mg/FTC 200 mg OD).\\n- Discuss combination prevention and risk reduction strategies, and offer additional HIV prevention services such as condoms.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 208,\n",
       "  'section': '## 30 Day Review\\n\\n### Adherence and Side Effects\\n- Assess adherence and provide counseling and support.\\n- Inquire about any side effects and help clients cope if necessary.\\n\\n### Clinical Assessment\\n- Assess for STIs, risk of acute HIV infection, and conduct a pregnancy test in women.\\n- Evaluate the risk of kidney disease by obtaining serum creatinine and calculating creatinine clearance.\\n\\n### Follow-Up Actions\\n- Discuss risk reduction and provide condoms.\\n- Perform a repeat HIV test; discontinue PrEP for those who test positive and link them to ART initiation.\\n- Provide a 60-day prescription for PrEP and schedule a 3-month return visit.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 208,\n",
       "  'section': '## 3-Monthly Reviews\\n\\n### Adherence Check\\n- Continue to assess adherence and offer counseling and support.\\n- Ask about any new side effects or concerns.\\n\\n### Routine Clinical Assessment\\n- Assess for STIs and pregnancy in women, and check for acute HIV infection.\\n- Conduct an HIV test every 3 months; self-tests may be used followed by confirmatory tests for positive results.\\n\\n### Risk Reduction\\n- Discuss risk reduction strategies and distribute condoms.\\n- Conduct serum creatinine tests and calculate creatinine clearance within 3 months of initiation and annually thereafter.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 208,\n",
       "  'section': '## Event-Driven PrEP (On Demand PrEP)\\n\\n### Definition of Event-Driven PrEP\\n- Event-driven PrEP is a strategy where oral PrEP is used in anticipation of a specific sexual act or event.\\n\\n### Recommended Demographics\\n- It is recommended for all individuals assigned male at birth who are not taking exogenous estradiol-based gender-affirming hormones.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 216,\n",
       "  'section': '## People Who Inject Drugs (PWID) and HIV\\n\\nThis section introduces the relationship between People Who Inject Drugs (PWID) and the risk of HIV infection. It emphasizes the importance of equitable access to HIV treatment and care for key populations, including PWID.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 216,\n",
       "  'section': '## Introduction\\n\\nThe introduction outlines the general principles for antiretroviral therapy (ART) for the treatment of HIV within key populations. It highlights the discrimination and marginalization that PWID face, which can impede their access to healthcare. Strategies to minimize missed opportunities and optimize service delivery are discussed, including decentralization of HIV care and integration of ART with other clinical services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 216,\n",
       "  'section': '## Prevalence and Risks\\n\\nThis section covers the increased risk of HIV among PWID, specifically noting that in Kenya, their HIV prevalence is significantly higher than that of the general population. It also addresses the higher burden of other health issues such as viral hepatitis, TB, and sexually transmitted infections that PWID experience, despite limited access to treatment and prevention services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 216,\n",
       "  'section': '## Package of Care for PWID\\n\\nThis section describes the complex needs of PWID, including issues related to drug dependency and health complications. It emphasizes the need for comprehensive management by trained providers who can address the specific challenges faced by these patients, including adverse drug reactions and non-adherence to treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 216,\n",
       "  'section': '## Conclusion\\n\\nIn conclusion, it stresses the importance of implementing evidence-informed interventions targeted at PWID as part of a comprehensive care package. The need for early identification and linkage to appropriate programs that can provide comprehensive care is highlighted.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nPre-Exposure Prophylaxis (PrEP) is a preventive strategy for individuals who are at high risk of contracting HIV. It involves taking medication to significantly reduce the risk of HIV infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Dosing Options for PrEP\\n\\nMen can choose between two dosing options: daily oral PrEP and Event Driven (ED) PrEP.\\n\\n- **Daily Oral PrEP**: This option is ideal for individuals whose sexual activity is unpredictable or who have potential exposures to HIV more than twice a week.\\n- **Event Driven (ED) PrEP**: Suitable for those whose sexual encounters are infrequent or predictable. If sexual activity continues beyond one day, an ED-PrEP user should take an additional pill daily, stopping two days after the last sexual encounter.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Changing Between ED PrEP and Daily Oral PrEP\\n\\n- If a user who started with daily oral PrEP finds their sexual encounters to be less frequent and predictable, they may switch to ED-PrEP. Conversely, if someone using ED-PrEP encounters frequent unpredictable sexual activity, they may opt for daily oral PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Managing Clinical and Laboratory Results on Initial and Follow-up Assessment\\n\\nThis section outlines the necessary laboratory tests for clients both initiating and following up on PrEP.\\n\\n### Initial Laboratory Tests for Clients Initiating PrEP\\n- **HIV Rapid Test**: Required before starting PrEP as per national guidelines.\\n- **Creatinine Test**: Should be conducted within 1-3 months of initiation. Recommended screening for those over 50 years every 6-12 months and for clients with renal comorbidities before starting PrEP.\\n- **Hepatitis B Surface Antigen (HBsAg)**: One-time test within 3 months of initiating PrEP; if negative, offer or refer for immunization.\\n- **Hepatitis C Virus Serology**: One-time test within 3 months of starting PrEP.\\n\\n### Follow-up Testing for Clients on PrEP\\n- **HIV Rapid Test**: At Month 1, Month 3, and then every 3 months.\\n- **Creatinine Test**: Recommended every 6-12 months for clients over 50 or those with renal comorbidities.\\n- **Hepatitis C Virus Serology**: Every 12 months for individuals at high risk of Hepatitis C infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Overview of HIV in Kenya\\n\\nThis section provides an introduction to the current status of HIV in Kenya, including statistics on prevalence, demographics, and the impact of the epidemic on public health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Prevention Strategies\\n\\nThis section outlines the various approaches employed in Kenya to prevent HIV transmission, including education, condom distribution, pre-exposure prophylaxis (PrEP), and harm reduction for key populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Treatment Guidelines\\n\\nThis section details the recommended guidelines for the treatment of individuals living with HIV in Kenya, including first-line and second-line antiretroviral therapy (ART) regimens, monitoring, and adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Key Populations\\n\\nThis section discusses the specific groups that are at a higher risk of HIV acquisition and transmission, such as Men who have Sex with Men (MSM), sex workers, and people who inject drugs. It also covers tailored interventions for these populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Involvement of Community Organizations\\n\\nThis section highlights the role of community-based organizations in HIV prevention, treatment, and support, showcasing successful collaborations and the importance of community engagement.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nThis section addresses the strategies for monitoring and evaluating HIV programs in Kenya, including data collection, reporting systems, and outcomes measurement to ensure effectiveness and accountability.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Funding and Resources\\n\\nThis section provides information on the financial resources available for HIV programs in Kenya, including government funding, international aid, and private sector involvement.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Challenges in HIV Management\\n\\nThis section discusses the barriers and challenges faced in HIV prevention and treatment efforts within Kenya, such as stigma, access to healthcare, and resource allocation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 215,\n",
       "  'section': '## Future Directions\\n\\nThis section explores the future of HIV prevention and treatment in Kenya, focusing on emerging strategies, research directions, and the importance of sustained political and financial commitment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 214,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nPre-Exposure Prophylaxis (PrEP) is a strategy used to reduce the risk of HIV acquisition for individuals at high risk. It involves the continuous use of antiretroviral medication to prevent HIV from taking hold in the body.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 214,\n",
       "  'section': '## Improving Adherence to PrEP\\n\\nApproaches to improve adherence to PrEP include:\\n- Encourage ring users to keep the ring in place continuously through the 28-day period from initial insertion.\\n- Disclosure of PrEP use to a partner or trusted person.\\n- Use of reminder devices like a cell phone alarm.\\n- SMS reminders where available and feasible.\\n- Exploring and mitigating other barriers to adherence.\\n- Peer support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 214,\n",
       "  'section': '## Monitoring Sero-conversion among PrEP Users\\n\\nPrEP substantially reduces the risk of HIV acquisition, and its efficacy is correlated with adherence. Sero-conversion during PrEP use should be monitored closely, as it increases the risk of developing drug resistance if clients continue PrEP while HIV infected. Factors that lead to HIV sero-conversion among PrEP sero-converters include:\\n- Inconsistency in the use of PrEP (non-adherence).\\n- Social-behavioral factors such as poverty, HIV stigma, and relationship status that may affect the ability to use PrEP as prescribed.\\n- Possible infections with drug-resistant strains.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 214,\n",
       "  'section': '## Actions Upon Identification of a PrEP Sero-converter\\n\\nWhen a new HIV positive diagnosis is identified among PrEP users, the following steps should be taken:\\n- Conduct HIV testing among PrEP users consistently as per the algorithm.\\n- Immediate discontinuation of PrEP.\\n- Counseling of the client on positive results.\\n- Linkage to care and ART (immediate ART initiation).\\n- Assessment of barriers to adherence that may affect the use of ART.\\n- Document sero-conversion in the client file, PrEP registers, and monthly reporting as required.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 213,\n",
       "  'section': '## PrEP Initial and Follow-Up Assessment\\n\\nDuring every visit for individuals using Pre-Exposure Prophylaxis (PrEP), the following assessments should be conducted:\\n- Assess adherence to PrEP.\\n- Reassess the risk of HIV infection and offer risk reduction counseling.\\n- Repeat HIV testing at month 1 and thereafter every 3 months (applicable for both daily and event-driven PrEP).\\n- Assess for adverse effects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 213,\n",
       "  'section': '## Contraindications to Oral PrEP\\n\\nOral PrEP (both daily and event-driven) should not be used if any of the following conditions apply:\\n- Known HIV infection or suspected acute HIV infection (e.g., flu-like symptoms in the last 4 weeks with a preceding high-risk exposure).\\n- Adolescents weighing less than 35 kg or aged under 15 years.\\n- Impaired renal function (estimated creatinine clearance of less than 50 ml/min).\\n- Inability or unwillingness to adhere to prescribed PrEP or follow-up schedule.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 213,\n",
       "  'section': '## Criteria for Discontinuing Oral PrEP\\n\\nPrEP should be discontinued if any of the following criteria are met:\\n- A positive HIV test during follow-up.\\n- A change in risk status where there is no ongoing risk.\\n- Renal dysfunction with creatinine clearance below 50 ml/min.\\n- Client request to stop.\\n- Sustained non-adherence.\\n\\n### Discontinuation Protocols\\n- **Daily Oral PrEP:** Users should continue PrEP for at least 7 days after the last potential exposure to HIV if discontinuing due to no ongoing risk or a request to stop.\\n- **Event-Driven PrEP:** Can be stopped after two daily doses following the last sexual exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 213,\n",
       "  'section': '## Restarting PrEP\\n\\nClients restarting PrEP should be assessed for HIV status with a rapid HIV test. \\n\\n### Daily Oral PrEP Restart Protocol\\n- If clients have stopped PrEP for more than 7 days and wish to restart, perform an assessment similar to the initial visit, including an HIV test.\\n- If a high-risk exposure occurred in the previous 7 days (suspected acute HIV infection), defer PrEP and conduct a repeat HIV test after 4 weeks. If negative, PrEP can be prescribed if other criteria are met.\\n- Recommend the use of condoms during the waiting period.\\n\\n### Event-Driven Oral PrEP Restart Protocol\\n- Clients who have stopped ED-PrEP for more than a week should restart with a double dose (two pills) as new initiators.\\n- Conduct a risk assessment. If a high-risk exposure occurred in the previous 7 days (suspected acute HIV infection), defer PrEP and conduct a repeat HIV test after 4 weeks. If negative, PrEP can be prescribed if other criteria are met.\\n- Recommend the use of condoms during the waiting period.'},\n",
       " ...]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "guides_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "23b111a3-a752-4b21-900d-a9bffb9778d7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Creating new vectorstore...\n",
      "Generating embeddings...\n",
      "✓ Created table with 286 records\n",
      "✓ Vectorstore created successfully!\n",
      "\n",
      "🔍 Searching for: 'What are the first-line ART regimens?'\n",
      "================================================================================\n",
      "\n",
      "📄 Result 1:\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf\n",
      "Page: 236\n",
      "\n",
      "Content:\n",
      "  \n",
      "Annexes  \n",
      " \n",
      "13 - 15 Annex 8: Cont.  \n",
      "Section 13: Management plan  \n",
      "• Which investigations will you have today  \n",
      "- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \n",
      "respectively  \n",
      "• Which medications will you start today  \n",
      "- May include: ART; CPT; TPT; other  \n",
      "• W...\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "📄 Result 2:\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf\n",
      "Page: 54\n",
      "\n",
      "Content:\n",
      "  \n",
      "Initial Evaluation and Follow up  \n",
      "3 - 9  3.5.1 First 6 months after ART initiation  \n",
      "After ART initiation, patients need to be monitored closely for development of adverse drug events, \n",
      "identify and address barriers to adherence, and development of IRIS. A reasonable follow -up \n",
      "schedule for mos...\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "📄 Result 3:\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf\n",
      "Page: 140\n",
      "\n",
      "Content:\n",
      "  \n",
      "Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \n",
      "6 - 1  \n",
      "6. Antiretroviral Therapy in Infants, Children, \n",
      "Adolescents, and Adults  \n",
      "ART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \n",
      "to suppress viral replication with the aim ...\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "📄 Result 4:\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf\n",
      "Page: 58\n",
      "\n",
      "Content:\n",
      "  \n",
      "Initial Evaluation and Follow up  \n",
      "3 - 13  Table 3. 6 Cont.  \n",
      "1 Recommended investigation should not delay ART initiation.  \n",
      " 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \n",
      "schedule additional appointments as needed. Patients should be encouraged t...\n",
      "--------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[2026-02-10T15:39:30Z WARN  lance::dataset] No existing dataset at /Users/itsmuriuki/Desktop/cdss-notebooks/kenya-hiv-cdss/kenya_arv_guidelines_lancedb/kenya-arv-guidelines.lance, it will be created\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.vectorstores import LanceDB\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from langchain.schema import Document\n",
    "import lancedb\n",
    "import pyarrow as pa\n",
    "\n",
    "\n",
    "# LanceDB configuration\n",
    "db_path = \"./kenya_arv_guidelines_lancedb\"\n",
    "table_name = \"kenya-arv-guidelines\"\n",
    "\n",
    "# Connect to LanceDB\n",
    "db = lancedb.connect(db_path)\n",
    "\n",
    "# Drop existing table if it exists (for fresh start)\n",
    "if table_name in db.table_names():\n",
    "    print(f\"Dropping existing table '{table_name}'...\")\n",
    "    db.drop_table(table_name)\n",
    "\n",
    "# Create vectorstore using add_texts method\n",
    "print(\"Creating new vectorstore...\")\n",
    "\n",
    "# Extract texts and metadatas\n",
    "texts = [doc.page_content for doc in documents]\n",
    "metadatas = [doc.metadata for doc in documents]\n",
    "\n",
    "# Generate embeddings manually\n",
    "print(\"Generating embeddings...\")\n",
    "vectors = embeddings.embed_documents(texts)\n",
    "\n",
    "# Create the table manually with proper schema\n",
    "data = []\n",
    "for i, (text, metadata, vector) in enumerate(zip(texts, metadatas, vectors)):\n",
    "    data.append({\n",
    "        \"text\": text,\n",
    "        \"vector\": vector,\n",
    "        \"id\": str(i),\n",
    "        \"source\": metadata.get(\"source\", \"\"),\n",
    "        \"page\": metadata.get(\"page\", 0)\n",
    "    })\n",
    "\n",
    "# Create table\n",
    "table = db.create_table(table_name, data=data, mode=\"overwrite\")\n",
    "print(f\"✓ Created table with {len(data)} records\")\n",
    "\n",
    "# Now create the LanceDB vectorstore wrapper\n",
    "vectorstore = LanceDB(\n",
    "    connection=table,\n",
    "    embedding=embeddings\n",
    ")\n",
    "print(\"✓ Vectorstore created successfully!\")\n",
    "\n",
    "# Search\n",
    "query = \"What are the first-line ART regimens?\"\n",
    "print(f\"\\n🔍 Searching for: '{query}'\")\n",
    "print(\"=\" * 80)\n",
    "\n",
    "results = vectorstore.similarity_search(query, k=4)\n",
    "\n",
    "for i, doc in enumerate(results, 1):\n",
    "    print(f\"\\n📄 Result {i}:\")\n",
    "    print(f\"Source: {doc.metadata.get('source', 'Unknown')}\")\n",
    "    print(f\"Page: {doc.metadata.get('page', 'N/A')}\")\n",
    "    print(f\"\\nContent:\\n{doc.page_content[:300]}...\")\n",
    "    print(\"-\" * 80)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (kenya-hiv-cdss)",
   "language": "python",
   "name": "kenya-hiv-cdss"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
